

(TM)

Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MSrch_n n.a. - n.a. database search, using Smith-Waterman algorithm

Run on: Sun Oct 24 17:42:44 1999; Maspar time 465.47 Seconds

Tabular output not generated. 1393.481 Million cell updates/sec

Title: >US-09-092-296-7
Description: (51-284) from US09092296.seq
Perfect Score: 234
N.A. Sequence: 51 ATGGGCTGCGGCTGCCCT.....ACCATGTTGTCGACACACA 284
Comp: TACCCGACGACCGGCGGCA.....TGCTACACAGACGCTTGTCT

Scoring table: TABLE default

Gap 6

Nmatch STD : Dbase 0; Query 0

Searched: 646147 seqs, 1385935633 bases x 2

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database:

emb158
1:em_ba1 2:em_ba2 3:em_fun 4:em_hlg 5:em_hum1 6:em_hum2
7:em_in 8:em_om 9:em_or 10:em_ov 11:em_pat 12:em_ph
13:em_pl 14:em_pt 15:em_sts 16:em_vt
Database:
genbank111
17:gb_ba1 18:gb_ba2 19:gb_hlg1 20:gb_hlg2 21:gb_in1
22:gb_in2 23:gb_om 24:gb_ov 25:gb_pat 26:gb_ph 27:gb_pl1
28:gb_pl2 29:gb_pt1 30:gb_pt2 31:gb_pt3 32:gb_pt4
33:gb_stc 34:gb_sts 35:gb_sy 36:gb_un 37:gb_vt

Statistics: Mean 9.653; Variance 4.972; scale 1.941

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description	Pred. No.
1	92	39.3	47323	31	AC005937	Homo sapiens clone UMG
2	48	20.5	7218	25	166494	Sequence 14 from paten
3	33	14.1	74371	31	AC005369	Homo sapiens chromosom
4	32	13.7	216021	31	HUCC004787	Homo sapiens chromosom
5	28	12.4	215	25	128278	Sequence 5 from paten
6	28	12.0	965	25	AR024229	Sequence 22 from paten
7	27	11.5	215	25	128278	Sequence 5 from paten
8	25	10.7	565	25	AB002302	gDNA encoding envelope
9	25	10.7	6252	29	AB002302	Human mRNA for KIAA030
10	24	10.3	60	25	A62989	Sequence 1 from Paten
11	24	10.3	1056	23	MY087256	Mustela vison GI dinuc
12	24	10.3	1056	23	MY087256	Mustela vison GI dinuc
13	23	9.8	1056	23	MY087256	Mustela vison GI dinuc

14	23	9.8	1514	31	HS047925	Human protein A altern
15	23	9.8	1678	32	MMHIS453	Mouse histone H4 gene-
16	23	9.8	2277	25	AR004980	Sequence 2 from paten
17	23	9.8	2516	31	HS047928	Human protein A altern
18	23	9.8	3032	31	AF104918	Homo sapiens myeloid/1
19	23	9.8	3290	29	HDMPTUCAS	H. sapiens fucosidase p
20	23	9.8	46251	30	AD000671	Homo sapiens DNA from
21	23	9.8	133457	30	AC003999	Human PAC clone DJ1139
22	23	9.8	167228	31	AC005552	Homo sapiens chromosom
23	23	9.8	175902	30	AC006992	Homo sapiens clone NH0
24	23	9.8	203418	19	AC004947	Homo sapiens clone 12p13
25	23	9.8	222930	18	HS047924	Human chromosome 12p13
26	22	9.4	30	25	A62994	Sequence 6 from paten
27	22	9.4	108	21	D87227	Trypanosoma cruzi mRNA
28	22	9.4	1004	27	SOYHREPA	soybean hydroxyproline
29	22	9.4	1420	32	RATBAS	Rattus norvegicus beta
30	22	9.4	1789	29	HSCPTINT1	H. sapiens CYP11B1 gene
31	22	9.4	1945	24	CHRCOMN45	Chicken connexin-45 mr
32	22	9.4	2180	21	DROSYT	D. melanogaster synapto
33	22	9.4	2223	32	AF081783	Rattus norvegicus aml1
34	22	9.4	2460	32	AB010742	Mus musculus mRNA for
35	22	9.4	3043	32	AB010414	Mus musculus gene for
36	22	9.4	3247	32	AB010140	Mus musculus mRNA for
37	22	9.4	4434	28	GM044838	Glycine max extensin (
38	22	9.4	6910	29	HDMC1PBB	Human CYP11B2 gene for
39	22	9.4	67919	20	AC005542	WORKING DRAFT SEQUENCE
40	22	9.4	1344700	22	AC005558	Drosophila melanogaste
41	22	9.4	133457	30	AC003999	Human PAC clone DJ1139
42	22	9.4	167217	30	AC002350	Homo sapiens 12q24 PAC
43	22	9.4	175339	31	AC005772	Homo sapiens chromosom
44	22	9.4	214646	20	AC006512	Homo sapiens clone RBC
45	22	9.4	241407	20	AC003059	Mouse Chromosome 10 BA

ALIGNMENTS

RESULT	1	AC005937	47323 bp	DNA	PRI	05-NOV-1998
LOCUS		Homo sapiens clone UMG	370M23.002	from 6p21, complete sequence.		
DEFINITION		AC005937				
ACCESSION		AC005937				
NID		G3845393				
KEYWORDS		AC005937.1	GI:3845393			
SOURCE		human.				
ORGANISM		Homo sapiens				
REFERENCE		Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;				
AUTHORS		Primates; Catarrhini; Hominoidea; Homo.				
TITLE		Janer, M., Guillaudoux, T., Vu, Q., Kutayavin, T., Harter, H. and				
JOURNAL		Geraghty, D.E.				
REMARK		Large scale sequence analysis of the human MHC class I region				
		Unpublished (1998)				
		Fred Hutchinson Cancer Research Center				
		The Clinical Research Division				
		1100 Fairview Ave., N., P.O. Box 19024				
		Seattle, WA 98109-1024				
		2 (bases 1 to 47323)				
REFERENCE		Geraghty, D.E. and Olson, M.V.				
AUTHORS		Submitted (05-NOV-1998) Human Genome Center, University of				
JOURNAL		Washington, Box 352145, Seattle, WA 98195, USA				
REMARK		University of Washington Human Genome Center				
		Box 352145 Seattle, WA 98195				
		Contact: Daniel E. Geraghty (geraghty@hcc.org)				
COMMENT		Overlapping Sequences:				
		5': UMG:370M23.013 (Genbank Accession: AC005350)				
		3': UMG:370M23.013 (Genbank Accession: AC004211)				

Sequence Quality Assessment:
This entry has been annotated with sequence quality estimates computed by the Phrap assembly program. All manually edited bases have been reduced to quality zero. Quality levels above 40 are expected to have less than

1 error in 10,000 bp.
Base-by-base quality values are not generally visible from the Genbank flat file format but are available as part of this entry's ASN.1 file.

Double stranded (DS) coverage: 75.5%
DS or two chemistry coverage: 98.9%
Single stranded regions: 3

Sequence Validation:
This sequence has been validated by Multiple Complete Digest Mapping. Comparison of the experimentally derived map digest fragments with sequence-predicted fragments is given below.
Small fragments below a variable cutoff (approximately 400-600bp) are not mapped and hence do not appear in the table. There are no significant remaining discrepancies between the experimental and predicted values. Uniquely ordered fragment groups are separated by dashed lines.

Map	Seq	Map	Seq	Map	Seq
BglII		HindIII		NsiI	
1069.11	1050.00	889.55	866.00	30541.40	30653.00
20320.67	20855.00	1050.18	1015.00	3279.08	3231.00
2171.50	2147.00	7268.78	7196.00		
2560.20	2531.00	10085.80	9992.00		
4335.42	4269.00	11212.78	11131.00		
2698.62	2628.00				
1927.50	1887.00				
3130.46	3090.00				
2166.69	2129.00				
2044.67	2005.00				

FEATURES
source

Location/Qualifiers
1..47323
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="6"
/map="6p21"
/sub_clone="UMGC:370M23.002"
/clone_1lb="Research Genetics BAC Library"
3647..3932
/rpt_family="Alu"
complement(4999..5277)
/rpt_family="Alu"
6285..6572
/rpt_family="Alu"
complement(6972..7050)
/rpt_family="MLT1"
7286..7584
/rpt_family="Alu"
complement(8164..8609)
/rpt_family="Alu"
complement(2187..21895)
/rpt_family="Alu"
22715..22957
/rpt_family="Alu"
25510..25802
/rpt_family="Alu"
27835..28010
/rpt_family="MER20"
31295..31594
/rpt_family="Alu"
33515..33767
/rpt_family="Alu"

repeat_region 34223..34290
/rpt_family="MIR"
repeat_region 37372..37648
/rpt_family="Alu"
repeat_region 38526..38700
/rpt_family="MER3"
repeat_region 39583..40010
/rpt_family="Alu"
repeat_region 40046..40156
/rpt_family="Alu"
repeat_region 43194..43372
/rpt_family="MER5"
variation 43325
/note="clonal variation with 3' overlapping clone"
variation 44149
/note="clonal variation with 3' overlapping clone"
variation 44451
/note="clonal variation with 3' overlapping clone"
variation 44337
/note="clonal variation with 3' overlapping clone"
variation 44814
/note="clonal variation with 3' overlapping clone"
variation 44965
/note="clonal variation with 3' overlapping clone"
variation 45760
/note="clonal variation with 3' overlapping clone"
variation 45900
/note="clonal variation with 3' overlapping clone"
variation 46851
/note="clonal variation with 3' overlapping clone"
variation 46859
/note="clonal variation with 3' overlapping clone"
variation 47032
/note="clonal variation with 3' overlapping clone"
variation 47240..47256
/note="clonal variation with 3' overlapping clone - insertion of 17bp repeat"
BASE COUNT 11556 a 11489 c 12284 g 11994 t
ORIGIN

Query Match 39.3%; Score 92; DB 31; Length 47323;
Best Local Similarity 100.0%; Pred. No. 1.14e-47;
Matches 92; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 35465 CAGGCCGGGTATGACTTTCGACACTGACGAGCTCTTTCGACAAATTCCTCT 35524
|||
Qy 109 CAGGCCGGGTATGACTTTCGACACTGACGAGCTCTTTCGACAAATTCCTCT 168
|||

Db 35525 ATGAGTCACACTCTCGAATTCGTTGAAAG 35556
|||
Qy 169 ATGAGTCACACTCTCGAATTCGTTGAAAG 200
|||

RESULT 2
LOCUS 166494 7218 bp DNA PAT 23-DEC-1997
DEFINITION Sequence 14 from patent US 5670367.
ACCESSION 166494
NID 92724471
VERSION 166494.1 GI:2724471
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 7218)
AUTHORS Dörner, F., Scheiflinger, F. and Falkner, F. Gunter.
TITLE Recombinant fowlpox virus
JOURNAL Patent: US 5670367-A 14 23-SEP-1997;
FEATURES
source
1..7218
/organism="unknown"
BASE COUNT 1944 a 1491 c 1486 g 1929 t 368 others
ORIGIN

[illegible]

```

repeat_region /rpt_unit-A
22321..22457
/rpt_family="Alu"
complement(22638..22981)
/standard_name="possible repeat"
repeat_region 23022..23326
/rpt_family="Alu"
23473..23761
/rpt_family="Alu"
23744..23767
/standard_name="A"24"
/rpt_type=tandem
/rpt_unit-A
repeat_region complement(24639..24694)
/rpt_family="MER42"
complement(25349..25713)
/rpt_family="Alu"
repeat_region complement(25727..26471)
/rpt_family="Alu"
27191..27477
/rpt_family="Alu"
27774..28057
/rpt_family="Alu"
28040..28066
/standard_name="A"27"
/rpt_type=tandem
/rpt_unit-A
repeat_region 28712..28930
/rpt_family="MER20"
complement(28769..28838)
/standard_name="GRAIL 2 excellent exon, frame 0"
repeat_region 28987..29214
/rpt_family="Alu"
join(29485..29559,29598..29779)
/standard_name="GRAIL 2 excellent exon, frame 1"
29495..29976
/standard_name="A1027942"
/standard_name="100% identity EST ov84a10.x1"
complement(30401..30536)
/standard_name="GRAIL 2 excellent exon, frame 2"
repeat_region complement(30682..30733)
/rpt_family="MIR"
complement(31573..31724)
/standard_name="GRAIL 2 excellent exon, frame 1"
32388..32488
/standard_name="GRAIL 2 excellent exon, frame 2"
repeat_region 32617..32908
/rpt_family="MT1"
32977..33088
/rpt_family="Alu"
complement(33670..33765)
/rpt_family="Alu"
complement(34021..34144)
/standard_name="GRAIL 2 excellent exon, frame 2"
repeat_region complement(35238..35331)
/standard_name="GRAIL 2 excellent exon, frame 1"
35392..36663
/rpt_family="Alu"
36901..37222
/standard_name="100% identity EST OUS5C09.X1"
/standard_name="dbEST:A1025011"
36901..37164
/standard_name="STS-9983"
/db_xref="dbSTS:G26554"
complement(37595..37654)
/standard_name="GRAIL 2 excellent exon, frame 0"
39071..39205,39532..39630,39935..40048,40300..40410,
40503..40661,41868..41972,42103..42225,42492..42569,
44379..44507))
/standard_name="hstidy1-trna synthetase"

misc_feature /note="78%-100% protein identity GenPept:U18937"
complement(38069..38215)
/standard_name="GRAIL 2 excellent exon, frame 0"

FEATURES
source
1..216021
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="16"
/map="*16q21-22"
/clone="A-952F10"
27765..27872
/standard_name="STS-27g3-ua/csrL-27g3-uz, Chr. 1, Homo
sapiens"
/db_xref="dbSTS:G02280"
73826..73943
STS
misc_feature
complement(37595..37654)
/standard_name="GRAIL 2 excellent exon, frame 0"
39071..39205,39532..39630,39935..40048,40300..40410,
40503..40661,41868..41972,42103..42225,42492..42569,
44379..44507))
/standard_name="hstidy1-trna synthetase"

RESULTS
LOCUS HUAC004787 216021 bp DNA PRI 24-JUL-1998
DEFINITION Homo sapiens Chromosome 16 BAC clone CIT987SK-A-952F10, complete
sequence.
ACCESSION AC004787
NID 93337381
VERSION AC004787.1 GI:3337381
KEYWORDS HUG.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
Primates; Catarrhini; Hominoidea; Homo.
1 (bases 1 to 216021)
Adams,M.D., Loftus,B.J., Zhou,L., Crosby,M., Fuhrmann,J.,
Mason,T.M., Brandon,R., Kim,U.J., Keilavage,A.R., and Venter,J.C.
Homo sapiens Chromosome 16 BAC clone CIT987SK-A-952F10
unpublished
2 (bases 1 to 216021)
Adams,M.D. and Loftus,B.J.
Direct Submission
Submitted (02-JUN-1998) The Institute for Genomic Research, 9712
Medical Center Dr, Rockville, MD 20850, USA, Email:
bjloftus@tigr.org
3 (bases 1 to 216021)
Adams,M.D. and Loftus,B.J.
Direct Submission
Submitted (24-JUL-1998) The Institute for Genomic Research, 9712
Medical Center Dr., Rockville, MD 20850, USA
On Jul 24, 1998 this sequence version replaced gi:3241936.
Address all correspondence to: Mark Adams The Institute for Genomic
Research 9712 Medical Center Dr, Rockville, MD 20850, USA e-mail
address: humgen@tigr.org. The orientation of the sequence is from
SP6 end to T7 end. Genes were identified by a combination of five
methods including: XGRAIL (available by anonymous ftp from
arthur.gem.orl.gov), GeneFinder (Phil Green, University of
Washington), GenScan (Chris Burge,
http://genomic.stanford.edu/~chris/GENSCAN.html) searches of the
complete sequence against a peptide database, and the Human gene
index database at TIGR (http://www.tigr.org/cdb/hgi/hgi.html).
Genes without peptide homology having spliced EST hits are termed
'Unknown gene product'. Genes encoding tRNAs are predicted by
tRNAscan-SE (Sean Eddy, http://genome.wustl.edu/eddy/tRNAscan-SE/).
location/Qualifiers
1..216021
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="16"
/map="*16q21-22"
/clone="A-952F10"
27765..27872
/standard_name="STS-27g3-ua/csrL-27g3-uz, Chr. 1, Homo
sapiens"
/db_xref="dbSTS:G02280"
73826..73943
STS

```


promoter /clone="53"
557..563
/note="pot. Sp1 binding site"
misc_feature /note="H4 specific box"
570..587
promoter /note="H4 specific box"
597..604
precursor_RNA /note="TATA-box"
627..1025
/note="pot. primary transcript"
precursor_RNA /note="pot. primary transcript"
628..1025
/note="pot. alt. primary transcript"
660..971
CDS /note="histone H4 (AA 1 - 103)"
/codon_start=1
/protein_id="CAA1622.1"
/db_xref="pid:951311"
/db_xref="gi:51311"
/db_xref="MGI:96099"
/db_xref="SWISS-PROT:P02304"
/translation="MSGKGGKGLGKGAARRKRYLRDNIQGITKPAIRRLARRGV
KRISGLIETRGVLKVFLENVIRDAVYTEHAKRKYTAMDVYRLKRGRTLYGFG
G"

BASE COUNT 414 a 340 c 284 g 349 t 291 others
ORIGIN

Query Match 9 88; Score 23; DB 32; Length 1678;
Best Local Similarity 78.08; Pred. No. 5.25e+00;
Matches 32; Conservative 0; Mismatches 9; Indels 0; Gaps 0;
Db 1028 GAATTCCTAATAAGCTGTGCAATTTGCTCCCTCACCCCTTC 1068
||||| ||| ||||||| ||| | |||| || ||||||
QY 186 GAATTCCTGAATAAGCTGTGCTCCTCCTCACCTCCTTC 226

Search completed: Sun Oct 24 17:50:39 1999
Job time : 475 secs.

Query Match	15.08;	Score 35;	DB 9;	Length 91;
Best Local Similarity	0.08;	Pred. No. 5.35e-07;		
Matches	0;	Conservative	41;	Mismatches 6;
				Indels 0;
				Gaps 0;

PN W09418318-A.

PI Fowlkes DM, Kay BK;
WPT: 94-279739/34
DR

DR P-PSDB; R58378

Query Match	12.4%;	Score 29;	DB 12;	Length 114;
Best Local Similarity	4.9%;	Pred. No. 8.13e-04;		
Matches	5;	Conservative	29;	Mismatches 69;
			Indels	0;
			Gaps	0;

[illegible]

CC RESULT 8

AC ID 070468 standard: DNA; 114 BP.

CC DT 070468:

CD 05-APR-1995 (first entry)

DE Generic DNA sequence to generate a random TSAR peptide library.

KM TSAR: totally synthetic to affinity reagent; synthetic; binding domain;

KW effector domain; concatenated heterofunctional protein; linker;

OS direct; rapid; detection; screening; treatment; generic; ss.

SS Synthetic.

FH misc_feature

FT Key

FT Location/Qualifiers

FT 55..60

FT /tag= a

FT /note= "this sequence represents 'Z'; Z can be a

FT sequence of 6, 9 or 12 nucleotides (see

FT comments)"

FT FT

FT FT

FT FT

PN MO9418318-A.

PD 18-AUG-1994.

PR 01-FEB-1994; U00977.

PR 01-FEB-1993; US-013415.

PR 30-DEC-1993; US-176500.

PA 31-JAN-1994; US-189351.

PA (UYNC-) UNIV NORTH CAROLINA.

PI Fowlkes DM, Key BK;

DR WPI: 94-279739/34.

PT P-PDSB: R65154.

DT Identifying proteins or peptide(s) which bind a ligand - by

PT screening a recombinant vector library expressing fusion proteins

PT comprising a binding domain and an effector domain

PS disclosure: Page 35; 255pp. English.

CC 070468 is a generic DNA sequence used to generate random TSAR (Totally

CC Synthetic Affinity Reagents) peptides. This generic formula can also be

CC represented as T(OLNB)_xI(TGC)(NNB)₆₂(NNB)₇(TGC)(NNB)_{10Y}. X

CC and Y are flanking restriction sites (X is not the same as Y) that are

CC not specified further. Other generic sequences are shown in O70466-68.

CC Other specific peptides generated by these generic sequences are shown in

CC CC

CC R65151-54, TSARS are concatenated heterofunctional proteins or peptides,
CC comprising at least two functional regions - a binding domain with
CC affinity for a ligand and a second effector peptide portion that is
CC chemically or biologically active. They may further comprise a linker
CC peptide between the 2 domains. The oligonucleotides are also designed so
CC that the expressed peptide contains 2 or 4 cysteine residues positioned
CC in, or flanking, the unpredicted or variant residues. These residues
CC confer some degree of conformational rigidity to the peptides. The TSARS
CC or compps. comprising a TSAR binding domain can be used in vivo to
CC deliver a chemically or biologically active moiety, eg. metal ion,
CC radioisotope, peptide, toxin or enzyme, to the specific target or on the
CC cell. The compps. can also replace the function of macromolecules, eg.
CC monoclonal or polyclonal antibodies and therefore circumvent the need
CC for complex methods of hybridoma formation or in vivo antibody
CC production. The TSARS are easily characterized and have designed activity
CC allowing direct and rapid detection in a screening process.

90 Sequence 114 Bp: 0 A: 2 C: 2 G: 2 T:

Query Match	12.0%;	Score 28;	DB 12;	Length 14;
Best Local Similarity	2.7%;	Pred. No. 2.65e-03;		
Matches	3;	Conservative	31;	Mismatches 78;
			Indels	0;
			Gaps	0;

Db 3 bnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnnnnn 62
 Oy 134 GAACTGAAGAGCTTTCTTGACAAATTCTCTCTATAGATGCAGCTTCTCGGAATTGCT 193
 Db 63 bnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnn 114
 Oy 194 TGAAGAAGCTGCTGCTCTCTCTCATCTTCTCTGAGGACAGCTGACCTC 245

RESULT	9	
ID	070472	standard; DNA; 114 BP.
AC	070472:	
DT	10-APR-1995	(first entry)
DE	Genetic DNA sequence to generate a random TSAR peptide library.	
DEFN	TSAR: totally synthetic affinity reagent; synthetic: binding domain;	
KW	effector domain; concatenated heterofunctional protein; linker;	
KW	direct; rapid; detection; screening; treatment; genetic; ss.	
OS	Synthetic.	
Key	Location/Qualifiers	
FM	55..60	
FT	misc-feature	

FT /note= "encoded by 2"
PD M090418318-A.
PR 18-AUG-1994.
PF 01-FEB-1994. U00977.
PR 01-FEB-1993; US-013416.
PR 30-DEC-1993; US-176500.
PR 31-JAN-1994; US-189331.
PA (UYNC-) UNIT NORTH CAROLINA.
PI Fowlkes DM, Kay BK;
DR WPL: 94-279739/34.
PR P-PDB: R58383.
PI Identifying proteins or peptide(s) which bind a ligand - by
PT screening a recombinant vector library expressing fusion proteins
PT comprising a binding domain and an effector domain
PT Disclosure: Page 35; 25pp; English.
CC Q70472 is a generic DNA sequence used to generate random TSAR (Totally
CC Synthetic Affinity Reagents) peptides. This generic formula can also be
CC represented as follows: X(NNB)1(CAC)(NNB)11(CAC)(NNB)(CAC)(NNB)22(CNNB)6
CC -(CAC)(NNB)5(CAC)2(CNNB)4. X and Y are flanking restriction sites
CC (X is not the same as Y) that are not specified further. The peptides
CC generated by this and other generic sequences (Q70470-73) have invariant
CC histidine residues incorporated into variant sequences. TSARs are
CC concatenated heterofunctional proteins or peptides, comprising at least
CC two functional regions - a binding domain with affinity for a ligand and
CC a second effector peptide portion that is chemically or biologically
CC active. They may further comprise a linker peptide between the 2 domains.
CC The TSARs or comps, comprising a TSAR binding domain can be used in
CC vivo to deliver a chemically or biologically active moiety, eg. metal
CC ion, radioisotope, peptide, toxin or enzyme, to the specific target or
CC on the cell. They can also replace the function of macromolecules, eg.

PD 18-AUG-1994.
 PD 01-FEB-1994: 000977.
 PR 01-FEB-1993: US-013416.
 PR 30-DEC-1993: US-176500.
 PR 31-JAN-1994: US-189331.
 PA (UTMC) UNIV NORTH CAROLINA.
 PA FOWLES DM, KAY BK;
 DR WPI: 94-279739/34.
 DR P-PSDB: R65152.
 PT Identifying proteins or peptide(s) which bind a ligand - by
 PT screening a recombinant vector library expressing fusion proteins
 PT comprising a binding domain and an effector domain
 PT Disclosure: Page 35: 255p: English.
 PS 070466 is a generic DNA sequence used to generate random TSAR (Totally
 CC Synthetic Affinity Reagents) peptides. This generic formula can also be
 CC represented as follows: X(NNB)11(TGC)(NNB)10(TGC)2(NNB)42(NNB)8(TGC)(NNB)
 CC 91. X and Y are flanking restriction sites (X is not the same as Y)
 CC that are not specified further. Other generic sequences are shown in
 CC 070466-68. Other specific peptides generated by these generic sequences
 CC are shown in R65151-54. TSARs are concatenated heterofunctional proteins
 CC or peptides, comprising at least two functional regions - a binding
 CC domain with affinity for a ligand and a second effector peptide portion
 CC that is chemically or biologically active. They may further comprise a
 CC linker peptide between the 2 domains. The oligonucleotides are also
 CC designed so that the expressed peptide contains 2 or 4 cysteine residues
 CC positioned in, or flanking, the unpredicted or variant residues. These
 CC residues confer some degree of conformational rigidity to the peptides.
 CC The TSARs or compans, comprising a TSAR binding domain can be used in
 CC vivo to deliver a chemically or biologically active moiety. eg. metal
 CC ion, radioisotope, peptide, toxin or enzyme, to the specific target or
 CC on the cell. They can also replace the function of macromolecules, eg.
 CC monoclonal or polyclonal antibodies and therefore circumvent the need for
 CC complex methods of hybridoma formation or in vivo antibody production.
 CC The TSARs are easily characterised and have designed actively allowing
 CC direct and rapid detection in a screening process.
 SO Sequence 114 BP: 0 A; 4 C; 4 G; 4 T;
 Query Match 11.5% Score 27: DB 12: Length 114;
 Best Local Similarity 4.9%: Pred. No. 8.51e-03;
 Matches 5: Conservative 28; Mismatches 70; Indels 0; Gaps 0;
 Db 9 bnnbnnbnnbnnbnnbnnbnnbnnbncgcgcnnbnnbnnnnnnnnbnnbnn 68
 Oy 149 TTTTCGCAAAATTCCTCTATGATGACCTTCCTCGAATTCGTTGAAGACCTCTCCT 208
 Db 69 bnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnn 111
 Oy 209 CCTCTCCATCTCCTTCAGGAGACGACGTCACCTCCACCAT 251
 RESULT 13
 ID 070469 standard: DNA: 114 BP.
 AC 070469;
 DT 07-APR-1995 (first entry)
 DE Generic DNA sequence to generate a random TSAR peptide library.
 KM TSAR: totally synthetic affinity reagent; synthetic; binding domain;
 KM effector domain: concatenated heterofunctional protein; linker;
 KM direct: rapid; detection; screening; treatment; generic; ss.
 OS Synthetic.
 PH Key Location/Qualifiers
 FT misc_feature 55..60
 FT /*tag= a
 FT /note= "this sequence represents 'Z', Z can be a
 FT sequence of 6,9 or 12 nucleotides (see
 FT comments)"
 PN MO9418318-A.
 PD 18-AUG-1994.
 PF 01-FEB-1994: 000977.
 PR 01-FEB-1993: US-013416.
 PR 30-DEC-1993: US-176500.
 PR 31-JAN-1994: US-189331.
 PA (UTMC) UNIV NORTH CAROLINA.
 PA FOWLES DM, KAY BK;
 DR WPI: 94-279739/34.
 DR P-PSDB: R65152.
 PT Identifying proteins or peptide(s) which bind a ligand - by
 PT screening a recombinant vector library expressing fusion proteins
 PT comprising a binding domain and an effector domain
 PT Disclosure: Page 35: 255p: English.
 PS 070466 is a generic DNA sequence used to generate random TSAR (Totally
 CC Synthetic Affinity Reagents) peptides. This generic formula can also be
 CC represented as follows: X(NNB)11(TGC)(NNB)10(TGC)2(NNB)42(NNB)8(TGC)(NNB)
 CC 91. X and Y are flanking restriction sites (X is not the same as Y)
 CC that are not specified further. Other generic sequences are shown in
 CC 070466-68. Other specific peptides generated by these generic sequences
 CC are shown in R65151-54. TSARs are concatenated heterofunctional proteins
 CC or peptides, comprising at least two functional regions - a binding
 CC domain with affinity for a ligand and a second effector peptide portion
 CC that is chemically or biologically active. They may further comprise a
 CC linker peptide between the 2 domains. The oligonucleotides are also
 CC designed so that the expressed peptide contains 2 or 4 cysteine residues
 CC positioned in, or flanking, the unpredicted or variant residues. These
 CC residues confer some degree of conformational rigidity to the peptides.
 CC The TSARs or compans, comprising a TSAR binding domain can be used in
 CC vivo to deliver a chemically or biologically active moiety. eg. metal
 CC ion, radioisotope, peptide, toxin or enzyme, to the specific target or
 CC on the cell. They can also replace the function of macromolecules, eg.
 CC monoclonal or polyclonal antibodies and therefore circumvent the need for
 CC complex methods of hybridoma formation or in vivo antibody production.
 CC The TSARs are easily characterised and have designed actively allowing
 CC direct and rapid detection in a screening process.
 SO Sequence 114 BP: 0 A; 4 C; 4 G; 4 T;
 Query Match 11.5% Score 27: DB 12: Length 114;
 Best Local Similarity 4.9%: Pred. No. 8.51e-03;
 Matches 5: Conservative 28; Mismatches 70; Indels 0; Gaps 0;
 Db 9 bnnbnnbnnbnnbnnbnnbnnbnnbncgcgcnnbnnbnnnnnnnnbnnbnn 68
 Oy 149 TTTTCGCAAAATTCCTCTATGATGACCTTCCTCGAATTCGTTGAAGACCTCTCCT 208
 Db 69 bnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnn 111
 Oy 209 CCTCTCCATCTCCTTCAGGAGACGACGTCACCTCCACCAT 251

[illegible]

```

PR 23-APR-1992: US-818221.
PA (GEMO ) GEN HOSPITAL CORP.
PA (PARH ) HOECHST AG.
PI Habermann F, Seed B, Stengelin S, Uhlmann E, Ullmer W;
DR WPI: 93-235119/29.
PT Fusion proteins for prodn. of e.g. pro-insulin - comprise gene
PT for desired protein and oligo-nucleotide(s) encoding ballast
PT protein
PS Claim 9; Column 30; 22pp; English.
CC This preferred mixed oligonucleotide encodes a ballast constituent
CC and is inserted between a regulatory region and the structural gene
CC encoding a desired protein, esp. pro-insulin. The short ballast
CC component improves protease resistance of the fusion protein while
CC still allowing the desired protein to adopt its correct conformation
CC prior to cleavage of the ballast constituent.
SQ Sequence 39 BP; 1 A; 11 C; 1 G; 1 T;

Query Match 10.7%; Score 25; DB 7; Length 39;
Best Local Similarity 27.3%; Pred. No. 8.42e-02;
Matches 9; Conservative 20; Mismatches 4; Indels 0; Gaps 0;

Db 2 tgcacccddccddccddccddccddccddccddcc 34
||:||||:||||:||||:||||:||||:||||:
CP 158 TGTCAAAAACACTCTTCAGCTTCAGTGTCA 126

RESULT 15
ID 070470 standard; DNA: 114 BP.
AC 070470;
AD 10-APR-1995
DT Generic DNA sequence to generate a random TSAR peptide library.
DE TSAR, totally synthetic affinity reagent; synthetic; binding domain;
KW effector domain; concatenated heterofunctional protein; linker;
KW direct; rapid; detection; screening; treatment; generic; ss.
OS Synthetic.
PH Key
PI Location/Qualifiers
FT 55..60
FT /*tag= a
FT /note= "encoded by 2 (see comments)"
FT
FT
FT msc_feature
FT
FT WC9418318-A.
FN 18-AUG-1994.
PF 01-FEB-1994; U00977.
PR 01-FEB-1993: US-013416.
PR 30-DEC-1993: US-176500.
PR 31-JAN-1994: US-189331.
PA (UYNC-) UNIV NORTH CAROLINA.
PI Fowlkes DM, Kay BK;
DR WPI: 94-279739/34.
DR P-PSDB: R58378.
PT Identifying proteins or peptide(s) which bind a ligand - by
PT screening a recombinant vector library expressing fusion proteins
PT comprising a binding domain and an effector domain
PT disclosure: Page 36; 25pp; English.
CC 070470 is a generic DNA sequence used to generate random TSAR (Totally
CC Synthetic Affinity Reagents) peptides. This generic formula can also be
CC represented as follows: X(NNB)4(CAC)(NNB)4(CAC)(NNB)8Z(NNB)6(CAC)(NNB)8
CC -(CAC)2(NNB)4 X and Y are flanking restriction sites (X is not the same
CC as Y) that are not identified further. The peptides generated by this and
CC other generic sequences (070471-73) have invariant histidine residues
CC incorporated into variant sequences. TSARs are concatenated
CC heterofunctional proteins or peptides, comprising at least two functional
CC regions - a binding domain with affinity for a ligand and a second
CC effector peptide portion that is chemically or biologically active. They
CC may further comprise a linker peptide between the 2 domains. The TSARs
CC or compns. comprising a TSAR binding domain can be used in vivo to
CC deliver a chemically or biologically active moiety, eg. metal ion,
CC radioisotope, peptide, toxin or enzyme, to the specific target or on the
CC cell. They can also replace the function of macromolecules, eg.
CC monoclonal or polyclonal antibodies and therefore circumvent the need
CC for complex methods of hybridoma formation or in vivo antibody
CC production. The TSARs are easily characterised and have designed
CC activity allowing direct and rapid detection in a screening process.
SQ Sequence 114 BP; 5 A; 10 C; 0 G; 0 T;

```

Query Match 10.7%; Score 25; DB 12; Length 114;
Best Local Similarity 8.6%; Pred. No. 8.42e-02;
Matches 8; Conservative 23; Mismatches 62; Indels 0; Gaps 0

[illegible]

Search completed: Sun Oct 24 18:00:18 1999
Job time : 78 secs.

[M] [O] [S] [E] [L] [H]

(TM)

Release 3.1a John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

Mperch_mn n.a. - n.a. database search, using Smith-Waterman algorithm

Run on: Sun Oct 24 18:00:35 1999; Maspar time 20.77 Seconds

Tabular output not generated. 974,454 Million cell updates/sec

Title: >US-09-092-296-7
Description: (51-284) from US09092296.seq
Perfect Score: 234
N.A. Sequence: 51 ATGGGCTGTGGGCTGCCCT.....ACCATGTCTGTGCACACA 284
Comp: TACCCGACACCCACGCGGA.....TGTACACAGACGCTGTCT

Scoring table: TABLE default

Gap 6

Mmatch STD: Dbase 0; Query 0

Searched: 165359 segs, 43243793 bases x 2

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database: n-issued

1:5A.COMB 2:5B.COMB 3:5C.COMB 4:PCT9.COMB 5:backfiles1

Statistics: Mean 7.399; Variance 4.241; scale 1.745

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result	No.	Score	Query	Match	Length	DB	ID	Description	Pred. No.
C	1	48	20.5	7218	2	US-08-332-	Sequence 14, Applicati	3.43e-17	
C	2	29	12.4	215	1	US-08-338-	Sequence 5, Applicatio	2.36e-07	
C	3	28	12.0	965	3	US-08-388-	Sequence 22, Applicati	9.00e-07	
C	4	27	11.5	215	1	US-08-238-	Sequence 5, Applicatio	3.38e-04	
C	5	23	9.8	2277	2	US-08-676-	Sequence 2, Applicatio	5.68e-07	
C	6	23	9.8	2277	3	US-08-676-	Sequence 2, Applicatio	5.68e-07	
C	7	22	9.4	75	4	PCT-US95-1	Sequence 99, Applicati	1.95e-01	
C	8	22	9.4	82	4	PCT-US95-1	Sequence 99, Applicati	1.95e-01	
C	9	22	9.4	965	3	US-08-388-	Sequence 22, Applicati	1.95e-01	
C	10	21	9.0	65	1	US-08-471-	Sequence 145, Applicat	6.54e-01	
C	11	21	9.0	68	1	US-08-471-	Sequence 145, Applicat	6.54e-01	
C	12	21	9.0	74	4	PCT-US95-1	Sequence 94, Applicati	6.54e-01	
C	13	21	9.0	74	4	PCT-US95-1	Sequence 94, Applicati	6.54e-01	
C	14	21	9.0	74	4	PCT-US95-1	Sequence 100, Applicat	6.54e-01	
C	15	21	9.0	75	4	PCT-US95-1	Sequence 99, Applicati	6.54e-01	
C	16	21	9.0	81	4	PCT-US95-1	Sequence 98, Applicati	6.54e-01	
C	17	21	9.0	81	4	PCT-US95-1	Sequence 92, Applicati	6.54e-01	
C	18	21	9.0	81	4	PCT-US95-1	Sequence 98, Applicati	6.54e-01	
C	19	21	9.0	82	4	PCT-US95-1	Sequence 97, Applicati	6.54e-01	
C	20	21	9.0	906	3	US-08-847-	Sequence 41, Applicati	6.54e-01	

21	21	9.0	906	3	US-09-031-	Sequence 41, Applicati	6.54e-01
22	21	9.0	906	3	US-08-847-	Sequence 40, Applicati	6.54e-01
23	21	9.0	906	3	US-09-031-	Sequence 40, Applicati	6.54e-01
24	21	9.0	908	3	US-09-031-	Sequence 39, Applicati	6.54e-01
25	21	9.0	908	3	US-08-847-	Sequence 39, Applicati	6.54e-01
26	21	9.0	908	3	US-08-847-	Sequence 37, Applicati	6.54e-01
27	21	9.0	908	3	US-09-031-	Sequence 37, Applicati	6.54e-01
28	21	9.0	908	3	US-08-847-	Sequence 37, Applicati	6.54e-01
29	21	9.0	909	3	US-09-031-	Sequence 26, Applicati	6.54e-01
30	21	9.0	909	3	US-08-847-	Sequence 26, Applicati	6.54e-01
31	21	9.0	909	3	US-09-031-	Sequence 25, Applicati	6.54e-01
32	21	9.0	911	3	US-08-847-	Sequence 24, Applicati	6.54e-01
33	21	9.0	911	3	US-08-847-	Sequence 24, Applicati	6.54e-01
34	21	9.0	911	3	US-08-847-	Sequence 22, Applicati	6.54e-01
35	21	9.0	911	3	US-09-031-	Sequence 22, Applicati	6.54e-01
36	21	9.0	5235	3	US-09-031-	Sequence 36, Applicati	6.54e-01
37	21	9.0	5235	3	US-08-847-	Sequence 36, Applicati	6.54e-01
38	21	9.0	5235	3	US-09-031-	Sequence 35, Applicati	6.54e-01
39	21	9.0	5235	3	US-08-847-	Sequence 35, Applicati	6.54e-01
40	21	9.0	5503	3	US-09-031-	Sequence 34, Applicati	6.54e-01
41	21	9.0	5503	3	US-08-847-	Sequence 34, Applicati	6.54e-01
42	21	9.0	5503	3	US-08-847-	Sequence 32, Applicati	6.54e-01
43	21	9.0	5503	3	US-09-031-	Sequence 32, Applicati	6.54e-01
44	20	8.5	81	4	PCT-US95-1	Sequence 92, Applicati	2.14e+00
45	20	8.5	2496	1	US-08-254-	Sequence 2, Applicatio	2.14e+00

ALIGNMENTS

RESULT 1
ID US-08-232-463-14 STANDARD; DNA; UNC; 7218 BP.
AC xxxxxx


Sequence 14, Application US/08232463
Patent No. 5670367
GENERAL INFORMATION:
APPLICANT: DORNER, F.
APPLICANT: SCHEFLINGER, F.
APPLICANT: FALKNER, F. G.
TITLE OF INVENTION: RECOMBINANT FOWLPOX VIRUS
NUMBER OF SEQUENCES: 52
CORRESPONDENCE ADDRESS:
ADDRESSEE: Foley & Lardner
STREET: 1800 Diagonal Road, Suite 500
CITY: Alexandria
STATE: VA
COUNTRY: USA
ZIP: 22313-0299
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/232.463
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/07/935.313
FILING DATE:
APPLICATION NUMBER: EP 91 114 300.6
FILING DATE: 26-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: BENT, Stephen A.
REGISTRATION NUMBER: 29,768
REFERENCE/DOCKET NUMBER: 30472/114 IMMU
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703)836-9300
TELEFAX: (703)683-4109
TELEX: 899149
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:

DE Sequence 22, Application US/08386872A
CC Sequence 22, Application US/08386872A
CC Patent No. 5795961
CC GENERAL INFORMATION:
CC APPLICANT: Maltace, T. Paul
CC APPLICANT: Harris, William J.
CC APPLICANT: Carr, Frank J.
CC APPLICANT: Old, Lloyd J.
CC APPLICANT: Welt, Sydney
CC APPLICANT: Kitamura, Kunito
CC TITLE OF INVENTION: Recombinant Human Anti-Lewis X
CC TITLE OF INVENTION: Antibodies
CC NUMBER OF SEQUENCES: 25
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Pelfe and Lynch
CC STREET: 805 Third Avenue
CC CITY: New York
CC STATE: New York
CC COUNTRY: U.S.A.
CC ZIP: 10022
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC COMPUTER: IBM PC Compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: Patentin Release #1.0, Version #1.30
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/388,672A
CC FILING DATE: 14-FEB-1995
CC CLASSIFICATION:
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Hanson, NO. 5795961man D.
CC REGISTRATION NUMBER: 30,946
CC REFERENCE/DOCKET NUMBER: LID 5409
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: 212-688-9200
CC TELEFAX: 212-838-3884
CC INFORMATION FOR SEQ ID NO: 22:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 965 base pairs
CC TYPE: nucleic acid
CC STRANDEDNESS: unknown
CC TOPOLOGY: unknown
CC MOLECULE TYPE: DNA (genomic)
CC SEQUENCE 965 BP: 192 A; 170 C; 226 G; 200 T; 177 OTHER

CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Science & Technology Law Group
CC STREET: 268 Bush Street, Suite 3200
CC CITY: San Francisco
CC STATE: CA
CC COUNTRY: USA
CC ZIP: 94104
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC COMPUTER: IBM PC compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: Patentin Release #1.0, Version #1.30
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/676,974
CC FILING DATE:
CC CLASSIFICATION: 530
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Osman Ph.D., Richard A
CC REGISTRATION NUMBER: 36,627
CC REFERENCE/DOCKET NUMBER: UCB96-055
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: (415)343-4341
CC TELEFAX: (415)343-4342
CC INFORMATION FOR SEQ ID NO: 2:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 2277 base pairs
CC TYPE: nucleic acid
CC STRANDEDNESS: double
CC TOPOLOGY: linear
CC MOLECULE TYPE: CDNA
CC SEQUENCE 2277 BP; 511 A; 212 C; 395 G; 216 T; 943 OTHER.
SO
Query Match 9.8%; Score 23; DB 3; Length 2277;
Best Local Similarity 40.0%; Pred. No. 5,68e-07;
Matches 18; Conservative 13; Mismatches 14; Indels 0; Gaps 0;
Db 1036 WSNMGARGARGARYTNGNGARYTYNTNCARCARTTYGGNGAR 1080
Cp 224 AGGAGATGGAGGAGGAGGAGGAGCTTTCAGCAATTCAGGMA 180
RESULT 7
ID PCT-US95-11934-99 STANDARD: DNA; UNC; 75 BP.
AC xxxxxx
DE Sequence 99, Application PC/TUS9511934
CC Sequence 99, Application PC/TUS9511934
CC GENERAL INFORMATION:
CC APPLICANT: Cytogen Corporation
CC TITLE OF INVENTION: Antigen Binding Peptides (Ablides) From
CC NUMBER OF SEQUENCES: 103
CC CLASSIFICATION:
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Pennie & Edmonds
CC STREET: 1155 Avenue of the Americas
CC CITY: New York
CC STATE: New York
CC COUNTRY: USA
CC ZIP: 10036
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC COMPUTER: IBM PC compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: Patentin Release #1.0, Version #1.30
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: PCT/US95/11934
CC FILING DATE: 20-SEP-1995
CC CLASSIFICATION:
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Mistrock, S. Leslie
CC REGISTRATION NUMBER: 18,872
CC REFERENCE/DOCKET NUMBER: 1101-196-228
CC TELECOMMUNICATION INFORMATION:

CC TELEPHONE: (212) 790-9090
CC TELEFAX: (212) 869-9741/8864
CC TELEX: 66141 PENNIE
CC INFORMATION FOR SEQ ID NO: 99:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 75 base pairs
CC TYPE: nucleic acid
CC STRANDEDNESS: single
CC TOPOLOGY: linear
CC MOLECULE TYPE: DNA (genomic)
CC SEQUENCE 75 BP; 1 A; 1 C; 7 G; 5 T; 61 OTHER.
SO
Query Match 9.4%; Score 22; DB 4; Length 75;
Best Local Similarity 8.7%; Pred. No. 1,95e-01;
Matches 6; Conservative 19; Mismatches 44; Indels 0; Gaps 0;
Db 5 GNN 64
Oy 54 GGCTGGGGCTGCCCCCTTGTCTCTCTGACCTCTCTGGCAGCTCAGACAGG 113
Db 65 NBGGTTGTG 73
Oy 114 CCGGGTATG 122
RESULT 8
ID PCT-US95-11934-97 STANDARD: DNA; UNC; 82 BP.
AC xxxxxx
DE Sequence 97, Application PC/TUS9511934
CC Sequence 97, Application PC/TUS9511934
CC GENERAL INFORMATION:
CC APPLICANT: Cytogen Corporation
CC TITLE OF INVENTION: Antigen Binding Peptides (Ablides) From
CC NUMBER OF SEQUENCES: 103
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Pennie & Edmonds
CC STREET: 1155 Avenue of the Americas
CC CITY: New York
CC STATE: New York
CC COUNTRY: USA
CC ZIP: 10036
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC COMPUTER: IBM PC compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: Patentin Release #1.0, Version #1.30
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: PCT/US95/11934
CC FILING DATE: 20-SEP-1995
CC CLASSIFICATION:
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Mistrock, S. Leslie
CC REGISTRATION NUMBER: 18,872
CC REFERENCE/DOCKET NUMBER: 1101-196-228
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: (212) 790-9090
CC TELEFAX: (212) 869-9741/8864
CC TELEX: 66141 PENNIE
CC INFORMATION FOR SEQ ID NO: 97:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 82 base pairs
CC TYPE: nucleic acid
CC STRANDEDNESS: single
CC TOPOLOGY: linear
CC MOLECULE TYPE: DNA (genomic)
CC SEQUENCE 82 BP; 1 A; 2 C; 10 G; 8 T; 61 OTHER.
SO
Query Match 9.4%; Score 22; DB 4; Length 82;
Best Local Similarity 8.7%; Pred. No. 1,95e-01;
Matches 6; Conservative 19; Mismatches 44; Indels 0; Gaps 0;

[illegible]



(TM)

Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

Mparch_un n.a. - n.a. database search, using Smith-Waterman algorithm

Run on: Sun Oct 24 17:50:56 1999; Maspar time 454.93 Seconds

Tubular output not generated. 1205.245 Million cell updates/sec

Title: >US-09-092-296-7
Description: (51-284) from US09092296.seq
Perfect Score: 234
N.A. Sequence: 51 ATGGGGCTGGGGCTGGCCCT.....ACCATGTCCTCCACACACA 284
Comp: TACCCCGACGCCGACGCGGGA.....TGGTACACACAGACGTTGT

Scoring table: TABLE default

Gap 6

Mmatch STD : Dbase 0; Query 0

Searched: 2883791 seqs, 1171580779 bases x 2

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database:

emb1-est58
1:em_est10 2:em_est11 3:em_est17 4:em_est18 5:em_est2
6:em_est19 7:em_gss1
Database: genbank-est111
8:gb_est1 9:gb_est10 10:gb_est11 11:gb_est12 12:gb_est13
13:gb_est14 14:gb_est15 15:gb_est16 16:gb_est17
17:gb_est18 18:gb_est19 19:gb_est20 20:gb_est21
21:gb_est22 22:gb_est23 23:gb_est24 24:gb_est25
25:gb_est26 26:gb_est27 27:gb_est28 28:gb_est29
29:gb_est30 30:gb_est31 31:gb_est32 32:gb_est33
33:gb_est34 34:gb_est35 35:gb_est36 36:gb_est37 37:gb_gss1 38:gb_gss2
39:gb_gss3 40:gb_gss4 41:gb_gss5 42:gb_gss6

Statistics: Mean 9.804; Variance 2.109; scale 4.649

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result	No.	Score	Match	Query Length	DB ID	Description	Pred. No.
c	1	73	31.2	328	23	AI136523	UT-R-C2p-ng-e-02-0-UI.
c	2	57	24.4	252	17	AAV54459	7.25e-84
c	3	41	17.5	252	17	AAV54459	2.49e-56
c	4	33	14.1	247	17	AAV54458	2.28e-30
c	5	33	14.1	247	17	AAV54458	2.20e-18
c	6	32	13.7	2275	20	AF034173	5.89e-17
c	7	27	11.5	1287	20	AF038250	4.09e-10
c	8	27	11.5	2275	20	AF038250	4.09e-10
c	9	26	11.1	190	21	AF034173	8.11e-09
c	10	25	10.7	176	19	T94049	1.51e-07

c	11	25	10.7	398	8	T52782	va79f01.r1 Stratagene	1.51e-07
c	12	25	10.7	582	37	B04965	CSRL-51a6-u cSRL flow	1.51e-07
c	13	23	9.8	364	34	B33870	mc65b03.r1 Soares	4.22e-05
c	14	23	9.8	397	30	R52894	yn01d09.r1 Soares	4.22e-05
c	15	23	9.8	400	28	AI354565	ln25f06.x1 NCI-CGAP	4.22e-05
c	16	23	9.8	420	31	H56592	yt88b09.r1 Soares	4.22e-05
c	17	23	9.8	426	8	T15255	cr58855.lambdAZAPst Ric	4.22e-05
c	18	23	9.8	459	13	AA475002	vh08h04.r1 Soares	4.22e-05
c	19	23	9.8	461	22	AI086444	qf25e01.x1 NCI-CGAP	4.22e-05
c	20	23	9.8	547	25	AI337590	qf91a08.r1 NCI-CGAP	4.22e-05
c	21	23	9.8	1287	20	AF038250	AF038250 Human mRNA (T	4.22e-05
c	22	22	9.4	201	28	AI535335	UT-R-C3-sw-e-12-0-UI.s	6.28e-04
c	23	22	9.4	259	38	B81136	CIT-RSP-2015F16.TFC CI	6.28e-04
c	24	22	9.4	305	38	D40392	RICS3342A Rice shoot O	6.28e-04
c	25	22	9.4	354	35	W84061	ml26e11.r1 Soares	6.28e-04
c	26	22	9.4	404	17	AA730403	n442c07.s1 NCI-CGAP	6.28e-04
c	27	22	9.4	408	17	T46345	9608.Lambda-PRL2 Arabi	6.28e-04
c	28	22	9.4	424	33	W13114	na86e10.r1 Soares	6.28e-04
c	29	22	9.4	433	34	W79098	zd75h10.r1 Soares	6.28e-04
c	30	22	9.4	441	14	C28493	C28493 Rice callus	6.28e-04
c	31	22	9.4	459	27	AI442028	sa66f12.y1 Gm-cl004 G1	6.28e-04
c	32	22	9.4	481	42	A0445188	GSSTC01459 Trypanosoma	6.28e-04
c	33	22	9.4	513	40	A0235722	HS-2015.B2.C08.r7 CIT	6.28e-04
c	34	22	9.4	602	23	AI166962	xylem.est.742 Poplar x	6.28e-04
c	35	22	9.4	634	22	AI063013	GH02423.5p1me GH Dros	6.28e-04
c	36	22	9.4	1025	37	B12587	F22011-5p6.1 IGF Arabi	6.28e-04
c	37	21	9.0	317	19	FI10052	HSC39H122 normalized 1	8.54e-03
c	38	21	9.0	354	26	AI398058	NCSM1A117 Subtracted	8.54e-03
c	39	21	9.0	422	33	M07189	za94b07.r1 Soares_feta	8.54e-03
c	40	21	9.0	516	31	H41536	yp71c01.s1 Soares_adul	8.54e-03
c	41	21	9.0	524	16	AA620971	at88f08.s1 Soares	8.54e-03
c	42	21	9.0	550	20	AA898701	NCM65G7Y Mycelial Neur	8.54e-03
c	43	21	9.0	567	30	R61539	yn16f01.s1 Soares_infa	8.54e-03
c	44	21	9.0	587	13	AA428548	zw47d06.r1 Soares_tota	8.54e-03
c	45	21	9.0	630	39	A0201160	RPC111-46K18.TJ RPC111	8.54e-03

ALIGNMENTS

RESULT	1	LOCUS	AI136523	328 bp	mRNA	EST	11-FEB-1999
DEFINITION	UT-R-C2p-ng-e-02-0-UI.s1	UT-R-C2p	Rattus norvegicus	CDNA clone			
ACCESSION	AI136523	UT-R-C2p-ng-e-02-0-UI 3', mRNA sequence.					
NID	93637300						
VERSION	AI136523.1	GI:3637300					
KEYWORDS	EST.						
SOURCE	EST.						
ORGANISM	EST.						
REFERENCE	EST.						
AUTHORS	EST.						
TITLE	EST.						
JOURNAL	EST.						
MEDLINE	EST.						
COMMENT	EST.						

On Jan 14, 1998 this sequence version replaced gi:1877567.

CONTACT: Soares, MB

Program for Rat Gene Discovery and Mapping
University of Iowa
451 Eckstein Medical Research Building Iowa City, IA 52242, USA
Tel: 319 335 8250
Fax: 319 335 9565
Email: msoares@iue.uiowa.edu

The sequence tag present in the CDNA between the NotI site and the

oligo of track served to identify it as a clone from the normalized
adult lung library. cDNA Library Preparation: M. Fatima Bonaldo,
Ph.D. Clone distribution: clones will be available through Research
Genetics
Seq primer: M13 Forward.

FEATURES

Location/Qualifiers

Fax: 82 331 290 0307
Email: myeun@sun20.astl.re.kr
Submitted by Beek Hie Nahm, Dept of Biological Science, Myongji University, Yongin, Korea, 449-728 bhinahm@biosever.myongji.ac.kr
Seq primer: M3 Reverse Primer.

FEATURES

source

```

/organism="Oryza sativa"
/cultivar="Milyang23"
/notes="Vector: pBluescript SK(+); Site_1: EcoRI; site_2:
XhoI. Directional cDNA library inserted into lambda ZapII
vector at 5' end with EcoRI and 3' end with Xho I site."
/db_xref="taxon:4530"
/map="6"
/clone="97SN187"
/clone_lib="Rice Immature Seed Lambda ZapII cDNA Library"
/tissue_type="Immature Seed"
/dev_stage="5 days after pollination"
/lab_host="E. coli SOLR"

```

[illegible]

	RESULT	4						
	LOCUS	AAT754458	247 bp	mRNA		EST	20-JAN-1998	
	DEFINITION	97SN1784 Rice Immature Seed Lambda ZapII cDNA Library Oryza sativa						
	ACCESSION	GNA C1 clone 97SN1784,	mRNA sequence.					
	NID	AAT754458						
	VERSION	g2801166						
	KEYWORDS	AA754436..1	GI:2801164					
	SOURCE	EST.						
	ORGANISM	Oryza sativa.						
		Eukaryota; Viridiplantae;	Streptophyta; Embryophyta; Tracheophyta;					
		euphyllophytes; Spermatophytas; Magnoliophyta; Liliopsida; Poales;						
		Poaceae; Oryza.						
	REFERENCE	N1 (bases 1 to 247)						
	AUTHORS	Nahm,B.H., Kim,J.K., Choong,J.J., Kim,S.I., Hahn,T.R., Moon,E.P., Kim,W.T., Kim,W.Y., Yang,M.S., Park,R.D., Sohn,U.I., Kang,K.Y., Lee,M.C. and Eun,M.Y.						
TITLE JOURNAL COMMENT	Large-scale Sequencing Analysis of ESTs from Rice Immature Seed unpublished (1998) On Jan 14, 1998 this sequence version replaced gi:1797455.							

Contact: Eun M.Y.
 Department of Cytogenetics
 National Inst. of Agri. Sci. and Tech, RDA
 Suwon, Kyunggi-do, Korea
 Tel.: 82 331 290 0301
 Fax: 82 331 290 0307
 Email: myeun@sun20.asi.re.kr
 Submitted by Baek Hie Nahm, Dept of Biological Science, Myongji
 University, Yongin, Korea. 449-728 dhnahmed@server.myongji.ac.kr
 Seq primer: M13 reverse primer.
 Location/Qualifiers
 1. 247
 FEATURES
 source
 /organism="Oryza sativa"

```

/cultivar="Milyang23"
/ote="Vector: pBluescript SK(+): Site.1: EcoRI; Site.2:
XhoI: Directional cDNA library inserted into lambda ZAPRI
vector at 5' end with EcoRI and 3' end with Xho I Site."
/db_xref="taxon:4550"
/map="6"
/clone="97SN1784"
/clone_lib="Rice Immature Seed Lambda ZAPRI cDNA Library"
/tissue_type="Immature Seed"
/dev_stage="5 days after pollination"
/lab_host="E. coli SOLR"

```

Db 9 VRRGCCCCBAANMKKHTHMTEBNCQVPRGCTTNNKNGRTTTTMDSCDAAHCRITYBM 68
 Oy 109 CAGGGCCGGGATGACACTTTGCAACTGAAGCTAAGAGACTCTTTCTGAAATATTCCTCT 168
 Db 69 YVARSXGYCTERYSMNDVTMGSTGYGKTTYVHSGNNKNSVYVYBMLATCDYBHY 128
 Oy 169 ATGATCTACAGCTTCTGGAGATTCCTTGAAAACTCTGCTCTCTCTCATCTCCCTTCAG 228
 Db 123 BDRANHVDYT 138
 Oy 229 GGACCAAGCGT 238

LOCUS	5	AA754458	247 bp	mRNA	EST	20-JAN-1998
DEFINITION		97SN1784 Rice Immature Seed Lambda ZAPIT cDNA Library Oryza sativa				
ACCESSION		AA754458				
NID		92801164				
VERSION		AA754458.1	GI:2801164			
KEYWORDS		EST.				
SOURCE		Oryza sativa.				
ORGANISM		Oryza sativa				
REFERENCE		Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Euphyllophytes; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Oryza.				
AUTHORS		1 (bases 1 to 247) Nahm,B.H., Kim,J.K., Cheong,J.J., Kim,S.I., Hahn,T.R., Moon,E.P., Kim,W.T., Kim,W.Y., Yang,M.S., Park,R.D., Sohn,U.I., Kang,K.Y., Lee,M.C. and Eun,M.Y.				
TITLE		Large-scale Sequencing Analysis of ESTs from Rice Immature Seed				
JOURNAL		unpublished (1998)				
COMMENT		On Jan 14, 1998 this sequence version replaced gi:1797455.				

Contact: Eun M.Y.
 Department of Cytogenetics
 National Inst. of Agril. Sci. and Tech, RDA
 Suwon, Kyunggi-do, Korea
 Tel: 82 331 290 0301
 Fax: 82 331 290 0307
 Email: myeunsaun20.assil.re.kr
 Submitted by Baek Hie Namh, Dept of Biological Science, Myongji
 University, Yongsin, Korea. 449-728 bhnahm@blosserver.myongji.ac.kr
 Seq primer: M13 Reverse Primer.
 Location/Qualifiers
 1..247
 /organism="Oryza sativa"
 /cultivar="Milyang23"
 /note="Vector: pBluescript SK(+). Site.1: EcoRI; Site.2:
 XhoI; Directional cDNA library inserted into lambda ZapII
 vector at 5' end with EcoRI and 3' end with Xho I site."
 /db_xref="taxon:4530"
 /map="6"
 /clone="97SN1784"
 /clone_lib="Rice Immature Seed Lambda ZapII cDNA Library"

polylinker; Site 1: Not I; Site 2: Eco RI; 1st strand cDNA was primed with a Not I - oligo(dT) primer (5' TGTACCACTGAGTGGAGCGCCGCGGAAATTTTCTTTTCTTTT T 3'), on equal amounts of mRNA from 2 13.5dpc and 2 14.5dpc embryos (total RNA provided by Minoru Ko, Wayne State Univ., from 2); double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of the modified pT73 vector. Library went through one round of normalization, and was constructed by Bento Soares and M. Fatima Bonaldo.

/db_xref="taxon:10090"
/clone_image:352493
/clone_lib="Soares mouse embryo NMEL3.5 14.5"
/sex="unknown"
/tissue_type="embryo"
/dev_stage="13.5-14.5dpc total fetus"
/lab_host="DH10B"

BASE COUNT 100 a 73 c 87 g 104 t

ORIGIN

Query Match 9.8%; Score 23; DB 34; Length 364;
Best Local Similarity 79.5%; Pred. No. 4.22e-05;
Matches 31; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Db 282 AACTGAAGGAGGAGGCTTTCCACATATTTCTCT 320
||||| ||||||| ||||| ||||| ||||| |||||
Oy 130 AACTGAGCTGAGGAGCTTTTTCGACAAATCTCTCT 168

RESULT 14
LOCUS R52894 397 bp mRNA EST 18-MAY-1995
DEFINITION yH01d09.11 Soares infant brain INIB Homo sapiens cDNA clone
IMAGE:41873 5', mRNA sequence.
ACCESSION R52894
NID 9814796
VERSION R52894.1 GI:814796
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE
AUTHORS Hillier, L., Clark, N., Dubuque, T., Elliston, K., Hawkins, M., Holman, M., Hultman, M., Kucaba, T., Le, M., Lennon, G., Merra, M., Parsons, J., Rifkin, L., Rohlfing, T., Soares, M., Tan, F., Treweek, E., Waterston, R., Williamson, A., Wohlmann, P., and Wilson, R.
TITLE The WashU-Merck EST Project
JOURNAL Unpublished (1995)
COMMENT On Sep 21, 1992 this sequence version replaced gi:275991.

TITLE

The WashU-Merck EST Project
Unpublished (1995)

On Sep 21, 1992 this sequence version replaced gi:275991.

CONTACT: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@wustl.edu

High quality sequence stops: 299
Source: IMAGE Consortium, LNL
This clone is available royalty-free through LNL; contact the
IMAGE Consortium (info@image.lnl.gov) for further information.
Seq primer: M13Rpl

High quality sequence stop: 299.

Location/Qualifiers
1..397

FEATURES

Source

/organism="Homo sapiens"
/note="Organ: whole brain; Vector: Laminid BA; Site 1: Not I; Site 2: Hind III; 1st strand cDNA was primed with a Not I - oligo(dT) primer 15'
AACTGAGAGATTCGGCGGAGGAGATTTTCTTTTCTTTT 3';
double-stranded cDNA was ligated to Hind III adaptors (Pharmacia), digested with Not I and directionally cloned

into the Not I and Hind III sites of the Laminid BA vector. Library went through one round of normalization. Library constructed by Bento Soares and M. Fatima Bonaldo.

/db_xref="GDB:414414"
/db_xref="taxon:9606"
/map="9"
/clone_image:41873
/clone_lib="Soares infant brain INIB"
/sex="female"
/dev_stage="73 days post natal"
/lab_host="DH10B (ampicillin resistant)"

BASE COUNT 115 a 74 c 100 g 104 t 4 others

ORIGIN

Query Match 9.8%; Score 23; DB 30; Length 397;
Best Local Similarity 78.0%; Pred. No. 4.22e-05;
Matches 32; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Db 7 GAGGAGAGTACAGACATTTCCAGATTTCCAGAGCTGC 47
||||| ||||| ||||| ||||| ||||| ||||| |||||
Cp 215 GAGGAGAGGAGGAGGCTTTTCAAGCATTTCCAGAGCTGC 175

RESULT 15
LOCUS A1554565 400 bp mRNA EST 23-MAR-1999
DEFINITION tm25106.x1 NCI_CGAP_Brn25 Homo sapiens cDNA clone IMAGE:2168675 3'
similar to TR:Q16664 Q16664 PROTEIN A-1. [1] ;, mRNA sequence.
ACCESSION A1554565
NID 94486928
VERSION A1554565.1 GI:4486928
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
Eutheria; Primates; Catarrhini; Homidae; Homo.

REFERENCE
AUTHORS NCI/NINDS-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE National Cancer Institute / National Institute of Neurological Disorders and Stroke, Brain Tumor Genome Anatomy Project (CGAP/BRGAP), Tumor Gene Index
JOURNAL Unpublished (1998)
COMMENT On May 7, 1998 this sequence version replaced gi:3121680.

CONTACT: Robert Strausberg, Ph.D.
Tel: (301) 496-1550
Email: Robert.Strausberg@nih.gov

Tissue Procurement: David N. Louis, M.D., Myrna R. Rosenfeld M.D., Ph.D.
cDNA Library Preparation: M. Bento Soares, Ph.D., M. Fatima Bonaldo, Ph.D.
cDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be found through the I.M.A.G.E. Consortium/LNL at:
www.bio.lnl.gov/bdrrp/image/image.html

Seq primer: -400p from Gibco.

FEATURES

Source

Location/Qualifiers
1..400

FEATURES

/organism="Homo sapiens"
/note="Organ: brain; Vector: pT73D-Pac (Pharmacia) with a modified polylinker; Site 1: Not I; Site 2: Eco RI; 1st strand cDNA was primed with a Not I - oligo(dT) primer 15'
TGTACCACTGAGTGGAGCGCGGCGGAGGATTTTCTTTTCTTTT T 3'; double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of the modified pT73 vector. Library is normalized, and was constructed by Bento Soares and M. Fatima Bonaldo."
/db_xref="taxon:9606"
/map="19p12-p13.1; p12"
/clone_image:2168675"
/clone_lib="NCI_CGAP_Brn25"

Mon Oct 25 11:54:09 1999

US-09-092-296-7.rst

Page 8

```

, /tissue_type="anaplastic oligodendroglioma"
  /lab_host="DH10B"
BASE COUNT 77 a 117 c 124 g 82 t
ORIGIN

```

(TM)

mpsrch_nn	n.a.	n.a.	database search, using Smith-Waterman algorithm
1	0	0	0
2	0	0	0
3	0	0	0
4	0	0	0
5	0	0	0
6	0	0	0
7	0	0	0
8	0	0	0
9	0	0	0
10	0	0	0
11	0	0	0
12	0	0	0
13	0	0	0
14	0	0	0
15	0	0	0
16	0	0	0
17	0	0	0
18	0	0	0
19	0	0	0
20	0	0	0
21	0	0	0
22	0	0	0
23	0	0	0
24	0	0	0
25	0	0	0
26	0	0	0
27	0	0	0
28	0	0	0
29	0	0	0
30	0	0	0
31	0	0	0
32	0	0	0
33	0	0	0
34	0	0	0
35	0	0	0
36	0	0	0
37	0	0	0
38	0	0	0
39	0	0	0
40	0	0	0
41	0	0	0
42	0	0	0
43	0	0	0
44	0	0	0
45	0	0	0
46	0	0	0
47	0	0	0
48	0	0	0
49	0	0	0
50	0	0	0
51	0	0	0
52	0	0	0
53	0	0	0
54	0	0	0
55	0	0	0
56	0	0	0
57	0	0	0
58	0	0	0
59	0	0	0
60	0	0	0
61	0	0	0
62	0	0	0
63	0	0	0
64	0	0	0
65	0	0	0
66	0	0	0
67	0	0	0
68	0	0	0
69	0	0	0
70	0	0	0
71	0	0	0
72	0	0	0
73	0	0	0
74	0	0	0
75	0	0	0
76	0	0	0
77	0	0	0
78	0	0	0
79	0	0	0
80	0	0	0
81	0	0	0
82	0	0	0
83	0	0	0
84	0	0	0
85	0	0	0
86	0	0	0
87	0	0	0
88	0	0	0
89	0	0	0
90	0	0	0
91	0	0	0
92	0	0	0
93	0	0	0
94	0	0	0
95	0	0	0
96	0	0	0
97	0	0	0
98	0	0	0
99	0	0	0
100	0	0	0

```
Run on: Sun Oct 24 17:19:23 1999; MasPar time 370.71 Seconds
```

Tabular output not generated.

```

Title:                >US-09-092-296-3
Description:          (1-180)
Perfect Score:       180
N.A. Sequence:
Comp:                1 CAGGAGCGCAGTGGCCACTA.....CTTGAAGAGCTGCTCCT 180
                   GTCTCCGCGTCAAGCGGTAT.....GAACCTTTGACAGCGAGAGA

```

Scoring table: TABLE default
Gap 6

Searched: 646147 seqs, 1385953633 bases x 2

Post-processing: Minimum Match 0%

Database:

Database: genbank111

22:gb_in2 23:gb_om 24:gb_ov 25:gb_pat 26:gb_ph 27:gb_p11
28:gb_p12 29:gb_pr1 30:gb_pr2 31:gb_pr3 32:gb_ro
33:gb_st 34:gb_sts 35:gb_sy 36:gb_un 37:gb_vl

Statistics: Mean 9.304; Variance 4.612; scale 2.018

Pred. NO. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed and is derived by analysis of the total score distribution.

SUMMARIES

Result	No.	Score	Query Match	Length	DB	ID	Description	Pred. No.
1	90	50.0	4.7323	31	AC005937	Homo sapiens clone UMG	8.42e-06	4
2	32	17.8	216021	31	HUAC004787	Homo sapiens Chromosome	7.20e-04	5
3	29	16.1	965	25	AR024229	Sequence 22 from paten	5.53e-04	5
4	28	15.6	7218	25	166494	Sequence 14 from paten	2.06e-03	5
5	27	15.0	215	25	128278	Sequence 5 from patent	9.05e-03	5
6	7	15.0	215	25	128278	Sequence 5 from patent	9.05e-03	5
7	26	14.4	965	25	AR024229	Sequence 22 from patent	3.54e-04	5
8	26	14.4	74371	31	AC005369	Homo sapiens Chromosome	3.54e-04	5
9	25	14.4	216021	31	HUAC004787	Homo sapiens Chromosome	3.54e-04	5
10	25	13.9	565	25	E04076	gDNA encoding envelope	1.35e-01	1
11	25	13.9	60966	31	AC003030	Homo sapiens Chromosome	1.35e-01	1
12	24	13.3	60	25	A62898	Sequence 1 from Patent	5.03e-01	1
13	24	13.3	1056	23	MV087256	Mustela vison Gr dinuc	5.03e-01	1

14	23	12.8	1056	23	MuH87256	Mustela vison cr. dnuic	1.82e+00
15	23	12.8	3290	29	HUMF97545	H. sapiens lucosidase p	1.82e+00
16	23	12.8	175902	20	AC006992	Homo sapiens clone NH0	6.36e+00
17	22	12.2			B62934	Sequence 6 from Patent	6.36e+00
18	22	12.2	108	21	D87227	Tyrosinoma cruzi mRNA	6.36e+00
19	22	12.2	1738	29	HUM0L041B	Human (clone SY7/10) g	6.36e+00
20	22	12.2	1945	24	CHKCONN45	Chicken conneXin-45 mr	6.36e+00
21	22	12.2	2180	21	DROXYT	Mus musculus Btk gene,	6.36e+00
22	12.2	2273	32		MMBAKEN	DNA encoding part of A	6.36e+00
23	22	12.2	3088	11	EL0775	Sequence 1 from patent	6.36e+00
24	22	12.2	3088	25	AR014574	Homo sapiens mRNA for	6.36e+00
25	22	12.2	6540	29	D63997	WORKING DRAFT SEQUENCE	6.36e+00
26	22	12.2	82999	20	AC006542	Homo sapiens 3p21.1 co	6.36e+00
27	22	12.2	87098	31	AC006252	Drosophila melanogaste	6.36e+00
28	22	12.2	124700	22	AC003598	Human P4C clone D1139	6.36e+00
29	22	12.2	133457	30	AC006060	Homo sapiens 3p22-8 Pa	6.36e+00
30	30	12.2	135039	31	HS4C038	Human DNA sequence ***	6.36e+00
31	22	12.2	151187	19	AC005772	Homo sapiens chromosom	6.36e+00
32	22	12.2	175539	31	AC004947	Homo sapiens clone D11	6.36e+00
33	22	12.2	203418	19	AC006572	Mouse Chromosome 10 BA	6.36e+00
34	22	12.2	241407	20	AC003059	Sequence 145 from patet	2.16e+01
35	21	11.7	65	25	U14365	Human Ca2+ ATPase of f	2.16e+01
36	21	11.7	631	30	HSAP26A152	H. sapiens tal-1 DNA.	2.16e+01
37	21	11.7	1000	30	HS27LIDNA	Homo sapiens mRNA for	2.16e+01
38	21	11.7	1755	29	HSZ70171	Homo sapiens mRNA for	2.16e+01
39	21	11.7	3425	29	AB006623	S. pombe chromosome II	2.16e+01
40	21	11.7	46213	28	SPBCLB10	Human DNA sequence fro	2.16e+01
41	21	11.7	56804	30	HS77N19	Homo sapiens chromosom	2.16e+01
42	21	11.7	74371	31	AC005369	Homo sapiens chromosom	2.16e+01
43	21	11.7	118995	31	AC005368	Homo sapiens chromosom	2.16e+01
44	21	11.7	127027	30	HS461217	Human DNA sequence fro	2.16e+01
45	21	11.7	187366	31	AC006486	Homo sapiens chromosom	2.16e+01

ALIGNMENTS

RESULT	LOCUS	DEFINITION	ACCESSION
1	AC005937	Homo sapiens clone UMGc:370M23.002 from AC005937	DNA PRI 05-NOV-1998 6p21, complete sequence

ORGANISM

REFERENCE

JOURNAL

REMARK

REFERENCE

AUTHORS
TITLE

JOURNAL

REMARK

COMMENT

[illegible]

1 error in 10,000 bp.
Base-by-base quality values are not generally visible from the Genbank flat file format but are available as part of this entry's ASN.1 file.

Double stranded (DS) coverage: 75.5%
DS or two chemistry coverage: 98.9%
Single stranded regions: 3

Sequence Validation:
This sequence has been validated by Multiple Complete Digest Mapping. Comparison of the experimentally derived map digest fragments with sequence-predicted fragments is given below.
Small fragments below a variable cutoff (approximately 400-600bp) are not mapped and hence do not appear in the table. There are no significant remaining discrepancies between the experimental and predicted values. Uniquely ordered fragment groups are separated by dashed lines.

Map	Seq	Map	Seq	Map	Seq
BglII		HindIII		NsiI	
1069.11	1050.00	889.55	866.00	30541.40	30653.00
20320.67	20855.00	1050.18	1015.00	3279.08	3231.00
2171.50	2147.00	7268.78	7196.00		
2560.20	2531.00	10085.80	9992.00		
4335.42	4269.00	11212.78	11131.00		
2698.62	2628.00				
1927.50	1887.00				
3130.46	3090.00				
2166.69	2129.00				
2044.67	2005.00				

FEATURES
source
Location/Qualifiers
1. 47323 Homo sapiens
/db_xref="taxon:9606"
/chromosome="6"
/map="6p21"
/sub_clone="UMGC:370M23.002"
/clone_1lb="Research Genetics BAC Library"
3647. 3932
/rpt_family="Alu"
complement(4999. 5277)
/rpt_family="Alu"
6285. 6572
/rpt_family="Alu"
complement(6972. 7050)
/rpt_family="MLT1"
7286. 7584
/rpt_family="Alu"
complement(8164. 8609)
/rpt_family="Alu"
complement(21287. 21895)
/rpt_family="Alu"
22715. 22957
/rpt_family="Alu"
25510. 25802
/rpt_family="Alu"
32835. 28010
/rpt_family="MER20"
31295. 31594
/rpt_family="Alu"
33515. 33767
/rpt_family="Alu"

repeat_region 34223..34290
/rpt_family="MTR"
repeat_region 37372..37648
/rpt_family="Alu"
repeat_region 38526..38700
/rpt_family="MER3"
repeat_region 39583..40010
/rpt_family="Alu"
repeat_region 40046..40156
/rpt_family="Alu"
repeat_region 43194..43372
/rpt_family="MERS"
43325
variation /note="clonal variation with 3' overlapping clone"
44149
variation /note="clonal variation with 3' overlapping clone"
44451
variation /note="clonal variation with 3' overlapping clone"
44537
variation /note="clonal variation with 3' overlapping clone"
44814
variation /note="clonal variation with 3' overlapping clone"
44965
variation /note="clonal variation with 3' overlapping clone"
45760
variation /note="clonal variation with 3' overlapping clone"
45900
variation /note="clonal variation with 3' overlapping clone"
46851
variation /note="clonal variation with 3' overlapping clone"
46859
variation /note="clonal variation with 3' overlapping clone"
47032
variation /note="clonal variation with 3' overlapping clone"
47240..47256
variation /note="clonal variation with 3' overlapping clone"
insertion of 17bp repeat

BASE COUNT 11556 a 11489 c 12284 g 11994 t
ORIGIN
Query Match 50.0%; Score 90; DB 31; Length 47323;
Best Local Similarity 98.9%; Pred. No. 8,42e-49;
Matches 91; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Db 35465 CAGGGCCGGATGACTTTCGCAACTGGAAGAGCTTTCTGCAATTCTCT 35524
|||||
Oy 78 CAGGGCCGGATGACTTTCGCAACTGGAAGAGCTTTCTGCAATTCTCT 137
Db 35525 ATGAGTCAGCTTCCTGGAATTGCTTGAAGA 35556
|||||
Oy 138 ATGAGTCAGCTTCCTGGAATTGCTTGAAGA 169
|||||
RESULT 2
LOCUS HUMC004787 216021 bp DNA PRI 24-JUL-1998
DEFINITION Homo sapiens Chromosome 16 BAC clone C1987SK-A-952F10, complete
sequence.
ACCESSION AC004787
NID 93337381
VERSION AC004787.1 GI:3337381
KEYWORDS HTG.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
Primates; Catarrhini; Hominoidea; Homo.
REFERENCE
AUTHORS Adams M.D., Loftus B.J., Zhou L., Crosby M., Fuhmann J.,
Mason T.M., Brandon R., Kim U.J., Kevlavage A.R. and Venter J.C.
TITLE Human sapiens Chromosome 16 BAC clone C1987SK-A-952F10
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 216021)
AUTHORS Adams M.D. and Loftus B.J.
TITLE Direct Submission

US-09-092-296-3.rge

Page 3

[illegible]

[illegible]

misc_feature join(3246..3410,3721..3828)
/standard_name="RLP"
/note="658 & 698 protein identity GenPept:U02377"
repeat_region 3431..3724
/rpt_family="Alu"
3707..3728
/note="(A)22"
/rpt_type=tandem
/rpt_unit=A
4366..4661
/rpt_family="Alu"
5327..5602
/rpt_family="Alu"
6586..6956
/rpt_family="L1"
6647..6684
/note="(CA)19"
/rpt_type=tandem
/rpt_unit=CA
7113..7373
/rpt_family="Alu"
/standard_name="MR42"
/standard_name="possible repeat"
8258..8503
/rpt_family="Alu"
9070..9387
/rpt_family="Alu"
complement(9740..9845)
/rpt_family="MR42"
complement(10440..11015)
/rpt_family="Alu"
11950..12250
/rpt_family="Alu"
12057..12085
/note="(A)29"
/rpt_type=tandem
/rpt_unit=A
12365..12645
/rpt_family="Alu"
13727..13750
/note="(AC)12"
/rpt_type=tandem
/rpt_unit=AC
13783..14024
/rpt_family="L1"
14175..14470
/rpt_family="Alu"
complement(14906..15259)
/standard_name="possible repeat"
15300..15613
/rpt_family="Alu"
16671..16690
/note="(T)20"
/rpt_type=tandem
/rpt_unit=T
complement(16675..16977)
/rpt_family="Alu"
complement(16993..17085)
/rpt_family="MR42"
complement(17678..18276)
/rpt_family="Alu"
19305..19583
/rpt_family="Alu"
19914..19945
/note="(GTTT)8"
/rpt_type=tandem
/rpt_unit=GTTT
complement(19943..20222)
/rpt_family="Alu"
21202..21496
/rpt_family="Alu"
21736..22035
/rpt_family="Alu"

repeat_region 22017..22038
/note="(A)22"
/rpt_type=tandem
/rpt_unit=A
22321..22457
/rpt_family="Alu"
complement(22638..22981)
/standard_name="possible repeat"
23022..23326
/rpt_family="Alu"
23473..23761
/rpt_family="Alu"
23744..23767
/note="(A)24"
/rpt_type=tandem
/rpt_unit=A
complement(24639..24694)
/rpt_family="MR42"
complement(25349..25713)
/rpt_family="Alu"
complement(25727..26471)
/rpt_family="Alu"
27191..27477
/rpt_family="Alu"
27774..28057
/rpt_family="Alu"
28040..28066
/note="(A)27"
/rpt_type=tandem
/rpt_unit=A
28712..28930
/rpt_family="MR20"
complement(28769..28838)
/note="GRAIL 2 excellent exon, frame 0"
28987..29214
/rpt_family="Alu"
join(29485..29559,29598..29779)
/note="95 identity dbSTS:G14522 (SHGC-11312)"
29495..29926
/standard_name="A1027942"
/note="100% identity EST ov84a10.x1"
complement(30401..30536)
/note="GRAIL 2 excellent exon, frame 2"
complement(30682..30733)
/rpt_family="MIR"
complement(31573..31724)
/note="GRAIL 2 excellent exon, frame 1"
/note="GRAIL 2 excellent exon, frame 2"
32386..32488
/rpt_family="ML1"
32617..32908
/rpt_family="Alu"
32977..33088
/rpt_family="MLR1"
complement(33670..33785)
/rpt_family="Alu"
complement(34021..34144)
/note="GRAIL 2 excellent exon, frame 2"
complement(35238..35331)
/note="GRAIL 2 excellent exon, frame 1"
36392..36663
/rpt_family="Alu"
36901..37222
/note="100% identity EST ou55c09.x1"
/db_xref="dbEST:A1025011"
36901..37164
/standard_name="STS6-9983"
/db_xref="dbSTS:G26554"
complement(37595..37654)
/note="GRAIL 2 excellent exon, frame 0"
complement(join(38063..38218,38462..38578,38741..38995,
39071..39205,39532..39630,39935..40048,40300..40410,


```

RESULT 11
LOCUS AC003030 60966 bp DNA PRI 06-JAN-1999
DEFINITION Homo sapiens chromosome 19, overlapping cosmids R29828 and F25496,
complete sequence.
ACCESSION AC003030
MID g4092821
VERSION AC003030.1 GI:4092821
KEYWORDS HTG.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
Primates; Catarrhini; Hominoidea; Homo.
REFERENCE 1 (bases 1 to 60966)
AUTHORS Lamerdin,J.E., McCready,P.M., Skowronski,E., Viswanathan,V.,
Burkhardt-Schultz,K., Gordon,L., Dias,J., Ramirez,M., Stillwagen,S.,
Danganan,L., Ertler,A., Christensen,M., Georgescu,A., Avila,J.,
Liu,S., Attix,C., Andreise,T., Tranbheim,M., Amico-Keller,G.,
Coeffield,J., Duarte,S., Lucas,S., Bruce,R., Thomas,P., Quan,G.,
Kromoller,B., Arellano,A., Sanders,C., Ow,D., Nolan,M., Trong,S.,
Kobayashi,A., Olsen,A.S. and Carrano,A.V.
TITLE Sequence analysis of a 2 Mb contig in 19p12 between UBA52 and
D19S453
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 60966)
AUTHORS Lamerdin,J.E.
TITLE Direct Submission
JOURNAL Submitted (04-JAN-1999) Joint Genome Institute, Lawrence Livermore
National Laboratory, 7000 East Ave., Livermore, CA 94551, USA
REFERENCE 4 (bases 1 to 60966)
AUTHORS Lamerdin,J.E.
TITLE Direct Submission
JOURNAL Submitted (06-JAN-1999) Joint Genome Institute, Lawrence Livermore
National Laboratory, 7000 East Ave., Livermore, CA 94551, USA
COMMENT Submitted (06-JAN-1999) Joint Genome Institute, Lawrence Livermore
National Laboratory, 7000 East Ave., Livermore, CA 94551, USA
Map and sequence oriented from p telomere to centromere. This
accession is comprised of overlapping cosmids R29828 (bases 1 to
40,974) and F25496 (bases 23,336 to 60,966). R29828 is separated
from cosmid F23858 (AC004475) to the left by a sequence gap of
approximately 14 kb which is to be filled by sequencing a
restriction fragment from cosmid R27236 (currently in progress).
Cosmid F25496 is separated from cosmid R31863 to the right by an
sequence information gap of at least 10 kb. Additional chr 19 map and
http://www.bio.lnl.gov/genome/genome.html.
location/Qualifiers
source
1. 60966
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="R29828-F25496"
/chromosome="19"
/map="19p12 between UBA52 and D19S455."
/cell_line="UV5HL9-5B for F25496, and 5HL2-B for R29828"
/clone_lib="LL19NC02 (for F25496) and LL19NC03 (for
R29828) chromosome 19-specific cosmid libraries"
/note="Cosmid libraries constructed at LBN from
flow-sorted chromosomes from human-hamster hybrid cell
lines UV5HL9-5B and 5HL2-B, each of which carries
chromosome 19 as its only human chromosome."
18. 219
/repeat_region
/rpt_family="AluDo"
530. 824
/repeat_region
/rpt_family="AluY"
930. 1066
/rpt_family="FLAM.C"
complement(1148..1315)
/note="predicted exon, program: grail2exons_human_1.3,

```

```

frame: 2, quality: good, score: 51.000"
complement(1477..1706)
/rpt_family="AluDo"
repeat_region
2105. 2406
/rpt_family="AluSp"
2513. 2809
/rpt_family="AluDo"
5028. 5045
/note="DGS similarity to overlapping ESTs: AA963316
UI-R-E1-g1-c-06-0-UI-s1 UI-R-E1 Rattus norvegicus CDNA
identity: --AA963275 EST197078 Normalized rat kidney, Bento
Soares Rattus sp. CDNA clone RKIB38 3' end; (240. 257);
100% identity."
join(53028..5045,5432..5497,6480..6575,8155..8249,
10156..10183,10562..10717,11845..11991,12086..12176,
13147..13250,14614..14679,18199..18248,18465..18542,
18635..18746,23665..23755,24574..24709,37283..37493)
/note="Hypothetical human protein (partial)"
/codon_start=1
/evidence-not-experimental
/product="R29828.1"
/protein_id="AAD03161.1"
/db_xref="PIR:g4106983"
/db_xref="GI:4106983"
/translation="WLISQIQIPQEDVRFENASLSLEYCOENSVDAKPLRKRAIOI
SOQTPYHCRLLFQLAQLHLEKDLVSACDILGVGEYRVRVSEYTRALFLSKML
LMERKLEVPRLTLGQIVENMOGNIOKESIRPEFVLYQTYXDAQGVSVRC
IKLODQCIOTISTLHDEPLSPNADLPFHMIRKHCIVLYVYTMHSMQAGLEKAO
KYNDRAQFTALRLXSLERINPDSFVSSHCKRAKATVGTGKRAIDQEGYEVARF
LREPTAKSNADRLRTRFCSLVLDGHITVYGNRHSNMVVPAMQALSKIPMSQVL
WSSALRQLNACGNMADHAEAOHNEFSQOLQDIHACISLPHNLITVRGHEG
IAATRLPYAFMEGGSTTLYVSADIKWIKHIOEDTESSEAWAPVRCETIKSLPOTRAII
LLEPLD"
complement(5186..5264)
/note="Predicted exon, program: grail2exons_human_1.3,
frame: 0, quality: excellent, score: 86.000"
5432. 5497
/note="DGS similarity to overlapping ESTs: AA963316
UI-R-E1-g1-c-06-0-UI-s1 UI-R-E1 Rattus norvegicus CDNA
clone UI-R-E1-g1-c-06-0-UI-3'; (236. 303); 88%
identity. --AA963275 EST197078 Normalized rat kidney, Bento
Soares Rattus sp. CDNA clone RKIB38 3' end; (258. 323);
88% identity."
complement(5602..5883)
/rpt_family="AluDo"
6480. 6575
/note="DGS similarity to overlapping ESTs: AA963316
UI-R-E1-g1-c-06-0-UI-s1 UI-R-E1 Rattus norvegicus CDNA
clone UI-R-E1-g1-c-06-0-UI-3'; (304. 399); 89%
identity. --AA963275 EST197078 Normalized rat kidney, Bento
Soares Rattus sp. CDNA clone RKIB38 3' end; (324. 419);
89% identity. --(6480. 6660) predicted exon, program:
grail2exons_human_1.3, frame: 2, quality: excellent,
score: 76.000"
8155. 8249
/note="Predicted exon, program: grail2exons_human_1.3,
frame: 0, quality: excellent, score: 94.000--DGS
similarity to overlapping ESTs: (8155. 8237) AA963316
UI-R-E1-g1-c-06-0-UI-s1 UI-R-E1 Rattus norvegicus CDNA
clone UI-R-E1-g1-c-06-0-UI-3'; (400. 482); 88%
identity. --(8155. 8240) AA963275 EST197078 Normalized rat
kidney, Bento Soares Rattus sp. CDNA clone RKIB38 3' end;
(420. 505); 85% identity."
8351. 8477
/rpt_family="AluDo"
8480. 8768
/rpt_family="AluSc"
8778. 8837
/note="Predicted exon, program: grail2exons_human_1.3,
frame: 2, quality: excellent, score: 83.000"
complement(8872..8996)

```

 W E S E R L E

 (TM)

Release 3.1A John F. Collins, Biocomputing Research Unit.
 Copyright (c) 1993-1998 University of Edinburgh, U.K.
 Distribution rights by Oxford Molecular Ltd

Mparch_nu n.a. - n.a. database search, using Smith-Waterman algorithm

Run on: Sun Oct 24 17:32:37 1999; MasPar time 60.50 Seconds

Tabular output not generated. 637,452 Million cell updates/sec

Title: >US-09-092-296-3
 Description: (1-180) from US09092296.seq
 Perfect Score: 180
 N.A. Sequence: 1 CAGGAGCGAGTGGCCACCTA.....CTGGAAGCTCTGCCCT 180
 Comp: GTCCCTCGGTCACCGGTGAT.....GAACCTTCGAGACGAGGA

Scoring table: TABLE default
 Gap 6

Mmatch STD: Dbase 0; Query 0

Searched: 271905 seqs, 107135622 bases x 2

Post-processing: Minimum Match 0%
 Listing first 45 summaries

Database:

n-geneseq35
 1:part1 2:part2 3:part3 4:part4 5:part5 6:part6 7:part7
 8:part8 9:part9 10:part10 11:part11 12:part12 13:part13
 14:part14 15:part15 16:part16 17:part17 18:part18
 19:part19 20:part20 21:part21 22:part22 23:part23
 24:part24 25:part25 26:part26 27:part27 28:part28
 29:part29 30:part30 31:part31 32:part32 33:part33
 34:part34 35:part35 36:part36 37:part37 38:part38
 39:part39 40:part40 41:part41 42:part42 43:part43
 44:part44 45:part45 46:part46 47:part47 48:part48
 49:part49 50:part50 51:part51 52:part52 53:part53
 54:part54 55:part55 56:part56 57:part57 58:part58
 59:part59 60:part60

Statistics: Mean 7.535; Variance 4.714; scale 1.598

Pred. No. is the number of results predicted by chance to have a
 score greater than or equal to the score of the result being printed,
 and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description	Pred. No.
1	178	98.9	439	60	V84366	Human stomach carcinoma	4,41e-99
2	37	20.6	91	9	O51746	Oligonucleotide probe	1.15e-08
3	37	20.6	204	1	N81164	Base substituted E.co	1.15e-08
4	34	18.9	91	9	O51746	Oligonucleotide probe	5.55e-07
5	33	18.3	204	1	N81164	Base substituted E.co	1.99e-06
6	31	17.2	114	12	O70467	Generic DNA sequence	2.48e-05
7	30	16.7	114	12	O70470	Generic DNA sequence	8.61e-05
8	29	16.1	114	12	O70470	Generic DNA sequence	2.96e-04
9	29	16.1	114	12	O70467	Generic DNA sequence	2.96e-04

10	28	15.6	114	12	O70469	Generic DNA sequence	1.00e-03
11	28	15.6	114	12	O70465	Generic DNA sequence	1.00e-03
12	28	15.6	114	12	O70468	Generic DNA sequence	1.00e-03
13	28	15.6	178	32	T76405	Human endothelin-1 an	3.36e-03
14	27	15.0	114	12	O70468	Generic DNA sequence	3.36e-03
15	27	15.0	114	12	O70465	Generic DNA sequence	3.36e-03
16	26	14.4	114	12	O70472	Generic DNA sequence	1.11e-02
17	26	14.4	114	12	O70466	Generic DNA sequence	1.11e-02
18	25	13.9	39	7	O51787	Mixed oligonucleotide	3.60e-02
19	25	13.9	114	12	O70469	Generic DNA sequence	3.60e-02
20	24	13.3	114	12	O70466	Generic DNA sequence	1.15e-01
21	24	13.3	114	12	O70472	Generic DNA sequence	1.15e-01
22	23	12.8	114	12	O70473	Generic DNA sequence	3.62e-01
23	23	12.8	114	12	O70471	Generic DNA sequence	3.62e-01
24	23	12.8	114	12	O70471	Human interleukin 8 a	3.62e-01
25	23	12.8	172	32	T76363	HCV envelope region n	3.62e-01
26	22	12.2	36	2	O35072	ADP ribosylation fact	1.11e+00
27	22	12.2	75	21	T13612	DC43 TSAR library gen	1.11e+00
28	22	12.2	82	21	T13610	DC43 TSAR library gen	1.11e+00
29	22	12.2	89	32	T76219	Human IL5 antisense o	1.11e+00
30	22	12.2	114	12	O70471	Generic DNA sequence	1.11e+00
31	22	12.2	114	12	O70473	Generic DNA sequence	1.11e+00
32	22	12.2	250	32	T76438	Substance P receptor	1.11e+00
33	22	12.2	264	32	T76445	Sequence encoding new	1.11e+00
34	22	12.2	501	3	N50025	Sequence encoding new	1.11e+00
35	22	12.2	501	3	N50026	ADP ribosylation fact	1.11e+00
36	22	12.2	3088	16	T05628	TSAR-9 library genera	3.36e+00
37	21	11.7	66	21	T13585	TSAR-9 library genera	3.36e+00
38	21	11.7	69	21	T13583	DC43 TSAR library gen	3.36e+00
39	21	11.7	82	21	T13610	B. malayi ankylrin cdn	3.36e+00
40	21	11.7	908	51	V63025	D. immitis ankylrin nm	3.36e+00
41	21	11.7	908	51	V63024	D. immitis ankylrin cd	3.36e+00
42	21	11.7	909	51	V63015	D. immitis ankylrin nd	3.36e+00
43	21	11.7	909	51	V63014	D. immitis ankylrin cd	3.36e+00
44	21	11.7	5235	51	V63023	D. immitis ankylrin cd	3.36e+00
45	21	11.7	5503	51	V63021	D. immitis ankylrin cd	3.36e+00

ALIGNMENTS

RESULT 1
 ID V84366 standard; cDNA to mRNA; 439 BP.
 AC 30-MAR-1999 (first entry)
 DI Human stomach carcinoma CDNA clone HP10408.
 DE Transmembrane protein; HP10408; human; stomach cancer; ds.
 OS Homo sapiens.
 FH Key Location/Qualifiers
 FT 75..311
 FT /*tag= a
 FT /note= "cDNA comprising the coding region (minus
 the stop codon) is claimed (Claim 3)"
 PN W0985508-A2.
 PD 10-DEC-1998; J02445.
 PF 03-JUN-1998; J02445.
 PR 03-JUN-1997; JP-144948.
 PA (PROT-) PROTEGENE INC.
 PA (SAGA) SAGAMI CHEM RES CENTRE.
 PI Kato S, Sekine S, Yamaguchi T;
 DR WPI: 99-045730/04.
 DR P-PSDB: W88498.
 PT New human proteins containing transmembrane domains and their
 encoding sequences - useful in the preparation of antibodies and
 large-scale protein production, gene diagnosis, and gene therapy
 PS Claim 4; Page 135; 178pp; English.
 CC This is the nucleotide sequence of cDNA clone HP10408, which
 includes a coding region (also claimed) for a novel human
 transmembrane protein (see W88498). The clone was isolated from a
 stomach cancer CDNA library using a signal sequence detection
 method, and by protein synthesis by in vitro translation. The
 encoded protein has a putative signal sequence and a putative
 internal transmembrane domain. The invention provides nucleotide
 sequences (see W84359-76) coding for 18 transmembrane proteins

(see W88491-508), vectors containing such polynucleotides, and CC eukaryotic cells containing the vectors. The proteins can be CC used as antigens or as compositions in the preparation of CC antibodies against the proteins. The polynucleotides can be used CC as probes for gene diagnosis, and as gene sources for gene therapy CC and large-scale production of proteins encoded by the cDNA. The CC host cells are used for the detection of ligands corresponding to CC the expressed proteins, and the screening of low mol.wt. medicines. SQ Sequence 439 BP; 89 A; 137 C; 109 G; 104 T;

Query Match 98.9%; Score 178; DB 60; Length 439;
Best Local Similarity 99.4%; Pred. No. 4,41e-99;
Matches 179; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Db 56 caggagcagatgagccacatctgggtctgggtccctctctctctctctctct 115
1 CAGGAGCGCAGTGGCCACTGTGGGCTCGGCTCCCTCTCTCTCTCTCTCTCT 60
Qy 116 tggcagctcactgagcagagccgggtatgacttcaactgaagcgaagatctt 175
61 TGGCACTCTCAGTGAAGAGCGCGGCTATGACTTTCACAGTGAAGTGAAGTCTTT 120
Db 176 tctgacaactctctctatgagtcagctctctctgaaatctctgaaagctctct 235
121 TCTGACAACTTCTCTATGATGACGCTTCTGGAATCTTGAAAGCTCTCTCT 180
Qy

RESULT 2
ID 051746 standard; cDNA; 91 BP.
AC 051746:
DT 31-MAY-1994 (first entry)
DE Oligonucleotide probe MK14-A
KW Oligonucleotide; DNA probe; mycobacteria; disease diagnosis;
KM ss.
OS Synthetic.
PN EP-571911-A.
PD 01-DEC-1993.
PF 24-MAY-1993; 108325.
PR 26-MAY-1992; US-889651.
PA (BECT) BECTON DICKINSON CO.
PI Shank DD, Spears PA;
DR WPI: 93-378844/48.
PT New oligo:nucleotide probes specific for Mycobacteria - used for
PT detection and amplification of Mycobacteria nucleic acid in
PT samples
PS Claim 3: Page 14; 23pp; English.
CC Oligonucleotide probe MK14-A consists of nucleotides 5-95 of MK14
CC (051735). It hybridized to all spp. of mycobacteria tested, but
CC cross reacted to a few non-mycobacterial spp. The probe may
CC be useful as an initial screen for mycobacterial infection.
CC See also 051735-45 and 051747-59.
SQ Sequence 91 BP; 5 A; 17 C; 15 G; 4 T;

Query Match 20.6%; Score 37; DB 9; Length 91;
Best Local Similarity 1.9%; Pred. No. 1.15e-08;
Matches 1; Conservative 46; Mismatches 4; Indels 1; Gaps 1;

Db 11 svsvyvvhvshhsvhvshvsvvvhvshvshvshvshvshvsv 61
133 GGAAGCTGTGAGAAAGACTCTTCACTTCACTTCACTTCACTTCACTTCACT 82
Cp

RESULT 3
ID N81164 standard; DNA; 204 BP.
AC N81164:
DT 08-NOV-1990 (first entry)
DE Base substituted E.coli beta-galactosidase alpha-fragment.
KW E.coli beta galactosidase alpha-fragment; base substitutions; ss.
OS Escherichia coli.
FH Key Location/Qualifiers
FT 19..69
FT misc_feature
FT /tag= a
FT /function= multiple cloning site

FT primer_bind 187..204
PN EP-285123-A.
PD 05-MAY-1988.
PF 30-MAR-1988; 105163.
PR 03-APR-1987; US-034819.
PA (SUSO) SUDMEN SOKERI OY.
PI Lehtovara P, Knowles J, Koivula A, Bamford J, Reinkainen T;
DR WPI: 88-27927/40.
PT Introducing random point mutations into nucleic acids -
PT by prep of single stranded template, annealing a primer, elongation,
PT misincorporation, completion of molecules and screening.
PS Disclosure; P; English.
CC Random point mutations were introduced into the alpha fragment of
CC E.coli beta-galactosidase. The wild type sequence was obtained as a
CC single stranded template and an oligonucleotide was hybridized to
CC it to generate a popn of DNA molecules which terminate at all
CC possible nucleotide positions within a specified region. The
CC variable 3' ends generated in this way are used as primers for
CC reverse transcriptase. Nucleotides are misincorporated by the
CC transcriptase and the molecules are completed to forms that can be
CC amplified and then expressed in a suitable host-vector system.
CC The sequence covers all 176 diff base substitutions, most of which
CC occurred singularly in any given mutant.
SQ See also P80575.
Sequence 204 BP; 21 A; 47 C; 17 G; 11 T; 108 Others;

Query Match 20.6%; Score 37; DB 1; Length 204;
Best Local Similarity 7.9%; Pred. No. 1.15e-08;
Matches 8; Conservative 54; Mismatches 39; Indels 0; Gaps 0;

Db 86 ymrthhymrmdnyridynrdaawycyrrsvkydcynachdhdyvbbvynv 145
141 TCATAGAGAGAACTGTGAGAAAGACTCTTCAGTTCAGTTCAGTTCAGTTCAGT 82
Cp 146 hmhmcccbmhvshvshvshvshvshvshvshvshvshvshvshvshvshv 186
81 CTTGTCATGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTG 41
Cp

RESULT 4
ID 051746 standard; cDNA; 91 BP.
AC 051746:
DT 31-MAY-1994 (first entry)
DE Oligonucleotide probe MK14-A
KW Oligonucleotide; DNA probe; mycobacteria; disease diagnosis;
KM ss.
OS Synthetic.
PN EP-571911-A.
PD 01-DEC-1993.
PF 24-MAY-1993; 108325.
PR 26-MAY-1992; US-889651.
PA (BECT) BECTON DICKINSON CO.
PI Shank DD, Spears PA;
DR WPI: 93-378844/48.
PT New oligo:nucleotide probes specific for Mycobacteria - used for
PT detection and amplification of Mycobacteria nucleic acid in
PT samples
PS Claim 3: Page 14; 23pp; English.
CC Oligonucleotide probe MK14-A consists of nucleotides 5-95 of MK14
CC (051735). It hybridized to all spp. of mycobacteria tested, but
CC cross reacted to a few non-mycobacterial spp. The probe may
CC be useful as an initial screen for mycobacterial infection.
CC See also 051735-45 and 051747-59.
SQ Sequence 91 BP; 5 A; 17 C; 15 G; 4 T;

Query Match 18.9%; Score 34; DB 9; Length 91;
Best Local Similarity 10.7%; Pred. No. 5.55e-07;
Matches 6; Conservative 39; Mismatches 11; Indels 0; Gaps 0;

Db 12 svsvyvvhvshhsvhvshvshvsvvvhvshvshvshvshvshvsv 67
52 GACCTCTCTTGGAGCTCAGTCAAGAGCGCGGCTATGACTTTCACATGAAAGC 107
Qy

```
RESULT 5
ID N81164 standard; DNA: 204 BP.
AC N81164.
DE 08-NOV-1990 (first entry)
DE Base substituted E.coli beta-galactosidase alpha-fragment.
KM E.coli beta galactosidase alpha-fragment; base substitutions: ss.
OS Escherichia coli.
FH Key
FT misc_feature Location/Qualifiers
FT 19..69
FT /*tag= a
FT /function= multiple cloning site
FT primer_bind 187..204
FT /*tag= b
PN EP-285123-A.
PD 05-MAY-1988.
PF 30-MAR-1988: 105163.
PR 03-APR-1987: US-034819.
PA (SUSO) SUDOMEN SOKERTI OY.
PI Lehtovirta P, Knowles J, Kotivula A, Bamford J, Reinkainen T;
DR WPI: 88-27927/40.
PT Introducing random point mutations into nucleic acids -
PT by prepn of single stranded template, annealing a primer, elongation,
PT misincorporation, completion of molecules and screening.
PS Disclosure: P: English.
CC Random point mutations were introduced into the alpha fragment of
CC E.coli beta-galactosidase. The wild type sequence was obtained as a
CC single stranded template and an oligonucleotide was hybridised to
CC it to generate a popn of DNA molecules which terminate at all
CC possible nucleotide positions within a specified region. The
CC variable 3' ends generated in this way are used as primers for
CC reverse transcriptase. Nucleotides are misincorporated by the
CC transcriptase and the molecules are completed to forms that can be
CC amplified and then expressed in a suitable host-vector system.
CC The sequence covers all 176 diff base substitutions, most of which
CC occurred singularly in any given mutant.
CC See also P80575.
SQ Sequence 204 BP: 21 A; 47 C; 17 G; 11 T; 108 Others;

Query Match 18.3%; Score 33; DB 1; Length 204;
Best Local Similarity 5.4%; Pred. No. 1,99e-06;
Matches 5; Conservative 51; Mismatches 37; Indels 0; Gaps 0;

Db 94 yrimthvnyrdyrrdaaawcyrrsvkydcynachdhvyybbvnyvnhmncnc 153
OY 1 CAGAGCGCAGTGCCTATGCGAGTGGGCTGCGCCCTGTCTCTTGACCTCT 60
Db 154 ccbnhvchvbnhbnhbmwayrhdardvnc 186
OY 61 TGGCAGCTCACATGACAGGCGCGGTATGAC 93

RESULT 6
ID 070467 standard; DNA: 114 BP.
AC 070467.
DE 03-APR-1995 (first entry)
DE Generic DNA sequence to generate a random TSAR peptide library.
KM TSAR: totally synthetic affinity reagent; synthetic; binding domain;
KM effector domain; concatenated heterofunctional protein; linker;
KM direct; rapid; detection; screening; treatment; generic; ss.
OS Synthetic.
FH Key
FT misc_feature Location/Qualifiers
FT 55..60
FT /*tag= a
FT /note= "this sequence represents 'Z'; Z can be a
FT sequence of 6, 9 or 12 nucleotides (see
FT comments)"
PN W09418318-A.
PD 18-AUG-1994.
PF 01-FEB-1994: U00977.
PR 01-FEB-1993: US-013416.
PR 30-DEC-1993: US-176500.
PR 01-FEB-1993: US-176500.
```

```
PR 31-JAN-1994: US-189331.
PA (UYNC-) UNIV NORTH CAROLINA.
PI Fowlkes DM, Kay BK;
DR WPI: 94-279739/34.
DR P-PSDB: R65153.
PT Identifying proteins or peptide(s) which bind a ligand - by
PT screening a recombinant vector library expressing fusion proteins
PT comprising a binding domain and an effector domain
PS Disclosure: Page 35; 255pp; English.
CC 070467 is a generic DNA sequence used to generate random TSAR (Totally
CC Synthetic Affinity Reagents) peptides. This generic formula can also be
CC represented as follows: X(NNB)16(TGC)(NNB)16(TGC)(NNB)1X. X
CC and Y are flanking restriction sites (X is not the same as Y) that are
CC not specified further. Other generic sequences are shown in 070466-68.
CC Other specific peptides generated by these generic sequences are shown in
CC R65151-54. TSARs are concatenated heterofunctional proteins or peptides,
CC comprising at least two functional regions - a binding domain with
CC affinity for a ligand and a second effector peptide portion that is
CC chemically or biologically active. They may further comprise a linker
CC peptide between the 2 domains. The oligonucleotides are also designed so
CC that the expressed peptide contains 2 or 4 cysteine residues positioned
CC in, or flanking, the unpredicted or variant residues. These residues
CC confer some degree of conformational rigidity to the peptides. The TSARs
CC or compps. comprising a TSAR binding domain can be used in vivo to
CC deliver a chemically or biologically active moiety, eg. metal ion,
CC radioisotope, peptide, toxin or enzyme, to the specific target or on the
CC cell. They can also replace the function of macromolecules, eg.
CC monoclonal or polyclonal antibodies and therefore circumvent the need for
CC complex methods of hybridoma formation or in vivo antibody production.
CC The TSARs are easily characterised and have designed activity allowing
CC direct and rapid detection in a screening process.
SQ Sequence 114 BP: 0 A; 2 C; 2 G; 2 T;

Query Match 17.2%; Score 31; DB 12; Length 114;
Best Local Similarity 4.6%; Pred. No. 2.48e-05;
Matches 5; Conservative 30; Mismatches 74; Indels 0; Gaps 0;

Db 6 dnbnbnbnbnbnbnbnbnbnbnbnbnbnbnbnbnbnbnbnbnbnbnbnbn 65
CP 113 CCTTCAGCTTCAGTTCGCAAGTATACCGGCCCTGTCATGTATGATGCCAAGAGGG 54
Db 66 dnbnbnbnbnbnbnbnbnbnbnbnbnbnbnbnbnbnbnbnbnbnbnbnbn 114
CP 53 TCAAGAGGAGGACAAAGGCGCAGCCAGCCATAGTGGCCACTGGCGT 5

RESULT 7
ID 070470 standard; DNA: 114 BP.
AC 070470.
DE 10-APR-1995 (first entry)
DE Generic DNA sequence to generate a random TSAR peptide library.
KM TSAR: totally synthetic affinity reagent; synthetic; binding domain;
KM effector domain; concatenated heterofunctional protein; linker;
KM direct; rapid; detection; screening; treatment; generic; ss.
OS Synthetic.
FH Key
FT misc_feature Location/Qualifiers
FT 55..60
FT /*tag= a
FT /note= "encoded by Z (see comments)"
PN W09418318-A.
PD 18-AUG-1994.
PF 01-FEB-1994: U00977.
PR 01-FEB-1993: US-013416.
PR 30-DEC-1993: US-176500.
PR 31-JAN-1994: US-189331.
PA (UYNC-) UNIV NORTH CAROLINA.
PI Fowlkes DM, Kay BK;
DR WPI: 94-279739/34.
DR P-PSDB: R58378.
PT Identifying proteins or peptide(s) which bind a ligand - by
PT screening a recombinant vector library expressing fusion proteins
PT comprising a binding domain and an effector domain
PS Disclosure: Page 36; 255pp; English.
```

070470 is a generic DNA sequence used to generate random TSAR (Totally Synthetic Affinity Reagents) peptides. This generic formula can also be represented as follows: X(NNB)4(CAC)(NNB)82(CAC)(NNB)8(CAC)(NNB)8(CAC)2(NNB)Y. X and Y are flanking restriction sites (X is not the same as Y) that are not specified further. The peptides generated by this and other generic sequences (070471-73) have invariant histidine residues incorporated into variant sequences. TSARs are concatenated heterofunctional proteins or peptides, comprising at least two functional regions - a binding domain with affinity for a ligand and a second effector peptide portion that is chemically or biologically active. They may further comprise a linker peptide between the 2 domains. The TSARs or compns. comprising a TSAR binding domain can be used in vivo to deliver a chemically or biologically active moiety, eg. metal ion, radioisotope, peptide, toxin or enzyme, to the specific target or on the cell. They can also replace the function of macromolecules, eg. monoclonal or polyclonal antibodies and therefore circumvent the need for complex methods of hybridoma formation or in vivo antibody production. The TSARs are easily characterised and have designed activity allowing direct and rapid detection in a screening process.

Sequence 114 BP: 5 A: 10 C: 0 G: 0 T;

Query Match 16.7%; Score 30; DB 12; Length 114;

Best Local Similarity 6.7%; Pred. No. 8.61e-05;

Matches 7; Conservative 28; Mismatches 69; Indels 0; Gaps 0;

Db 3 bnbhnbhnbcbacnbhnbhnbhnbhnbhnbhnbhnbhnbhnbhnnnnnn 62

Cp 107 GCTTCAGTTCACAAAGTACCCGCGCTTCTCATGTGAGCTGCCAAGAGGTCAAGA 48

Db 63 bnbhnbhnbhnbhnbhnbhnbhnbhnbhnbhnbhnbhnbhnbhnbhnbhnc 106

Cp 47 GGAGGACAAAGGGGACGCCACCAATGATGGCCATCGGCGCTC 4

RESULT 8
ID 070470 standard; DNA: 114 BP.

AC 070470;

DT 10-APR-1995 (first entry)

DE Generic DNA sequence to generate a random TSAR peptide library.

KW TSAR: totally synthetic affinity reagent; synthetic; binding domain;

KW effector domain; concatenated heterofunctional protein; linker;

KW direct; rapid; detection; screening; treatment; generic; ss.

OS Synthetic.

FN Key Location/Qualifiers

FT misc_feature 55..60

FT /tag= a /note= "encoded by Z (see comments)"

PN W09418318-A.

PD 18-AUG-1994.

PF 01-FEB-1994; 000977.

PR 01-FEB-1993; US-013416.

PR 30-DEC-1993; US-176500.

PR 31-JAN-1994; US-189331.

PA (UYN-C-) UNIV NORTH CAROLINA.

PI Fowlkes DM, Kay BK;

DR WPI: 94-279739/34.

P-PSDB: R58378.

PT Identifying proteins or peptide(s) which bind a ligand - by

PT screening a recombinant vector library expressing fusion proteins

PT comprising a binding domain and an effector domain

PS Disclosure; Page 36; 255pp; English.

CC 070470 is a generic DNA sequence used to generate random TSAR (Totally

CC Synthetic Affinity Reagents) peptides. This generic formula can also be

CC represented as follows: X(NNB)4(CAC)(NNB)82(CAC)(NNB)8(CAC)(NNB)8

CC -(CAC)2(NNB)Y. X and Y are flanking restriction sites (X is not the same

CC as Y) that are not specified further. The peptides generated by this and

CC other generic sequences (070471-73) have invariant histidine residues

CC incorporated into variant sequences. TSARs are concatenated

CC heterofunctional proteins or peptides, comprising at least two functional

CC regions - a binding domain with affinity for a ligand and a second

CC effector peptide portion that is chemically or biologically active. They

CC may further comprise a linker peptide between the 2 domains. The TSARs

CC or compns. comprising a TSAR binding domain can be used in vivo to

CC deliver a chemically or biologically active moiety, eg. metal ion,

CC radioisotope, peptide, toxin or enzyme, to the specific target or on the

CC cell. They can also replace the function of macromolecules, eg.

CC monoclonal or polyclonal antibodies and therefore circumvent the need

CC for complex methods of hybridoma formation or in vivo antibody

CC production. The TSARs are easily characterised and have designed

CC activity allowing direct and rapid detection in a screening process.

Sequence 114 BP: 5 A: 10 C: 0 G: 0 T;

Db 13 cacnbhnbhnbcbacnbhnbhnbhnbhnbhnbhnbhnbhnbhnbhnnnnnnb 72

Oy 1 CAGAGGCCATGCGCAGTATGGGTGCGGCTGCGCTTGTCTCTGTACCTCT 60

Db 73 nbhnbcbacnbhnbhnbhnbhnbhnbhnbhnbhnbhnbhnbhnbhnbhnbhnbhnbh 105

Oy 61 TGCGAGCTTCACATGGAACAGGGCGGATATGAC 93

Query Match 16.1%; Score 29; DB 12; Length 114;

Best Local Similarity 7.5%; Pred. No. 2.96e-04;

Matches 7; Conservative 25; Mismatches 61; Indels 0; Gaps 0;

Db 05-APR-1995 (first entry)

DE Generic DNA sequence to generate a random TSAR peptide library.

KW TSAR: totally synthetic affinity reagent; synthetic; binding domain;

KW effector domain; concatenated heterofunctional protein; linker;

KW direct; rapid; detection; screening; treatment; generic; ss.

OS Synthetic.

FN Key Location/Qualifiers

FT misc_feature 55..60

FT /tag= a /note= "this sequence represents 'Z'; Z can be a

FT sequence of 6, 9 or 12 nucleotides (see

FT comments)"

PN W09418318-A.

PD 18-AUG-1994.

PF 01-FEB-1994; 000977.

PR 01-FEB-1993; US-013416.

PR 30-DEC-1993; US-176500.

PR 31-JAN-1994; US-189331.

PA (UYN-C-) UNIV NORTH CAROLINA.

PI Fowlkes DM, Kay BK;

DR WPI: 94-279739/34.

P-PSDB: R65153.

PT Identifying proteins or peptide(s) which bind a ligand - by

PT screening a recombinant vector library expressing fusion proteins

PT comprising a binding domain and an effector domain

PS Disclosure; Page 35; 255pp; English.

CC 070467 is a generic DNA sequence used to generate random TSAR (Totally

CC Synthetic Affinity Reagents) peptides. This generic formula can also be

CC represented as follows: X(NNB)16(TGC)(NNB)1X(NNB)16(TGC)(NNB)1Y. X

CC and Y are flanking restriction sites (X is not the same as Y) that are

CC not specified further. Other generic sequences are shown in 070466-68.

CC Other specific peptides generated by these generic sequences are shown in

CC R65151-54. TSARs are concatenated heterofunctional proteins or peptides,

CC comprising at least two functional regions - a binding domain with

CC affinity for a ligand and a second effector peptide portion that is

CC chemically or biologically active. They may further comprise a linker

CC peptide between the 2 domains. The oligonucleotides are also designed so

CC that the expressed peptide contains 2 or 4 cysteine residues positioned

CC in, or flanking, the unpredicted or variant residues. These residues

CC confer some degree of conformational rigidity to the peptides. The TSARs

CC or compns. comprising a TSAR binding domain can be used in vivo to

CC deliver a chemically or biologically active moiety, eg. metal ion,

CC radioisotope, peptide, toxin or enzyme, to the specific target or on the

CC cell. They can also replace the function of macromolecules, eg.

CC monoclonal or polyclonal antibodies and therefore circumvent the need for

CC complex methods of hybridoma formation or in vivo antibody production.

CC The TSARs are easily characterised and have designed activity allowing

CC direct and rapid detection in a screening process.


```
RESULT 12
ID Q70468 standard; DNA: 114 BP.
AC Q70468;
DE 05-APR-1995 (first entry)
DE Generic DNA sequence to generate a random TSAR peptide library.
KW TSAR: totally synthetic affinity reagent; synthetic; binding domain;
KW effector domain; concatenated heterofunctional protein; linker;
KW direct; rapid; detection; screening; treatment; generic; ss.
OS Synthetic.
FH Key
FT misc_feature
FT 55..60 Location/Qualifiers
FT /*tag= a
FT /note= "this sequence represents '2'; 2 can be a
FT sequence of 6, 9 or 12 nucleotides (see
FT comments)"
FN W09418318-A.
PD 18-AUG-1994.
PF 01-FEB-1994; U00977.
PR 01-FEB-1993; US-013416.
PR 30-DEC-1993; US-176500.
PR 31-JAN-1994; US-189331.
PA (UYNC-) UNIV NORTH CAROLINA.
PI Fowlkes DM, Kay BK.
PI WPI: 94-279739/34.
DR P-PSDB; R65154.
DR Identifying proteins or peptide(s) which bind a ligand - by
PT screening a recombinant vector library expressing fusion proteins
PT comprising a binding domain and an effector domain
PS Disclosure: Page 35; 255pp; English.
CC Q70468 is a generic DNA sequence used to generate random TSAR (Totally
CC Synthetic Affinity Reagents) peptides. This generic formula can also be
CC represented as follows: X(NNB)11(TGC)(NNB)62(NNB)7(TGC)(NNB)10Y. X
CC and Y are flanking restriction sites (X is not the same as Y) that are
CC not specified further. Other generic sequences are shown in Q70466-68.
CC Other specific peptides generated by these generic sequences are shown in
CC R65151-54. TSARs are concatenated heterofunctional proteins or peptides,
CC comprising at least two functional regions - a binding domain with
CC affinity for a ligand and a second effector peptide portion that is
CC chemically or biologically active. They may further comprise a linker
CC peptide between the 2 domains. The oligonucleotides are also designed so
CC that the expressed peptide contains 2 or 4 cysteine residues positioned
CC in, or flanking, the unpredicted or variant residues. These residues
CC confer some degree of conformational rigidity to the peptides. The TSARs
CC or compsns. comprising a TSAR binding domain can be used in vivo to
CC deliver a chemically or biologically active moiety, eg. metal ion,
CC radioisotope, peptide, toxin or enzyme, to the specific target or on the
CC cell. They can also replace the function of macromolecules, eg.
CC monoclonal or polyclonal antibodies and therefore circumvent the need
CC for complex methods of hybridoma formation or in vivo antibody
CC production. The TSARs are easily characterised and have designed activity
CC allowing direct and rapid detection in a screening process.
CC Sequence 114 BP: 0 A; 2 C; 2 G; 2 T;
SQ
Query Match 15.6%; Score 28; DB 12; Length 114;
Best Local Similarity 2.8%; Pred. No. 1,00e-03;
Matches 3; Conservative 30; Mismatches 73; Indels 0; Gaps 0;
```

```
RESULT 14
ID Q70468 standard; DNA: 114 BP.
AC Q70468;
DE 05-APR-1995 (first entry)
DE Generic DNA sequence to generate a random TSAR peptide library.
KW TSAR: totally synthetic affinity reagent; synthetic; binding domain;
KW effector domain; concatenated heterofunctional protein; linker;
KW direct; rapid; detection; screening; treatment; generic; ss.
OS Synthetic.
FH Key
FT misc_feature
FT 55..60 Location/Qualifiers
FT /*tag= a
FT /note= "this sequence represents '2'; 2 can be a
FT sequence of 6, 9 or 12 nucleotides (see
FT comments)"
FN W09418318-A.
PD 18-AUG-1994.
PF 01-FEB-1994; U00977.
PR 01-FEB-1993; US-013416.
PR 30-DEC-1993; US-176500.
PR 31-JAN-1994; US-189331.
PA (UYNC-) UNIV NORTH CAROLINA.
PI Fowlkes DM, Kay BK.
PI WPI: 94-279739/34.
DR P-PSDB; R65154.
DR Identifying proteins or peptide(s) which bind a ligand - by
PT screening a recombinant vector library expressing fusion proteins
PT comprising a binding domain and an effector domain
PS Disclosure: Page 35; 255pp; English.
CC Q70468 is a generic DNA sequence used to generate random TSAR (Totally
CC Synthetic Affinity Reagents) peptides. This generic formula can also be
CC represented as follows: X(NNB)11(TGC)(NNB)62(NNB)7(TGC)(NNB)10Y. X
CC and Y are flanking restriction sites (X is not the same as Y) that are
CC not specified further. Other generic sequences are shown in Q70466-68.
KW Chronic obstructive pulmonary disease; bronchitis; ss.
OS Synthetic.
PN W09640162-A1.
PD 19-DEC-1996.
PF 06-JUN-1996; U09306.
PR 07-JUN-1995; US-474497.
PA (UYEC-) UNIV EAST CAROLINA.
PI Metzger WJ, Nye JW.
PI WPI:97-051871/05
DR Treatment of airway diseases such as asthma - by topically applying
PT adenosine-free antisense oligo:nucleotide to airway epithelium of
PT subject
PT Claim 5; Page 38; 71pp; English.
PS A method for treating airway disease in a subject has been produced,
CC which involves the topical administration of an essentially adenosine
CC free antisense oligonucleotide (ON) to the airway epithelium of the
CC subject. The present sequence is an antisense oligonucleotide specific
CC for the human endothelin-1, targeted at the initiation codon. The
CC method can be used to treat airway diseases such as cystic fibrosis,
CC asthma, chronic obstructive pulmonary disease, bronchitis and other
CC airway diseases characterised by an inflammatory response. By
CC eliminating adenosine from the antisense ON, its liberation upon
CC antisense degradation is prevented, thereby preventing adenosine-
CC induced bronchoconstriction in patients with hyper-reactive airways.
CC Sequence 178 BP: 0 A; 52 C; 46 G; 32 T;
SQ
Query Match 15.6%; Score 28; DB 32; Length 178;
Best Local Similarity 25.0%; Pred. No. 1,00e-03;
Matches 18; Conservative 32; Mismatches 22; Indels 0; Gaps 0;
```

M O S E L E Y

(TM)

Release 3.1a John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MPerch_mn n.a. - n.a. database search, using Smith-Waterman algorithm

Run on: Sun Oct 24 17:33:58 1999; MasPar time 16.98 Seconds

Tabular output not generated. 916.867 Million cell updates/sec

Title: >US-09-092-296-3
Description: (1-180) from US09092296.seq
Perfect Score: 180
N.A. Sequence: 1 CAGAGGCGCAGTGGCCACTA.....CTTGAAGACTGCTGCTCTCT 180
Comp: GTCTCTGCGTCACCGCTGCT.....GAACCTTTGAGAGCGAGGA

Scoring table: TABLE default

Gap 6

Mmatch STD: Dbase 0; Query 0

Searched: 165359 segs, 43243793 bases x 2

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database:

n-issued
1:5A_COMB 2:5B_COMB 3:5C_COMB 4:PCT9_COMB 5:backfiles1

Statistics: Mean 7.135; Variance 3.967; scale 1.799

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result	Query	Score	Match	Length	ID	Description	Pred. No.
1	29	16.1	965	3	US-08-388-	Sequence 22, Applicati	6.29e-06
2	28	15.6	7218	2	US-08-232-	Sequence 14, Applicati	2.53e-05
3	27	15.0	215	1	US-08-238-	Sequence 5, Applicatio	1.01e-04
4	27	15.0	215	1	US-08-238-	Sequence 5, Applicatio	1.01e-04
5	26	14.4	965	3	US-08-388-	Sequence 22, Applicati	3.93e-04
6	22	12.2	82	4	PCT-US95-1	Sequence 97, Applicati	7.70e-02
7	22	12.2	3088	3	US-08-418-	Sequence 97, Applicati	7.70e-02
8	21	11.7	65	1	US-08-471-	Sequence 145, Applicat	2.73e-01
9	21	11.7	65	1	US-08-471-	Sequence 145, Applicat	2.73e-01
10	21	11.7	68	1	US-08-471-	Sequence 145, Applicat	2.73e-01
11	21	11.7	69	1	US-08-471-	Sequence 145, Applicat	2.73e-01
12	21	11.7	74	4	PCT-US95-1	Sequence 99, Applicati	2.73e-01
13	21	11.7	74	4	PCT-US95-1	Sequence 99, Applicati	2.73e-01
14	21	11.7	74	4	PCT-US95-1	Sequence 99, Applicati	2.73e-01
15	21	11.7	74	4	PCT-US95-1	Sequence 99, Applicati	2.73e-01
16	21	11.7	81	4	PCT-US95-1	Sequence 92, Applicati	2.73e-01
17	21	11.7	81	4	PCT-US95-1	Sequence 92, Applicati	2.73e-01
18	21	11.7	81	4	PCT-US95-1	Sequence 92, Applicati	2.73e-01
19	21	11.7	82	4	PCT-US95-1	Sequence 97, Applicati	2.73e-01
20	21	11.7	906	3	US-09-031-	Sequence 41, Applicati	2.73e-01

ALIGNMENTS

RESULT 1
ID US-08-388-672A-22 STANDARD; DNA; UNC; 965 BP.
AC xxxxxx
DT
DE Sequence 22, Application US/08388672A
CC Sequence 22, Application US/08388672A
CC Patent No. 5795961
CC GENERAL INFORMATION:
CC APPLICANT: Wallace, T. Paul
CC APPLICANT: Harris, William J.
CC APPLICANT: Carr, Frank J.
CC APPLICANT: Old, Lloyd J.
CC APPLICANT: Wely, Sydney
CC APPLICANT: Kitamura, Kunio
CC TITLE OF INVENTION: Recombinant Human Anti-Lewis B
CC NUMBER OF SEQUENCES: 25
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Felfe and Lynch
CC STREET: 805 Third Avenue
CC CITY: New York
CC STATE: New York
CC COUNTRY: U.S.A.
CC ZIP: 10022
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC COMPUTER: IBM PC compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: Patentin Release #1.0, Version #1.30.
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/388,672A
CC FILING DATE: 14-FEB-1995
CC CLASSIFICATION:
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Hanson, NO. 5795961man D.
CC REGISTRATION NUMBER: 30,946
CC REFERENCE/DOCKET NUMBER: LUD 5409
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: 212-688-9200
CC TELEFAX: 212-838-3864
CC INFORMATION FOR SEQ ID NO: 22:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 965 base pairs
CC TYPE: nucleic acid


```
CC      TITLE OF INVENTION: Peptide Libraries
CC      NUMBER OF SEQUENCES: 103
CC      CORRESPONDENCE ADDRESS:
CC      ADDRESSEE: Pennie & Edmonds
CC      STREET: 1155 Avenue of the Americas
CC      CITY: New York
CC      STATE: New York
CC      COUNTRY: USA
CC      ZIP: 10036
CC      COMPUTER READABLE FORM:
CC      MEDIUM TYPE: Floppy disk
CC      OPERATING SYSTEM: PC-DOS/M5-DOS
CC      SOFTWARE: Patentin Release #1.0, Version #1.30
CC      CURRENT APPLICATION DATA:
CC      APPLICATION NUMBER: PCT/US95/11934
CC      FILING DATE: 20-SEP-1995
CC      CLASSIFICATION:
CC      ATTORNEY/AGENT INFORMATION:
CC      NAME: Mistrock, S. Leslie
CC      REGISTRATION NUMBER: 18, 872
CC      REFERENCE/DOCKET NUMBER: 1101-196-228
CC      TELECOMMUNICATION INFORMATION:
CC      TELEPHONE: (212) 790-9090
CC      TELEFAX: (212) 869-9741/8864
CC      TELEX: 66141 PENNIE
CC      INFORMATION FOR SEQ ID NO: 99:
CC      SEQUENCE CHARACTERISTICS:
CC          LENGTH: 75 base pairs
CC          TYPE: nucleic acid
CC          STRANDEDNESS: single
CC          TOPOLOGY: linear
CC      MOLECULE TYPE: DNA (genomic)
SQ      SEQUENCE 75 BP; 1 A; 1 G; 7 G; 5 T; 61 OTHER.


Query Match           12.2% Score 22; DB 4; Length 75;
Best Local Similarity 8.7%; Pred No. 7,70e+02;
Matches   6; Conservative    19; Mismatches 44; Indels    0; Gaps    0

Db     5 GNNBNNBNNBNNBNNBNNBNNBNNBNNBNNBNNBNNBNNBNNBNNBNNBN 64
QY      | : : : : : : : : : : : : : : : : : : : : : : : :
       23 GGGTCTGGGCGTCGCCCTTGCTCCTTGCACCCCTCTGGCACGCAATGAGMACGGG 82
DB     65 NBSGTTGTG 73
       ||| ||
QY      83 CCGCGGTATG 91

RESULT        7
PCT-US95-11934-97 STANDARD; DNA; UNC; 82 BP.
DT         xxxxxx
DE      Sequence 97, Application PC/TUS9511934
CC      Sequence 97, Application PC/TUS9511934
CC      GENERAL INFORMATION:
CC      APPLICANT: CytoGen Corporation
CC      TITLE OF INVENTION: Antigen Binding Peptides (Ablides) From
CC      TITLE OF INVENTION: Peptide Libraries
CC      NUMBER OF SEQUENCES: 103
CC      CORRESPONDENCE ADDRESS:
CC      ADDRESSEE: Pennie & Edmonds
CC      STREET: 1155 Avenue of the Americas
CC      CITY: New York
CC      STATE: New York
CC      COUNTRY: USA
CC      ZIP: 10036
CC      COMPUTER READABLE FORM:
CC      MEDIUM TYPE: Floppy disk
CC      OPERATING SYSTEM: PC-DOS/M5-DOS
CC      SOFTWARE: Patentin Release #1.0, Version #1.30
CC      CURRENT APPLICATION DATA:
CC      APPLICATION NUMBER: PCT/US95/11934
```

[illegible]

[illegible]



(TM)

Release 3.1a John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MPerch_un n.a. - n.a. database search, using Smith-Waterman algorithm

Run on: Sun Oct 24 17:26:03 1999; Maspar time 365.62 Seconds

Tabular output not generated. 1153.579 Million cell updates/sec

Title: >US-09-092-296-3

Description: (1-180) from US0902296.seq

Perfect Score: 180

N.A. Sequence: 1 CAGGAGCGCAGTCGCGACCA.....CTTGAAAGCTCTCTCCCTCT 180

Comp: GTCCTCCGCTCACCGCTGAT.....GAACTTTTCGAGAGGAGGA

Scoring table:

TABLE default
Gap 6

Match STD : Dbase 0; Query 0

Searched: 2883791 seqs, 1171560779 bases x 2

Post-processing: Minimum Match 08
Listing first 45 summaries

Database:

emb1-est58
1:em_est10 2:em_est11 3:em_est17 4:em_est18 5:em_est2
6:em_est9 7:em_gss1
genbank-est111

Database:

8:gb_est1 9:gb_est10 10:gb_est11 11:gb_est12 12:gb_est13
13:gb_est14 14:gb_est15 15:gb_est16 16:gb_est17
17:gb_est18 18:gb_est19 19:gb_est20 20:gb_est21
21:gb_est22 22:gb_est23 23:gb_est24 24:gb_est25
25:gb_est26 26:gb_est27 27:gb_est28 28:gb_est29
29:gb_est30 30:gb_est31 31:gb_est32 32:gb_est33
33:gb_est34 34:gb_est35 35:gb_est36 36:gb_est37 37:gb_est38
38:gb_est39 39:gb_gss3 40:gb_gss4 41:gb_gss5 42:gb_gss6

Statistics:

Mean 9.460; Variance 1.952; scale 4.848

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result	No.	Score	Query	Match	Length	DB	ID	Description	Pred. No.
1	51	28.3	252	17	AA754459	97SN1787	Rice	Immature	9.68e-50
2	43	23.9	328	23	A1136523	UI-R-C2P-nq-e-02-0-UI			3.33e-36
3	39	21.7	252	17	AA754459	97SN1787	Rice	Immature	1.13e-29
4	31	17.2	247	17	AA754458	97SN1784	Rice	Immature	2.88e-17
5	30	16.7	247	17	AA754458	97SN1784	Rice	Immature	8.54e-16
6	28	15.6	2275	20	AF034173	AF034173	Human	mRNA (T	6.48e-13
7	27	15.0	2275	20	AF034173	AF034173	Human	mRNA (T	1.64e-11
8	23	12.8	311	11	AA475002	EST26816	Cerebellum	IT	3.57e-06
9	23	12.8	459	13	AA475002	EST26816	Cerebellum	IT	3.57e-06
10	23	12.8	1287	20	AF038250	AF038250	Human	mRNA (T	3.57e-06

11	22	12.2	259	38	B81136	CIT-HSP-2015F16.TFC	CI	6.38e-05	
12	22	12.2	308	8	D40392	RICS23428	Rice shoot	0	6.38e-05
13	22	12.2	339	19	F08745	HSC1DB011	normalized	1	6.38e-05
14	22	12.2	427	33	N80550	zai10h06.r1	Soares feta	1	6.38e-05
15	22	12.2	433	34	W79098	zaf5h10.r1	Soares feta	1	6.38e-05
16	22	12.2	441	14	C28493	C28493	Rice callus	CDN	6.38e-05
17	22	12.2	513	40	A0235722	HS-2015_B2_C08	AT CT	6.38e-05	
18	22	12.2	634	22	A1063013	GH2423	5p-time GH Dros	6.38e-05	
19	22	12.2	1025	37	B12587	P22011-Sp6.1	1GF Arabi	1.04e-03	
20	21	11.7	243	8	D22101	RIC10342A	Rice callus	1.04e-03	
21	21	11.7	288	11	AA335414	EST39832	Epilidynus Ho	1.04e-03	
22	21	11.7	299	26	A1382671	q205f06.r1	NCI_CGAP	CT	1.04e-03
23	21	11.7	299	8	M79528	WEST00065	Mixed stage,	1.04e-03	
24	21	11.7	317	19	F10052	HSC39h122	normalized	1	1.04e-03
25	21	11.7	343	8	T47417	Yb13f12.r1	Stratogene	1.04e-03	
26	21	11.7	364	34	W33870	mc56b03.r1	Soares mus	1.04e-03	
27	21	11.7	412	38	AQ007423	CIT-HSP-2292F15	TR CIT	1.04e-03	
28	21	11.7	416	8	T08769	EST06661	Infant Brain,	1.04e-03	
29	21	11.7	417	30	R36249	Yb11f09.r1	Soares plac	1.04e-03	
30	21	11.7	422	10	AA275959	vc27e03.r1	Barstead MP	1.04e-03	
31	21	11.7	426	8	T15255	crs855	lambda2APST Ric	1.04e-03	
32	21	11.7	437	37	FR0032574	Fugu rubripes	GSS sequ	1.04e-03	
33	21	11.7	451	38	AQ024376	HS-2182	Al.D09	MF CIT	1.04e-03
34	21	11.7	451	38	AQ024376	zfs0a10.r1	NCI_CGAP	KI	1.04e-03
35	21	11.7	475	28	A1522104	t433906.r1	NCI_CGAP	KI	1.04e-03
36	21	11.7	502	15	AA586074	28123	Lambda-FRL2	Arab	1.04e-03
37	21	11.7	516	31	H41536	Yp11c01.r1	Soares adu1	1.04e-03	
38	21	11.7	524	10	AA239967	mw24907.r1	Soares mus	1.04e-03	
39	21	11.7	533	15	AA593745	n183911.r1	NCI_CGAP	BR	1.04e-03
40	21	11.7	557	23	A1102979	EST212268	Normalized	r	1.04e-03
41	21	11.7	567	30	R61539	Yh16f01.r1	Soares infa	1.04e-03	
42	21	11.7	630	39	AQ201160	RpC111-46k18	TJ RptC11	1.04e-03	
43	21	11.7	694	36	AA140679	CR00462	5p-time CK Dros	1.04e-03	
44	21	11.7	762	37	B19344	T2711-Sp6.1	TRMU Arabi	1.04e-03	
45	20	11.1	492	34	W96005	ze09b02.r1	Soares feta	1.35e-02	

ALIGNMENTS

RESULT 1
LOCUS AA754459 252 bp mRNA
DEFINITION 97SN1787 Rice Immature Seed Lambda ZAP11 cDNA Library Oryza sativa
ACCESSION AA754459
VERSION 92801165
KEYWORDS AA754459.1 GI:2801165
SOURCE EST.
ORGANISM Oryza sativa.
Oryza sativa.
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
euphyllophytes; Spermatophyta; Magnoliophyta; Liliopsida; Poales;
Poaceae; Oryza.

REFERENCE 1 (bases 1 to 252)

AUTHORS Nahm,B.H., Kim,J.K., Cheong,J.J., Kim,S.I., Hahn,T.R., Moon,E.P.,
Kim,W.T., Kim,W.Y., Yang,M.S., Park,R.D., Sohn,U.I., Kang,K.Y.,
Lee,M.C. and Eun,M.Y.

TITLE Large-scale Sequencing Analysis of ESTs from Rice Immature Seed
JOURNAL Unpublished (1998)
COMMENT On Jan 14, 1998 this sequence version replaced gi:1797457.

Contact: Eun M.Y.

Department of Cytogenetics
National Inst. of Agri. Sci. and Tech, RDA
Suwon, Kyunggi-do, Korea
Tel: 82 331 290 0301
Fax: 82 331 290 0307

Email: myeunesun20@astel.re.kr
Submitted by: Baek Hie Nahm, Dept of Biological Science, Myongji
University, Yongin, Korea. 449-728 bhinahm@bioserver.myongji.ac.kr
Seq primer: M13 Reverse Primer.

FEATURES
Location/Qualifiers
1..252
/organism="Oryza sativa"

```

/cultivar="Milyang23"
/notes="Vector: pBluescript SK(+); Site_1: EcoRI; Site_2:
XhoI; Directional cDNA library inserted into lambda ZAPIT
vector at 5' end with EcoRI and 3' end with Xho I site."
/db_xref="taxon:4530"
/map="6"
/clone="97SN1787"
/clone.lib="Rice Immature Seed Lambda ZAPIT cDNA library"
/tissue.type="Immature Seed"
/dev_stage="5 days after pollination"
/lab_host="E. coli SOLR"

BASE COUNT      5 a      21 c      12 g      35 t      179 others
ORIGIN

Query Match      28.3%; Score 51; DB 17; Length 252;
Best Local Similarity 12.3%; Pred. No. 9.68e-50;
Matches 20; Conservative 84; Mismatches 56; Indels 2; Gaps 2;

29  BWAVCAASHGNMNSYHNCBTRGHCDCRKNMSTMTGTYNMBNVSQDMHMBVBNKVD 88
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Oy  4  GACCGGAGTGGCCACTATGGGGTGTGGCTGCCCTTCTCTTGCACCCCTCTTG 63
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db  89  VGNHTFCSRMBRYTMAH-YHDTNCBRYNNNDYHMHBMRYBTGCMTCMGBHYNT 147
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Oy  64  CACCTCATGAGACAGCGCGGTATGACTTTCGACACTGACAGCTAGAGAGTCTTTCT 123
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db  148  KCTASGMHTSTNYDKS-STNTWGYBSTDMSHMCYSBV 188
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Oy  124  GACAGTCTCTCTATGAGTCAGCTTCTGGAATCTTGA 165
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :

RESULT 2
LOCUS      A116523      328 bp      mRNA      EST      11-FEB-1999
DEFINITION UI-R-C2P-ng-e-02-0-ui.s1 UI-R-C2P Rattus norvegicus cDNA clone
ACCESSION  A116523
VERSION    93637300
KEYWORDS   A116523.1 GI:3637300
SOURCE     EST.
ORGANISM   Norway rat.
            Rattus norvegicus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
            Eutheria; Rodentia; Sciurognathi; Muridae; Murine; Rattus.
REFERENCE  1 (bases 1 to 328)
AUTHORS   Bonaldo,M.F., Lennon,G. and Soares,M.B.
TITLE     Normalization and subtraction: two approaches to facilitate gene
          discovery
JOURNAL   Genome Res. 6 (9), 791-806 (1996)
MEDLINE   97044477
COMMENT   On Jan 14, 1998 this sequence version replaced gi:1877567.

Contact: Soares, MB
Program for Rat Gene Discovery and Mapping
University of Iowa
451 Einstein Medical Research Building Iowa City, IA 52242, USA
Tel: 319 335 8250
Fax: 319 335 9565
Email: msoares@blue.weeg.uiowa.edu
The sequence tag present in the cDNA between the NotI site and the
oligo-dT track served to identify it as a clone from the normalized
adult lung library. cDNA Library Preparation: M. Fatima Bonaldo,
Ph.D. Clone distribution: clones will be available through Research
Genetics
Seq primer: M13 Forward.
Location/Qualifiers
1..328
/organism="Rattus norvegicus"
/strain="Sprague-Dawley"
/notes="Vector: p77TD-Pac (Pharmacia) with a modified
polylinker; Site_1: Not I; Site_2: Eco RI; The UI-R-C2P
library is a subtracted library derived from the UI-R-C1
library, which is a subtracted library derived from the
UI-R-C0 library. The UI-R-C0 library consisted of a

```

```

mixture of individually tagged normalized libraries
constructed from rat placenta, adult lung, brain, liver,
kidney, heart, spleen, ovary, muscle, 8, 12 and 18-day
embryo. The tag is a string of 3-5 nucleotides present
between the Not I site and the oligo-dT track which allows
identification of the library of origin of a clone within
the mixture. The subtracted library (UI-R-C2P) was
constructed as follows: PCR amplified cDNA inserts from
UI-R-C1 clones from which 3' ESTs had been derived was
used as a driver in a hybridization with the UI-R-C1
library in the form of single-stranded circles. The
remaining single-stranded circles (subtracted library) was
purified by hydroxyapatite column chromatography,
converted to double-stranded circles and electroporated
into DH10B bacteria (Life Technologies) to generate the
UI-R-C2P library. This procedure has been previously
described (Bonaldo, Lennon and Soares, Genome Research 6:
791-806, 1996)."
/db_xref="taxon:10116"
/clone="UI-R-C2P-ng-e-02-0-UI"
/clone.lib="UI-R-C2P"
/dev_stage="adult"
/lab_host="DH10B (Life Technologies)"

BASE COUNT      62 a      77 c      98 g      91 t
ORIGIN

Query Match      23.9%; Score 43; DB 23; Length 328;
Best Local Similarity 73.6%; Pred. No. 3.33e-36;
Matches 67; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Db  210  AGAGGAGATCTTTGGAGCATGTCGAGAAACCGAGCTTGGAGCTTGGCGCTGA 269
   ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Cp  180  AGAGGAGACACTTTCACAGCATTCGAGAGAGCTGATGAGGAGACTTTCAGCA 121
   ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db  270  GATGCTCGTCAGCTTCTTACTTCGCAAGTCA 300
   ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Cp  120  AAGACTCTTCACTTCAGTTCAGTCAAGTCA 90
   ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 3
LOCUS      AA754459      252 bp      mRNA      EST      20-JAN-1998
DEFINITION 97SN1787 Rice Immature Seed Lambda ZAPIT cDNA library Oryza sativa
ACCESSION  AA754459
VERSION    92801165
KEYWORDS   AA754459.1 GI:2801165
SOURCE     EST.
ORGANISM   Oryza sativa.
            Oryza sativa
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            euphyllophytes; Spermatophyta; Magnoliophyta; Liliopsida; Poales;
            Poaceae; Oryza.
REFERENCE  1 (bases 1 to 252)
AUTHORS   Nahm,B.H., Kim,J.K., Cheong,J.U., Kim,S.I., Nahm,T.R., Moon,E.P.,
          Kim,W.T., Kim,W.Y., Yang,M.S., Park,R.D., Sohn,U.I., Kang,K.Y.,
          Lee,M.C. and Eun,M.Y.
TITLE     Large-scale Sequencing Analysis of ESTs from Rice Immature Seed
          Unpublished (1998)
JOURNAL   Unpublished
COMMENT   On Jan 14, 1998 this sequence version replaced gi:1797457.

Contact: Eun M.Y.
Department of Cytogenetics
National Inst. of Agri. Sci. and Tech, RDA
Suwon, Kyunggi-do, Korea
Tel: 82 331 290 0301
Fax: 82 331 290 0307
Email: myeun@ns20.asi.re.kr
Submitted by Baek Hie Nahm, Dept of Biological Science, Myongji
University, Yongin, Korea, 449-728 bnaime@jserver.myongji.ac.kr
Seq primer: M13 Reverse Primer.
Location/Qualifiers
1..252
/organism="Oryza sativa"

```

	Query Match	21.7%	Score 39;	DB 17;	Length 252;
	Best Local Similarity	8.88;	Pred. No. 1,13e-29;	Mismatches 43;	Gaps 0;
	Matches	10;	Conservative	61;	
Db	68 VMBBNVSCDMHYBVBNTKVDGNHTKCSFMRBYTRMAHYHDYTCNBRYNNNDYHMMHB 127				
Cp	151 GAAGTGTGACATCATAGGAGCACTGTGCAGAAAGACTCCTCAGCTCAGTGCGAAGT 92				
Db	128 MYBTBGCTATMCMCBHYTKTCTSGNHTSTNDVKSSNTWGTSTSYKSHMG 161				
Cp	91 CATACGCCGCCCTGTTCCATGTGAGCTGCCAAGAGGGTCAAGAGGACAAAG 38				
RESULT	4				
LOCUS	AA754458	247 bp	mRNA	EST	20-JAN-1998
DEFINITION	97SN1784 Rice Immature Seed Lambda ZAPII cDNA Library Oryza sativa				
ACCESSION	AA754458				
NID	92801164				
VERSION	AA754458.1	GI:2801164			
KEYWORDS	EST.				
SOURCE	Oryza sativa.				
ORGANISM	Oryza sativa.				
REFERENCE	Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; euphyllophytes; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Oryza.				
AUTHORS	I (bases 1 to 247) Nahm,B.H., Kim,J.K., Cheong,J.J., Kim,S.I., Hahn,T.R., Moon,E.P., Lee,M.T., Kim,W.Y., Yang,M.S., Park,R.D., Sohn,U.I., Kang,K.Y., Lee,M.C. and Eun,M.Y.				
TITLE	Large-scale Sequencing Analysis of ESTs from Rice Immature Seed Unpublished (1998)				
JOURNAL	On Jan 14, 1998 this sequence version replaced gi:1797455.				
COMMENT	Contact: Eun M.Y. Department of Cyto genetics National Inst. of Agri. Sci. and Tech, RDA Suwon, Kyungido, Korea Tel.: 82 331 290 0301 Fax: 82 331 290 0307 Email: myune@sun20.asri.re.kr Submitted by Baek He Nahm, Dept of Biological Science, Myongji University, Yongin, Korea, 449-728 bhnahe@bioserver.myongji.ac.kr Seq primer: M13 Reverse Primer. location/Qualifiers 1..247 /organism="Oryza sativa" /cultivar="Milyang23" /note="Vector: pBluescript SK(+); Site.1: EcoRI; Site.2: XhoI; Directional cDNA library inserted into lambda ZAPII vector at 5' end with EcoRI and 3' end with Xho I site." /db_xref="taxon:4530" /map=6* /clone="97SN1784" /clone_lib="Rice Immature Seed Lambda ZAPII cDNA Library" /tissue_type="Immature Seed" /dev_stage="5 days after pollination" /lab_host="E. coli SOLR" /db_xref="taxon:4530" /map=6* /clone="97SN1784" /clone_lib="Rice Immature Seed Lambda ZAPII cDNA Library" /tissue_type="Immature Seed" /dev_stage="5 days after pollination" /lab_host="E. coli SOLR" 16 c 21 g 34 t 169 others				
BASE COUNT	5 a	21 c	12 g	35 t	179 others
ORIGIN					

```

Query Match      17.2%; Score 31; DB 17; Length 247;
Best Local Similarity 8.3%; Pred. No. 2,88e-17;
Matches 11; Conservative 71; Mismatches 49; Indels 2; Gaps 2;

Db 100 VVHSGNNRNCNSVYVWBAICDYBHYBDANVDTRCTDRGRCNYTASDNGTSAT 159
      111 : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Cp 174 CAGAGCTTTTCAGCAATCCAGGAGACCTGACATCATGAGGAGCACTTGTCAGAAAAGC 115
      111 : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 160 KRTGYDXTDSDGGGCMKXTYSSSYBRCGVNMVTTSMTDXSTKMSM-DMSRS 218
      111 : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Cp 114 TCTTTCACCTTCAGTTGCAGAAAGT-CATACCGCGCCCTGCTTCATGTGAGCTGCCAAGAG 56
      111 : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 219 RVHYGRNMBNKR 231
      111 : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Cp 55 GGTCAAGAGCAGG 43

RESULT 5 AA754458 247 bp mRNA EST 20-JAN-1998
LOCUS 9/5NI184 Rice Immature Seed Lambda ZAPII cDNA Library Oryza sativa
DEFINITION g/SNI184, mRNA sequence.
ACCESSION AA754458
NID 92801164
VERSION AA754458.1 GI:2801164
KEYWORDS EST.
SOURCE Oryza sativa.
ORGANISM Oryza sativa.
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
euphyllophytes; Spermatophyta; Magnoliophyta; Liliopsida; Poales;
Poaceae; Oryza.
1 (bases 1 to 247)
Name: B.H., Kim, Y.J., Cheong, J.J., Kim, S.I., Hahn, T.R., Moon, E.P.,
Kim, W.T., Kim, M.Y., Yang, M.S., Park, R.D., Sohn, U.I., Kang, K.Y.,
Lee, M.C. and Eun, M.Y.
Large-scale Sequencing Analysis of ESTs from Rice Immature Seed
Unpublished (1998)
On Jan 14, 1998 this sequence version replaced gi:1797455.

TITLE
JOURNAL
COMMENT

Contact: Eun M.Y.
Department of Cytogenetics
National Inst. of Agri. Sci. and Tech, RDA
Suwon, Kyunggido, Korea
Tel: 82 331 290 0301
Fax: 82 331 290 0307
Email: myeunsun20@astel.re.kr
Submitted by Baek Hie Nahm, Dept of Biological science, Myongji
University, Yongin, Korea. 449-728 bhnahm@loserver.myongji.ac.kr
Seq primer: M13 Reverse Primer.
Location/Qualifiers
1. 247
/organism="Oryza sativa"
/cultivar="Milyang23"
/note="vector: pBluescript SK(+); Site_1: EcoRI; Site_2:
XhoI; Directional cDNA library inserted into lambda ZAPII
vector at 5' end with EcoRI and 3' end with Xho I site."
/ad_xref="taxon:4530"
/map="6"
/clone="97SNI184"
/clone_1lb="Rice Immature Seed Lambda ZAPII cDNA Library"
/tissue_type="Immature Seed"
/dev_stage="5 days after pollination"
/lab_host="E. coli SOLR"
/lab_c 21 g 34 t 169 others

BASE COUNT 7 a 16 c 21 g 34 t 169 others
ORIGIN

Query Match      16.7%; Score 30; DB 17; Length 247;
Best Local Similarity 9.8%; Pred. No. 8.54e-16;
Matches 13; Conservative 64; Mismatches 55; Indels 0; Gaps 0;

Db 111 SSVVYVWBAICDYBHYBDANVDTRCTDRGRCNYTASDNGTSAT 170
      111 : : : : : : : : : : : : : : : : : : : : : : : : : : : :

```

TITLE	JOURNAL	COMMENT
Generation of a transcription map in the region immediately centromeric to human MHC across the 6p21.2-6p21.3 chromosomal boundary	Unpublished (1997)	On Jan 19, 1998 this sequence version replaced gi:2045115.
CONTACT: Tripodis, Nikos Division of Medical and Molecular Genetics Guys Hospital 7th floor, Guy's Tower, London SE1 9RT, UK Email: nikos@nki.nl.	Location/Qualifiers 1. .2275 /organism="Homo sapiens" /db_xref="taxon:9606" /map="6p21.3" /clone="ntcon2 contig" /clone_1b="Human mRNA (Tripodis and Ragoussis)"	
BASE COUNT	438 a 619 c 470 g 599 t 149 others	
ORIGIN		
Query Match	15.0%; Score 27; DB 20; Length 2275;	
Best Local Similarity	17.8%; Pred. No. 1.64e-11;	
Matches	19; Conservative 53; Mismatches 33; Indels 2; Gaps 2;	
Db 1534	YKKTSTYVYSSRMWYWTYTYWCTCMTKASACAWRMGMSRSPRSRYGWS 1593	
Qy 39	TTCCTCCTCCTTGACCTCCTCCTGACCTACATGACGACGCGGATGACCTTTC 98	
Db 1594	MSGCGATKTRTRYSWGTWKMTTWKMSKTRMTTYYTWTWT 1640	
Qy 99	AA-CTGAAGCTAAGACGCTTTTTCGA-CAAGTCTCCTATGAGT 143	
RESULT 8	AA323964 311 bp mRNA EST 20-APR-1997	
LOCUS	EST228181 Cerebellum II Homo sapiens cDNA 5' end, mRNA sequence.	
DEFINITION	AA323960	
ACCESSION	G1976290	
NID	AA323964.1 GI:1976290	
VERSION	EST.	
KEYWORDS	human.	
SOURCE	Homo sapiens	
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.	
REFERENCE	1 (bases 1 to 311)	
AUTHORS	Adams,M.D., Kerlavage,A.R., Fleischmann,R.D., Fuldner,R.A., Bult,C.J., Lee,N.H., Kiglass,E.F., Weissstock,K.G., Cooney,J.D., White,O., Sutton,G., Blake,J.A., Brandon,R.C., Man-Whi,C., Clayton,R.A., Cline,T.R., Cotton,M.D., Earle-Hughes,J., Fine,L.D., Fitzgerald,L.M., Fitzhugh,W.M., Fitzhugh,J.L., Geoghegan,N.S., Glodde,A., Gnehm,C.L., Hanna,M.C., Hedblom,E., Hinkle,P.S., Jr., Kelley,J.M., Kelley,J.C., Liu,L.-I., Marmaros,S.M., Merrick,J.M., Moreno-Balaguer,R.F., McDonald,L.A., Nguyen,D.T., Pelligrino,S.M., Phillips,C.A., Ryder,S.E., Scott,J.L., Saudek,D.M., Shirley,R., Small,K.V., Spriggs,T.A., Uterback,T.R., Weidman,J.F., Li,Y., Benharik,D.P., Cao,L., Cepeda,M.A., Coleman,T.A., Collins,E.J., DiMke,D., Feng,D.-F., Ferrie,A., Fischer,C., Hastings,G.A., He,M.W., Hu,Y.S., Greene,J.M., Gruber,J., Hudson,P., Kim,A.K., Korak,D.L., Kunsch,C., Hungjun,J., Li,H., Melsner,P.S., Olsen,H., Raymond,L., Wei,Y.-F., Wang,Y., Xu,C., Yu,G.L., Ruben,S.M., Dillon,P.J., Fannon,M.R., Rosen,C.A., Haseltine,W.A., Fields,C., Fraser,C.M., and Venter,J.C.	
TITLE	Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence	
JOURNAL	Nature 377 (6547 Suppl.), 3-174 (1995)	
MEDLINE	96026780	
COMMENT	On Apr 14, 1993 this sequence version replaced gi:693635.	
	Contact: Kerlavage, AR Bioinformatics The Institute for Genomic Research 9712 Medical Center Drive, Rockville, MD 20850 USA	


Mon Oct 25 11:54:02 1999

US-09-092-296-3.rst

Page 8

36 CCCTGTCTCTCTTGACCTCTCTTGCGAGCTCACATGG 75

Search completed: Sun Oct 24 17:32:17 1999
Job time : 374 secs.



(TM)

Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MSPrch_bp protein - protein database search, using Smith-Waterman algorithm

Run on: Fri Oct 22 18:41:27 1999; MasPar time 5.65 Seconds

Tabular output not generated. 293.555 Million cell updates/sec

Title: >US-09-092-296-15

Description: (1-78) from US09092296.pap

Perfect Score: 558

Sequence: 1 MSGGLPVLVLLTLGSSHGT.....SGTSTVLHARSQHVCNT 78

Scoring table: PAM 150

Searched: 170751 seqs, 21266608 residues

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database:

a-geneseq35
1:part1 2:part2 3:part3 4:part4 5:part5 6:part6 7:part7
8:part8 9:part9 10:part10 11:part11 12:part12 13:part13
14:part14 15:part15 16:part16 17:part17 18:part18
19:part19 20:part20 21:part21 22:part22 23:part23
24:part24 25:part25 26:part26 27:part27 28:part28
29:part29 30:part30 31:part31 32:part32 33:part33
34:part34 35:part35 36:part36 37:part37 38:part38
39:part39

Statistics: Mean 27.329; Variance 130.705; scale 0.209

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description	Pred. No.
1	558	100.0	78 39	W88498	Human stomach carcinoma	2.84e-38
2	86	15.4	46 36	W70327	Secreted protein FB78	3.89e+01
3	85	15.4	47 38	W73408	Human secreted protei	3.89e+01
4	85	15.2	325 19	W02702	G-protein coupled prot	4.56e+01
5	85	15.2	325 16	R48730	G-protein coupled bov	4.56e+01
6	83	14.9	194 9	R47338	Peptide fragment of t	6.23e+01
7	83	14.9	411 31	W57046	Mouse apoptosis induc	6.23e+01
8	82	14.7	110 5	R26954	Human T lymphocyte re	7.28e+01
9	82	14.7	169 23	W21674	Human mitochondrial e	7.28e+01
10	81	14.5	401 35	W59924	Human 7-transmembran	8.50e+01
11	81	14.5	1253 25	W10038	Mad binding protein,	8.50e+01
12	81	14.5	1261 25	W10040	Mad binding protein,	8.50e+01
13	80	14.3	398 3	R15138	Human secretin ID re	9.93e+01
14	80	14.3	713 2	R10052	Cyclomalodextrin glu	9.93e+01
15	80	14.3	713 1	R06110	Sequence of cyclomalt	9.93e+01
16	80	14.3	945 12	R66060	Human NMDAR2 receptor	9.93e+01

17	80	14.3	1214 38	W87509	Human N-methyl-D-aspa	9.93e+01
18	80	14.3	1214 12	R66065	Human NMDAR2 receptor	9.93e+01
19	80	14.3	1219 12	R66063	Human NMDAR2 receptor	9.93e+01
20	80	14.3	1219 38	W87507	Human N-methyl-D-aspa	9.93e+01
21	80	14.3	1231 38	W87506	Human N-methyl-D-aspa	9.93e+01
22	80	14.3	1231 12	R66062	Human NMDAR2 receptor	9.93e+01
23	80	14.3	1236 38	W85574	Human N-methyl-D-aspa	9.93e+01
24	80	14.3	1236 12	R66037	Human N-methyl-D-aspa	9.93e+01
25	80	14.3	1239 38	W87508	Human N-methyl-D-aspa	9.93e+01
26	80	14.3	1239 12	R66064	Human NMDAR2 receptor	9.93e+01
27	80	14.3	1244 38	W87505	Human N-methyl-D-aspa	9.93e+01
28	80	14.3	1244 12	R66061	Human NMDAR2 receptor	9.93e+01
29	79	14.2	620 22	W14993	Human c-Fos induced g	1.10e+02
30	79	14.2	652 34	W49879	Human c-Fos induced g	1.10e+02
31	79	14.2	962 24	W25170	Human insulinoma-asso	1.16e+02
32	79	14.2	986 24	W25171	Human insulinoma-asso	1.16e+02
33	79	14.2	1015 23	W18092	Type I diabetes-assoc	1.16e+02
34	79	14.2	1015 27	W35345	Human protein tyrosin	1.16e+02
35	78	14.0	99 39	W67828	Human secreted protei	1.35e+02
36	78	14.0	120 17	R93614	Kaposi's sarcoma asso	1.35e+02
37	78	14.0	120 18	R97838	Kaposi's sarcoma asso	1.35e+02
38	78	14.0	727 21	W17719	C-Delta-1 polypeptide	1.35e+02
39	78	14.0	740 21	W00876	C-Delta-1 polypeptide	1.35e+02
40	78	14.0	1238 10	R45945	Glutamic acid recepto	1.35e+02
41	77	13.8	528 10	R54206	snR gene product inv	1.57e+02
42	76	13.6	318 38	W81969	Mouse E124 protein #2	1.83e+02
43	76	13.6	481 22	W16829	Recombinant endotoxin	1.83e+02
44	76	13.6	481 13	R68922	Lipopolysaccharide bl	1.83e+02
45	76	13.6	1045 39	W86354	Human DNAX toll-like	1.83e+02

ALIGNMENTS

RESULT 1
ID W88498 standard; Protein; 78 AA.
AC W88498;
DT 30-MAR-1999 (first entry)
DE Human stomach carcinoma Hpi0408-encoded transmembrane protein.
KW Transmembrane protein; HP10408; human; stomach cancer.
OS Homo sapiens.
PN 10-DEC-1998.
PR 03-JUN-1998; J02445.
PF 03-JUN-1997; JP-14948.
PA (PROT-) PROTEGENE INC.
PI (SAGA) SAGAMI CHEM RES CENTRE.
PI Kato S, Sekine S, Yamaguchi T;
DR WPI: 99-045730/04.
DR N-PSDB: V84366.
PT New human proteins containing transmembrane domains and their
FT encoding sequences - useful in the preparation of antibodies and
FT large-scale protein production, gene diagnosis, and gene therapy
PS Claim 1; Page 135; 178pp; English.
CC This is the amino acid sequence of a novel transmembrane
CC encoded by human stomach cancer cDNA clone HP10408 (see V84366).
CC Internal transmembrane domain. The invention provides nucleotide
CC sequences (see V84359-76) coding for 18 transmembrane proteins
CC (see W88491-508), vectors containing such polynucleotides, and
CC used as antigens or as compositions in the preparation of
CC antibodies against the proteins. The polynucleotides can be
CC as probes for gene diagnosis, and as gene sources for gene therapy
CC and large-scale production of proteins encoded by the cDNA. The
CC host cells are used for the detection of ligands corresponding to
CC the expressed proteins, and the screening of low mol.wt. medicines.
SQ Sequence 78 AA;

Query Match 100.0%; Score 558; DB 39; Length 78;
Best local similarity 100.0%; Pred. No. 2.84e-38;
Matches 78; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Db 1 msgglpvlvlltlgsshtgptgmllqklkksfltnssyesflleklclllhpsg 60

```

OY 1 MGSGLPVLVLTLLGSSHGPGMTLQTLKESFLTNSSTESSFLELLKCLLHLHPG 60
DB 61 tsvtltharsghvncvnt 78
OY 61 TSVTLHARSQHVNCVT 78

RESULT 2
ID W0327 standard; Protein: 46 AA.
AC W0327;
DE 21-DEC-1998 (first entry)
DE Secreted protein FB78_1.
KW Secreted protein; D0123_1: human.
OS Homo sapiens.
FH key Location/Qualifiers
FT Peptide 8..20
FT /note= "predicted leader/signal sequence, or
FT Transmembrane domain"
FN W09838209-A2.
PD 03-SEP-1998.
PF 25-FEB-1998; U03697.
PR 24-FEB-1998; US-028724.
PR 26-FEB-1997; US-805819.
PA (GENM ) GENETICS INST INC.
PI Acostino MJ, Jacobs K, Lavallie ER, McCoy JM, Merberg D,
PI Racie LA, Spaulding V, Treacy M;
DR WPI: 98-481139/41.
DR N-PSDB: V33199.
PT New isolated polynucleotide(s) and encoded polypeptide(s) -
PT brain and placenta cDNA libraries.
PS Claim 36: Page 83: 103pp: English.
CC This is the amino acid sequence of novel human secreted protein
CC FB78_1, as deduced from a full-length cDNA clone (see V33199)
CC obtained from a human adult placenta cDNA library. Database
CC searching revealed some similarity between FB78_1 and some known
CC sequences. The invention provides new isolated polynucleotides
CC (see V33199-99), from human foetal kidney, adult colon, adult brain,
CC foetal brain and placenta cDNA libraries, that code for secreted
CC proteins (see W0319-27). The clones can be used for recombinant
CC production of the polypeptides, which may have activities such as
CC e.g. nutritional activity, cytokine and cell proliferation or
CC differentiation activity, immunostimulant or immunosuppressive,
CC hematopoiesis regulating activity, tissue growth activity, activin
CC or inhibin activity, chemotactic or chemokinetic activity,
CC haemostatic and thrombolytic activity, receptor/ligand activity,
CC antiinflammatory activity, cadherin/tumour invasion suppressor
CC activity, tumour inhibition activity, or other activities.
SQ Sequence 46 AA:

Query Match 15.4%; Score 86; DB 36; Length 46;
Best Local Similarity 56.5%; Pred. No. 3.89e+01;
Matches 13; Conservative 6; Mismatches 3; Indels 1; Gaps 1;

DB 6 gaalpllllllalgctfngarp 28
OY 2 GSGLP-LVLLTLTLGSSHGTPG 23

RESULT 3
ID W73408 standard; Protein: 47 AA.
AC W73408;
DE 19-FEB-1999 (first entry)
DE Human secreted protein encoded by Gene No. 12.
DE Secreted protein; human; protein therapy; gene therapy; blood disorder;
KW pathological condition; diagnosis; cancer; neurological disorder;
KW developmental abnormality; foetal deficiency; leukemia; hepatic disease;
KW immune system disorder; Alzheimer's disease; cognitive disorder;
KW schizophrenia; prostate disease; autoimmune disorder; AIDS.
OS Homo sapiens.
FH key Location/Qualifiers
FT Misc_difference 47

```

```

FN /note= "unspecified amino acid"
PN W09854206-A1.
PD 03-DEC-1998.
PF 28-MAY-1998; U10868.
PR 29-AUG-1997; US-056296.
PR 30-MAY-1997; US-044039.
PR 30-MAY-1997; US-048093.
PR 30-MAY-1997; US-048101.
PR 30-MAY-1997; US-048190.
PR 30-MAY-1997; US-048356.
PR 30-MAY-1997; US-050925.
PR 29-AUG-1997; US-056250.
PR 29-AUG-1997; US-056293.
PA (HUMA-) HUMAN GENOME SCI INC.
PI Carter KC, Dillon PJ, Endress GA, Feng P, Ni J,
PI Rosen CA, Ruben SM, Yu G;
DR WPI: 99-070209/06.
DR N-PSDB: V08822.
PT New isolated human genes - useful for diagnosis and treatment of,
PT e.g. cancers, neurological disorders, immune diseases, developmental
PT disorders or blood disorders
PS Claim 11; Page 152-153; 188pp: English.
CC This sequence is encoded by a cDNA of the invention, designated
CC Gene No. 12. This sequence represents a human secreted protein, and is
CC expressed in activated neutrophils, endothelial cells, T-cells and
CC to a lesser extent in brain and liver.
CC The DNA sequences of the invention and their corresponding secreted
CC polypeptides are useful for preventing, treating or ameliorating medical
CC conditions, e.g. by protein or gene therapy. Also pathological conditions
CC can be diagnosed by determining the amount of the new polypeptides in a
CC sample or by determining the presence of mutations in the DNA sequences.
CC Specific uses are described for each of the DNA sequences and the encoded
CC proteins, based on which tissues they are most highly expressed in, and
CC include developing products for the diagnosis or treatment of cancer,
CC tumours, neurological disorders, developmental abnormalities and foetal
CC deficiencies, blood disorders, leukemias, diseases of the immune system
CC (including allergies or asthma), hepatic disease, Alzheimer's and
CC cognitive disorders, schizophrenia, prostate diseases, autoimmune
CC disorders and AIDS. The polypeptides are also useful for identifying
CC their binding partners.
SQ Sequence 47 AA:

Query Match 15.4%; Score 86; DB 38; Length 47;
Best Local Similarity 56.5%; Pred. No. 3.89e+01;
Matches 13; Conservative 6; Mismatches 3; Indels 1; Gaps 1;

DB 6 gaalpllllllalgctfngarp 28
OY 2 GSGLP-LVLLTLTLGSSHGTPG 23

RESULT 4
ID W02702 standard; Peptide: 325 AA.
AC W02702;
DE 13-NOV-1996 (first entry)
DE G-protein coupled bovine adrenal angiotensin II type-1 receptor.
DE G-protein coupled receptor; ligand binding assay; transmembrane domain;
KW schizophrenia; dopamine; cAMP; adenosine; thrombin; adrenergic; opsin;
KW muscarinic acetylcholine; bombesin; endocrine; rhodopsin;
KW odorant; cytomagalovirus; serotonergic.
OS Bos taurus.
PN US5508384-A.
PD 16-APR-1996.
PF 10-SEP-1992; 943236.
PF 10-SEP-1992; US-943236.
PR 09-SEP-1993; US-118270.
PA (UNYV ) UNIV NEW YORK STATE.
PI Murphy RB, Schuster DI;
PI WPI: 96-208785/11.
PT New dopamine receptor peptide - useful as antipsychotic agent, e.g.
PT for treating schizophrenia
PS Disclosure; Column 128-132; 184pp: English.
CC Proteins W02657-W02730 represent a range of G-protein coupled receptor

```


QY 5 LPLVLLTLTGSSHGTPGMT 25

RESULT 8

ID R26954 standard; Protein: 110 AA.

AC R26954:

DT 10-FEB-1993 (first entry)

DE Human T lymphocyte receptor V-alpha22 segment.

KW TCR: IGR a 12; variable region; Immune system modulation;

KM T cell subtype.

OS Homo sapiens.

PN MO9213949-A.

PD 20-AUG-1992.

PF 07-FEB-1992: F00111.

PR 08-FEB-1991: FR-001487.

PA 12-APR-1991: FR-004527.

(ROUS) ROUSSEL-UCIAF.

PI Ferradini L, Hercend T, Roman-roman S, Triebel F;

DR WPI: 92-300035/36.

DN N-PSDB: Q28129.

DT Nucleotide sequences and their monoclonal antibodies and

PT oligo:nucleotide primers - encode variable alpha-chain regions of

human T-lymphocyte receptors, for studying immune responses and

for therapy

PS Claim 8: Page 35: 65pp; French.

CC RNA was isolated from peripheral lymphocytes and converted to cDNA.

CC The cDNA was amplified by anchored PCR using C-alpha and polyC

CC primers, then amplified again using a different C-alpha specific

CC primer. The amplified product was SacII-restricted, inserted into

CC Bluescript SK+ vector and used to transform E.coli XL7-blue.

CC Transformants were screened with a C-alpha specific probe and DNA

CC from positive clones was sequenced in the C-alpha region. The

CC sequence designated "IGR a 12" comprises the complete coding region

CC of a gene of the subfamily V alpha 22: this subfamily was

CC previously identified by the partial sequence (113bp) AC9 (Klein M.H.,

CC et al., Proc.Natl.Acad.Sci. USA 84:6884, 1987). The peptide encoded

CC by it can be used to block specific T cell epitopes or in vaccines.

CC See Q28120-Q28172.

CC Sequence 110 AA;

SQ

Query Match

Best Local Similarity 34.0%; Pred. No. 7.28e+01;

Matches 18; Conservative 12; Mismatches 18; Indels 5; Gaps 5;

Db

1 myspgslvslililgrtgdsyvmegpvtlseafitnctycaatypelf 53

I MGSGLPLV-LLLTLTGSSHGTG-PGMTLQLKKE-SFLT-NSSY-ESSFIELD 48

QY

RESULT 9

ID W21674 standard; Protein: 169 AA.

AC W21674:

DT 29-SEP-1997 (first entry)

DE Human mitochondrial electron transport chain subunit CIT-3;

KW Mammalian artificial chromosome; MAC; selectable marker; CIT-3;

KM mitochondrial electron transport chain complex II.

OS Homo sapiens.

PN MO9716533-A1.

PD 09-MAY-1997.

PF 28-OCT-1996: U17476.

PR 31-OCT-1995: US-550717.

(REGC) UNIV CALIFORNIA.

PI Scheffler IE;

DR WPI: 97-27103/24.

DN N-PSDB: T72466.

DT New mammalian artificial chromosomes - comprising a mammalian

PT centromere and a unique cloning site, used for stable expression of

PT large fragments of DNA

PS Disclosure: Page 54-55: 71pp; English.

CC CIT-3 (W21674) comprises a subunit of complex II of the human

CC mitochondrial electron transport chain. It is the expression

CC product of the CIT-3 gene identified in mammalian artificial

CC chromosome MAC-8.2.3, which is contained in the human-hamster

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC hybrid cell line XEM8.2.3 (ATCC CRL 11991). A portion of the

CC CIT-3 gene (see also T72461-65) or of CIT-3 cDNA (T72466) can be

CC utilised as a unique cloning site and selectable marker in an MAC,

CC allowing the site-specific integration of an exogenous nucleic acid

CC sequence into the MAC. The MAC can be used for stable expression

CC of large fragments of DNA and also for the production of transgenic

CC animals.

SQ Sequence 169 AA;

Query Match

Best Local Similarity 28.0%; Pred. No. 7.28e+01;

Matches 14; Conservative 20; Mismatches 13; Indels 3; Gaps 3;

Db

62 slpmanichrgyalaaaysl-fgms-allpufes-ylelvkslcl 108

4 GLPLVLLTLTGSSHGTPGMTLQLKKEPSFLTNSSYSSEFLLEKLCL 53

QY

RESULT 10

ID W59924 standard; Protein: 401 AA.

AC W59924:

DT 07-DEC-1998 (first entry)

DE Human 7-transmembrane receptor HNFY20.

KM HNFY20: G-protein coupled receptor; human; infection; HIV; pain;

KM cancer; anorexia; asthma; Parkinson's disease; acute heart failure;

KM hypotension; hypertension; urinary retention; osteoporosis;

KM angina pectoris; myocardial infarction; ulcer; allergy;

KM benign prostatic hyperplasia; psychosis; anxiety; schizophrenia;

KM manic depression; delirium; dementia; mental retardation;

KM dyskinesia; Huntington's disease; Gilles de la Tourette's syndrome;

KM therapy; diagnosis.

OS Homo sapiens.

PN EP-866126-A1.

PD 23-SEP-1998.

PF 16-FEB-1998: 301122.

PR 19-MAR-1997: US-820521.

PA (SMR) SMITHKLINE BEECHAM CORP.

PI Bergsma DJ, Fuetterer WS, Mao JT, Sathe GM;

DR WPI: 98-482962/42.

DN N-PSDB: V53631.

DT New polynucleotides and polypeptides encoding a novel human

PT 7-transmembrane receptor - useful for diagnosing and treating e.g.

PT cancer, osteoporosis and Parkinson's disease and infections caused

PT by HIV-1 or -2.

PS Claim 1: Page 18-19: 24pp; English.

CC This polypeptide comprises HNFY20, a novel human 7-transmembrane

CC G-protein coupled receptor that shows about 30.8% identity in 293

CC amino acid residues with the thrombin receptor. Its amino acid

CC sequence was deduced from an isolated HNFY20 polynucleotide

CC sequence (see V53631). The invention relates to HNFY20

CC polypeptides and recombinant materials and methods for their

CC production. It also provides methods for using such polypeptides

CC and HNFY20 polynucleotides for treatment of infections such as

CC bacterial, fungal, protozoan and particularly HIV-1 or HIV-2

CC infections, and conditions including pain, cancers, anorexia,

CC asthma, Parkinson's disease, acute heart failure, hypotension,

CC hypertension, urinary retention, osteoporosis, angina pectoris,

CC myocardial infarction, ulcers, allergies, benign prostatic

CC hypertrophy, and psychotic and neurological disorders, including

CC anxiety, schizophrenia, manic depression, delirium, dementia,

CC severe mental retardation and dyskinesias, such as Huntington's

CC disease or Gilles de la Tourette's syndrome. Gene therapy using

CC RNA encoding HNFY20 can be used to treat conditions caused by

CC under-expression of the protein. The invention also relates to

CC methods of identifying agonists and antagonists and for using

CC such compounds to treat conditions associated with HNFY20

CC imbalance. Diagnostic assays for detecting diseases associated

CC with inappropriate HNFY20 activity or levels are also provided.

SQ Sequence 401 AA;

Query Match

Best Local Similarity 14.5%; Score 81; DB 35; Length 401;

Matches 8; Conservative 9; Mismatches 4; Indels 0; Gaps 0;

Db 332 yfsssgfqadfhellrltlogl 352
:::|:::| | | | |
QY 34 FLINSSYESSFELLEKLCL 54

RESULT 11
ID W10038 standard; Protein; 1253 AA.
AC W10038:
DT 07-FEB-1998 (first entry)
DE Mad binding protein, mslnA.
KW murine; mslnA; mammalian homologue; Saccharomyces cerevisiae; repressor;
KW Sin3; Mad; Max; mSin:Mad complex; mSin:Mad:Max complex; Myc; promoter;
KW basic helix-loop-helix zipper protein; compete; DNA-binding;
KW Myc:Max complex; activate; transcription; gene regulation.
OS Mus musculus.
FH Key
FT Misc_difference 10 Location/Qualifiers
FT /label= unknown
FT /note= "encoded by TAG"
FT Misc_difference 1238 /label= unknown
FT /note= "encoded by TAG"
PN US5624818-A.
PD 29-APR-1997.
PF 01-JUN-1994; 252966.
PR 01-JUN-1994; US-252966.
PR 19-SEP-1991; US-756195.
PR 23-JUN-1992; US-903710.
PR 01-APR-1994; US-222638.
PA (HUTC-) HUTCHINSON CANCER RES CENT FRED.
PI Ayer DE, Eisenman RN;
DR WPI: 97-258216/23.
DR N-PSDB: T70126.
PT mSin nucleic acids encoding recombinant polypeptide(s) that
PT associate with Mad polypeptide - are possible homologues of S.
PT cerevisiae general repressor protein Sin3
PS Example 12; Fig 23A-C; 111pp; English.
CC This sequence represents the murine protein, designated mslnA, which may
CC be a mammalian homologue of the Saccharomyces cerevisiae general
CC repressor protein Sin3. The mSin protein associates with a Mad
CC polypeptide to form a mSin:Mad complex, which preferably associates
CC with a Max polypeptide to form a mSin:Mad:Max complex which binds to a
CC nucleotide sequence comprising CACGTG. Mad is a basic helix-loop-helix
CC (bHLH) zipper protein which can compete with Myc by forming sequence-
CC specific DNA-binding heterocomplexes with Max. Mad:Max complexes repress,
CC while Myc:Max complexes activate, transcription from promoters containing
CC proximal CACGTG binding sites for these proteins. Expression of Mad is
CC closely linked to differentiation in at least two distinct cell lineages.
CC The switch from Myc:Max to Mad:Max complexes may reflect the repression
CC of transcription of Myc regulated genes by Mad. The DNA, vectors and host
CC cells of the invention are useful for the recombinant production of mSin
CC proteins useful in elucidation of Mad repressor functions.
SQ Sequence 1253 AA;
Query Match 14.5%; Score 81; DB 25; Length 1253;
Best Local Similarity 27.5%; Pred. No. 8.50e+01;
Matches 11; Conservative 14; Mismatches 14; Indels 1; Gaps 1;

OS Mus musculus.
FH Key
FT Misc_difference 10 Location/Qualifiers
FT /label= unknown
FT /note= "encoded by TAG"
FT Misc_difference 1247 /label= unknown
FT /note= "encoded by TAG"

PN US5624818-A.
PD 29-APR-1997.
PF 01-JUN-1994; 252966.
PR 01-JUN-1994; US-252966.
PR 19-SEP-1991; US-756195.
PR 23-JUN-1992; US-903710.
PR 01-APR-1994; US-222638.
PA (HUTC-) HUTCHINSON CANCER RES CENT FRED.
PI Ayer DE, Eisenman RN;
DR WPI: 97-258216/23.
DR N-PSDB: T70128.
PT mSin nucleic acids encoding recombinant polypeptide(s) that
PT associate with Mad polypeptide - are possible homologues of S.
PT cerevisiae general repressor protein Sin3
PS Example 12; Fig 29A-C; 111pp; English.
CC This sequence represents the murine protein, designated mslnA, which
CC may be a mammalian homologue of the Saccharomyces cerevisiae general
CC repressor protein Sin3. The mSin protein associates with a Mad
CC polypeptide to form a mSin:Mad complex, which preferably associates
CC with a Max polypeptide to form a mSin:Mad:Max complex which binds to a
CC nucleotide sequence comprising CACGTG. Mad is a basic helix-loop-helix
CC (bHLH) zipper protein which can compete with Myc by forming sequence-
CC specific DNA-binding heterocomplexes with Max. Mad:Max complexes repress,
CC while Myc:Max complexes activate, transcription from promoters containing
CC proximal CACGTG binding sites for these proteins. Expression of Mad is
CC closely linked to differentiation in at least two distinct cell lineages.
CC The switch from Myc:Max to Mad:Max complexes may reflect the repression
CC of transcription of Myc regulated genes by Mad. The DNA, vectors and host
CC cells of the invention are useful for the recombinant production of mSin
CC proteins useful in elucidation of Mad repressor functions.
SQ Sequence 1261 AA;
Query Match 14.5%; Score 81; DB 25; Length 1261;
Best Local Similarity 27.5%; Pred. No. 8.50e+01;
Matches 11; Conservative 14; Mismatches 14; Indels 1; Gaps 1;

CC STRANDEDNESS: single
CC TOPOLOGY: linear
CC MOLECULE TYPE: peptide
SQ SEQUENCE 325 AA; 37288 MW; 592694 CN;

Query Match 15.2%; Score 85; DB 1; Length 325;
Best Local Similarity 44.4%; Pred. No. 2.00e+01;
Matches 12; Conservative 5; Mismatches 8; Indels 2; Gaps 2;

Db 27 YMKLKYASVFLNLALADICELLTP 53
OY 34 FLTNSYESSFL-EL-LEKLCLLHL 58

RESULT 2
ID PCT-US93-08528-51 STANDARD: PRT: 325 AA.
XX
AC xxxxxx
DT
XX
XX
DE
XX
XX

Sequence 51, Application PC/TUS9308528
GENERAL INFORMATION:
APPLICANT: New York University
TITLE OF INVENTION: POLYPEPTIDES OF G-COUPLED PROTEIN
NUMBER OF SEQUENCES: 348
CORRESPONDENCE ADDRESS:
ADDRESSEE: BROWDY AND NEIMARK
STREET: 419 Seventh Street, N.W., Suite 300
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20004

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/08528
FILING DATE: 09-SEP-1993
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 07/943,236
FILING DATE: 10-SEP-1992
ATTORNEY/AGENT INFORMATION:
NAME: Townsend, Kevin G.
REGISTRATION NUMBER: 34,033
REFERENCE/DOCKET NUMBER: MURPHY-2 PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-628-5197
TELEFAX: 202-737-3528
TELEX: 248633
INFORMATION FOR SEQ ID NO: 51:
SEQUENCE CHARACTERISTICS:
LENGTH: 325 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
SEQUENCE 325 AA; 37288 MW; 592694 CN;

Query Match 15.2%; Score 85; DB 3; Length 325;
Best Local Similarity 44.4%; Pred. No. 2.00e+01;
Matches 12; Conservative 5; Mismatches 8; Indels 2; Gaps 2;

Db 27 YMKLKYASVFLNLALADICELLTP 53
OY 34 FLTNSYESSFL-EL-LEKLCLLHL 58

RESULT 3
ID US-08-063-552-8 STANDARD: PRT: 194 AA.
XX
AC xxxxxx
DT
XX
XX
DE
XX
XX

Sequence 8, Application US/08063552

Sequence 8, Application US/08063552
Patent No. 5686936
GENERAL INFORMATION:
APPLICANT: Edwards, Robert H
TITLE OF INVENTION: Vesicle Membrane Transport Proteins
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sheldon & Mak
STREET: 225 South Lake Avenue, Ninth Floor
CITY: Pasadena
STATE: California
COUNTRY: USA
ZIP: 91101

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/063,552
FILING DATE: 19930514
CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:
NAME: Farber, Michael B
REGISTRATION NUMBER: 32,612
REFERENCE/DOCKET NUMBER: 9067-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (818) 796-4000
TELEFAX: (818) 795-6321

INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 194 amino acids
TYPE: AMINO ACID
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: NO
FRAGMENT TYPE: Internal
ORIGINAL SOURCE:
ORGANISM: Transposon 10
SEQUENCE 194 AA; 20868 MW; 201442 CN;

Query Match 14.9%; Score 83; DB 1; Length 194;
Best Local Similarity 31.0%; Pred. No. 2.75e+01;
Matches 18; Conservative 13; Mismatches 23; Indels 4; Gaps 4;

Db 1 MNSSTIALVITLIDAM-GIGLIMVPLTLRE-FIASDDINHGCVILA-LVALNOV 55
OY 1 MGGSLPVLVLTLLGSSHGPGMT-LQDKLKSFLTNSYESSFLLEKLCLLHL 57

Sequence 8, Application PC/TUS9305704

Sequence 8, Application PC/TUS9305704
GENERAL INFORMATION:
APPLICANT: Edwards, Robert H
TITLE OF INVENTION: Vesicle Membrane Transport Proteins
NUMBER OF SEQUENCES: 17

CC CORRESPONDENCE ADDRESS:
 CC ADDRESSEE: Sheldon & Max
 CC STREET: 225 South Lake Avenue, Ninth Floor
 CC CITY: Pasadena
 CC STATE: California
 CC COUNTRY: USA
 CC ZIP: 91001
 CC COMPUTER READABLE FORM:
 CC MEDIUM TYPE: Floppy disk
 CC COMPUTER: IBM PC compatible
 CC OPERATING SYSTEM: PC-DOS/MS-DOS
 CC SOFTWARE: Patentin Release #1.0, Version #1.25
 CC CURRENT APPLICATION DATA:
 CC APPLICATION NUMBER: PCT/US93/05704
 CC FILING DATE: 19930611
 CC CLASSIFICATION:
 CC ATTORNEY/AGENT INFORMATION:
 CC NAME: Faider, Michael B
 CC REGISTRATION NUMBER: 32,612
 CC REFERENCE/DOCKET NUMBER: 9067-1PCT
 CC TELECOMMUNICATION INFORMATION:
 CC TELEPHONE: (818) 796-4000
 CC TELEFAX: (818) 795-6321
 CC INFORMATION FOR SEQ ID NO: 8:
 CC SEQUENCE CHARACTERISTICS:
 CC LENGTH: 194 amino acids
 CC TYPE: AMINO ACID
 CC TOPOLOGY: linear
 CC MOLECULE TYPE: peptide
 CC HYPOTHEICAL: NO
 CC FRAGMENT TYPE: Internal
 CC ORIGINAL SOURCE:
 CC ORGANISM: transposon 10
 CC SEQUENCE 194 AA; 20868 MW; 201442 CN;
 SQ
 Query Match 14.9%; Score 83; DB 3; Length 194;
 Best Local Similarity 31.0%; Pred. No. 2.75e+01;
 Matches 18; Conservative 13; Mismatches 23; Indels 4; Gaps 4;
 DB 1 MNSSTIALVITLDAM-GIGLIMPLVPLIRE-PIASEDIANHEGVLLA-LYALMOV 55
 1 MGSGLPVLLTLGSSHGTPGMT-LQKLKESFTLNSSYESSFLELKLCLLHL 57
 QY
 RESULT 5
 ID US-08-741-406-2 STANDARD: PRT; 169 AA.
 AC xxxxxx
 XX
 XX
 DT
 DE
 CC Sequence 2, Application US/08741406
 CC Patent No. 5721118
 CC GENERAL INFORMATION:
 CC APPLICANT: Scheffler, Immo E.
 CC TITLE OF INVENTION: Mammalian Artificial Chromosomes and
 CC TITLE OF INVENTION: Methods of using same
 CC NUMBER OF SEQUENCES: 16
 CC CORRESPONDENCE ADDRESSES:
 CC ADDRESSEE: Campbell & Flores LLP
 CC STREET: 4370 La Jolla Village Drive, Suite 700
 CC CITY: San Diego
 CC STATE: California
 CC COUNTRY: United States
 CC ZIP: 92122
 CC COMPUTER READABLE FORM:
 CC MEDIUM TYPE: Floppy disk
 CC COMPUTER: IBM PC compatible
 CC OPERATING SYSTEM: PC-DOS/MS-DOS
 CC SOFTWARE: Patentin Release #1.0, Version #1.25
 CC CURRENT APPLICATION DATA:

CC APPLICATION NUMBER: US/08/741,406
 CC FILING DATE:
 CC CLASSIFICATION: 514
 CC PRIOR APPLICATION DATA:
 CC APPLICATION NUMBER: US 08/550,717
 CC FILING DATE: 31-OCT-1995
 CC ATTORNEY/AGENT INFORMATION:
 CC NAME: Campbell, Cathryn A.
 CC REGISTRATION NUMBER: 31,815
 CC REFERENCE/DOCKET NUMBER: P-UD 2317
 CC TELECOMMUNICATION INFORMATION:
 CC TELEPHONE: (619) 535-9001
 CC TELEFAX: (619) 535-8949
 CC INFORMATION FOR SEQ ID NO: 2:
 CC SEQUENCE CHARACTERISTICS:
 CC LENGTH: 169 amino acids
 CC TYPE: amino acid
 CC TOPOLOGY: linear
 CC MOLECULE TYPE: protein
 CC SEQUENCE 169 AA; 18610 MW; 162524 CN;
 SQ
 Query Match 14.7%; Score 82; DB 1; Length 169;
 Best Local Similarity 28.0%; Pred. No. 3.23e+01;
 Matches 14; Conservative 20; Mismatches 13; Indels 3; Gaps 3;
 DB 62 SLPMASICHGICGIALSAGVSL-FGMS-ALLPGNFES-YELVKSICL 108
 4 GDLVLLTLGSSHGTPGMTLQKLKESFTLNSSYESSFLELKLCL 53
 QY
 RESULT 6
 ID US-08-820-521-2 STANDARD: PRT; 401 AA.
 AC xxxxxx
 XX
 XX
 DT
 DE
 CC Sequence 2, Application US/08820521
 CC Patent No. 5942416
 CC GENERAL INFORMATION:
 CC APPLICANT: Bergema, Derk
 CC APPLICANT: Ganesu, Sathe
 CC APPLICANT: Fuelteler, Wendy
 CC APPLICANT: Mao, Joyce
 CC TITLE OF INVENTION: CDNA CLONE HNFY20 THAT ENCODES
 CC TITLE OF INVENTION: A NOVEL HUMAN 7-TRANSMEMBRANE RECEPTOR
 CC NUMBER OF SEQUENCES: 2
 CC CORRESPONDENCE ADDRESSES:
 CC ADDRESSEE: SmithKline Beecham Corporation
 CC STREET: 709 Swedeland Road
 CC CITY: King of Prussia
 CC STATE: PA
 CC COUNTRY: USA
 CC ZIP: 19406
 CC COMPUTER READABLE FORM:
 CC MEDIUM TYPE: Diskette
 CC COMPUTER: IBM Compatible
 CC OPERATING SYSTEM: DOS
 CC SOFTWARE: FASTSEQ for Windows Version 2.0
 CC CURRENT APPLICATION DATA:
 CC APPLICATION NUMBER: US/08/820,521
 CC FILING DATE: 19-MAR-1997
 CC CLASSIFICATION: 435
 CC PRIOR APPLICATION DATA:
 CC APPLICATION NUMBER:
 CC FILING DATE:
 CC ATTORNEY/AGENT INFORMATION:
 CC NAME: Han, William T
 CC REGISTRATION NUMBER: 34,344
 CC REFERENCE/DOCKET NUMBER: GH50011
 CC TELECOMMUNICATION INFORMATION:

CC TELEPHONE: 610-270-5219
CC TELEFAX: 610-270-4026
CC INFORMATION FOR SEQ ID NO: 2:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 401 amino acids
CC TYPE: amino acid
CC STRANDEDNESS: single
CC TOPOLOGY: linear
CC MOLECULE TYPE: protein
CC SEQUENCE: 401 AA; 44386 MW; 853771 CN;
SQ
Query Match 14.5%; Score 81; DB 2; Length 401;
Best Local Similarity 38.1%; Pred. No. 3.78e+01;
Matches 8; Conservative 9; Mismatches 4; Indels 0; Gaps 0;
Db 332 YFSSGFQADFHLLRLCGL 352
QY 34 FLTNSYSSFLLEKLCL 54
DE
XX
AC
XX
DT
XX
Sequence 12, Application US/08252966B
XX Sequence 12, Application US/08252966B
CC Patent No. 5624818
CC GENERAL INFORMATION:
CC APPLICANT: Eisenman, Robert N.
CC APPLICANT: Hurlin, Peter J.
CC TITLE OF INVENTION: Regulatory Proteins that Dimerize with
CC TITLE OF INVENTION: Mad or Max
CC NUMBER OF SEQUENCES: 19
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Christensen, O'Connor, Johnson, and KindnessPLLC
CC STREET: 1420 Fifth Ave., Suite 2800
CC CITY: Seattle
CC STATE: Washington
CC COUNTRY: USA
CC ZIP: 98101-2347
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: floppy disk
CC COMPUTER: IBM PC compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: Patentin Release #1.0, Version #1.25
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/252,966B
CC FILING DATE: 01-JUN-1994
CC CLASSIFICATION: 435
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Shelton, Dennis K.
CC REGISTRATION NUMBER: 26,997.
CC REFERENCE/DOCKET NUMBER: FHCRI7694
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: (206) 682-8100
CC TELEFAX: (206) 224-0779
CC INFORMATION FOR SEQ ID NO: 12:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 1253 amino acids
CC TYPE: amino acid
CC STRANDEDNESS: single
CC TOPOLOGY: linear
CC MOLECULE TYPE: protein
CC DESCRIPTION: translation of msina cDNA; see Figure 23
CC HYPOTHETICAL: YES
CC ORIGINAL SOURCE:
CC ORGANISM: Mus musculus

SQ SEQUENCE 1253 AA; 142589 MW; 7863283 CN;
Query Match 14.5%; Score 81; DB 1; Length 1253;
Best Local Similarity 27.5%; Pred. No. 3.78e+01;
Matches 11; Conservative 14; Mismatches 14; Indels 1; Gaps 1;
Db 949 VGIKRDSDSPAIOLRLEKPMVDVEDYYPAPFLDMVRSI 988
QY 13 LIGSSHGTPGMTLOLKLKESF-LTNSYSSFLLEKL 51
DE
XX
AC
XX
DT
XX
Sequence 18, Application US/08252966B
XX Sequence 18, Application US/08252966B
CC Patent No. 5624818
CC GENERAL INFORMATION:
CC APPLICANT: Eisenman, Robert N.
CC APPLICANT: Hurlin, Peter J.
CC TITLE OF INVENTION: Regulatory Proteins that Dimerize with
CC TITLE OF INVENTION: Mad or Max
CC NUMBER OF SEQUENCES: 19
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Christensen, O'Connor, Johnson, and KindnessPLLC
CC STREET: 1420 Fifth Ave., Suite 2800
CC CITY: Seattle
CC STATE: Washington
CC COUNTRY: USA
CC ZIP: 98101-2347
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: floppy disk
CC COMPUTER: IBM PC compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: Patentin Release #1.0, Version #1.25
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/252,966B
CC FILING DATE: 01-JUN-1994
CC CLASSIFICATION: 435
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Shelton, Dennis K.
CC REGISTRATION NUMBER: 26,997.
CC REFERENCE/DOCKET NUMBER: FHCRI7694
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: (206) 682-8100
CC TELEFAX: (206) 224-0779
CC INFORMATION FOR SEQ ID NO: 18:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 1261 amino acids
CC TYPE: amino acid
CC STRANDEDNESS: single
CC TOPOLOGY: linear
CC MOLECULE TYPE: protein
CC DESCRIPTION: translation of msina9 cDNA; see Figure 29A, B, C, D
CC HYPOTHETICAL: YES
CC ORIGINAL SOURCE:
CC ORGANISM: Mus musculus
SQ SEQUENCE 1261 AA; 143711 MW; 7937040 CN;
Query Match 14.5%; Score 81; DB 1; Length 1261;
Best Local Similarity 27.5%; Pred. No. 3.78e+01;
Matches 11; Conservative 14; Mismatches 14; Indels 1; Gaps 1;
Db 949 VGIKRDSDSPAIOLRLEKPMVDVEDYYPAPFLDMVRSI 988
QY 13 LIGSSHGTPGMTLOLKLKESF-LTNSYSSFLLEKL 51


```

CC      PRIOR APPLICATION DATA:
CC      APPLICATION NUMBER: US/08/194,113
CC      FILING DATE:
CC      APPLICATION NUMBER: US/07/803,626
CC      FILING DATE:
CC      ATTORNEY/AGENT INFORMATION:
CC      NAME: White, John P.
CC      REGISTRATION NUMBER: 28,678
CC      REFERENCE/DOCKET NUMBER: 1795/39317
CC      TELECOMMUNICATION INFORMATION:
CC      TELEPHONE: 212-977-9550
CC      TELEFAX: 212-664-0525
CC      TELEX: 422523 COOP UI
CC      INFORMATION FOR SEQ ID NO: 6:
CC      SEQUENCE CHARACTERISTICS:
CC      LENGTH: 398 amino acids
CC      TYPE: amino acid
CC      STRANDEDNESS: unknown
CC      TOPOLOGY: unknown
CC      MOLECULE TYPE: protein
CC      HYPOTHETICAL: NO
CC      ANTI-SENSE: NO
CC      FRAGMENT TYPE: N-terminal
SO      SEQUENCE 398 AA; 44384 MW; 880684 CN;

Query Match      14.38; Score 80; DB 1; Length 398;
Best Local Similarity 23.68; Pred. No. 4.43e+01;
Matches 17; Conservative 22; Mismatches 32; Indels 1; Gaps 1;

Db      52 LVMLALITLATTLSNAFVIAIVYRTKLTNPANYLIASLDVYDLVSILVPISTWTV 111
Oy      7 LVLLLTLLSSHGTPGPMITLQTLKRESFL-TNSSYESSFLELLEKLCILHLPGSTVTL 65

Db      112 TDRWTLNQVCD 123
Oy      66 HHARSOHVVCN 77

```

Search completed: Fri Oct 22 18:45:24 1999
 Job time : 9 secs.

#authors Paguin, B.; Lang, B.F.
#journal J. Mol. Biol. (1996) 255:688-701
#title The mitochondrial DNA of *Allomyces macrogynus*: the complete
#cross-references genomic sequence from an ancestral fungus.
#accession M53638
#status nucleic acid sequence not shown; translation not shown
#molecule_type DNA
#residues 1382
#cross-references EMBL:U41288; NID:g1236403; PID:g1236404
#note the nucleotide sequence was submitted to the EMBL Data
Library, November 1995

GENETICS
#gene cob
#introns mitochondrion
#introns 67/3; 137/3; 143/3; 164/1; 200/2; 252/3
CLASSIFICATION
#superfamily cytochrome b; cytochrome b homology; cytochrome
b6 homology; plastocyanin--plastocyanin reductase 17K
protein homology
mitochondrion; oxidoreductase

KEYWORDS
FEATURE
10-340 #domain cytochrome b homology #label CBH\
10-210 #domain cytochrome b6 homology #label CB6\
222-340 #domain plastocyanin--plastocyanin reductase 17K protein
homology #label 17K

SUMMARY
#length 382 #molecular-weight 43467 #checksum 6973

Query Match
Best Local Similarity 16.7%; Score 93; DB 2; Length 382;
Matches 17; Conservative 15; Mismatches 16; Indels 3; Gaps 3;

Db 8 PYLISANFLDSPLENTITLWNGSLG-LCLVIOITYGTGLAMHYAP 57
22 PGMITLQLK-LKESTL-TNSSESFLELLEKLLCHLHSGISVLIHARS 70

RESULT 3
ENTRY A48156 #type complete
TITLE translation regulator GCD6 - yeast (*Saccharomyces cerevisiae*)
ALTERNATE_NAMES guanine nucleotide exchange factor chain GCD6; protein
YD8142B.03; protein YDR211w; translation initiation factor
eIF-2B homolog

ORGANISM #formal_name *Saccharomyces cerevisiae*
DATE 28-May-1993 #sequence_revision 03-May-1994 #text_change
06-Feb-1998

ACCESSIONS A48156; S61578; S30776

REFERENCE
#authors Busman, J.L.; Asuru, A.I.; Mats, R.L.; Hinebusch, A.G.
#journal Mol. Cell. Biol. (1993) 13:1920-1932
#title Evidence that GCD6 and GCD7, translational regulators of
GCN4, are subunits of the guanine nucleotide exchange
factor for eIF-2 in *Saccharomyces cerevisiae*.
#cross-references MUID:93180841
#accession A48156
#molecule_type DNA
#residues 1-712 #label BUS
#cross-references EMBL:L07115; NID:g171572; PID:g171574
#note sequence extracted from NCBI backbone (NCBIN:126018,
NCBIP:126021)

REFERENCE
#authors Oliver, K.; Harris, D.
#submission submitted to the EMBL Data Library, December 1995
#accession S61578
#molecule_type DNA
#residues 1-712 #label OLI
#cross-references EMBL:Z68195; NID:g1122341; PID:e213795; PID:g1122344;
MIPS:YDR211w

GENETICS
#gene SGD:GCD6
#map_position 4R
#cross-references SGD:S0002619; MIPS:YDR211w
KEYWORDS translation regulation

SUMMARY #length 712 #molecular-weight 81160 #checksum 142

Query Match
Best Local Similarity 16.5%; Score 92; DB 2; Length 712;
Matches 17; Conservative 8; Mismatches 14; Indels 4; Gaps 4;

Db 12 LGN-HGKNSDMDVEDRLQAVLUDS-YETREMPILAVKPRCLL 52
14 LGSSHTGPGMTLQLKKESTLNSSESFLELLE-KL-CLL 54

RESULT 4
ENTRY JC5237 #type complete
TITLE osmotin-like protein precursor - tomato
ORGANISM #formal_name *Lycopersicon esculentum* #common_name tomato
DATE 13-Mar-1997 #sequence_revision 13-Mar-1997 #text_change
13-Nov-1998

ACCESSIONS JC5237
REFERENCE
#authors Chen, R.; Wang, F.; Smith, A.G.
#journal Gene (1996) 179:301-302
#title A flower-specific gene encoding an osmotin-like protein from
Lycopersicon esculentum.
#cross-references MUID:97128324
#contents flower
#accession JC5237

FEATURE
1-23 #domain signal sequence #status predicted #label sig\
24-252 #product osmotin-like protein #status predicted #label
MAT

SUMMARY #length 252 #molecular-weight 27265 #checksum 2939

Query Match
Best Local Similarity 16.3%; Score 91; DB 2; Length 252;
Matches 13; Conservative 4; Mismatches 7; Indels 0; Gaps 0;


Db 10 LPLSLFTLLSLQSSTNPFIITL 33
5 LPLVLLTLTGSSHTGPGMTLQL 28

RESULT 5
ENTRY S73757 #type complete
TITLE hypothetical protein Fl_0r1879 - *Mycoplasma pneumoniae* (ATCC
29342) (SGC3)
ORGANISM #formal_name *Mycoplasma pneumoniae*
DATE 27-Feb-1997 #sequence_revision 25-Apr-1997 #text_change
17-Jul-1998

ACCESSIONS S73757
REFERENCE
#authors Himeleirich, R.; Hilbert, H.; Plagens, H.; Pirkl, E.; Li,
B.C.; Hermann, R.
#journal Nucleic Acids Res. (1996) 24:4420-4449
#title Complete sequence analysis of the genome of the bacterium
Mycoplasma pneumoniae.
#cross-references MUID:97105885
#accession S73757
#status preliminary; nucleic acid sequence not shown;
translation not shown

GENETICS
#molecule_type DNA
#residues 1-879 #label HIM
#cross-references EMBL:AE000042; GB:U00089; NID:g1674112; PID:g1674117
#note the nucleotide sequence was submitted to the EMBL Data
Library, November 1996

GENETICS
#genetic_code SGC3



(TM)

Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MPsrch_DP protein - protein database search, using Smith-Waterman algorithm
Run on: Fri Oct 22 18:43:27 1999. Maspar time 4.02 Seconds
Tabular output not generated. 548.762 Million cell updates/sec

Title: >US-09-092-296-15
Description: (1-78) from US09092296.pep
Perfect Score: 558
Sequence: 1 MSGGLPLVLLTLIGSSHGT.....SGISVTLHARSQHVCNT 78

Scoring table: PAM 150
Gap 11

Searched: 77977 seqs, 28268293 residues

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database: swiss-prot37
1:swissprot

Statistics: Mean 40.060; Variance 77.694; scale 0.516

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description	Pred. No.
1	92	16.5	712	1	E2BE_YEAST TRANSLATION INITIATION	3.33e-01
2	91	16.3	252	1	OLP1_LACIS OSMOTIN-LIKE PROTEIN P	4.53e-01
3	89	15.9	3005	1	ZFH2_DROME ZINC-FINGER PROTEIN 2	8.33e-01
4	88	15.8	1822	1	YM68_CAEBL HYPOHETICAL HELICASE	1.13e+00
5	87	15.6	396	1	REFLM_SCHPO PUTATIVE MITOCHONDRIAL	1.52e+00
6	86	15.4	272	1	VTXD_BACSU HYPOHETICAL 30.1 KD P	2.04e+00
7	85	15.2	315	1	RSEB_HAETN SIGMA-E FACTOR REGULA	2.74e+00
8	84	15.1	191	1	YDB3_SCHPO HYPOHETICAL 21.1 KD P	3.67e+00
9	83	14.9	401	1	TCR2_ECOLI TETRACYCLINE RESISTANC	4.90e+00
10	83	14.9	445	1	YGCS_ECOLI HYPOHETICAL METABOLIT	4.90e+00
11	83	14.9	647	1	BGAL_MOUSE BETA-GALACTOSIDASE PRE	4.90e+00
12	83	14.9	1233	1	NME3_HUMAN GLUTAMATE (NMDA) RECEP	4.90e+00
13	82	14.7	372	1	INVE_SALTY INVASION PROTEIN INVE	6.52e+00
14	82	14.7	385	1	CYB_ASPNG CYTOCHROME B (EC 1.10.	8.66e+00
15	81	14.5	253	1	MOTR_RHOSH ACROSOMAL PROTEIN SP-1	8.66e+00
16	81	14.5	261	1	ASPX_MOUSE PUTATIVE G PROTEIN-COU	8.66e+00
17	81	14.5	346	1	GP41_HUMAN PUTATIVE G PROTEIN-COU	8.66e+00
18	81	14.5	346	1	GP42_HUMAN PUTATIVE G PROTEIN-COU	8.66e+00
19	81	14.5	387	1	CYB_PODAN CYTOCHROME B (EC 1.10.	8.66e+00
20	81	14.5	482	1	LBP_RABIT LIPOPOLYSACCHARIDE-BIN	8.66e+00
21	80	14.3	169	1	C560_BOVIN SUCCINATE DEHYDROGENAS	1.15e+01
22	80	14.3	191	1	Y064_TREPA HYPOHETICAL PROTEIN T	1.15e+01
23	80	14.3	387	1	CYB_EMENI CYTOCHROME B (EC 1.10.	1.15e+01

24	80	14.3	400	1	TCR8_PASNU TETRACYCLINE RESISTANC	1.15e+01
25	80	14.3	402	1	OPDE_PSEAE TRANSCRIPTION REGULATO	1.15e+01
26	80	14.3	411	1	VGLM_HSVAC GLYCOPROTEIN M.	1.15e+01
27	80	14.3	488	1	MB1L_EMENI MRNA MATURASE B11 (COB	1.15e+01
28	80	14.3	713	1	CDGT_BACSP CYCLOMALDOXETRIN GLUC	1.15e+01
29	80	14.3	772	1	TEP1_HUMAN TRANSCRIPTION FACTOR 1	1.15e+01
30	79	14.2	252	1	ATP6_YEAST ATP SYNTHASE A CHAIN P	1.52e+01
31	79	14.2	408	1	BIN1_PROTEIN BIN1 PROTEIN	1.52e+01
32	79	14.2	413	1	REFLM_YEAST MITOCHONDRIAL PEPTIDE	1.52e+01
33	79	14.2	493	1	ACHE_MOUSE ACETYLCHOLINE RECEPTOR	1.52e+01
34	79	14.2	505	1	ACHB_BOVIN ACETYLCHOLINE RECEPTOR	1.52e+01
35	79	14.2	511	1	MVIN_ECOLI VIRULENCE FACTOR MVIN	1.52e+01
36	79	14.2	662	1	GARP_HUMAN GARP PROTEIN PRECURSOR	1.52e+01
37	79	14.2	1015	1	PPTX_HUMAN PROTEIN-TTROSINE PHOSP	1.52e+01
38	78	14.0	101	1	GRO_CRIGR GROWTH REGULATED PROTE	2.00e+01
39	78	14.0	267	1	YTXD_BACME HYPOHETICAL 29.3 KD P	2.00e+01
40	78	14.0	450	1	FALO_RABIT COAGULATION FACTOR X P	2.00e+01
41	78	14.0	991	1	BME1_MOUSE BONE MORPHOGENETIC PRO	2.00e+01
42	78	14.0	1239	1	NME3_MOUSE GLUTAMATE (NMDA) RECEP	2.00e+01
43	77	13.8	253	1	POMA_VIBAL CHEMOTAXIS POMA PROTEI	2.62e+01
44	77	13.8	530	1	UD18_RAT UDP-GLUCURONOSYLTRANSF	2.62e+01
45	77	13.8	1156	1	HIS_DROME HU-LI TAI SHAO PROTEIN	2.62e+01

ALIGNMENTS

RESULT 1
ID E2BE_YEAST STANDARD; PRT; 712 AA.

AC P32501;
DT 01-OCT-1993 (REL. 27, CREATED)
DT 01-OCT-1993 (REL. 27, LAST SEQUENCE UPDATE)
DE 01-NOV-1997 (REL. 35, LAST ANNOTATION UPDATE)
DE TRANSLATION INITIATION FACTOR EIF-2B EPSILON SUBUNIT (EIF-2B GDP-GTP
DE EXCHANGE FACTOR) (GUANINE NUCLEOTIDE EXCHANGE FACTOR SUBUNIT GCD6)
DE (GCD COMPLEX SUBUNIT GCD6).
GN GCD6 OR TIF225 OR YDR211W OR YD8142.12 OR YD8142B.03.
OS SACCCHAROMYCES CEREVISIAE (BAKER'S YEAST).
OC EUKARYOTA; FUNGI; ASCOMYCOTA; HEMIASCOMYCETES; SACCCHAROMYCETALS;
CC SACCCHAROMYCETACEAE; SACCCHAROMYCES.
[1]
PP SEQUENCE FROM N.A.
RX MEDLINE: 9310841.
RA BUSHMAN J.L., ASURU A.I., MATTS R.L., HINNERBUSCH A.G.;
RT *Evidence that Gcd6 and Gcd7, translational regulators of GCN4, are
RT subunits of the guanine nucleotide exchange factor for eif-2 in
RT Saccharomyces cerevisiae*.
RL MOL. CELL. BIOL. 13:1920-1932(1993).
RN [2].

RP SEQUENCE FROM N.A.
RC STRAIN-S288C / AB972.
RC OLIVER K., SHORE L., HARRIS D., BARRELL B.G., RAUANDREAN M.A.,
RA WALSH S.V.;
SUBMITTED (DEC-1995) TO EMBL/GENBANK/DBJ DATA BANKS.
-1- FUNCTION: SUBUNIT OF THE GUANINE NUCLEOTIDE EXCHANGE FACTOR FOR
EIF-2. REQUIRED TO REPRESS GCN4 TRANSLATION UNDER NONSTARVATION
CONDITIONS. GCD6 AND GCD7 REPRESS GCN4 EXPRESSION AT THE
TRANSLATIONAL LEVEL BY ENSURING THAT RIBOSOMES WHICH HAVE
TRANSLATED OVERT WILL REINITIATE AT UORF2, -3, OR -4 AND THUS FAIL
TO REACH THE GCN4 START SITE.

-1- SUBUNIT: COMPLEX OF FIVE DIFFERENT SUBUNITS: ALPHA (GCN3), BETA
(GCD7), GAMMA (GCD1), DELTA (GCD2) AND EPSILON (GCD6).
-1- SIMILARITY: BELONGS TO THE EIF-2B GAMMA/EPSILON SUBUNITS FAMILY.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation-
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).

DR EMBL: L07115; G171574; -;
DR EMBL: Z68194; E223719; -;

	DR	EMBL:	Z68195;	E213795;	-.
	DR	PIR:	S30776;	S30776;	-
	DR	PIR:	A48156;	A48156;	-
	DR	SGD:	L0000674;	GCD6.	-
	DR	PFAM:	PF00132;	Hexapep.	3.
	KW	AMINO-ACID BIOSYNTHESIS;	TRANSLATION REGULATION.		
	SQ	SEQUENCE	712 AA;	81161 MW;	SDAD189F CRC32;

	Query Match	16.5%	Score 92;	DB 1;	Length 712;
	Best Local Similarity	39.5%;	Pred. NO. 3.33e-01;		
	Matches	17; Conservative	8; Mismatches	14;	Indels
				Gaps	4;

Dn	12	GGNSMDVDVEDRDQAVLTDS-YETFFMFLTAIVPRCLL	52
Oy	14	LGSSHGCGKMTLDLKAKESFELTNSYSYSEFLLELL-KL-CIL	54

CC	EUKARYOTA; METAZOA; ARTHROPODA; TRACHEATA; HEXAPODA; INSECTA;
OC	PNEUMOGTA; DIPTERA; BRACHYCERA; MUSCOPORPHA; EPHYROIDEA;
OC	DROSOPHILIDAE; DROSOPHILA.
RN	[1]
RP	SEQUENCE FROM N.A.
RX	MEDLINE; 92001539.
RA	FORTINI M.E., LAI Z., RUBIN G.M.:
RT	"The Drosophila zfh-1 and zfh-2 genes encode novel proteins containing both zinc-finger and homeodomain motifs."
RL	MCH. DEV. 34:113-122(1991).
CC	-!- FUNCTION: INVOLVED IN THE DEVELOPMENT OF THE EMBRYONIC CENTRAL NERVOUS SYSTEM.
CC	-!- SUBCELLULAR LOCATION: NUCLEAR (PROBABLE).
CC	-!- TISSUE SPECIFICITY: LARGELY RESTRICTED TO THE CNS OF LATE EMBRIO.
CC	-!- SIMILARITY: CONTAINS THREE HOMEBOX DOMAINS.
CC	This SWISS-PROT entry is copyrighted. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL Outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (see http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch). -----
CC	EMBL; M63450; GI58823; ..
DR	PIR; S27817; S27817.
DR	PIR; S33642; S33642.
DR	FLYBASE; FBgn0004607; zfh2.
DR	PROSITE; PS00027; HOMEBOX_1; 2.
DR	PROSITE; PS00028; ZINC_FINGER_C2H2; 8.
DR	PROSITE; PSS0071; HOMEBOX_2; 3.
DR	PFM; PF00046; homeobox; 3.
DR	PFAM; PFO0096; zf-C2H2; 12.
DR	HSSP; P15822; 4ZNF.
KM	TRANSFAC; T00920; ..
KM	ZINC-FINGER; METAL-BINDING; DNA-BINDING; HOMEBOX; NUCLEAR PROTEIN; REPEAT.
KW	REPAT.
FT	ZN_FING 133 156 C2H2-TYPE.
FT	ZN_FING 559 582 C2H2-TYPE.
FT	ZN_FING 614 638 C2H2-TYPE.
FT	ZN_FING 732 756 C2H2-TYPE.
FT	ZN_FING 897 916 C2H2-TYPE (DEGENERATE).
FT	ZN_FING 940 964 C2H2-TYPE.
FT	ZN_FING 999 1023 C2H2-TYPE.
FT	ZN_FING 1074 1098 C2H2-TYPE.
FT	ZN_FING 1210 1233 C2H2-TYPE.
FT	ZN_FING 1341 1365 C2H2-TYPE.
FT	ZN_FING 1438 1462 C2H2-TYPE.
FT	ZN_FING 1477 1500 C2H2-TYPE (DEGENERATE).
FT	ZN_FING 1513 1535 C2H2-TYPE.
FT	ZN_FING 1541 1564 C2H2-TYPE.
FT	DNAB_BIND 1797 1856 HOMEBOX 1.
FT	DNAB_BIND 2154 2213 HOMEBOX 2.
FT	ZN_FING 2234 2256 C2H2-TYPE.
FT	ZN_FING 2371 2393 C2H2-TYPE.
FT	DNAB_BIND 2760 2819 HOMEBOX 3.
SQ	SEQUENCE 3005 AA; 332056 MW; 89dCc45f CRC32;

DE HYPOTHETICAL HELICASE KI2H4.8 IN CHROMOSOME III.
 GN KI2H4.8
 OS CAENORHABDITIS ELEGANS.
 OC EUKARYOTA: METAZOA: NEMATODA: SECERNENTEA: RHABDITIA: RHABDITIDA;
 OC RHABDITINA: RHABDITOIDEA: RHABDITIDAE: PELODERINAE: CAENORHABDITIS.
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN-BRISTOL N2;
 RX MEDLINE: 94150718
 RA WILSON R., AINSCOUGH R., ANDERSON K., BAYNES C., BEKKS M.,
 RA BONFIELD J., BURTON J., CONNELL M., COPSEY T., COOPER J., COULSON A.,
 RA CRATON M., DEAR S., DU Z., DURBIN R., FAVELLO A., FRASER A.,
 RA FULTON L., GARDNER A., GREEN P., HAMKINS T., HILLIER L., JIER M.,
 RA JOHNSTON L., JONES M., KERSHAW J., KIRSTEN J., LAISTER N.,
 RA LATREILLE P., LIGHTNING J., LLOYD C., MORTIMORE B., O'CALLAGHAN M.,
 RA PARSONS J., PERCY C., RIFKEN L., ROOPRA A., SAUNDERS D., SHOMMEEN R.,
 RA SIMS M., SMALDON N., SMITH A., SMITH M., SONNHAMMER E., STADEN R.,
 RA SUSTON J., THIERRY-MIEG J., THOMAS K., VAUDIN M., VAUGHAN K.,
 RA WATERSON R., WATSON A., WEINSTOCK L., WILKINSON-SPROAT J.,
 RA WOHLDMAN P.,
 RA "2.2 kb of contiguous nucleotide sequence from chromosome III of C.
 RT elegans".
 RL NATURE 368:32-38(1994).
 CC -1- SIMILARITY: WITH OTHER ATP DEPENDENT HELICASES.
 CC -1- SIMILARITY: CONTAINS A RNASE III DOMAIN.
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC
 DR EMBL: L14331; G289703; -
 DR PIR: S44849; S44849
 DR WORMPEP: KI2H4.8; CE00273.
 DR PROSITE: PS00517; RIBONUCLEASE_III. 1.
 DR PFAM: PF00035; dsrm: 1.
 DR PFAM: PF00271; helicase_C: 1.
 DR PFAM: PF00636; Ribonuclease_3: 2.
 DR KW HYPOTHETICAL PROTEIN: HELICASE; ATP-BINDING; HYDROLASE; NUCLEASE;
 KW ENDONUCLEASE.
 FT NP_BIND 33 40 ATP (POTENTIAL).
 FT SITE 145 148 DECH BOX.
 FT DOMAIN 1554 1822 RNASE III DOMAIN.
 FT SEQUENCE 1822 AA: 208291 MW: 4F8E56AE CRC32:
 SQ
 Query Match 15.8%; Score 88; DB 1; Length 1822;
 Best Local Similarity 31.4%; Pred. No. 1,13e+00;
 Matches 16; Conservative 17; Mismatches 15; Indels 3; Gaps 3;
 Db 1300 IGLGVSPCLLTATLTSSNAAD-GMSLEFETIGDSFLKFAATDYLTHTLTD 1349
 QY 1 MGSGLPLVLTLLTLLSGHGTGPGMTLD-L-KIKESFLNNSYESSFLEELLE 49
 RESULT 5
 ID REF1M_SCHPO STANDARD; PRT: 396 AA.
 AC 009691;
 DT 01-NOV-1995 (REL. 32, CREATED)
 DT 01-NOV-1995 (REL. 32, LAST SEQUENCE UPDATE)
 DE PUTATIVE MITOCHONDRIAL PEPTIDE CHAIN RELEASE FACTOR PRECURSOR.
 GN SPAC27.17.
 OS SCHIZOSACCHAROMYCES POMBE (FISSION YEAST).
 OC EUKARYOTA: FUNGI: ASCOMYCOTA: ARCHIASCOMYCETES;
 OC SCHIZOSACCHAROMYCETALES: SCHIZOSACCHAROMYCETACEAE;
 OC SCHIZOSACCHAROMYCES.
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN-972;
 RA GENTLES S., CHURCHER C.M., BARRELL B.G., RAJANDREAM M.A., WALSH S.V.;

RL SUBMITTED (JUL-1995) TO EMBL/GENBANK/DBJ DATA BANKS.
 CC -1- SIMILARITY: BELONGS TO THE PROKARYOTIC AND MITOCHONDRIAL RELEASE
 CC FACTORS FAMILY. STRONG, TO YEAST MRP-1.
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC
 DR EMBL: Z50142; G1052800; -
 DR PROSITE: PS00745; RE_PROK_I. 1.
 DR PFAM: PF00472; RE-1. 1.
 DR KW HYPOTHETICAL PROTEIN: PROTEIN BIOSYNTHESIS; MITOCHONDRION;
 KW TRANSIT PEPTIDE.
 FT TRANSIT 1 ?
 FT CHAIN 1 ? 396 MITOCHONDRION (POTENTIAL).
 FT SEQUENCE 396 AA: 44954 MW: 988689CB CRC32:
 SQ
 Query Match 15.6%; Score 87; DB 1; Length 396;
 Best Local Similarity 45.0%; Pred. No. 1,52e+00;
 Matches 9; Conservative 8; Mismatches 3; Indels 0; Gaps 0;
 Db 281 LTHIPGIVTSMQDSRSQHQ 300
 QY 54 LHLPGSTVTLTHARSQHH 73
 RESULT 6
 ID XYTD_BACSU STANDARD; PRT: 272 AA.
 AC P39063;
 DT 01-FEB-1995 (REL. 31, CREATED)
 DT 01-FEB-1995 (REL. 31, LAST SEQUENCE UPDATE)
 DT 15-DEC-1998 (REL. 37, LAST ANNOTATION UPDATE)
 GN HYPOTHETICAL 30.1 KD PROTEIN IN ACDC 5' REGION (ORFA).
 DE XYTD.
 OS BACILLUS SUBTILIS.
 OC BACTERIA: FIRMICUTES; BACILLUS/CLOSTRIDIUM GROUP; BACILLACEAE;
 OC BACILLUS.
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN-168;
 RC MEDLINE: 95020526.
 RA GRUNDY F.J., WATERS D.A., TAKOVA T.Y., HENKIN T.M.;
 RT "Identification of genes involved in utilization of acetate and
 RT acetoin in Bacillus subtilis".
 RL MOL. MICROBIOL. 10:259-271(1993).
 RN [2]
 RP SEQUENCE FROM N.A.
 RX MEDLINE: 96048467.
 RA LAPIDUS A., GALLERON N., SOROKIN A., EHRLICH S.D.;
 RT "Sequencing and functional annotation of the Bacillus subtilis genes
 RT in the 200 kb rnpB-dnaB region.";
 RL MICROBIOLOGY 143:3431-3441(1997).
 CC -1- FUNCTION: MAY BE INVOLVED IN SOME TRANSPORT FUNCTION.
 CC -1- SUBCELLULAR LOCATION: INTERMEMBRANE MEMBRANE PROTEIN (POTENTIAL).
 CC -1- SIMILARITY: BELONGS TO THE MOTA FAMILY.
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC
 DR EMBL: L17309; G348048; -
 DR EMBL: AF008220; G2293222; -
 DR EMBL: Z99119; E1185846; -
 DR PIR: S39641; S39641.

DR SUBSTITUTED: BG10365; YTXD.
 DR PROSITE: PS01307; MOTA; 1.
 KW HYPOTHETICAL PROTEIN; TRANSPORT; TRANSMEMBRANE.
 FT TRANSMEM 9 POTENTIAL.
 FT TRANSMEM 38 58 POTENTIAL.
 FT TRANSMEM 154 174 POTENTIAL.
 FT TRANSMEM 188 208 POTENTIAL.
 FT DOMAIN 209 272 CYTOPLASMIC (POTENTIAL).
 SQ SEQUENCE 272 AA: 30143 MW: E89FDP9C CRC32:

Query Match 15.4%; Score 86; DB 1; Length 272;
 Best Local Similarity 34.6%; Pred. No. 2.04e+00;
 Matches 18; Conservative 12; Mismatches 20; Indels 2; Gaps 1;

DB 164 IGTGVGLVLMKLNDDPHMGPMNAITALLTLYGSLANVNPRIAKLEK 215
 QY 1 MGSGLPVLLLTLLSSHGTPGMQTLQKESFLLNSYSFLELLEK 50

RESULT 7
 ID RSEB_HAEIN STANDARD; PRT; 315 AA.

AC P44792;
 DT 01-NOV-1995 (REL. 32, CREATED)
 DT 01-NOV-1995 (REL. 32, LAST SEQUENCE UPDATE)
 DT 01-NOV-1995 (REL. 32, LAST ANNOTATION UPDATE)
 DE SIGMA-E FACTOR REGULATORY PROTEIN RSEB HOMOLOG PRECURSOR.
 GN RSEB OR HI0630.
 OS HAEMOPHILUS INFLUENZAE.
 OC BACTERIA; PROTEOBACTERIA; GAMMA SUBDIVISION; PASTEURELLACEAE;
 OC HAEMOPHILUS.
 RN [1]

RP SEQUENCE FROM N.A.
 RC STRAIN-RD / KM20:
 RX MEDLINE: 95350630.
 RA FLEISCHMANN R.D., ADAMS M.D., WHITE O., CLAYTON R.A., KIRKNESS E.F.,
 RA KERLAVAGE A.R., BULT C.J., TOMB J.F., DOUGHERTY B.A., MERRICK J.M.,
 RA MCKENNEY K., SUTTON G., FITZHUGH W., FIELDS C.A., GOCAYNE J.D.,
 RA SCOTT J.D., SHIRLEY R., LIU L.-I., GLADKE A., KELLEY J.M.,
 RA WEIDMANN J.F., PHILLIPS C.A., SPRIGGS T., HEDBLUM E., COTTON M.D.,
 RA UETTERACK T.R., HANNA M.C., NGUYEN D.T., SAUDEK D.M., BRANDON R.C.,
 RA FINE L.D., FRITCHMAN J.L., FUHRMANN J.L., GEOGHAGEN N.S.M.,
 RA GNEHM C.L., McDONALD L.A., SMALL K.V., FRASER C.M., SMITH H.O.,
 RA VENTER J.C.;

RT "Whole-genome random sequencing and assembly of Haemophilus

influenzae Rd.;"

RL SCIENCE 269:496-512(1995).

CC -1- FUNCTION: SEEMS TO MODULATE THE ACTIVITY OF POE (SIGMA-E)

(BY SIMILARITY).

CC -1- SUBCELLULAR LOCATION: PERIPLASMIC (POTENTIAL).

CC -1- SIMILARITY: TO E.COLI RSEB AND P.AERUGINOSA MUCB.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration

between the Swiss Institute of Bioinformatics and the EMBL outstation

at the European Bioinformatics Institute. There are no restrictions on its

use by non-profit institutions as long as its content is in no way

modified and this statement is not removed. Usage by and for commercial

entities requires a license agreement (See <http://www.isb-sib.ch/announce/>

or send an email to license@isb-sib.ch).

CC EMBL: U03746; G1573637; -

DR TIGR: H10630; -

KW PERIPLASMIC; SIGNAL.

FT SIGNAL 1 23 POTENTIAL.

FT CHAIN 24 315 SIGMA-E FACTOR REGULATORY PROTEIN RSEB

FT SEQUENCE 315 AA: 35906 MW: 8081C11D CRC32:

Query Match 15.2%; Score 85; DB 1; Length 315;
 Best Local Similarity 29.5%; Pred. No. 2.74e+00;
 Matches 13; Conservative 18; Mismatches 11; Indels 2; Gaps 2;

DB 9 TALSLSLLSIASAEELASQSD-KMGA-LDNLENTAFAVQ 50

Query Match 15.2%; Score 85; DB 1; Length 315;
 Best Local Similarity 29.5%; Pred. No. 2.74e+00;
 Matches 13; Conservative 18; Mismatches 11; Indels 2; Gaps 2;

QY 3 SGLPVLLLTLLSSHGTPGMQTLQKESFLLNSYSFLELLEK 46

RESULT 8
 ID YDB3_SCHPO STANDARD; PRT; 191 AA.

AC Q10356;
 DT 01-OCT-1996 (REL. 34, CREATED)
 DT 01-OCT-1996 (REL. 34, LAST SEQUENCE UPDATE)
 DT 15-JUL-1998 (REL. 36, LAST ANNOTATION UPDATE)
 DE HYPOTHETICAL 21.1 KD PROTEIN C22E12.03C IN CHROMOSOME I.
 GN SPAC22E12.03C.
 OS SCHIZOSACCHAROMYCES POMBE (FISSION YEAST).
 OC EUKARYOTA; FUNGI; ASCOMYCOTA; ARCHIASCOMYCETES;
 OC SCHIZOSACCHAROMYCETALES; SCHIZOSACCHAROMYCETACEAE;
 OC SCHIZOSACCHAROMYCES.
 RN [1]

RP SEQUENCE FROM N.A.

RC STRAIN-972; CHURCHER C.M., BARRELL B.G., RAJANDREAN M.A., WALSH S.V.,

RA DEVLIN K., CHURCHER C.M., BARRELL B.G., RAJANDREAN M.A., WALSH S.V.,

RA SUBMITTED (MAR-1996) TO EMBL/GENBANK/DOBI DATA BANKS.

CC -1- SIMILARITY: BELONGS TO THE TH1 / PEP1 FAMILY.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration

between the Swiss Institute of Bioinformatics and the EMBL outstation

at the European Bioinformatics Institute. There are no restrictions on its

use by non-profit institutions as long as its content is in no way

modified and this statement is not removed. Usage by and for commercial

entities requires a license agreement (See <http://www.isb-sib.ch/announce/>

or send an email to license@isb-sib.ch).

CC EMBL: 270043; E228197; -

DR HYPOTHETICAL PROTEIN.

KW SEQUENCE 191 AA: 21078 MW: D47EB47B CRC32:

Query Match 15.1%; Score 84; DB 1; Length 191;
 Best Local Similarity 33.3%; Pred. No. 3.67e+00;
 Matches 14; Conservative 11; Mismatches 16; Indels 1; Gaps 1;

DB 148 PVYLEENLI-TSGPGTAMFGKILEQVASKDKYNAVYKSL 188

QY 6 PLVILLTLSSHGTPGMQTLQKESFLLNSYSFLELLEK 47

RESULT 9
 ID TCR2_ECOLI STANDARD; PRT; 401 AA.

AC P02960;
 DT 21-JUL-1986 (REL. 01, CREATED)
 DT 21-JUL-1986 (REL. 01, LAST SEQUENCE UPDATE)
 DT 15-DEC-1998 (REL. 37, LAST ANNOTATION UPDATE)
 DE TETRACYCLINE RESISTANCE PROTEIN, CLASS B (TETRA(B)) (METAL-
 DE TETRACYCLINE/H+ ANTI-PORTER).
 GN TETRA.

OS ESCHERICHIA COLI.

OC BACTERIA; PROTEOBACTERIA; GAMMA SUBDIVISION; ENTEROBACTERIACEAE;
 OC ESCHERICHIA.

CC [1]

RP SEQUENCE FROM N.A.

RX MEDLINE: 84109550.

RA NGUYEN T.T., POSTLE K., BERTRAND K.P.;

RT "Sequence homology between the tetracycline-resistance determinants

of Tn10 and pBR32.;"

RL GENE 25:83-92(1983).

RN [2]

RP SEQUENCE FROM N.A.

RX MEDLINE: 83143319.

RA HILLEN W., SCHOLIMMEIER K.;

RT "Nucleotide sequence of the Tn10 encoded tetracycline resistance

gene.;"

RL NUCLEIC ACIDS RES. 11:525-539(1983).

RN [3]

RP MUTAGENESIS OF HIS-257.

RX MEDLINE: 91177844.

RA YAMAGUCHI A., ADACHI K., AKASAKA T., ONO N., SAWAI T.;

RT "Metal-tetracycline/H+ antiporter of Escherichia coli encoded by a
transposon Tn10. Histidine 257 plays an essential role in H+
translocation."
RT J. BIOL. CHEM. 266:6045-6051(1991).
RN [4]
RP MUTAGENESIS OF 65-66.
RX YAMAGUCHI A., ONO N., AKASAKA T., NOUNI T., SAWAI T.;
"Metal-tetracycline/H+ antiporter of Escherichia coli encoded by a
transposon, Tn10. The role of the conserved dipeptide, Ser65-Asp66,
in tetracycline transport."
RT J. BIOL. CHEM. 265:15525-15530(1990).
CC -I- FUNCTION: RESISTANCE TO TETRACYCLINE BY AN ACTIVE TETRACYCLINE
EFFLUX. THIS IS AN ENERGY-DEPENDENT PROCESS THAT DECREASES THE
ACCUMULATION OF THE ANTIBIOTIC IN WHOLE CELLS. THIS PROTEIN
FUNCTIONS AS A METAL-TETRACYCLINE/H+ ANTIPORTER.
CC -I- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. INNER MEMBRANE.
CC -I- SIMILARITY: BELONGS TO THE MAJOR FACILITATOR FAMILY (ALSO KNOWN
AS THE DRUG RESISTANCE TRANSDUCASE FAMILY).
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL Outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
or send an email to license@isb-sib.ch).
CC -----
DR EMBL: V00611; G43701; -
DR EMBL: J01830; G154847; -
DR PIR: A03507; YTECTO
DR PROSITE: PS00216; SUGAR_TRANSPORT_1; UNKNOWN_1.
KW ANTI-BIOTIC RESISTANCE; TRANSMEMBRANE; INNER MEMBRANE; TRANSPORT;
KM SYMPTOT; TRANSPOSABLE ELEMENT.
KW TRANSMEM 6 26
FT TRANSMEM 42 62 POTENTIAL.
FT TRANSMEM 74 94 POTENTIAL.
FT TRANSMEM 102 122 POTENTIAL.
FT TRANSMEM 131 151 POTENTIAL.
FT TRANSMEM 159 179 POTENTIAL.
FT TRANSMEM 214 234 POTENTIAL.
FT TRANSMEM 244 265 POTENTIAL.
FT TRANSMEM 277 297 POTENTIAL.
FT TRANSMEM 298 318 POTENTIAL.
FT TRANSMEM 336 356 POTENTIAL.
FT TRANSMEM 363 383 POTENTIAL.
FT TRANSMEM 65 65 S->C: ALMOST NO CHANGE IN ACTIVITY.
FT TRANSMEM 65 65 S->A: NO CHANGE IN ACTIVITY.
FT TRANSMEM 66 66 D->N: UNABLE TO EXTENDED TETRACYCLINE.
FT TRANSMEM 66 66 D->E: MODERATE RESISTANCE TO
TETRACYCLINE.
FT TRANSMEM 257 257 H->E: NO H+ TRANSDUCATION.
FT TRANSMEM 257 257 H->D: NO H+ TRANSDUCATION.
FT TRANSMEM 281 281 G->D: E (IN REF. 2).
FT TRANSMEM 301 301 V->D: E (IN REF. 2).
FT TRANSMEM 330 330 Q->E (IN REF. 2).
FT TRANSMEM 354 354 A->T (IN REF. 2).
SQ SEQUENCE 401 AA; 43267 MW; 4823C395 CRC32;
Query Match 14.9%; Score 83; DB 1; Length 401;
Best Local Similarity 31.0%; Pred. No. 4,90e+00;
Matches 18; Conservative 13; Mismatches 23; Indels 4; Gaps 4;
Db 1 MNSSTIAIVITLDM-GIGLIMPVPLPLLE-FIASEDIANHEGVLA-LYALMOV 55
Oy 1 MGSGLPVLTLTSSHGTPQPT-LQIKLESFTNSSESSFLEIKLCLHL 57
RESULT 10 STANDARD: PRT: 445 AA.
ID YGCS_ECOLI
AC 046909;
DT 01-NOV-1997 (REL. 35, CREATED)
DT 01-NOV-1997 (REL. 35, LAST SEQUENCE UPDATE)

DT 01-NOV-1997 (REL. 35, LAST SEQUENCE UPDATE)
DE HYPOTHETICAL METABOLITE TRANSPORT PROTEIN IN CISJ-ENO INTERGENIC
REGION.
GN YGCS.
OS ESCHERICHIA COLI.
OC BACTERIA; PROTEOBACTERIA; GAMMA SUBDIVISION; ENTEROBACTERIACEAE;
CC ESCHERICHIA.
RN [1]
RP SEQUENCE FROM N.A.
RX STRAIN-K12 / MG1655.
RX MEDLINE: 97426617.
RA BLATNER F.R., PUNKETT G. III, BLOCH C.A., PERNA N.T., BURLAND V.,
RA RILEY M., COLLADO-VIDES J., GLASNER F.D., RODE C.K., MAYHEW G.F.,
RA GREGOR J., DAVIS N.W., KIRKPATRICK H.A., GOEDEN M.A., ROSE D.J.,
RA MAU B., SHAO Y.;
RT "The complete genome sequence of Escherichia coli K-12."
RL SCIENCE 277:1453-1474(1997).
CC -I- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. INNER MEMBRANE
(POTENTIAL).
CC -----
CC -I- SIMILARITY: BELONGS TO THE SUGAR TRANSPORTER FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL Outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
or send an email to license@isb-sib.ch).
CC -----
DR EMBL: U29579; G882664; ALT_INIT.
DR EMBL: AEO00360; G1789130; ALT_INIT.
DR ECOGENE: EG13126; YGCS.
DR PROSITE: PS00216; SUGAR_TRANSPORT_1; FALSE_NEG.
DR PROSITE: PS00217; SUGAR_TRANSPORT_2; 1.
DR PFAM: PF00083; sugar_tr_1.
KW HYPOTHETICAL PROTEIN; TRANSPORT; TRANSMEMBRANE; INNER MEMBRANE.
KM TRANSMEM 23 43
FT TRANSMEM 57 77 POTENTIAL.
FT TRANSMEM 86 106 POTENTIAL.
FT TRANSMEM 115 135 POTENTIAL.
FT TRANSMEM 143 163 POTENTIAL.
FT TRANSMEM 176 196 POTENTIAL.
FT TRANSMEM 254 274 POTENTIAL.
FT TRANSMEM 287 307 POTENTIAL.
FT TRANSMEM 312 332 POTENTIAL.
FT TRANSMEM 338 358 POTENTIAL.
FT TRANSMEM 370 390 POTENTIAL.
FT TRANSMEM 401 421 POTENTIAL.
SQ SEQUENCE 445 AA; 48234 MW; BDD078EF CRC32;
Query Match 14.9%; Score 83; DB 1; Length 445;
Best Local Similarity 38.6%; Pred. No. 4,90e+00;
Matches 17; Conservative 9; Mismatches 16; Indels 2; Gaps 2;
Db 296 GALLGLVLTG-LAHRKFLGSLLAATVWACLPSSGSTL 338
Oy 23 GMTLQIKLESFTNSSESSFLEIKLCLHLPLSGSTVTL 65
RESULT 11 STANDARD: PRT: 647 AA.
ID BGAL_MOUSE
AC P23780;
DT 01-NOV-1991 (REL. 20, CREATED)
DT 01-NOV-1991 (REL. 20, LAST SEQUENCE UPDATE)
DT 01-NOV-1997 (REL. 35, LAST SEQUENCE UPDATE)
DE BETA-GALACTOSIDASE PRECURSOR (EC 3.2.1.23) (LACTASE) (ACID BETA-
DE GALACTOSIDASE).
GN GLB1 OR GLB-1 OR BGL.
OS MUS MUSCULUS (MOUSE).
OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; MAMMALIA; EUTHERIA;
OC RODENTIA; SCIROGNATHI; MURIDAE; MURINAE; MUS.
RN [1]
RP SEQUENCE FROM N.A.

RC TISSUE-BRAIN;
RX MEDLINE: 91076843.
RA NANBA E., SUZUKI K.;
RT "Molecular cloning of mouse acid beta-galactosidase cDNA: sequence,
expression of catalytic activity and comparison with the human
enzyme.";
RL BIOCHEM. BIOPHYS. RES. COMMUN. 173:141-148(1990).
RN [2]
RP SEQUENCE FROM N.A.
RX STRAIN-DBA/2J;
RX MEDLINE: 91298941.
RA NANBA E., SUZUKI K.;
RT "Organization of the mouse acid beta-galactosidase gene.";
RL BIOCHEM. BIOPHYS. RES. COMMUN. 178:158-166(1991)
CC -1- FUNCTION: CLEAVES BETA-LINKED TERMINAL GALACTOSYL RESIDUES FROM
GALACTOSIDES, GLYCOPROTEINS, AND GLYCOSAMINOGLYCAN.
CC -1- CATALYTIC ACTIVITY: HYDROLYSIS OF TERMINAL, NON-REDUCING BETA-D-
GALACTOSE RESIDUES IN BETA-D-GALACTOSIDES.
CC -1- SIMILARITY: BELONGS TO FAMILY 35 OF GLYCOSYL HYDROLASES.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
or send an email to license@isb-sib.ch).
CC -----
DR EMBL: M57734: G192185: -
DR EMBL: M75122: G192185: -
DR EMBL: M75137: G192185: JOINED.
DR EMBL: M75107: G192185: JOINED.
DR EMBL: M75108: G192185: JOINED.
DR EMBL: M75109: G192185: JOINED.
DR EMBL: M75111: G192185: JOINED.
DR EMBL: M75112: G192185: JOINED.
DR EMBL: M75113: G192185: JOINED.
DR EMBL: M75114: G192185: JOINED.
DR EMBL: M75115: G192185: JOINED.
DR EMBL: M75116: G192185: JOINED.
DR EMBL: M75117: G192185: JOINED.
DR EMBL: M75118: G192185: JOINED.
DR EMBL: M75119: G192185: JOINED.
DR EMBL: M75120: G192185: JOINED.
DR EMBL: M75121: G192185: JOINED.
DR PIR: A37086: A37086.
DR MGD: MGT:88151: BGL.
DR PROSITE: PS01182: GLYCOSYL_HYDROL_F35: 1.
DR PIRAM: PF01501: GLYCOSYL_HYDRL7: 1.
KW HYDROLASE; GLYCOSIDASE; LYSOSOME; SIGNAL; GLYCOPROTEIN.
FT SIGNAL 1 24
FT PROPEP 25 29
FT CHAIN 30 647
FT ACT_SITE 189 189 BETA-GALACTOSIDASE.
FT ACT_SITE 269 269 PROTON DONOR (POTENTIAL).
FT CARBOHYD 27 27 NICLEOPHILE (POTENTIAL).
FT CARBOHYD 268 268 POTENTIAL.
FT CARBOHYD 500 500 POTENTIAL.
FT CARBOHYD 504 504 POTENTIAL.
FT CARBOHYD 510 510 POTENTIAL.
FT CARBOHYD 544 544 POTENTIAL.
FT CARBOHYD 557 557 POTENTIAL.
FT CARBOHYD 617 617 POTENTIAL.
FT CONFLICT 517 517 N -> D (IN REF. 2).
FT CONFLICT 539 539 G -> R (IN REF. 2).
SQ SEQUENCE 647 AA: 73121 MW: 158CF158 CRC32:
Query Match 14.9%; Score 83; DB 1; Length 647;
Best Local Similarity 37.8%; Pred. No. 4.90e+00;
Matches 14; Conservative 8; Mismatches 12; Indels 3; Gaps 3;

Oy |||: || |||||: ||: | :: ||: |
5 LPVILLTLTGSSHG-G-PGNTLQKL-KESFLTNS 38
ID NME3 HUMAN STANDARD: PRT: 1233 AA.
AC 014957;
DT 01-NOV-1997 (REL. 35, CREATED)
DT 01-NOV-1997 (REL. 35, LAST SEQUENCE UPDATE)
DT 01-NOV-1997 (REL. 35, LAST ANNOTATION UPDATE)
DE GLUTAMATE [NMDA] RECEPTOR SUBUNIT EPSILON 3 PRECURSOR (N-METHYL
D-ASPARTATE RECEPTOR SUBTYPE 2C) (NR2C) (NMDAR2C).
GN GRIN2C.
OS HOMO SAPIENS (HUMAN).
OC EUKARYOTA, METAZOA, CHORDATA, VERTEBRATA, MAMMALIA, EUTHERIA:
OC PRIMATES; CATARRHINI; HOMINIDAE; HOMO.
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE-BRAIN.
RA LIN Y.J., BOVETTO S., CARVER J., GIORIANO T.;
RL SUBMITTED (FEB-1996) TO EMBL/GENBANK/DBJ DATA BANKS.
CC -1- FUNCTION: NMDA RECEPTOR SUBTYPE OF GLUTAMATE-GATED ION CHANNELS
POSSESSES HIGH CALCIUM PERMEABILITY AND VOLTAGE-DEPENDENT
SENSITIVITY TO MAGNESIUM AND IS MEDIATED BY GLYCINE.
CC -1- SUBUNIT: HETERODIMER OF AN EPSILON SUBUNIT AND A ZETA SUBUNIT.
CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN.
CC -1- SIMILARITY: BELONGS TO THE LIGAND-GATED IONIC CHANNELS FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
or send an email to license@isb-sib.ch).
CC -----
DR EMBL: L76224: G1196449: -
DR MIM: 138254: -
DR PIRAM: PF00060: I1g_chan: 1.
KW RECEPTOR; SIGNAL; TRANSMEMBRANE; POSTSYNAPTIC MEMBRANE; CALCIUM;
KN IONIC CHANNEL; MAGNESIUM.
FT SIGNAL 1 19
FT CHAIN 20 1233
FT TRANSMEM 554 574
FT TRANSMEM 597 617
FT TRANSMEM 627 647
FT TRANSMEM 815 835
FT SITE 612 612
FT CARBOHYD 70 70
FT CARBOHYD 337 337
FT CARBOHYD 438 438
FT CARBOHYD 539 539
SQ SEQUENCE 1233 AA: 134239 MW: 671F9981 CRC32:
Query Match 14.9%; Score 83; DB 1; Length 1233;
Best Local Similarity 33.3%; Pred. No. 4.90e+00;
Matches 20; Conservative 13; Mismatches 24; Indels 3; Gaps 3;
Db 1 MCGALPALLTLTSLFAMAGLPGGEGMTVAVSSSGPPQAQFARLTPOSFL-DLP 59
Oy 1 MSGGLPVLILT-LTGSSHGTPGNTLQ-LKLESFLTNSYSESEFLEKLCILLHP 58
RESULT 13
ID INVE_SALTY STANDARD: PRT: 372 AA.
AC P35671;
DT 01-JUN-1994 (REL. 29, CREATED)
DT 01-FEB-1995 (REL. 31, LAST SEQUENCE UPDATE)
DT 01-FEB-1996 (REL. 33, LAST ANNOTATION UPDATE)
DE INVASION PROTEIN INVE.
GN INVE.

OS SALMONELLA TYPHIMURIUM.
OC BACTERIA: PROTEOBACTERIA; GAMMA SUBDIVISION; ENTEROBACTERIACEAE;
OC SALMONELLA.
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-SR11 / SL1344;
RX MEDLINE: 92335220.
RA GIROCCIO C., PACE J., GALAN J.E.;
RT "Identification and molecular characterization of a Salmonella
typhimurium gene involved in triggering the internalization of
salmonellae into cultured epithelial cells."
RL PROC. NATL. ACAD. SCI. U.S.A. 89:5976-5980(1992).
RN [2]
RP SEQUENCE OF 1-69 FROM N.A.
RC STRAIN-SR11 / SL1344;
RX MEDLINE: 95089692.
RA KANIGA K., BOSSIO J.C., GALAN J.E.;
RT "The Salmonella typhimurium invasion genes invF and invG encode
homologues of the Arac and Pvd family of proteins."
RL MOL. MICROBIOL. 13:555-568(1994).
RN [3]
RP SEQUENCE OF 1-5 FROM N.A.
RC STRAIN-TML;
RA LODGE J.M., AMIN I.I., DOUCE G.R., BROWN N.L., STEPHEN J.;
RL SUBMITTED (SEP-1993) TO EMBL/GENBANK/DBJ DATA BANKS.
CC -1- FUNCTION: INVOLVED IN THE TRIGGERING OF INTRACELLULAR EVENTS THAT
LEAD TO MICROBIAL INTERNALIZATION OF THE INTESTINAL EPITHELIUM.
CC THESE EVENTS INCLUDE INCREASE IN CALCIUM LEVEL, REDISTRIBUTION OF
ACTIN MICROFILAMENTS, AND CHANGES IN THE NORMAL STRUCTURE OF THE
MICROVILLI.
CC -1- SIMILARITY: TO YERSINIA OUTER MEMBRANE PROTEIN YOPN (LCRE).
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
or send an email to license@isb-sib.ch).
CC -----
DR EMBL: M90714; -; NOT_ANNOTATED_CDS.
DR EMBL: U08280; G497226; -
DR EMBL: X75302; E86775; ALT_FRAME.
DR STYGENE: SG10187; INVE.
KW VIRULENCE.
SQ SEQUENCE 372 AA: 42436 MW: A3450026 CRC32:
Query Match 14.7%; Score 82; DB 1; Length 372;
Best Local Similarity 26.1%; Pred. No. 6.52e+00;
Matches 12; Conservative 17; Mismatches 16; Indels 1; Gaps 1;
Db 284 LILMISLQPHVDLSLADIDIGLNLISLKHK-ASFLDIFQVC 328
QY 7 LVLLTLGLSSHGTPGNTQLKLSKESFLTNSYSSFLDLRLK 52

FT niger WD-2223L.";
RL SUBMITTED (JUL-1995) TO EMBL/GENBANK/DBJ DATA BANKS.
RN [2]
RP SEQUENCE OF 142-286 FROM N.A.
RC STRAIN-IFM 5367, IFM 5368, IFM 40606, IFM 41398, IFM 41399, IFM 46897;
RX MEDLINE: 99065785.
RA WANG L., YOKOYAMA K., MIYAJI M., NISHIMURA K.;
RT "The identification and phylogenetic relationship of pathogenic
species of Aspergillus based on the mitochondrial cytochrome b gene."
RL MED. MYCOL. 36:153-164(1998).
CC -1- FUNCTION: COMPONENT OF THE UBIQUINOL-CYTOCHROME C REDUCTASE
COMPLEX (COMPLEX III OR CYTOCHROME B-C1 COMPLEX), WHICH IS A
RESPIRATORY CHAIN THAT GENERATES AN ELECTROCHEMICAL POTENTIAL
COUPLED TO ATP SYNTHESIS.
CC -1- CATALYTIC ACTIVITY: OX(2) + 2 FERRICYTOCHROME C = Q +
CYTOCHROME C
CC -1- COFACTOR: TWO HEME GROUPS (B562 AND B566) WHICH ARE NOT COVALENTLY
BOUND TO THE PROTEIN.
CC -1- SUBUNIT: THE MAIN SUBUNITS OF COMPLEX B-C1 ARE: CYTOCHROME B,
CYTOCHROME C1 AND THE RIESKE PROTEIN.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
or send an email to license@isb-sib.ch).
CC -----
DR EMBL: D63375; G1000910; -
DR EMBL: AB000575; D1035119; -
DR EMBL: AB000576; D1035120; -
DR EMBL: AB000577; D1035121; -
DR EMBL: AB000578; D1035122; -
DR EMBL: AB000583; D1035127; -
DR EMBL: AB000587; D1035139; -
DR PROSITE: PS00192; CYTOCHROME B-HEME: 1.
DR PROSITE: PS00193; CYTOCHROME B-OO: 1.
DR PFAM: PF00032; Cytochrome B-C1.
DR PFAM: PF00033; Cytochrome B-N.
KW ELECTRON TRANSPORT; MITOCHONDRION; RESPIRATORY CHAIN; TRANSMEMBRANE;
FT METAL 82 82 IRON 1 (HEME B562 AXIAL LIGAND).
FT METAL 96 96 IRON 2 (HEME B566 AXIAL LIGAND).
FT METAL 183 183 IRON 2 (HEME B562 AXIAL LIGAND).
FT METAL 197 197 IRON 1 (HEME B566 AXIAL LIGAND).
SQ SEQUENCE 385 AA: 43078 MW: 17050CE1 CRC32:
Query Match 14.7%; Score 82; DB 1; Length 385;
Best Local Similarity 34.3%; Pred. No. 6.52e+00;
Matches 12; Conservative 11; Mismatches 11; Indels 1; Gaps 1;
Db 24 ANISTYLMNFGSLA-LDGLQIVTGVTLAMHYTPS 57
QY 36 TNSYSESFLELEKICLLILHPSGTSTVLHHARS 70

RESULT 14
ID CYB.ASPNG STANDARD: PRT: 385 AA.
AC 033798;
DT 15-DEC-1998 (REL. 37, CREATED)
DT 15-DEC-1998 (REL. 37, LAST SEQUENCE UPDATE)
DE CYTOCHROME B (EC 1.10.2.2).
GN COB OR CYTB OR COBA.
OS ASPERGILLUS NIGER.
OC MITOCHONDRION.
OC EUKARYOTA: FUNGI: ASCOMYCOTA: EUASCOMYCETES: PLECOMYCETES:
OC EURHOTIALES: TRICHOCOMACEAE; MITOSPORIC TRICHOCOMACEAE; ASPERGILLUS.
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-WD-2223L;
RA NARUSAMA T., KANAYAMA S., KIRIMURA K., USAMI S.;
RT "Nucleotide sequence of the apocytochrome b gene of Aspergillus

RESULT 15
ID MOTA.RHOSE STANDARD: PRT: 253 AA.
AC 033174;
DT 15-JUL-1998 (REL. 36, CREATED)
DT 15-JUL-1998 (REL. 36, LAST SEQUENCE UPDATE)
DE CHEMOTAXIS MOTA PROTEIN (MOTILITY PROTEIN A).
GN MOTA.
OS RHODOPACTER SPHAEROIDES (RHODOSPIRIDIUM SPHAEROIDES)
OC BACTERIA: PROTEOBACTERIA; ALPHA SUBDIVISION; RHODOPACTER GROUP:
OC RHODOPACTER.
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-W58;
RX MEDLINE: 96123438.
RA SHAH D.S.H., SOCKERT R.E.;

```

RT "Analysis of the motA flagellar motor gene from Rhodospirillum rubrum, a bacterium with a unidirectional, stop-start
RT flagellum."
RL MOL. MICROBIOL. 17:961-969(1995).
CC -I- FUNCTION: REQUIRED FOR ROTATION OF THE FLAGELLAR MOTOR. PROBABLE
CC -I- TRANSMEMBRANE PROTON CHANNEL (BY SIMILARITY).
CC -I- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN. INNER MEMBRANE.
CC -I- SIMILARITY: BELONGS TO THE MOT A FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL: X85986; G758646; -.
DR PROSITE: PS01307; MOT A; 1.
KW CHEMOTAXIS; FLAGELLA; TRANSMEMBRANE; INNER MEMBRANE;
KW FLAGELLAR ROTATION; HYDROGEN ION TRANSPORT.
FT TRANSMEM 3 23 POTENTIAL.
FT TRANSMEM 29 49 POTENTIAL.
FT TRANSMEM 146 166 POTENTIAL.
FT TRANSMEM 181 201 POTENTIAL.
FT DOMAIN 202 253 CYTOPLASMIC (POTENTIAL).
SQ SEQUENCE 253 AA; 27194 MW; F594C09C CRC32;

Query Match 14.5% Score 81; DB 1; Length 253;
Best Local Similarity 27.5% Pred. No. 8.66e+00;
Matches 14; Conservative 20; Mismatches 14; Indels 3; Gaps 2;

Db 156 VGTILGLVLMGNMSPKSGIPAMVALLTLYGALMANVF-APLNKLE 205
OY 1 MMSGELPLVLLLTLLGSSHGCGPMTQL-RLKSEPLTNSSESEFELLE 49

```

Search completed: Fri Oct 22 18:43:49 1999
Job time : 22 secs.

MIRISORLI

(TM)

Release 3.1a John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

Mperch_lp protein - protein database search, using Smith-Waterman algorithm

Run on: Fri Oct 22 18:44:06 1999; Maspar time 8.07 Seconds

Tabular output not generated. 527,481 Million cell updates/sec

Title: >US-09-092-296-15
Description: (1-78) from US09092296.pap
Perfect Score: 558
Sequence: 1 MGSGLPLVLLTLGLSSHGT.....SCTSVTLHARSQHVCNT 78

Scoring table:
PAM 150
Gap 11

Searched: 179066 seqs, 54579741 residues

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database:

sptrembl9
1:sp_archaea 2:sp_bacteria 3:sp_fungi 4:sp_human
5:sp_invertebrate 6:sp_mammal 7:sp_mhc 8:sp_organelle
9:sp_phase 10:sp_plant 11:sp_rodent 12:sp_unclassified
13:sp_vertebrate 14:sp_virus

Statistics: Mean 38.815; Variance 83.141; scale 0.467

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description	Pred. No.
1	101	18.1	501	2	067102	PROTEIN EXPORT MEMBRAN	8.20e-02
2	93	16.7	382	8	037395	APOCYTOCHROME B (FC 1.	8.75e-01
3	92	16.5	209	2	068567	RESTRICTION ENDONUCLEA	1.17e+00
4	92	16.5	863	14	P89688	ENV POLYPROTEIN.	1.17e+00
5	89	15.9	879	2	P75377	F11.0RE879 PROTEIN.	2.74e+00
6	88	15.8	297	8	003305	CYTOCHROME B (FRAGMENT	3.63e+00
7	87	15.6	143	14	069582	HERPESVIRUS TYPE 6 DNA	4.79e+00
8	86	15.4	322	4	014968	RHOOPSIN	6.32e+00
9	86	15.4	562	5	023220	MOB82.3 PROTEIN.	6.32e+00
10	85	15.2	297	8	003394	CYTOCHROME B (FRAGMENT	8.31e+00
11	85	15.2	297	8	003395	CYTOCHROME B (FRAGMENT	8.31e+00
12	85	15.2	395	10	023674	CHALCONE SYNTHASE HOMO	8.31e+00
13	85	15.2	448	13	042453	SERPIN PRECURSOR.	8.31e+00
14	85	15.2	676	5	045649	KO3D7.3.	8.31e+00
15	84	15.1	371	4	043190	PURINERGIC P2Y11 RECEP	1.09e+01
16	84	15.1	441	2	P72934	DIHYDROOROTASE.	1.09e+01
17	84	15.1	454	14	036385	PUTATIVE TYROSINE KINA	1.09e+01
18	84	15.1	509	2	P74537	HYPOTHEICAL 56.7 KD P	1.09e+01
19	84	15.1	1016	5	017485	AMINOPEPTIDASE.	1.09e+01
20	84	15.1	1016	5	017484	AMINOPEPTIDASE.	1.09e+01

ALIGNMENTS

RESULT ID	1	PRELIMINARY;	PRT:	501 AA.
AC	067102;			
DT	01-AUG-1998 (TREMBLREL. 07, CREATED)			
DT	01-AUG-1998 (TREMBLREL. 07, LAST SEQUENCE UPDATE)			
DT	01-NOV-1996 (TREMBLREL. 08, LAST ANNOTATION UPDATE)			
DE	PROTEIN EXPORT MEMBRANE PROTEIN SECD.			
GN	SECD.			
OS	AQUIFEX AEOLICUS.			
OC	BACTERIA; AQUIFICALES; AQUIFICACEAE; AQUIFEX.			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RC	STRAIN-VF5.			
RX	MEDLINE; 96196666.			
RA	DECKERT G., WARREN P.V., GAASTERLAND T., YOUNG M.G., LENOX A.L.,			
RA	GRAHAM D.E., OVERBECK R., SNEAD M.A., KELLER M., AUIY M., HUBER R.,			
RA	FELDMAN R.A., SHORT J.M., OLSON G.J., SWANSON R.V.;			
RT	"The complete genome of the hyperthermophilic bacterium Aquifex			
RT	aeolicus.";			
RL	NATURE 392:353-358(1998).			
RN	[2]			
RP	SEQUENCE FROM N.A.			
RC	STRAIN-VF5.			
RA	DECKERT G., WARREN P.V., GAASTERLAND T., YOUNG M.G., LENOX A.L.,			
RA	GRAHAM D.E., OVERBECK R., SNEAD M.A., KELLER M., AUIY M., HUBER R.,			
RA	FELDMAN R.A., SHORT J.M., OLSON G.J., SWANSON R.V.;			
DR	EMBL; AE000716; G2983481.;			
DR	SEQUENCE 501 AA; 55459 MW; E67F690C CRC32;			
Query Match	18.18;	Score 101;	DB 2;	Length 501;
Best Local Similarity	38.38;	Pred. No. 8.20e-02;		
Matches	18;	Conservative 10;	Mismatches 18;	Indels 1;
DB	454	VILFOP-GSGPVKGFATTLGTFISFISNYAKVFLDLNLKTL 499		
OY	8	VLLTLTGLSSHGTPGNTLQTKIKESFIFNSVSFLELKLCLL 54		

RESULT 2
ID 037395; PRELIMINARY; PRT: 382 AA.
AC 037395;
DT 01-NOV-1996 (TREMBLREL. 01, CREATED)
DT 01-NOV-1996 (TREMBLREL. 01, LAST SEQUENCE UPDATE)

Query Match 16.7% Score 93: D8-01 Length 382:
Best Local Similarity 33.3% Pred. No. 8,75E+01:
Matches 17; Conservative 15; Mismatches 16; Indels 3; Gaps 3

Dd 8 PULSANSFLIDSPRSNIITLYNFGSLG-LCLVQIVGVTLAAHVPAS 57
:::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
22 PPTLTQLK-LKESFL-TNSSIESFLELTKTLLHLHPSTGVSTLHHARS 70

RESULT	3			
ID	068567	PRELIMINARY;	PRT:	209 AA.
AC	068567.			
DT	01-AUG-1998 (TREMBLREL. 07, CREATED)			
DT	01-AUG-1998 (TREMBLREL. 07, LAST SEQUENCE UPDATE)			
DT	01-AUG-1998 (TREMBLREL. 07, LAST ANNOTATION UPDATE)			
DE	RESTRICTION ENDONUCLEASE R.XBAI.			
GN	XBAIR.			
OS	XANTHOMONS CAMPESTRIS.			
OC	BACTERIA; PROTEOBACTERIA; GAMMA SUBDIVISION; LYSOBACTERIALES;			
CC	XANTHOMONS GROUP; XANTHOMONS.			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RC	STRAIN-BADRII;			
RA	ZHANG B.-H., WILSON G.G.;			
RL	SUBMITTED (FEB-1998) TO EMBL/CGBANK/DDBJ DATA BANKS.			
DR	EMBL: AF051092; G2995645; .			
KW	ENDONUCLEASE.			
SO	SEQUENCE	209 AA; 23834 MM; IEC63DOB CRC32;		
	Query Match	16.5%; Score 92; DB 2; Length 209;		
	Best Local Similarity	28.2%; Pred. NO. 1.17e+00;		
	Matches	20; Conservative 21; Mismatches 27; Indels 3; Gaps 2		
Db	31 GDVSHLYIRVLGVAOEGRLIDYVN-KGRFLYK--VAGSFLEAATLCFKFAFPDSA 87			
Oy	2 GGCGPVLVLLITLGSSHOTGPQNTDLQAKRESFTLSSTESSFLEELTCLLHLPSGT 61			
	I : : : : I : : : : I : : : : I : : : : I : : : : I : : : :			
Db	88 SLRLPTNGQR 98			
Oy	I : : : : I :			
Qy	62 SVTLHHARSOH 72			
RESULT	4			
ID	P89568	PRELIMINARY;	PRT:	863 AA.
AC	P89568;			
DT	01-MAY-1997 (TREMBLREL. 03, CREATED)			

[illegible]

```

0y          59 SGTSTVLTH 67      :|||:
ID RESULT    5 PRELIMINARY; PRT; 879 AA.
AC E75377;
DT 01-FEB-1997 (TREMBLREL. 02, CREATED)
DT 01-FEB-1997 (TREMBLREL. 02, LAST SEQUENCE UPDATE)
DE 01-NOV-1998 (TREMBLREL. 08, LAST ANNOTATION UPDATE)
DF P11.ORB879 PROTEIN.
OS MYCOPLASMA PNEUMONIE.
OC BACTERIA; FIRMICUTES; BACILLUS/CLOSTRIDIUM GROUP; MOLICUTES;
   MYCOPLASMATACEAE; MYCOPLASMA.
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-M129;
RX MEDLINE: 97105885.
RA HIMMELREICH R., HILBERT H., PLAGENS H., PIKRL E., LI B.C.,
   HERGMANN R.;
RT "Complete sequence analysis of the genome of the bacterium Mycoplasma
   pneumoniae";
RL NUCLEIC ACIDS RES. 24:4420-4449(1996).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN-M129;
RA HIMMELREICH R., HILBERT H., LI B.-C.;
   SUBMITTED (NOV-1996) TO EMBL/GENE BANK/DDBJ DATA BANKS.
DR EMBL: AE000042; G1674117; -
SO SEQUENCE 879 AA; 101086 MW; 94D21E0 CRC32;

Query Match      15.9%; Score 89; DB 2; Length 879;
Best local Similarity 28.9%; Pred. No. 2,74e+00;
Matches 11; Conservative 15; Mismatches 11; Indels 1; Gaps 1.
Db 677 EGIPRDSNV-SSEVHLDQKSFLIOLAVSGIDINEKN 713
:::|||||::: ||:|:::|:::

```

QY 32 ESFLNNSYESSFLELLEKLCILLHPGSLVTLHAR 69

RESULT 6
ID 003305 PRELIMINARY; PRT: 297 AA.
AC 003305;
DT 01-JUL-1997 (TREMBLREL. 04, CREATED)
DT 01-JUL-1997 (TREMBLREL. 04, LAST SEQUENCE UPDATE)
DT 01-NOV-1996 (TREMBLREL. 01, LAST SEQUENCE UPDATE)
DE CYTOCHROME B (FRAGMENT).
OS CYTOCHROME B (FRAGMENT).
OC MITOCHONDRION.
CC EUKARYOTA: METAZOA: CHORDATA: VERTEBRATA: TESTUDINES: CRYPTODIRA:
CC TRIONCHOIDEA: CARETTOCHELYIDAE: CARETTOCHELYS.
CC [1]
CC SEQUENCE FROM N.A.
CC SHAFFER H.B., MEYLAN P., MCKNIGHT M.L.;
CC SYST. BIOL. 0:0-0(0).
CC -1- CATALYTIC ACTIVITY: OH(2) + 2 FERRICCYTOCHROME C = Q + 2
CC FERROCYTOCHROME C.
CC -1- COFACTOR: TWO HEME GROUPS
CC (B562 AND B566) WHICH ARE NOT COVALENTLY BOUND TO THE PROTEIN
CC (BY SIMILARITY).
CC EMBL: U01355; G2098653;
CC PROSITE: P500192; CYTOCHROME_B_HEME; 1.
CC DR PFAM: PF00032; cytochrome_b_c; 1.
CC DR PFAM: PF00033; cytochrome_b_n; 1.
CC KW MITOCHONDRION; ELECTRON TRANSPORT; RESPIRATORY CHAIN; TRANSMEMBRANE;
CC HEME.
CC NON_TER 1
CC FT NON_TER 1
CC SEQUENCE 297 AA; 33587 MW; 7D5808B5 CRC32;

Query Match 15.8%; Score 88; DB 8; Length 297;
Best Local Similarity 31.5%; Pred. No. 3.63e+00;
Matches 17; Conservative 10; Mismatches 25; Indels 2; Gaps 2;

DB 165 GLIVLLEFLYETGSGNPTGLNSMD-KIPEPPISTKDYF-GLIMAILLNL 216
QY 4 GLPVLILLGLSSHGTPGMTLQIKLESFLNNSYESSFLELLEKLCILLHL 57

RESULT 7
ID 069582 PRELIMINARY; PRT: 143 AA.
AC 069582;
DT 01-NOV-1996 (TREMBLREL. 01, CREATED)
DT 01-NOV-1996 (TREMBLREL. 01, LAST SEQUENCE UPDATE)
DT 01-NOV-1998 (TREMBLREL. 08, LAST SEQUENCE UPDATE)
DE HERPESVIRUS TYPE 6 DNA.
OS HUMAN HERPESVIRUS-6.
OC VIRUSES: DSDNA VIRUSES, NO RNA STAGE; HERPESVIRIDAE; BETAHERPESVIRINAE;
OC ROSELOVIRUS.
CC [1]
CC SEQUENCE FROM N.A.
CC MEDLINE: 94181269.
CC THOMPSON J., CHOUDHURY S., KASHANCHI F., DONIGER J., BERNEMAN Z.,
CC FRENKEL N., ROSENTHAL L.J.;
CC "A transforming fragment within the direct repeat region of human
CC herpesvirus type 6 that transactivates HIV-1."
CC RT ONCOGENE 9:1167-1175(1994).
CC DR EMBL: X73675; G469957;
CC SEQUENCE 143 AA; 13317 MW; 597857A6 CRC32;

Query Match 15.6%; Score 87; DB 14; Length 143;
Best Local Similarity 47.2%; Pred. No. 4.79e+00;
Matches 17; Conservative 4; Mismatches 14; Indels 1; Caps 1;

DB 88 LGLGLAGLGLAGLGLAGLGLAGLGLAGLGL 123
QY 1 MGSGPLVLLLT-LGSSHGTCGKMTLQIKLESFL 35

RESULT 8

ID 014968 PRELIMINARY; PRT: 322 AA.

AC 014968;
DT 01-NOV-1996 (TREMBLREL. 01, CREATED)
DT 01-NOV-1996 (TREMBLREL. 01, LAST SEQUENCE UPDATE)
DT 01-NOV-1998 (TREMBLREL. 08, LAST SEQUENCE UPDATE)
DE RHODOPHOSIN.
OS HOMO SAPIENS (HUMAN).
OC EUKARYOTA: METAZOA: CHORDATA: VERTEBRATA: MAMMALIA: EUTHERIA: PRIMATES;
OC CATARRHINI: HOMINIDAE: HOMO.
CC [1]
CC SEQUENCE FROM N.A.
CC MEDLINE: 92250505.
CC KINZ D., GERARD N.P., GERARD C.;
CC "The human leukocyte platelet-activating factor receptor. cDNA
CC cloning, cell surface expression, and construction of a novel
CC clone-bearing analog."
CC RT cloning, cell surface expression, and construction of a novel
CC clone-bearing analog."
CC RL J. BIOL. CHEM. 267:9101-9106(1992).
CC DR EMBL: M76676; G189270;
CC DR PFAM: PF00001; 7tm_1; 2.
CC KW GTP-BINDING.
CC SEQUENCE 322 AA; 33096 MW; 70F54EC8 CRC32;

Query Match 15.4%; Score 86; DB 4; Length 322;
Best Local Similarity 34.5%; Pred. No. 6.32e+00;
Matches 19; Conservative 13; Mismatches 22; Indels 1; Gaps 1;

DB 95 ALVLLILFLSSLCNCAWGVYKRLVYNAFLIS-LSLSIDLALCLPAA 148
QY 6 PLVLLILLGLSSHGTPGMTLQIKLESFLNNSYESSFLELLEKLCILLHPSG 60

RESULT 9
ID 023220 PRELIMINARY; PRT: 562 AA.
AC 023220;
DT 01-NOV-1996 (TREMBLREL. 01, CREATED)
DT 01-NOV-1996 (TREMBLREL. 01, LAST SEQUENCE UPDATE)
DT 01-JAN-1999 (TREMBLREL. 09, LAST SEQUENCE UPDATE)
DE W08D2.3 PROTEIN.
GN W08D2.3.
OS CAENORHABDITIS ELEGANS.
CC EUKARYOTA: METAZOA: NEMATODA: SECERNENTEA: RHABDITIA: RHABDITIA;
CC RHABDITINA: RHABDITOIDEA: RHABDITIDAE: PELIODERINAE; CAENORHABDITIS.
CC [1]
CC SEQUENCE FROM N.A.
CC SWINBURNE J., AINSCOUGH R.;
CC SUBMITTED (MAR-1996) TO EMBL/GENBANK/DDJ DATA BANKS.
CC [2]
CC SEQUENCE FROM N.A.
CC MEDLINE: 94150718.
CC WILSON R., AINSCOUGH R., ANDERSON K., BAYNES C., BEKS M.,
CC BONTFIELD J., BURTON J., CONNELL M., CORSET T., COOPER J., COULSON A.,
CC CRAWTON M., DEAR S., DU Z., DURBIN R., FAVELLO A., FULTON L.,
CC GARDNER A., GREEN P., HAKINS T., HILLIER L., JIER M., JOHNSON L.,
CC JONES M., KERSHAW J., KIRSTEN J., LAISTER N., LATEVILLE P.,
CC LIGHTNING J., LLOYD C., MCMURRAY A., MORTIMORE B., O'CALLAGHAN M.,
CC PARSONS J., PERCY C., RIFKEN L., ROOPRA A., SAUNDERS D., SHOWNKEEN R.,
CC SALMON N., SMITH A., SONNHAMMER E., STADEN R., SUTLTON J.,
CC THIERRY-MIEG J., THOMAS K., VAUDIN M., VAUGHAN K., WATERSON R.,
CC WATSON A., WINTSTOCK L., WILKINSON-SPROAT J., WOHIDMAN P.,
CC "2.2 Mb of contiguous nucleotide sequence from chromosome III of C.
CC elegans."
CC RT NATURE 368:32-38(1994).
CC DR EMBL: Z70271; E135011;
CC SEQUENCE 562 AA; 63331 MW; 5272E400 CRC32;

Query Match 15.4%; Score 86; DB 5; Length 562;
Best Local Similarity 31.5%; Pred. No. 6.32e+00;
Matches 23; Conservative 19; Mismatches 27; Indels 4; Gaps 4;

DB 122 ILILCLIVETVETGLISLAVISN-FVVIK-QQSFL-LLQFLHLIGAFGSAVAVMY 178
QY 7 LVLLILLGLSSHGTPGMTLQIKLESFLNNSYESSFLELLEKLCILLHPGSLVTLH 66

RESULT 14
ID 045649 PRELIMINARY: PRT: 676 AA.

AC 045649:
DT 01-JUN-1998 (TREMBLREL. 06, CREATED)
DT 01-JUN-1998 (TREMBLREL. 06, LAST SEQUENCE UPDATE)
DT 01-NOV-1998 (TREMBLREL. 08, LAST ANNOTATION UPDATE)
DE K03D7.3.

OS CAENORHABDITIS ELEGANS.
OC EUKARYOTA; METAZOA; NEMATODA; SECERNENTEA; RHABDITIDA; RHABDITIDA;
RHABDITIDA; RHABDITOIDEA; RHABDITIDAE; PELODERINAE; CAENORHABDITIS.
RN [1]

RP SEQUENCE FROM N.A.
RA MATTHEWS L.;
RL SUBMITTED (NOV-1996) TO EMBL/GENBANK/DBJ DATA BANKS.
RN [2]

RP SEQUENCE FROM N.A.
RX MEDLINE: 94150718.
RA WILSON R., AINSCOUGH R., ANDERSON K., BAYNES C., BERKS M.,
RA BONEFIELD J., BURTON J., CONNELL M., CORSEY T., COOPER J., COULSON A.,
RA CRAXTON M., DEAR S., DU Z., DURBIN R., FAVELLO A., FULTON L.,
RA GARDNER A., GREEN P., HAWKINS T., HILLIER L., JIER M., JOHNSTON L.,
RA JONES M., KERSHAW J., KIRSTEN J., LAISTER N., LATREILLE P.,
RA LIGHTNING J., LLOYD C., MCMURRAY A., MORTIMORE B., O'CALLAGHAN M.,
RA PARSONS J., PERCY C., RIEKEN L., ROOPRA A., SAUNDERS D., SHOWNKEEN R.,
RA SMALDON N., SMITH A., SONNHAMMER E., STADEN R., SUTSTON J.,
RA THIERRY-MIEG J., THOMAS K., VAUDIN M., VAUGHAN K., WATERSTON R.,
RA WATSON A., WEINSTOCK L., WILKINSON-SPROAT J., WOHLDMAN P.;
RT "2.2 Mb of contiguous nucleotide sequence from chromosome III of C.
RT elegans.";
RL NATURE 368:32-38(1994).
DR EMBL: 281562; E1188135;
SQ SEQUENCE 676 AA: 77673 MW: 366C5777 CRC32;

Query Match 15.2%; Score 85; DB 5; Length 676;
Best Local Similarity 41.5%; Pred. No. 8.31e+00;
Matches 17; Conservative 9; Mismatches 13; Indels 2; Gaps 2;


DB 380 LEIKEINTNAKEFKESFOLSVPMELLHF-SNVSYTLQO 419
QY 28 LKLEKESFLTNS-YESSFLELLEKLCILHLPSGTSVTLHH 67

RESULT 15
ID 043190 PRELIMINARY: PRT: 371 AA.
AC 043190:
DT 01-JUN-1998 (TREMBLREL. 06, CREATED)
DT 01-JUN-1998 (TREMBLREL. 06, LAST SEQUENCE UPDATE)
DT 01-JUN-1998 (TREMBLREL. 06, LAST ANNOTATION UPDATE)
DE PURINERGIC P2Y11 RECEPTOR.
GN P2Y11.
OS HOMO SAPIENS (HUMAN).
OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; MAMMALIA; EUTHERIA; PRIMATES;
OC CATARRHINI; HOMINIDAE; HOMO.
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE-PLACENTA;
RA COMMINI D., GOVAERTS C., PARMENTIER M., BOEYNAENS J.M.;
RL J. BIOL. CHEM. 0:0-0(1997).
DR EMBL: AF030335; G2674120;
SQ SEQUENCE 371 AA: 40174 MW: 5686F41C CRC32;

Query Match 15.1%; Score 84; DB 4; Length 371;
Best Local Similarity 38.1%; Pred. No. 1.09e+01;
Matches 16; Conservative 12; Mismatches 11; Indels 3; Gaps 2;

DB 209 LGGCLPLLTLLAAYGALGRAVLSPGTVAEKVAALVASG 250
QY 1 MGSGPLVLLTLIGS-SHGT--GPGMTIQLKKESTLNS 39

Search completed: Fri Oct 22 18:44:57 1999
Job time : 51 secs.



Release 3.1a John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MPearch_n n.a. - n.a. database search, using Smith-Waterman algorithm

Run on: Sun Oct 24 16:51:21 1999; Maspar time 456.53 Seconds

Tabular output not generated. 1390.417 Million cell updates/sec

Title: >US-09-092-296-2
Description: (1-229) from US09092296.seq
Perfect Score: 229
N.A. Sequence: 1 ACCGGAGCTTCAGTGTCTC.....CCATCTCCCTTCAGGAGCA 229
Comp: TGGCCCTGAGGTACAGAGG.....GGTAGAGGAGAGTCTCTGGT

Scoring table: TABLE default
Gap 6

Mmatch STD: Dbase 0; Query 0

Searched: 646147 seqs, 138593633 bases x 2

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database:

emb158
1:em_ba1 2:em_ba2 3:em_fun 4:em_hlg 5:em_hum1 6:em_hum2
7:em_in 8:em_com 9:em_or 10:em_ov 11:em_pat 12:em_ph
13:em_pl 14:em_ro 15:em_sts 16:em_vi
genbank111

17:gb_ba1 18:gb_ba2 19:gb_hlg1 20:gb_hlg2 21:gb_in1
22:gb_in2 23:gb_com 24:gb_ov 25:gb_pat 26:gb_ph 27:gb_pl1
28:gb_pl2 29:gb_pl3 30:gb_pl4 31:gb_pl5 32:gb_pl6
33:gb_pl7 34:gb_pl8 35:gb_pl9 36:gb_pl10 37:gb_pl11

Statistics: Mean 9.569; Variance 4.802; scale 1.993

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description	Pred. No.
1	108	47.2	47323	31	AC005937	Homo sapiens clone UMG 8.69e-62
2	46	20.1	7218	25	166494	Sequence 14 from patent 9.04e-15
3	33	14.4	215	25	128278	Sequence 5 from patent 4.40e-06
4	33	14.4	216021	31	HUAC004787	Homo sapiens Chromosome 4,40e-06
5	31	13.5	965	25	AR024229	Sequence 22 from patent 7.82e-05
6	26	12.7	74371	31	AC005369	Homo sapiens Chromosome 1.30e-03
7	29	12.7	216021	31	HUAC004787	Homo sapiens Chromosome 1.98e-02
8	27	11.8	215	25	128278	Sequence 5 from patent 1.98e-02
9	27	11.8	1065	23	AR024229	Sequence 22 from patent 1.98e-02
10	26	11.4	956	23	MY07256	Mustela vison GT dinuc 7.48e-02
11	25	10.9	565	25	E04076	gDNA encoding envelope 2.75e-01
12	25	10.9	60966	31	AC003030	Homo sapiens chromosome 2.75e-01
13	24	10.5	60	25	A62989	Sequence 1 from Patent 9.88e-01

C	14	24	10.5	1056	23	MY07256	Mustela vison GT dinuc	9.88e-01
C	15	23	10.0	3290	29	HUMPFUCAS	H. sapiens ficoidase P	3.44e+00
C	16	23	10.0	133457	30	AC003999	Human PAC clone D1139	3.44e+00
C	17	23	10.0	203418	19	AC004947	Homo sapiens clone D11	3.44e+00
C	18	22	9.6	30	25	A62984	Sequence 6 from Patent	1.16e+01
C	19	22	9.6	108	21	D87227	Trypanosoma cruzi mRNA	1.16e+01
C	20	22	9.6	1738	29	HS1665R	H. sapiens Cpg Island 9	1.16e+01
C	21	22	9.6	2180	21	HUMGOLGINB	D. melanogaster synapto	1.16e+01
C	22	22	9.6	2273	32	DROSYST	Mus musculus Bak gene	1.16e+01
C	23	22	9.6	3088	25	MMBAKEXN	DNA encoding part of A	1.16e+01
C	24	22	9.6	3088	25	E10775	Sequence 1 from patent	1.16e+01
C	25	22	9.6	3890	30	AR014574	Homo sapiens MUC4 gene	1.16e+01
C	26	22	9.6	4472	17	HSAP10901	Neisseria meningitidis	1.16e+01
C	27	22	9.6	6640	29	MSRPRRORF	Homo sapiens mRNA for	1.16e+01
C	28	22	9.6	67919	20	D63897	Homo sapiens genomic D	1.16e+01
C	29	22	9.6	79482	19	AP000029	WORKING DRAFT SEQUENCE	1.16e+01
C	30	22	9.6	82098	31	AC006252	Homo sapiens genomic D	1.16e+01
C	31	22	9.6	82201	19	HS593C16	Human DNA sequence ***	1.16e+01
C	32	22	9.6	124700	22	AC005558	Drosophila melanogaste	1.16e+01
C	33	22	9.6	135039	31	AC006060	Homo sapiens 3p22-8 PA	1.16e+01
C	34	22	9.6	151187	19	HS460J8	Human DNA sequence ***	1.16e+01
C	35	22	9.6	175339	31	AC005772	Homo sapiens chromosome	1.16e+01
C	36	22	9.6	175933	31	AC005920	Homo sapiens chromosome	1.16e+01
C	37	22	9.6	192853	19	AC005096	Homo sapiens clone RG3	1.16e+01
C	38	22	9.6	241407	20	AC003059	Mouse Chromosome 10 BA	1.16e+01
C	39	22	9.6	66	25	I41364	Sequence 143 from pate	3.79e+01
C	40	21	9.2	2976	21	PFAPA2B	Plasmodium knowlesi P-	3.79e+01
C	41	21	9.2	3043	32	AB010141S4	Mus musculus gene for	3.79e+01
C	42	21	9.2	130560	19	HS508115	Human DNA sequence ***	3.79e+01
C	43	21	9.2	149298	19	AP000031	Homo sapiens genomic D	3.79e+01
C	44	21	9.2	149298	19	AP000031	Homo sapiens genomic D	3.79e+01
C	45	21	9.2	149298	19	AP000031	Homo sapiens genomic D	3.79e+01

ALIGNMENTS

RESULT	1	AC005937	47323 bp	DNA	PRI	05-NOV-1998
LOCUS		Homo sapiens clone UMG:370M23.002	from 6p21, complete sequence.			
DEFINITION		AC005937				
ACCESSION		93845393				
NID		AC005937.1	GT:3845393			
VERSION		AC005937.1	GT:3845393			
KEYWORDS		HTG.				
SOURCE		human.				
ORGANISM		Homo sapiens				
REFERENCE		Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;				
AUTHORS		Primates; Catarrhini; Hominiidae; Homo.				
TITLE		Janez, M., Guillaudoux, T., Vu, Q., Kutayav, T., Harter, H. and				
JOURNAL		Large scale sequence analysis of the human MHC class I region				
REMARK		Unpublished (1998)				
REMARK		Fred Hutchinson Cancer Research Center				
REMARK		The Clinical Research Division				
REMARK		1100 Fairview Ave. N., P.O. Box 19024				
REMARK		Seattle, WA 98109-1024				
REMARK		2 (bases 1 to 47323)				
REMARK		Geraghty, D.E. and Olson, M.V.				
REMARK		Submitted (05-NOV-1998) Human Genome Center, University of				
REMARK		Washington, Box 352145, Seattle, WA 98195, USA				
REMARK		University of Washington Human Genome Center				
REMARK		Box 352145 Seattle, WA 98195				
REMARK		Contact: Daniel E. Geraghty (geraghty@fhcr.org)				
REMARK		Overlapping Sequences:				
REMARK		5': UMG:370M23.013 (Genbank Accession: AC005530)				
REMARK		3': UMG:370M23.012 (Genbank Accession: AC004211)				

Sequence Quality Assessment:
This entry has been annotated with sequence quality estimates computed by the Phrap assembly program. All manually edited bases have been reduced to quality zero. Quality levels above 40 are expected to have less than

1 error in 10,000 bp.
Base-by-base quality values are not generally visible from the
GenBank flat file format but are available as part
of this entry's ASN.1 file.

Double stranded (DS) coverage: 75.5%
DS or two chemistry coverage: 98.9%
Single stranded regions: 3

Sequence Validation:
This sequence has been validated by Multiple Complete Digest
Mapping. Comparison of the experimentally derived map digest
fragments with sequence-predicted fragments is given below.
Small fragments below a variable cutoff (approximately 400-600bp)
are not mapped and hence do not appear in the table. There are no
significant remaining discrepancies between the experimental and
predicted values. Uniquely ordered fragment groups are separated
by dashed lines.

Map	Seq	Map	Seq	Map	Seq
BglII		HindIII		NsiI	
1069.11	1050.00	889.55	866.00	30541.40	30653.00
20320.67	20855.00	1050.18	1015.00	3279.08	3231.00
2171.50	2147.00	7268.78	7196.00		
2560.20	2531.00	10085.80	9992.00		
4335.42	4269.00	11212.78	11131.00		
2698.62	2628.00				
1927.50	1887.00				
3130.46	3090.00				
2166.69	2129.00				
2044.67	2005.00				

FEATURES
source
1..47323 Location/Qualifiers
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="6"
/map="6p21"
/sub_clone="UMGC:370W23.002"
/clone_lib="Research Genetics BAC Library"
3647..3932
/rpt_family="Alu"
complement(4999..5277)
/rpt_family="Alu"
6285..6572
/rpt_family="Alu"
complement(6972..7050)
/rpt_family="MLT1"
7286..7584
/rpt_family="Alu"
complement(8164..8609)
/rpt_family="Alu"
complement(21287..21895)
/rpt_family="Alu"
22715..22957
/rpt_family="Alu"
25510..25802
/rpt_family="Alu"
27835..28010
/rpt_family="MER20"
31295..31594
/rpt_family="Alu"
33515..33767
/rpt_family="Alu"

repeat_region 34223..34290
/rpt_family="MIR"
repeat_region 37372..37648
/rpt_family="Alu"
repeat_region 38526..38700
/rpt_family="MER3"
repeat_region 39583..40010
/rpt_family="Alu"
repeat_region 40046..440156
/rpt_family="Alu"
repeat_region 43194..43372
/rpt_family="MERS"
variation 43325
/note="clonal variation with 3' overlapping clone"
variation 44149
/note="clonal variation with 3' overlapping clone"
variation 44451
/note="clonal variation with 3' overlapping clone"
variation 44537
/note="clonal variation with 3' overlapping clone"
variation 44814
/note="clonal variation with 3' overlapping clone"
variation 44965
/note="clonal variation with 3' overlapping clone"
variation 45760
/note="clonal variation with 3' overlapping clone"
variation 45900
/note="clonal variation with 3' overlapping clone"
variation 46851
/note="clonal variation with 3' overlapping clone"
variation 46859
/note="clonal variation with 3' overlapping clone"
variation 47032
/note="clonal variation with 3' overlapping clone"
variation 47240..47256
/note="clonal variation with 3' overlapping clone"
variation insertion of 17bp repeat

BASE COUNT 11556 a 11489 c 12284 g 11994 t
ORIGIN

Query Match 47.2%; Score 108; DB 31; Length 47323;
Best Local Similarity 100.0%; Pred. No. 8,69e-62;
Matches 108; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 35121 ACCGGACTTACGTCCTCCTCCATCCAGGAGCGAGGCGGCACTATGGGCTGCGCT 35180
|||||
Oy 1 ACCGGACTTACGTCCTCCTCCATCCAGGAGCGAGGCGGCACTATGGGCTGCGCT 60
|||||
Db 35181 GCCCCTGTCTCCTCTGTGACCCCTTGCGAGCTCATGTGAACAGG 35228
|||||
Oy 61 GCCCCTGTCTCCTCTGTGACCCCTTGCGAGCTCATGTGAACAGG 108
|||||

RESULT 2
LOCUS 166494 7218 bp DNA PAT 23-DEC-1997
DEFINITION Sequence 14 from patent US 5670367.
ACCESSION 166494
NID 92724471
VERSION 166494.1 GI:2724471
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 7218)
AUTHORS Dörner,F., Scheitlinger,F. and Falkner,F.Günter.
TITLE Recombinant fowlpox virus
JOURNAL Patent: US 5670367-A 14 23-SEP-1997;
FEATURES
source Location/Qualifiers
1..7218
/organism="unknown"
BASE COUNT 1944 a 1491 c 1486 g 1929 t 368 others
ORIGIN

LOCUS AR024229 965 bp DNA PAT 04-DEC-1998
DEFINITION Sequence 22 from patent US 5795961.
ACCESSION AR024229
NID 93977523
VERSION AR024229.1 GI:3977523
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 965)
Wallace,T.Paul, Harris,W.J., Carr,F.J., Old,L.J., Meli,S. and
Kikumura,K.
TITLE Recombinant human anti-Lewis b antibodies
JOURNAL Patent: US 5795961-A 22 18-AUG-1998.
FEATURES
Source 1..965
Location/Qualifiers
BASE COUNT 192 a 170 c 226 g 205 t 172 others
ORIGIN
Query Match 13.5%; Score 31; DB 25; Length 965;
Best Local Similarity 20.2%; Pred. No. 7.82e-05;
Matches 24; Conservative 52; Mismatches 42; Indels 1; Gaps 1;
Db 845 SVTADTAYTCVGRSRSDSGDYMGTTVYVSHYKMDTSSASVGDRTTCRSST 904
19 CCTCATCCAGGAGCGACGCTATGGGCTGGGCTCCCTTGTCTCTCTT 78
Db 905 THGNGNTYYWYKAKRYVNSRSGSGDTYTTSDATYVCGTHARTGRTKYG 963
79 GACC-CCTCTGTGCGAGTCACATGGAACAGGCCGGGTATGACTTTCACATGAAGCTG 136
RESULT 6
LOCUS AC005369 74371 bp DNA PRI 01-AUG-1998
DEFINITION Homo sapiens chromosome 5, BAC clone 119j3 (LBNL H175), complete
sequence.
ACCESSION AC005369
NID 93367505
VERSION AC005369.1 GI:3367505
KEYWORDS HTG.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
Primates; Catarrhini; Homidae; Homo.
REFERENCE
AUTHORS 1 (bases 1 to 74371)
Kimmerly,W., Bondoc,M., Cheng,J., Connolly,K.S., Gunning,K.M.,
Kadner,K., Miguel,T., Miller,C., Piltuck,S., Pollard,M.,
Rojeski,H., Subramanian,S. and Martin,C.H.
TITLE Sequencing of human chromosome 5
JOURNAL Unpublished
REFERENCE
AUTHORS 2 (bases 1 to 74371)
Ricke,D.O.
TITLE Large Scale Sequence Analysis and Annotation with the Sequence
Comparison Analysis (SCAN) System
JOURNAL Unpublished
REFERENCE
AUTHORS 3 (bases 1 to 74371)
Kimmerly,W., Bondoc,M., Cheng,J., Connolly,K.S., Gunning,K.M.,
Davis,C.A., Kadner,K., Miguel,T., Piltuck,S., Pollard,M.,
Rojeski,H., Subramanian,S. and Martin,C.H.
TITLE Direct Submission
JOURNAL Submitted (01-AUG-1998) Human Genome Center, DOE Joint Genome
Institute, Lawrence Berkeley National Laboratory, MS 74-157,
Berkeley, CA 94720, U.S.A.
COMMENT Sequence submitted by:
DOE Joint Genome Institute.
Location/Qualifiers
FEATURES
Source 1..74371
Location/Qualifiers
1..74371
/organism="Homo sapiens"
/db_xref="taxon:9606"
/map="3g"
/clone="119j3"
/chromosome="5"

repeat_region /note="LBNL H175"
893..1030
/rpt_family="Alu"
repeat_region 2295..2438
/rpt_family="Alu"
repeat_region 2818..2859
/note="(GT)21"
/rpt_type=tandem
/rpt_unit=GT
misc_feature join(3246..3410,3721..3828)
/standard_name="HLF"
/note="65% & 69% protein identity GenPept:U22377"
repeat_region 3431..3724
/rpt_family="Alu"
repeat_region 3707..3728
/note="(A)22"
/rpt_type=tandem
repeat_region 4386..4661
/rpt_family="Alu"
repeat_region 5327..5602
/rpt_family="Alu"
repeat_region 6586..6956
/rpt_family="L1"
6647..6684
/note="(CA)19"
/rpt_type=tandem
/rpt_unit=CA
repeat_region 7113..7373
/rpt_family="Alu"
complement(7830..8185)
/standard_name="possible repeat"
8258..8503
/rpt_family="Alu"
9070..9387
/rpt_family="Alu"
complement(9740..9845)
/rpt_family="MER42"
complement(10440..11015)
/rpt_family="Alu"
11950..12250
/rpt_family="Alu"
12057..12085
/note="(A)29"
/rpt_type=tandem
/rpt_unit=A
12365..12645
/rpt_family="Alu"
13727..13750
/note="(AC)12"
/rpt_type=tandem
/rpt_unit=AC
13783..14024
/rpt_family="L1"
14175..14470
/rpt_family="Alu"
complement(14906..15259)
/standard_name="possible repeat"
15300..15613
/rpt_family="Alu"
16671..16690
/note="(T)20"
/rpt_type=tandem
/rpt_unit=T
complement(16675..16977)
/rpt_family="Alu"
complement(16993..17085)
/rpt_family="MER42"
complement(17678..18276)
/rpt_family="Alu"
19305..19583
/rpt_family="Alu"
19914..19945
repeat_region

```

/note="(GTTT)8"
/rpt_type=tandem
/rpt_unit=GTIT
repeat_region complement(19943..20222)
/rpt_family="Alu"
repeat_region 21202..21496
/rpt_family="Alu"
repeat_region 21736..22035
/rpt_family="Alu"
repeat_region 22017..22038
/note="(A)22"
/rpt_type=tandem
/rpt_unit=A
repeat_region 22321..22457
/rpt_family="Alu"
repeat_region complement(22638..22981)
/standard_name="possible repeat"
repeat_region 23022..23326
/rpt_family="Alu"
repeat_region 23473..23761
/rpt_family="Alu"
repeat_region 23744..23767
/note="(A)24"
/rpt_type=tandem
/rpt_unit=A
repeat_region complement(24639..24694)
/rpt_family="MER42"
repeat_region complement(25349..25713)
/rpt_family="Alu"
repeat_region complement(25727..26471)
/rpt_family="Alu"
repeat_region 27191..27477
/rpt_family="Alu"
repeat_region 27774..28057
/rpt_family="Alu"
repeat_region 28040..28066
/note="(A)27"
/rpt_type=tandem
/rpt_unit=A
repeat_region 28712..28930
/rpt_family="MER20"
repeat_region complement(28769..28838)
/note="GRAIL 2 excellent exon, frame 0"
repeat_region 28987..29214
/rpt_family="Alu"
repeat_region join(29485..29559,29598..29779)
/note="95% identity dbSTS:G14522 (SHG-11312)"
29495..29976
/standard_name="A1027942"
/note="100% identity EST cv84a10.x1"
repeat_region complement(30401..30536)
/note="GRAIL 2 excellent exon, frame 2"
repeat_region complement(30682..30733)
/rpt_family="MIR"
repeat_region complement(31573..31724)
/note="GRAIL 2 excellent exon, frame 1"
repeat_region complement(32159..32232)
/note="GRAIL 2 excellent exon, frame 2"
repeat_region 32388..32488
/rpt_family="MLT1"
repeat_region 32617..32908
/rpt_family="Alu"
repeat_region 32977..33068
/rpt_family="MRT1"
repeat_region complement(33670..33785)
/rpt_family="Alu"
repeat_region complement(34021..34144)
/note="GRAIL 2 excellent exon, frame 2"
repeat_region complement(35238..35331)
/note="GRAIL 2 excellent exon, frame 1"
repeat_region 36392..36663
/rpt_family="Alu"
repeat_region 36901..37222
misc_feature

```

```

STS
/note="100% identity EST ou55c09.x1"
/db_xref="dbEST:A102501"
36901..37164
/standard_name="STSG-9983"
/db_xref="dbSTS:G26354"
misc_feature
/note="GRAIL 2 excellent exon, frame 0"
complement(join(38063..38218,38462..38578,38741..38995,
39071..39205,39532..39630,39935..40048,40300..40410,
40503..40661,41868..41972,42103..42225,42492..42569,
44379..44507))
/standard_name="histidyl-CRNA synthetase"
/note="78% 100% protein identity GenPept:U18937"
complement(38069..38215)
misc_feature
/note="GRAIL 2 excellent exon, frame 0"

```

... Note: remainder of annotations omitted.

```

Query Match      12.7% Score 29; DB 31; Length 74371;
Best Local Similarity 16.7%; Pred. No. 1,30e-03;
Matches 14; Conservative 45; Mismatches 24; Indels 1; Gaps 1;

```

```

Db 15929 CMSRSKSKGAGYNSWKYRCAMAMTKSS-KCWCWSYRMRKCYSCYCSGSKKRYC 15987
QY 2 CCGGAGCTTCAGTCTCTCCATCCAGAGAGCGCAGCTACGTATGGGTCTGGCTG 61
Db 15988 RCMYWTCTCYCYKXYSMSYCTC 16011
QY 62 CCCCTGTCTCTCTCTGACCTC 85

```

```

RESULT 7
LOCUS HUAC004787 216021 bp DNA PRI 24-JUL-1998
DEFINITION Homo sapiens Chromosome 16 BAC clone C11987SK-A-952P10, complete
sequence.
ACCESSION AC004787
NID 93337381
VERSION AC004787.1 GI:3337381
KEYWORDS HTG.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
Primates; Catarrhini; Hominoidea; Homo.

```

```

REFERENCE 1 (bases 1 to 216021)
AUTHORS Adams,M.D., Loftus,B.J., Zhou,L., Crosby,M., Fuhmann,J.,
Mason,T.M., Brandon,R., Kim,U.J., Kerlavage,A.R. and Venter,J.C.
Homo sapiens Chromosome 16 BAC clone C11987SK-A-952P10
Unpublished
2 (bases 1 to 216021)
AUTHORS Adams,M.D. and Loftus,B.J.
Direct Submission
Submitted (02-JUN-1998) The Institute for Genomic Research, 9712
Medical Center Dr., Rockville, MD 20850, USA, Email:
bjloftus@tigr.org
3 (bases 1 to 216021)
AUTHORS Adams,M.D. and Loftus,B.J.
Direct Submission
Submitted (24-JUL-1998) The Institute for Genomic Research, 9712
Medical Center Dr., Rockville, MD 20850, USA
On Jul 24, 1998 this sequence version replaced gi:3241936.
Address all correspondence to: Mark Adams The Institute for Genomic
Research 9712 Medical Center Dr., Rockville, MD 20850, USA e-mail
sp6 end to T7 end. Genes were identified by a combination of five
methods including: XGRAIL (available by anonymous ftp from
arthur.epm.cnl.gov), GeneFinder (Phil Green, University of
Washington), GenScan (Chris Burge,
http://genomc.stanford.edu/~chris/GENSCAN.html) searches of the
complete sequence against a peptide database, and the Human gene
index database at RIGR (http://www.tigr.org/db/hg1/hgi.html).
Genes without peptide homology having spliced EST hits are termed
'Unknown gene product'. Genes encoding tRNAs are predicted by
tRNAscan-se (Sean Eddy, http://genome.wustl.edu/eddy/tRNAscan-se/).

```

```

REFERENCE 1 (bases 1 to 216021)
AUTHORS Adams,M.D. and Loftus,B.J.
Direct Submission
Submitted (24-JUL-1998) The Institute for Genomic Research, 9712
Medical Center Dr., Rockville, MD 20850, USA
On Jul 24, 1998 this sequence version replaced gi:3241936.
Address all correspondence to: Mark Adams The Institute for Genomic
Research 9712 Medical Center Dr., Rockville, MD 20850, USA e-mail
sp6 end to T7 end. Genes were identified by a combination of five
methods including: XGRAIL (available by anonymous ftp from
arthur.epm.cnl.gov), GeneFinder (Phil Green, University of
Washington), GenScan (Chris Burge,
http://genomc.stanford.edu/~chris/GENSCAN.html) searches of the
complete sequence against a peptide database, and the Human gene
index database at RIGR (http://www.tigr.org/db/hg1/hgi.html).
Genes without peptide homology having spliced EST hits are termed
'Unknown gene product'. Genes encoding tRNAs are predicted by
tRNAscan-se (Sean Eddy, http://genome.wustl.edu/eddy/tRNAscan-se/).

```

Location/Qualifiers
1. .216021

27765. .27872
/note="27765 STS1-CSR1-27a3-uA/CSR1-27a3-uZ, Chr. -, Homo

73826. :/3943
/note="7608, STS1-CSRL-24q1-ua/CSRL-24q1-uz, Chr. -, Homo

175810.175945 chr - Homo sapiens

BASE COUNT	60960 a	51778 c	49172 g	53987 t	124 others
ORIGIN					

Query Match	12.7%	Score 29;	DB 31;	Length 216021;
Best Local Similarity	14.7%	Pred. No. 1.30e-03;		
Matches	19;	Conservative	60;	Mismatches 50;
			Indels	0;
			Gaps	0;

```

Db      1457 KKYMKKSNRRARRRSGAGKKKKKKYCYYYYYYYCMRAMAAAYTTRSCAAMNY   1516
          : : : : : : : : : : : : : : : : | : : : : :
Cp      222 TGAAGGAGATGGAGGAGGAGGACGACTTTCAACCAATTCCAGAGAGCTGACTATAG   163

Db      1517 YMGARARTTYVMAABRGASRYKKYVMYVMAATTCAAAANAAYTTYYYMMMYKXNN   1576
          : : : : : : : : : : : : : : : : | : : : : :
Cp      162 GAGCANITTTGCAGAAAAAACAICTCTTAGCTTCAAGTCAATACC GGCGCTGT   103

Db      1577 MYTCCTGAG 1585
          : : : : : |||||
Cp      102 CCACTGTGAG 94

```

RESULT	8			
LOCUS	128278	215 bp	DNA	PAT
DEFINITION	Sequence 5 from patent US 5569830.			30-OCT-1996

REFERENCE	Bennett, A. (bases 1 to 215)
AUTHORS	Bennett, A., Labavitch, J. M., Powell, A. and Stoltz, H.
TITLE	Plant inhibitors of fungal polygalacturonases and their use to control fungal disease
JOURNAL	Patent: US 5569830-A 5 29-Oct-1996.
FEATURES	Location/Qualifiers

	BASE COUNT	ORIGIN
15	a	8 c 25 g 26 t 141 others

Query Match	11.88;	Score 27;	DB 25;	Length 215;
Best Local Similarity	20.03;	Pred. No. 1.98e-02;		
Matches	22;	Conservative	42;	Mismatches 45; Indels 1; Gaps 1;

Ddb 18 CNDKAKKDGNTTSSWTTDDCCRTGWCYCDITTYRRNNDSCHNKISSANTNYGGNNVGAAK 77
|:::||::||::||::||::||::||:
85 CCTTGCGACGTCAACAATGGAACAGGCCGGGTATGACTTTGCACACTGMACTG-AAAGAGT 143

D_b 78 THYTHHNWGADSKVITVSYNASGSSNGTDGNRSGADSYGSSTKAM 127
::|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:

O_y 144 CTHTTTCAGCAAAATCCTCCATTAGACTCACAGCTTCTTGGAATGGTTGAA 193

LOCUS	9	965 bp	DNA	PAT	04-DEC-1998
DEFINITION	Sequence	22	from patent US 5795961.		
ACCESSION	AR024229				
NID	93977523				
VERSION	AR024229.1		GI:3977523		

ORGANI.

REFERENCE	1 (bases 1 to 965)
AUTHORS	Wallace T. Paul, Harris, W. T., Carr, F. J., Old, L. J., Welt, S. and

TITLE	Recombinant human anti-Lewis b antibodies
JOURNAL	Patent: US 5795961-A 22 18-AUG-1998;
FEATURES	Location/Qualifiers
	1 05

BASE COUNT	192 a	170 c	226 g	205 t	172 others
ORIGIN	/organism="unknown"				

DB	Query Match	11.8%	Score 27:	DB 25:	Length 965:
	Best Local Similarity	15.6%	Pred. No.	1.98e-02:	
	Matches 27:	Conservative	39:	Mismatches 60:	Indels 0:
				Gaps 0:	
790	GGVRSSTCTCAADYTTTSMGCVAGRGNDGEGGVTNNKRGKRVATNADTSSNSSSVTLAA	849			

Db 790 GGRATSTCTSDTTTSSYMGWRGMDGGGYNINAKSKHYHIMULDISNKRSSVIAA 8
Cp 202 GCAGACATTTTCAAGCAATTCAGCAGAACCTGGACTATAGGAGGAATTTCTCAGAAAAA 143
Db 850 DFLVYTCVGRSSYSDGDGDMGTTVTYSSHTYKMDTSSSSASVGRVTTCRSSTTHNG 909
Cp 142 CTCCTTCAGGCTTCAAGTTCGAAAGATCATCCGCGCCTGTTCCATGATGAGCTGCCAAGAG 83
Db 910 NTYYWYKKAATRYVSNSSVS 930
Cp 82 GGTCAAGAGGAGCAAGAGG 62

RESULT	10			
LOCUS	MYU87256	1056 bp	DNA	MAM
DEFINITION	Mustela vison GT dinucleotide repeat, chromosome 1q.			

ORGANISM
Muscula visch
Eukaryote; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
Carnivora; Fissipedia; Mustelidae; Muscula.
1 (bases 1 to 1056)
REFERENCE
AUTHORS
Brusgaard, K., Shkrtir, N.M., Malchenko, S., Koroleva, I. and Loh, O.
TITLE
Direct Submission
JOURNAL
Submitted (27-JAN-1997) Breeding and Genetics, Danish Institute of
Animal Science, Artillerivej 85, Tjele 8830, DK
FEATURES
Location/Qualifiers

/map= 14
/note="primers: 1167F: agccctgcatactactctt, 1167R:

primer_bind

primer_bind

/standard_name= 110/A				
BASE COUNT	211 a	221 c	210 g	225 t
ORIGIN				
				189 others


```
CDS
100% identity. "-"
join(<5028..5045,5432..5497,6480..6575,8155..8249,
10156..10183,10562..10717,11845..11991,12086..12176,
13147..13250,14614..14679,18495..18248,18465..18542,
18635..18746,23665..23755,24574..24709,37283..37493)
/notes="Hypothetical human protein (partial)"
/codon_start=1
/evidence="not_experimental"
/product="R29828_1"
/protein_id="AAD3161.1"
/db_xref="pid:94106983"
/db_xref="gi:4106983"
/translation="MISQIPEFEDVKEASLISELYCEKSNVDAAKPLLRKAIQI
SOOTPRWCRILLFQADLHLEKIDYSODLIGAYAVVSEETRALFLSKGL
LMERKLDVHFPLILGCGVVENWQGNPQKESRIFAVLYVTHLADGQVSKPC
KQLOQCOTISTLHDEPLSPADLFPMKCEKCVLYLYTVWHSQAKCYERKQ
KYTDKALMQLERKMLDSCPLSPFVILLHETLCKLVGHRKATLQDGLCYSVNC
MDNAEQFTTALRLYSLEIRINPDHSFVAAAFVRCLEFQGRNKAKE
LRETLMSNAEDLNRLTACSLVILGHIFVGNHRESNNVAPAMQLASKIPMSVOL
WSSALLRDINKACGNADHAQMHQNSQLQDIEACSLPEHNLITVRVHMG
IAATRLPVAFMEGCTTIVSADIMKHIOEDTESESAMAPVRCIEKSLRPTRAII
LIPPLD"
/misc_feature
Complement(5186..5264)
/notes="predicted exon, program: graill2exons_human_1.3,
frame: 0, quality: excellent, score: 86.000"
/misc_feature
5432..5497
/notes="DS similarity to overlapping ESTs:-AA963316
UI-R-EI-g1-c-06-0-UI-s1 UI-R-EI Rattus norvegicus cDNA
clone UI-R-EI- g1-c-06-0-UI 3' ; (238..303); 88%
identity. --AA893275 EST197078 Normalized rat kidney; Bento
Scores Rattus sp. cDNA clone RK1BE38 3' end; (258..333);
88% identity."
Complement(5602..5683)
/rpt_family="Aluub"
/misc_feature
6480..6575
/notes="DS similarity to overlapping ESTs:-AA963316
UI-R-EI-g1-c-06-0-UI-s1 UI-R-EI Rattus norvegicus cDNA
clone UI-R-EI- g1-c-06-0-UI 3' ; (304..399); 89%
identity. --AA893275 EST197078 Normalized rat kidney; Bento
Scores Rattus sp. cDNA clone RK1BE38 3' end; (324..419);
89% identity. --(6480..6660) predicted exon, program:
grail2exons_human_1.3, frame: 2, quality: excellent,
score: 76.000"
/misc_feature
8155..8249
/notes="predicted exon, program: graill2exons_human_1.3,
frame: 0, quality: excellent, score: 94.000-DS
similarity to overlapping ESTs:-(8155..8237) AA963316
UI-R-EI-g1-c-06-0-UI-s1 UI-R-EI Rattus norvegicus cDNA
clone UI-R-EI- g1-c-06-0-UI 3' ; (400..482); 88%
identity. --(8155..8240) AA893275 EST197078 Normalized rat
kidney; Bento Scores Rattus sp. cDNA clone RK1BE38 3' end;
(420..505); 85% identity."
repeat_region
8351..8477
/rpt_family="Aluub"
repeat_region
8480..8768
/rpt_family="Alusx"
misc_feature
8778..8837
/notes="predicted exon, program: graill2exons_human_1.3,
frame: 2, quality: excellent, score: 83.000"
Complement(8872..8996)
/rpt_family="Aluub"
repeat_region
9052..9196
/rpt_family="Alusx"
repeat_region
9197..9493
/rpt_family="Aluy"
repeat_region
9494..9658
/rpt_family="Alusx"
repeat_region
9658..9667
/rpt_family="Aluy"
misc_feature
10136..10183
/notes="predicted exon, program: graill2exons_human_1.3,
frame: 1, quality: excellent, score: 86.000"
misc_feature
10562..10721
```

```
/notes="predicted exon, program: graill2exons_human_1.3,
frame: 1, quality: excellent, score: 100.000"
/misc_feature
11845..11991
/notes="predicted exon, program: graill2exons_human_1.3,
frame: 0, quality: excellent, score: 97.000"
/misc_feature
12086..12176
/notes="predicted exon, program: graill2exons_human_1.3,
frame: 1, quality: excellent, score: 96.000"
/misc_feature
13147..13250
/notes="predicted exon, program: graill2exons_human_1.3,
frame: 2, quality: excellent, score: 100.000"
repeat_region
13440..13741
/rpt_family="Alusx"
/misc_feature
14614..14679
/notes="predicted exon, program: graill2exons_human_1.3,
frame: 0, quality: excellent, score: 100.000"
/misc_feature
16463..16747
/notes="DS similarity to AA212842 mw82d12.r1 Scores mouse
NMU Mus musculus cDNA clone 677207 5' ; (200..468); 80%
identity."
repeat_region
17395..17687
/rpt_family="Aluub"
/misc_feature
18199..18248
/notes="predicted exon, program: graill2exons_human_1.3,
frame: 0, quality: excellent, score: 89.000"
/misc_feature
18465..18542
/notes="predicted exon, program: graill2exons_human_1.3,
frame: 0, quality: excellent, score: 100.000"
/misc_feature
18635..18746
/notes="predicted exon, program: graill2exons_human_1.3,
frame: 2, quality: excellent, score: 97.000"
Complement(19286..19309)
/rpt_family="POLY_A"
repeat_region
19323..19623
/rpt_family="Alusx"
repeat_region
19632..19928
/rpt_family="Alusx"
repeat_region
19929..20226
/rpt_family="Aluy"
repeat_region
20234..20341
/rpt_family="Aluub/FLAM"
repeat_region
Complement(20344..20655)
```

```
..
Note: remainder of annotations omitted.
Query Match 10 94; Score 25; DB 31; Length 60966;
Best Local Similarity 85.78; Pred.No. 2.76e-01;
Matches 30; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
DB 13976 TGTCCACGATGCGATCTGGCGCTTGGCCCTC 14010
Gy 39 TGGCCACTGTGGGCTGTGGCGCTTGTCTC 73
RESULT 13
LOCUS A62989 60 bp DNA PAT 12-MAR-1998
DEFINITION Sequence 1 from Patent W09720068.
ACCESSION A62989
NID 93716861
VERSION A62989.1 GI:3716861
KEYWORDS
SOURCE unidentified.
ORGANISM unidentified.
REFERENCE 1 (bases 1 to 60)
AUTHORS Oerum,H. and Seeger,C.
TITLE METHOD FOR GENERATING MULTIPLE DOUBLE STRANDED NUCLEIC ACIDS
JOURNAL Patent: WO 9720068-A 1 05-JUN-1997;
BOEHRINGER MANNHEIM GMBH (DE)
FEATURES
LOCATION/Qualifiers
1..60
/organism="unidentified"
/db_xref="taxon:32644"
```

Location/Qualifiers

Search completed: Sun Oct 24 16:59:07 1999
Job time : 466 secs.

range obtained compared with the range obtained for the possible nucleotide positions within a specified region. The

PT screening a recombinant vector library expressing fusion proteins comprising a binding domain and an effector domain

```

Query Match      13.5%; Score 31; DB 12; Length 114;
Best Local Similarity 4.6%; Pred. No. 5.71e-05;
Matches 5; Conservative 30; Mismatches 74; Indels 0; Gaps 0;

```

[illegible]

RESULT: 8
ID: Q70468; standard; DNA; 114 BP.
AC: Q70468;
DT: 05-Apr-1995 (first entry)
DE: Generic DNA sequence to generate a random TSPR peptide library.
KW: TSPR; totally synthetic affinity reagent; synthetic; binding domain;
KW: effector domain; concatenated heterofunctional protein; linker;
KW: direct; rapid; detection; screening; treatment; generic; ss.
OS: Synthetic.

FT	Key	Location/Qualifiers
FT	misc_feature	55..60
FT		/tag= a
FT		/note= "this sequence represents 'Z'; Z can be a
FT		sequence of 6, 9 or 12 nucleotides (see
FT		comments)"

PN M03418318-A.
PD 18-AUG-1994.
PE 01-FEB-1994. U00977.
PR 01-FEB-1993; US-013416.
PR 30-DEC-1993; US-176500.
PR 31-JAN-1994; US-189331.
PA (UYN-) UNIV NORTH CAROLINA.
PI Fowlkes DM, Kay BK;
DR Wpi: 94-279739/34.
PT P-FSD; R65154.
PT Identifying proteins or peptide(s) which bind a ligand - by
screening a recombinant vector library expressing fusion proteins
comprising a binding domain and an effector domain
PT Disclosure: Page 35: 255pp; English.
PS Q70466 is a generic DNA sequence used to generate random T5AR (Totally
CC Synthetic Affinity Reagents) peptides. This generic formula can also be
CC represented as follows: X(NNB)17(TGC)(NNB)62(NNB)7(TTC)(NNB)10Y. X
CC and Y are flanking restriction sites (X is not the same as Y that are
CC not specified further. Other generic sequences are shown in Q70466-68.
CC Other specific peptides generated by these generic sequences are shown in

CC R65151-54. TSARs are concatenated heterofunctional proteins or peptides,
CC comprising at least two functional regions - a binding domain with
CC affinity for a ligand and a second effector peptide portion that is
CC chemically or biologically active. They may further comprise a linker
CC peptide between the 2 domains. The oligonucleotides are also designed so
CC that the expressed peptide contains 2 or 4 cysteine residues positioned
CC in, or flanking, the unpredicted or variant residues. These residues
CC confer some degree of conformational rigidity to the peptides. The TSARs
CC or conspms. comprising a TSAR binding active moiety, eg. metal ion, to
CC deliver a chemically or biologically active moiety, eg. metal ion, on the
CC radioisotope, peptide, toxin or enzyme, to the specific target or on the
CC cell. They can also replace the function of macromolecules, eg.
CC monoclonal or polyclonal antibodies and therefore circumvent the need
CC for complex methods of hybridoma formation or in vivo antibody
CC production. The TSARs are easily characterised and have designed activity
CC allowing direct and rapid detection in a screening process.
50 Sequence 114 Bp: 2 C A: 2 G: 2 T:

```

Query Match      13.1%; Score 30; DB 12; Length 114;
Best Local Similarity 3.8%; Pred. No. 1.93e-04;
Matches 4; Conservative 30; Mismatches 72; Indels 0; Gaps 0;

```

[illegible]

RESULT	9
ID	Q70470 standard; DNA; 114 BP.

DT 10-Apr-1995 (first entry)
DE Generic DNA sequence to generate a random TSAR peptide library.
KW TSAR: totally synthetic affinity reagent; synthetic; binding domain
KW effector domain; concatenated heterofunctional protein; linker
KW direct; rapid; detection; screening; treatment; generic; ss.

OS	Synthetic.	Location/Qualifiers
FH	Key	55..60
FT	misc_feature	/*tag= a
FT		/note= "encoded by 2 (see comments)"

PN MO9418318-R.
PD 18-AUG-1994.
PE 01-FEB-1994: U00977.
PR 01-FEB-1993: US-03416.
PR 30-DEC-1993: US-176500.
PR 31-JAN-1994: US-189331.
PA (UNCL) UNTY NORTH CAROLINA.
PI FOWLES DN Kay BK;
DR WP1: 94-275739/34.

pm Identifying proteins or peptide(s) which bind a ligand - by
 pm screening a recombinant vector library expressing fusion proteins
 pm comprising a binding domain and an effector domain
 ps Disclosure, page 36, 25pp, English.
 Q70470 is a genetic DNA sequence used to generate random TSAR (Totally
 CC Synthetic Affinity Reagents), peptides this genetic formula can also be
 CC represented as follows: X(NNB)/6(CAC)(NNB)/8(CNC)(NNB)/8(CNC)(NNB)8
 CC -(CAC)2(NNB)/Y. X and Y are flanking restriction sites (X is not the same
 CC as Y) that are not specified further. The peptides generated by this and
 CC other genetic sequences (Q70471-73) have invariant histidine residues
 CC incorporated into variant sequences. TSARs are concatenated
 CC heurofunctional proteins or peptides, comprising at least two functional
 CC regions - a binding domain with affinity for a ligand and a second
 CC effector peptide portion that is chemically or biologically active. They
 CC may further comprise a linker peptide between the 2 domains. The TSARs
 CC or compus, comprising a TSAR binding domain can be used in vivo to
 CC deliver a chemically or biologically active moiety, eg. metal ion,
 CC radioisotope, peptide, toxin or enzyme, to the specific target or on the
 CC cell. They can also replace the function of macromolecules, eg.

[illegible][illegible]

CC 10F0001: unknown
CC MOLECULE TYPE: DNA (genomic)
CC MOLECULE ACC NO: 1001-170-0-336-0-300-0-177 OTHER

[illegible]

```

CC      ZIP: 10036
CC      COMPUTER READABLE FORM:
CC      MEDIUM TYPE: Floppy disk
CC      COMPUTER: IBM PC compatible
CC      OPERATING SYSTEM: PC-DOS/MS-DOS
CC      SOFTWARE: Patentin Release #1.0, Version #1.30
CC      CURRENT APPLICATION DATA:
CC      APPLICATION NUMBER: PCT/US95/11934
CC      FILING DATE: 20-SEP-1995
CC      CLASSIFICATION:
CC      ATTORNEY/AGENT INFORMATION:
CC      NAME: Mistrock, S. Leslie
CC      REGISTRATION NUMBER: 18,872
CC      REFERENCE/DOCKET NUMBER: 1101-196-228
CC      TELECOMMUNICATION INFORMATION:
CC      TELEPHONE: (212) 790-9049
CC      TELEFAX: (212) 869-9741/8864
CC      TELEX: 66141 PENNIE
CC      INFORMATION FOR SEQ ID NO: 98:
CC      SEQUENCE CHARACTERISTICS:
CC      LENGTH: 81 base pairs
CC      TYPE: nucleic acid
CC      STRANDEDNESS: single
CC      TOPOLOGY: linear
CC      MOLECULE TYPE: DNA (genomic)
CC      SEQUENCE 81 BP: 6 A; 6 C; 4 G; 5 T; 60 OTHER.
S0

```



```
CC TELEFAX: (212) 869-9741/8864
CC TELEX: 66141 PENNIE
CC INFORMATION FOR SEQ ID NO.: 97:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 82 base pairs
CC TYPE: nucleic acid
CC STRANDEDNESS: single
CC TOPOLOGY: linear
CC MOLECULE TYPE: DNA (genomic)
SQ SEQUENCE 82 BP; 1 A; 2 C; 10 G; 8 T; 61 OTHER.

Query Match      9.6%; Score 22; DB 4; Length 82;
Best Local Similarity 8.7%; Pred. No. 1,54e+01;
Matches        6; Conservative    19; Mismatches   44; Indels     0; Gaps     0;

Db          Db       72 NBSGTTGTGG 80
           :||| ||
OY         50 GGCGTGGGCCTGCCCTTGTCCTCCTTGACCCCTCTTGCGAGCTCACATGAACAGGG 109

OY         110 CCGGGATAG 118

RESULT
9
ID US-08-418-444A-1 STANDARD; DNA; UNC; 3088 BP.
AC xxxxxx

DE Sequence 1, Application US/08418444A
CC Sequence 1, Application US/08418444A
CC Patent No. 5773688
CC GENERAL INFORMATION:
CC APPLICANT: KURODA, HISAO
CC APPLICANT: HIROTA, NAOHICO
CC APPLICANT: ITO, KAZUTOSHI
CC TITLE OF INVENTION: GENE EXPRESSION VECTOR USING THE GENE
CC TITLE OF INVENTION: EXPRESSION REGULATING REGION OF THE ADP RIBOSYLATION
CC FACTOR
CC NUMBER OF SEQUENCES: 9
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT
CC STREET: 1755 S. JEFFERSON DAVIS HIGHWAY, SUITE 400
CC CITY: ARLINGTON
CC STATE: VIRGINIA
CC COUNTRY: USA
CC ZIP: 22202
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC COMPUTER: IBM PC compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: Patentin Release #1.0, Version #1.30
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/418,444A
CC FILING DATE: 07-APR-1995
CC CLASSIFICATION: 800
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: JP HEI 6-71048
CC FILING DATE: 08-APR-1994
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Oblon, No. 5773688man F.
CC REGISTRATION NUMBER: 24,618
CC REFERENCE/DOCKET NUMBER: 2589-024-0
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: (703) 413-3000
CC TELEFAX: (703) 413-2220
CC TELEX: 248855 OPAT UR
CC INFORMATION FOR SEQ ID NO.: 1:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 3088 base pairs
CC TYPE: nucleic acid
CC STRANDEDNESS: double
CC TOPOLOGY: linear
CC MOLECULE TYPE: DNA (genomic)
```

```

SQ SEQUENCE 3088 BP; 716 A; 761 C; 672 G; 929 T; 0 OTHER.
Query Match 9.6%; Score 27; DB 3; Length 3088;
Best Local Similarity 72.0%; Pred. No. 1.54e-01;
Matches 36; Conservative 0; Mismatches 14; Indels 0; Gaps 0
Dd 15 CCGAAGATGGGCGACAGGGGGGCCAGGGGCTGCCAGCGGCGCTCTGTGC 64
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Cp 90 CCAGAGAGGCTCAAGAGAGGACAGACGGGGGCGACGCCAGACCCCATAGTGC 41

RESULT 10
ID US-08-471-052A-145 STANDARD; DNA; UNC; 65 BP.
AC xxxxxx
DT
DE Sequence 145, Application US/0841052A
CC Sequence 145, Application US/0841052A
CC Patent No. 5625033
CC GENERAL INFORMATION:
CC APPLICANT: Kay, B. K.
CC APPLICANT: Fowles, D. M.
CC TITLE OF INVENTION: Totally Synthetic Affinity Reagents
CC NUMBER OF SEQUENCES: 166
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Pennie & Edmonds
CC STREET: 1155 Avenue of the Americas
CC CITY: New York
CC STATE: New York
CC COUNTRY: U.S.A.
CC ZIP: 10036-2711
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC COMPUTER: IBM PC compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: PatentIn Release #1.0, Version #1.25
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/471,052A
CC FILING DATE: 06-JUNE-1995
CC CLASSIFICATION: 530
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Mastrock, S. Leslie
CC REGISTRATION NUMBER: 18,872
CC REFERENCE/DOCKET NUMBER: 1101-179
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: 212 790-0900
CC TELEFAX: 212 869-8864/9741
CC TELEX: 66141 PENNIE
CC INFORMATION FOR SEQ ID NO: 145:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 65 bases
CC TYPE: nucleic acid
CC STRANDEDNESS: single
CC TOPOLOGY: unknown
CC MOLECULE TYPE: DNA
CC SEQUENCE 65 BP; 3 A; 3 C; 3 G; 2 T; 54 OTHER.

Query Match 9.2%; Score 21; DB 1; Length 65;
Best Local Similarity 13.8%; Pred. No. 5.27e-01;
Matches 9; Conservative 16; Mismatches 40; Indels 0; Gaps 0;
Dd 1 CTGAAVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNNA 60
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Cp 174 CTGACACCTAGAGGAGATTGTCTGAGAAAGACCTCTCAGCTTCAGTCAAGACGATCA 115

Dd 61 CTTGG 65
||| |||
Cp 114 CCGCG 110

RESULT 11
ID US-08-471-052A-144 STANDARD; DNA; UNC; 66 BP.
AC xxxxxx
DT

```



```

source
1. .328
/organism="Rattus norvegicus"
/strain="Sprague-Dawley"
/notes="Vector: pT73D-Pac (Pharmacia) with a modified
polylinker. Site_1: Not I; Site_2: Eco RI; The UI-R-C2P
library is a subtracted library derived from the UI-R-C1
library, which is a subtracted library derived from the
UI-R-C0 library. The UI-R-C0 library consisted of a
mixture of individually tagged normalized libraries
constructed from rat placenta, adult lung, brain, liver,
kidney, heart, spleen, ovary, muscle, 8, 12 and 18-day
embryo. The tag is a string of 3-5 nucleotides present
between the Not I site and the oligo-dr track which allows
identification of the library of origin of a clone within
the mixture. The subtracted library (UI-R-C2P) was
constructed as follows: PCR amplified cDNA inserts from
UI-R-C1 clones from which 3' ESTs had been derived was
used as a driver in a hybridization with the UI-R-C1
library in the form of single-stranded circles. The
remaining single-stranded circles (subtracted library) was
purified by hydroxapatite column chromatography,
converted to double-stranded circles and electroporated
into DH10B bacteria (Life Technologies) to generate the
UI-R-C2P library. This procedure has been previously
described (Bonaldo, Lennon and Soares, Genome Research 6:
791-806, 1996)."
/db_xref="taxon:10116"
/clone="UI-R-C2P-nq-e-02-0-UI"
/clone_1lb="UI-R-C2P"
/dev_stage="adult"
/lab_host="DH10B (Life Technologies)"

BASE COUNT      62 a      77 c      98 g      91 t

Query Match      23.1%; Score 53; DB 23; Length 328;
Best Local Similarity 75.4%; Pred. No. 4.59e-50;
Matches 86; Conservative 0; Mismatches 27; Indels 1; Gaps 1;

Db 187 TGGTCCCGGTGAGAGCGTGGAGAGGAGCGATCTTTTGGACATGTCGAGAAAGCCG 246
      ||||| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cp 229 TGGTCCCGGTGAGAGGAGATGAGAGAGGAGAGGAGAGGAGAGGAGAGGAGAGGAG 171
      ||||| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 247 AGCTTGGAGAGCTGCTGGCTGAGATGCTGGCTGCTGCTGCTGCTGCTGCTGCTGCTG 300
      ||||| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cp 170 ACTCATGAGAGGAAATTGTGCAGAAAGACTCTTCACCTTCAGTTCAGAAAGTCA 117
      ||||| | | | | | | | | | | | | | | | | | | | | | | | | | | | |

RESULT 2
LOCUS      AA754459      252 bp      mRNA      EST      20-JAN-1998
DEFINITION      97SN1787 Rice Immature Seed Lambda ZAPII cDNA library Oryza sativa
ACCESSION      AA754459
VERSION      92801165
KEYWORDS      AA754459.1 GI:2801165
SOURCE
ORGANISM      Oryza sativa.
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
euphyllophytes; Spermatophyta; Magnoliophyta; Liliopsida; Poales;
Poaceae; Oryza.
1 (bases 1 to 252)
Nahm,B.H., Kim,J.K., Cheong,J.J., Kim,S.I., Hahn,T.R., Moon,E.P.,
Kim,M.T., Kim,W.Y., Yang,M.S., Park,R.D., Sohn,U.I., Kang,K.Y.,
Lee,M.C. and Eun,M.Y.
Large-scale Sequencing Analysis of ESTs from Rice Immature Seed
Unpublished (1998)
On Jan 14, 1998 this sequence version replaced gi:1797457.

TITLE
JOURNAL
COMMENT
Contact: Eun M.Y.
Department of Cytoogenetics
National Inst. of Agri. Sci. and Tech, RDA
Suwon, Kyungido, Korea
Tel: 82 331 290 0301

FEATURES
source
1. .252
/organism="Oryza sativa"
/cultivar="Milyang23"
/notes="Vector: pBluescript SK(+); Site_1: EcoRI; Site_2:
XhoI; Directional cDNA library inserted into lambda ZAPII
vector at 5' end with EcoRI and 3' end with Xho I site."
/db_xref="taxon:4530"
/map="6"
/clone="97SN1787"
/clone_1lb="Rice Immature Seed Lambda ZAPII cDNA library"
/tissue_type="Immature Seed"
/dev_stage="5 days after pollination"
/lab_host="E. coli SOLR"

BASE COUNT      5 a      21 c      12 g      35 t      179 others

Query Match      22.7%; Score 52; DB 17; Length 252;
Best Local Similarity 11.9%; Pred. No. 2.11e-48;
Matches 20; Conservative 87; Mismatches 59; Indels 2; Gaps 2;

Db 23 YBCHGNBWWCVASHGNTSVNCTBRGTHCDCKXNVNMTGCTVNBWVSGDHWYBV 82
      ::||:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Oy 25 TCCGAGGCGCGAGTGGCAGCTATGAGGCTGTGGCGCCCTTCTCTCTTGACCT 84
      :|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Db 83 BNTKYVGNHTRCSSRRBYTRMAH-YHDYTNCBYNNNDYIMHBKBYBTGCMCTYMC 141
      :|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Oy 85 CTTGCGAGCTCATGACGAGACAGCGCGGTATGACTTTCGACACTGACGTAAGCTAAGAGACTC 144
      :|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Db 142 WBHYTKCTASGWHSTNYDVS-STNTMGVTSYDKSMHGYCSBV 188
      :|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Oy 145 TTTTGTGACAAATTCCTCTATGAGCTCAGCTTCCTGAGATGCTTGA 192
      :|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|

RESULT 3
LOCUS      AA754459      252 bp      mRNA      EST      20-JAN-1998
DEFINITION      97SN1787 Rice Immature Seed Lambda ZAPII cDNA library Oryza sativa
ACCESSION      AA754459
VERSION      92801165
KEYWORDS      AA754459.1 GI:2801165
SOURCE
ORGANISM      Oryza sativa.
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
euphyllophytes; Spermatophyta; Magnoliophyta; Liliopsida; Poales;
Poaceae; Oryza.
1 (bases 1 to 252)
Nahm,B.H., Kim,J.K., Cheong,J.J., Kim,S.I., Hahn,T.R., Moon,E.P.,
Kim,M.T., Kim,W.Y., Yang,M.S., Park,R.D., Sohn,U.I., Kang,K.Y.,
Lee,M.C. and Eun,M.Y.
Large-scale Sequencing Analysis of ESTs from Rice Immature Seed
Unpublished (1998)
On Jan 14, 1998 this sequence version replaced gi:1797457.

TITLE
JOURNAL
COMMENT
Contact: Eun M.Y.
Department of Cytoogenetics
National Inst. of Agri. Sci. and Tech, RDA
Suwon, Kyungido, Korea
Tel: 82 331 290 0301
Fax: 82 331 290 0307
Email: myeun@sun20.asi.re.kr
Submitted by Baek Hie Nahm, Dept of Biological Science, Myongji
University, Yongin, Korea. 449-728 bhnahm@bioserver.myongji.ac.kr
Seq primer: M13 Reverse Primer.
Location/Qualifiers
1. .252
/organism="Oryza sativa"

```

```

/cultivar="Milyang23"
/notes="vector: pBluescript SK(+); Site_1: EcoRI; Site_2:
XhoI; Directional cDNA library inserted into Lambda ZAPII
vector at 5' end with EcoRI and 3' end with Xho I site."
/db_xref="taxon:4530"
/map="6"
/clone="975SN187"
/clone_lib="Rice Immature Seed Lambda ZAPII cDNA Library"
/tissue_type="Immature Seed"
/dev_stage="5 days after pollination"
/lab_host="E. coli SOLR"

```

BASE COUNT	ORIGIN
5 a	21 c 12 g 35 t 179 others

Query Match	21.88;	Score 50;	DB 17;	Length 252;
Best Local Similarity	9.88;	Pred. No. 4.21e-45;		
Matches	21; Conservative	108; Mismatches	83; Indels	2; Gaps 2;

```

Db      22  SYCHGNGNWMVCAHSGHNGNMYHNCNTBVGTHQCCAKVNMNLSMTGTGNNMNSYSGMNNHY  81
Cp      224  CCTGAAGGGAACATGTGGAGAGGAGGAGGACCTTTTTCAGCAATTCACAGAACTGTGACTAT  165
Db      82  VBNTKYDGNNTRCSSRRBYVTRMAHYHDYTCNBVYNNNDYHMHMBYBGTGNTCTMYC  141
Cp      164  AGAGAGAAATTTGTCAAAAAAGACTCTTCACACTCAGTTTGCAGAAATCATACCGGCGCCT  105
Db      142  WBHYNTKCTASGHTTSTINDVKSSTNTTGTVBTSDXSMHGY-C-SBVKYTHFKYSTTRA  199
Cp      104  TTCATGTGAGACTCCCAAGAGAGGTCAAGAGAGGAGCAAGGGCAGCCAGACCCCATAG  45
Db      200  TRSYTCVRKCYMMNTKKVKKYHNVBGCBEYD  233
Cp      44  TGCCCACTGCGCTCTTGGATGGAGGAACAACACTG  11

```

RESULT	4	AA754458	247 bp	mrna	EST	20-JAN-1998
LOCUS		97SN1784	Rice Immature Seed	lambda ZAPII	CDNA Library	Oryza sativa
DEFINITION		CDNA clone 97SN1784,	mrna sequence.			
ACCESSION		AA754458				
NTD		92801164				
VERSION		AA754458.1	GI:2801164			
KEYWORDS		EST.				
SOURCE		Oryza sativa.				
ORGANISM		Oryza sativa				
		Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Euphyllophytes; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Oryza.				
REFERENCE		1 (bases 1 to 247)				
AUTHORS		Nahn,B.H., Kim,J.K., Cheong,J.J., Kim,S.I., Hahn,T.R., Moon,E.P., Kim,W.T., Kim,W.Y., Yang,M.S., Park,R.D., Sohn,U.I., Kang,K.Y., Lee,M.C. and Eun,M.Y.				
TITLE		Large-scale Sequencing Analysis of ESTs from Rice Immature Seed				
JOURNAL		Unpublished (1998)				
COMMENT		On Jan 14, 1998 this sequence version replaced gi:1797455.				

Contact: Eun M.Y.
 Department of Cytogenetics
 National Inst. of Agri. Sci. and Tech., RDA
 Suwon, Kyunggi-do, Korea
 Tel: 82 331 290 0301
 Fax: 82 331 290 0307
 Email: myeun@sunsu20.asti.re.kr
 Submitted by Baek Hie Nam, Dept of Biological Science, Myongji
 University, Yongin, Korea, 449-728 bhnamm@losetver.myongji.ac.kr
 Seq primer: M13 Reverse Primer.
 Location/Qualifiers
 1. 247

```
/organism="Oryza sativa"  
/cultivar="Milyang23"  
/note="Vector: pBluescript SK(+); Site_1: EcoRI; Site_2:  
XhoI; Directional cDNA library inserted into lambda ZapIII  
vector at 5' end with EcoRI and 3' end with Xho I site."
```

```

/db_xref="taxon:4530"
/map="6"
/clone="97SN1784"
/clone_id="Rice Immature Seed Lambda ZAPIT cDNA Library"
/tissue_type="Immature Seed"
/dev_stage="5 days after pollination"
/lab_host="E. coli SOLR"

BASE COUNT      7 a      16 c      21 g      34 t      169 others
ORIGIN

Query Match      17.5%; Score 40; DB 17; Length 247;
Best Local Similarity 10.7%; Pred. No. 4, 11e-29;
Matches      22; Conservative 100; Mismatches 81; Indels 3; Gaps 3;
```

Db 34 VRRVETTTNNNGKNGRTTMTDNCSDNACHCYIVBMYIARSKSYGIBYBSNMVDTNGGT 93
 Cp 218 GGGAGATGTGGAGGAGGAGGACAGCTTTTCAAGCAATTCAGAGACGTGACT-CATTAGGAG 160
 Db 94 GVGKTTVNVHSGMNNRCSNYSVYVMTAYCDYBHYBDRAHVDTRCTNDRGNCYNTASD 153
 Cp 159 GAATTTGCAAGAAAGACTCTCTCAGCTTCAAGTCAATACCCGGCCGTGTCCA 100
 Db 154 NGTSAT-KRYTYGIDKTDSDCGGGCKRKYTYGSS-BYBRCVNTMVTTSMTMDKSTMB 211
 Cp 99 TGTGAGCTGCCAAGGAGGAGGTCAAGAGGAGACAAAGGACCCAGACCATCATGTGGCC 40
 Db 212 MDKRSRVRHYGRMMNBKTKRGRSMN 237
 Cp 39 ACTGGCTCTCTGGATGAGGAGAGACA 14

RESULT	5	AA754458	247 bp	mRNA	EST	20-JAN-1998
LOCUS		97SN1784	Rice Immature Seed	Lambda Zapri	CDNA Library	Oryza sativa
DEFINITION		CDNA clone 97SN1784,	mRNA sequence.			
ACCESSION		AA754458				
NTD		92801164				
VERSION		AA754458.1	GI:2801164			
KEYWORDS		EST.				
SOURCE		Oryza sativa.				
ORGANISM		Oryza sativa				
		Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Euphyllophytes; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Oryza.				
REFERENCE		1 (bases 1 to 247)				
AUTHORS		Nahn,B.H., Kim,J.K., Cheong,J.J., Kim,S.I., Hahn,T.R., Moon,E.P., Kim,W.T., Kim,M.Y., Yang,M.S., Park,R.D., Sohn,U.I., Kang,K.Y., Lee,M.C. and Eun,M.Y.				
TITLE		Large-Scale Sequencing Analysis of ESTs from Rice Immature Seed				
JOURNAL		COMMENT (1899)				
COMMENT		On Jan 14, 1998 this sequence version replaced gi:1797455.				

CONTACT: Eun M.Y.
Department of Cytogenetics
National Inst. of Agri. Sci. and Tech, RDA
Suwon, Kyunggi-do, Korea
Tel.: 82 331 290 0301
Fax: 82 331 290 0307
Email: myeun@sunn20.asi.re.kr
Submitted by Baek Hie Nahm, Dept of Biological Science, Myongji
University, Yongin, Korea, 449-728 bnhnmbioserver.myongji.ac.kr
Seq primer: M13 Reverse Primer.
Location/Qualifiers
1. 247


```

"organism="Oryza sativa"
/cultivar="Milyang23"
/note="Vector: plusscript SR(+). Site 1: EcoRI; Site 2:
XhoI; Directional cDNA library inserted into lambda ZapI
vector at 5' end with EcoRI and 3' end with Xho I site."
/vdb.Xref="taxon:4530"
/map="6"
/clone="97SN1784"
/clone_lib="Rice Immature Seed Lambda ZapI cDNA Library"

```


Bull, C. J., Lee, N. H., Kirkness, E. F., Weinstein, K. G., Coccyne, J. D., White, O., Sutton, G., Blake, J. A., Brandon, R. C., Man-Wai, C., Clayton, R. A., Cling, T. R., Cotton, M. D., Earle-Hughes, J., Fine, L. D., Fitzgerald, L. M., Fitzhugh, W. M., Fritschman, J. L., Geoghegan, N. S., Glodde, A., Gnehm, C. L., Hanna, M. C., Hebbloom, E., Hinkle, P. S, Jr., Kelley, J. M., Kelley, J. C., Liu, L.-I., Marmaros, S. M., Merrick, J. M., Moreno-Palauques, R. F., McDonald, L. A., Nguyen, D. T., Pelligrino, S. M., Phillips, C. A., Ryder, S. E., Scott, J. L., Saneck, D. M., Shirley, R., Small, K. V., Spriggs, T. A., Utterback, T. R., Weidman, J. F., Li, Y., Bednarek, D. P., Cao, L., Cepeda, M. A., Coleman, T. A., Collins, E. J., Dlake, D., Feng, D. F., Ferrite, A., Fischer, C., Hastings, G. A., He, W. W., Hu, J. S., Greene, J. M., Gruber, J., Hudson, P., Kim, A. K., Kosak, D. L., Kunsch, C., Hungjun, J., Li, H., Meisner, P. S., Olsen, H., Raymond, L., Wei, Y. F., Wing, J., Xu, C., Yu, G. L., Ruben, S. M., Dillon, P. J., Fannon, M. R., Rosen, C. A., Haseltine, W. A., Fields, C.,

Balt, C. J., Lee, N. H., Kirkness, E. F., Weinstein, K. G., Gocayne, J. D., White, O., Sutton, G., Blake, J. A., Brandon, R. C., Man-
Mali, C., Clayton, R. A., Cline, T. R., Cotton, M. D., Earle-Hughes, J., Fine, L. D., Fitzgerald, L. M., Fitzhugh, W. M., Friedman, J. R., Geophagen, N. S., Glodde, A., Gnehm, C. L., Hanna, M. C., Hedblom, E., Hinkle, P. S., Jr., Kelley, J. M., Kelley, J. C., Liu, L. I., Mamaratos, S. M., Merrick, J. M., Moreno-Falanes, R. F., McDonald, L. A., Nguyen, D. T., Pelligriano, S. M., Phillips, C. A., Ryder, S. E., Scott, J. L., Saudek, D. M., Shirley, R., Small, K. V., Spriggs, T. A., Utterback, T. R., Weidman, J. F., Li, Y., Benchari, D. P., Cao, L., Cepeda, M. A., Coleman, T. A., Collins, E. J., Dilke, D., Feng, D. F., Ferrite, A., Fischer, C., Hastings, G. A., He, M. W., Hu, J. S., Greene, J. M., Gruber, J., Hudson, P., Kim, A. R., Kozak, D. L., Kunsch, C., Hungjun, J., Li, H., Meisner, P. S., Olsen, H., Raymond, L., Wei, Y. F., Ming, J., Xu, C., Yu, G. L., Ruben, S. M., Dillon, P. J., Fannon, M. R., Rosen, C. A., Haseltine, W. A., Fields, C., Fraser, C. M., and Venter, J. C.



Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MPearch_n n.a. - n.a. database search, using Smith-Waterman algorithm

Run on: Sun Oct 24 16:22:19 1999; MasPar time 475.19 Seconds

Tabular output not generated. 1394.147 Million cell updates/sec

Title: >US-09-092-296-1
Description: (1-239) from US0902296.seq
Perfect Score: 238
N.A. Sequence: 1 GCCGACGGGAGCTTCAAGTGT.....CCCTTACGAGGACGACGCTCA 239
Comp: CCGGTGGGCGCTGAGACACA.....GGGAGTCCCTGTGCGCAGT

Scoring table: TABLE default
Gap 6

Nmatch STD: Dbase 0; Query 0

Searched: 646147 seqs, 1385953633 bases x 2

Post-processing: Minimum Match 0%

Database: emb156

1:em_ba1 2:em_ba2 3:em_fun 4:em_htg 5:em_hum1 6:em_hum2
7:em_in 8:em_com 9:em_or 10:em_ov 11:em_pat 12:em_ph
13:em_pl 14:em_ro 15:em_sts 16:em_vi
genbank111

17:gb_ba1 18:gb_ba2 19:gb_htg1 20:gb_htg2 21:gb_in1
22:gb_in2 23:gb_com 24:gb_ov 25:gb_pat 26:gb_ph 27:gb_pl1
28:gb_pl2 29:gb_pl1 30:gb_pr2 31:gb_pr3 32:gb_ro
33:gb_st 34:gb_sts 35:gb_sy 36:gb_un 37:gb_vi

Statistics: Mean 9.507; Variance 4.824; scale 1.991

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result	Query	Score	Match	Length	DB	ID	Description	Pred. No.
1	112	47.1	47323	31	AC005937		Homo sapiens clone UMG	7.72e+5
2	47	19.7	7218	25	166494		Sequence 14 from paten	2.10e+15
3	36	15.1	215	25	128278		Sequence 5 from patent	3.87e+08
4	33	13.0	216021	31	HRAC004787		Homo sapiens Chromosom	4.91e+06
5	31	13.0	965	25	AR024229		Sequence 22 from paten	8.69e+05
6	29	12.2	74371	31	AC005369		Homo sapiens Chromosom	1.43e+03
7	28	11.8	1056	23	MYU87256		Mustela vison GT dinuc	5.63e+03
8	28	11.8	216021	31	HUAC004787		Homo sapiens Chromosom	2.17e+02
9	27	11.3	215	25	AR024229		Sequence 5 from patent	8.16e+02
10	26	10.9	965	25	AR024229		Sequence 22 from paten	3.00e+01
11	25	10.5	565	31	EC04076		gDNA encoding envelope	3.00e+01
12	25	10.5	60966	31	AC003030		Homo sapiens chromosom	1.07e+00
13	24	10.1	60	25	A62989		Sequence 1 from Patent	1.07e+00

C	14	24	10.1	1056	23	MYU87256	Mustela vison GT dinuc	1.07e+00
C	15	23	10.1	175793	31	AC005920	Homo sapiens chromosom	1.07e+00
C	16	23	9.7	3390	29	HUMFPCAS	H. sapiens fucosidase P	3.72e+00
C	17	23	9.7	4472	17	NKSEB0RF	Neisseria meningitidis	3.72e+00
C	18	23	9.7	133457	30	AC003999	Human PAC clone D11139	3.72e+00
C	19	23	9.7	192853	19	AC005096	Homo sapiens clone R03	3.72e+00
C	20	23	9.7	203418	19	AC004947	Homo sapiens clone R03	3.72e+00
C	21	22	9.2	30	25	A62994	Sequence 6 from Patent	1.25e+01
C	22	22	9.2	108	21	D87227	Human (clone SV210) g	1.25e+01
C	23	22	9.2	1738	29	HUMGOLGINB	D. melanogaster synapo	1.25e+01
C	24	22	9.2	2180	21	DR05T	Sequence 1 from patent	1.25e+01
C	25	22	9.2	2273	32	MMBAEXN	DNA encoding part of A	1.25e+01
C	26	22	9.2	3088	25	AR014574	Homo sapiens mRNA for	1.25e+01
C	27	22	9.2	3088	15	EL0775	Homo sapiens WOC4 gene	1.25e+01
C	28	22	9.2	3628	29	AB018292	Mus musculus Bak gene,	1.25e+01
C	29	22	9.2	3890	30	HS010901	Homo sapiens CDO (Cdo)	1.25e+01
C	30	22	9.2	3814	32	AF050866	Mus musculus mRNA for	1.25e+01
C	31	22	9.2	6640	29	D63997	WORKING DRAFT SEQUENCE	1.25e+01
C	32	22	9.2	67919	20	AC006542	Homo sapiens 3p21.1 co	1.25e+01
C	33	22	9.2	82098	31	AC006252	Drosophila melanogaste	1.25e+01
C	34	22	9.2	124700	22	AC006558	Homo sapiens 3p22-8 PA	1.25e+01
C	35	22	9.2	135039	31	AC006060	Human DNA sequence ***	1.25e+01
C	36	22	9.2	151187	19	HS460J8	Homo sapiens chromosom	1.25e+01
C	37	22	9.2	175339	31	AC005772	Mouse Chromosome 10 BA	1.25e+01
C	38	22	9.2	241407	20	AC003059	Homo sapiens mRNA for	4.06e+01
C	39	21	8.8	1155	29	HS237017	Robinia pseudacacia 9	4.06e+01
C	40	21	8.8	2817	27	AB012632	Mus musculus gene for	4.06e+01
C	41	21	8.8	3043	32	AB010141s4	Mus musculus mRNA for	4.06e+01
C	42	21	8.8	3247	32	AB010140	S. pombe chromosome II	4.06e+01
C	43	21	8.8	46213	28	SPBC18H10	Homo sapiens clone NH0	4.06e+01
C	44	21	8.8	113887	20	AC006158	Human DNA sequence ***	4.06e+01
C	45	21	8.8	130560	19	HS508115		4.06e+01

ALIGNMENTS

RESULT 1 AC005937 47323 bp DNA 05-NOV-1998
LOCUS Homo sapiens clone UMG:370M23.002 from 6p21, complete sequence.
DEFINITION AC005937
ACCESSION G3845393
NID AC005937.1 GI:3845393
VERSION
KEYWORDS
SOURCE
ORGANISM
human.
Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
Primates; Catarrhini; Hominiidae; Homo.
REFERENCE
AUTHORS
Taner, M., Guillaudoux, T., Vu, O., Kutay, T., Harter, H. and
Geraghty, D. E.
TITLE
Large scale sequence analysis of the human MHC class I region
JOURNAL
Unpublished (1998)
REMARK
Fred Hutchinson Cancer Research Center
The Clinical Research Division
1100 Fairview Ave. N., P.O. Box 19024
Seattle, WA 98109-1024
2 (bases 1 to 47323)
3 (bases 1 to 47323)
REFERENCE
Geraghty, D. E. and Olson, M. V.
TITLE
Direct Submission
JOURNAL
Submitted (05-NOV-1998) Human Genome Center, University of
Washington, Box 352145, Seattle, WA 98195, USA
University of Washington Human Genome Center
Box 352145 Seattle, WA 98195
Contact: Daniel E. Geraghty (geraghty@hrc.org)
Overlapping Sequences:
5': UMG:370M23.013 (Genbank Accession: AC005330)
3': UMG:Y67C112 (Genbank Accession: AC004211)

Sequence Quality Assessment:
This entry has been annotated with sequence quality
estimates computed by the Phrap assembly program.
All manually edited bases have been reduced to quality zero.
Quality levels above 40 are expected to have less than

1 error in 10,000 bp.
Base-by-base quality values are not generally visible from the
GenBank flat file format but are available as part
of this entry's ASN.1 file.

Double stranded (DS) coverage: 75.58
DS or two chemistry coverage: 98.98
Single stranded regions: 3

Sequence Validation:

This sequence has been validated by Multiple Complete Digest
Mapping. Comparison of the experimentally derived map digest
fragments with sequence-predicted fragments is given below.
Small fragments below a variable cutoff (approximately 400-600bp)
are not mapped and hence do not appear in the table. There are no
significant remaining discrepancies between the experimental and
predicted values. Uniquely ordered fragment groups are separated
by dashed lines.

BglII		HindIII		NsiI	
Map	Seq	Map	Seq	Map	Seq
1069.11	1050.00	889.55	866.00	30541.40	30653.00
20320.67	20855.00	1050.18	1015.00	3279.08	3231.00
2171.50	2147.00	7268.78	7196.00		
2560.20	2531.00	10085.80	9992.00		
4335.42	4269.00	11212.78	11131.00		
2698.62	2628.00				
1927.50	1887.00				
3130.46	3090.00				
2166.69	2129.00				
2044.67	2005.00				

FEATURES

Location/Qualifiers

SOURCE

1. 47323
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="6"
/map="6p21"
/sub_clone="UMGC:370M23.002"
/clone_id="Research Genetics BMC Library"
/rpl_family="Alu"
complement(499..5277)
/rpl_family="Alu"
6285..6572
/rpl_family="Alu"
complement(6572..7050)
/rpl_family="MLT1"
7286..7584
/rpl_family="Alu"
complement(8164..8609)
/rpl_family="Alu"
complement(21287..21895)
/rpl_family="Alu"
22715..22957
/rpl_family="Alu"
25510..25802
/rpl_family="Alu"
27835..28010
/rpl_family="MER20"
31295..31594
/rpl_family="Alu"
33515..33767
/rpl_family="Alu"

repeat_region 34223..34290
/rpl_family="MIR"
repeat_region 37372..37648
/rpl_family="Alu"
repeat_region 38526..38700
/rpl_family="MER3"
repeat_region 39583..40010
/rpl_family="Alu"
repeat_region 40046..40156
/rpl_family="Alu"
repeat_region 43194..43372
/rpl_family="MER5"
variation 43325
/note="clonal variation with 3' overlapping clone"
variation 44149
/note="clonal variation with 3' overlapping clone"
variation 44451
/note="clonal variation with 3' overlapping clone"
variation 44537
/note="clonal variation with 3' overlapping clone"
variation 44814
/note="clonal variation with 3' overlapping clone"
variation 44965
/note="clonal variation with 3' overlapping clone"
variation 45760
/note="clonal variation with 3' overlapping clone"
variation 45900
/note="clonal variation with 3' overlapping clone"
variation 46851
/note="clonal variation with 3' overlapping clone"
variation 46859
/note="clonal variation with 3' overlapping clone"
variation 47032
/note="clonal variation with 3' overlapping clone"
variation 47240..47256
/note="clonal variation with 3' overlapping clone"
insertion of 17bp repeat

BASE COUNT 11556 a 11489 c 12284 g 11994 t
ORIGIN

Query Match 47.1%; Score 112; DB 31; Length 47323;
Best Local Similarity 100.0%; Pred. No. 7.72e-65;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 35117 GGCACCGGAGCTCACTGTCCTCCATCCACAGAGCCAGTGGCCTG 35176
|||||
OY 1 GGCACCGGAGCTCACTGTCCTCCATCCACAGAGCCAGTGGCCTG 60
DB 35177 GCGTGGCCCTGCTCCTCTTGACCTCTTGACGACTGCATGGAACG 35228
|||||
OY 61 GCGTGGCCCTGCTCCTCTTGACCTCTTGACGACTGCATGGAACG 112

RESULT 2 166494 7218 bp DNA PAT 23-DEC-1997
LOCUS Sequence 14 from patent US 5670367.
DEFINITION
ACCESSION 166494
NID 92724471
VERSION 166494.1 GI:2724471
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 7218)
AUTHORS Dornier,F., Scheitlinger,F. and Falkner,F.Gunter.
TITLE Recombinant fowlpox virus
JOURNAL Patent: US 5670367-A 14 23-SEP-1997;
FEATURES
source 1. 7218
/organism="unknown"
BASE COUNT 1944 a 1491 c 1486 g 1929 t 368 others
ORIGIN

Query Match	19.7%	Score 47	DB 25	Length 7218
Best Local Similarity	2.3%	Pred No. 2.10e-15	Mismatches 86	Indels 0
Matches	5	Conservative	129	Mismatches 86
Db 1219	YYYYY	Y	Y	Y
Y	12	CTTCACTGCTCTCCATCCAGACCGACGAGTGGCCACTATGAGGGCTGGGCGCCCTT	71	
Db 1279	Y	Y	Y	Y
Y	72	GTCCTCTCTTACCCCTCTTGACAGCTCACATGAAACAGGCGCCGATGACTTTGCA	131	
Db 1339	Y	Y	Y	Y
Y	132	CTAAGCTGAGAGAGCTCTTTTCGACAAATTCCTCTAAGAGCTCAGGCTCTTGAAATG	191	
Db 1399	Y	Y	Y	Y
Y	192	CTTGAAATNTCTGCCTCTCTCTCTCCATCTCCCTTACGAGGACCA	233	
RESULT 3	128278	215 bp	DNA	PAT
LOCUS	Sequence 5 from patent US 5569830.			30-OCT-1996
DEFINITION	128278			
ACCESSION	91819054			
NID	128278.1	GI:1819054		
VERSION	Unknown.			
KEYWORDS	Unknown.			
SOURCE	Unknown.			
ORGANISM	Unclassified.			
REFERENCE	1 (bases 1 to 215)			
AUTHORS	Bennett,A., Labavitch,J.M., Powell,A. and Stotz,H.			
TITLE	Plant inhibitors of fungal polygalacturonases and their use to control fungal disease			
JOURNAL	Patent: US 5569830-A 5 29-OCT-1996.			
FEATURES	Location/Qualifiers			
source	1..215			
BASE COUNT	15 a	8 c	25 g	26 t
ORIGIN	/organism="unknown"			
	141 others			
Query Match	15.1%	Score 36	DB 25	Length 215
Best Local Similarity	14.7%	Pred. No. 5.87e-08		
Matches	28	Conservative	77	Mismatches 83
				Indels 2
				Gaps 2
Db 1	MTNTMSSSVSTASCDKAKKDDTSSMTTDCNFTMGVCDTDTTRYVNDGHNK	60		
CP 189	ATTCCAGGACCTGACATCATAGGAGGAAATTTGTGAGAAAGACTCCTCAGCTTC	131		
Db 61	YSANYNVGNNGNNVGAATKTHYHTVNVSGADSKTYTDSYNASGTSSNSGTFD	119		
CP 130	TCCAAAGCATACACCGGCGCTGTCTCATGTGAGCTCCAGAGAGGTCAGAGAGACCA	71		
Db 120	YSSSTATSTSNRTGRTANNANVDSNNMGDASVGSDDKNTKKAKKNSADGKVGSKNNGDRNN	179		
CP 70	AGGGCCACCCAGACCCCATATGAGCCACTGCGCTCTGAGGATGAGGAGACACTGAAGT	11		
Db 180	RTGTGATKSNNV	189		
CP 10	CCCGGTGGCC	1		
RESULT 4	HUAC004787	216021 bp	DNA	PAT
LOCUS	Homo sapiens Chromosome 16 BAC clone C1967SR-A-952F10, complete			24-JUL-1998
DEFINITION	sequence			
ACCESSION	AC004787			
NID	93337381			
VERSION	AC004787.1	GI:3337381		
KEYWORDS	HTG.			
SOURCE	human.			
ORGANISM	Homo sapiens			

REFERENCE	1 (bases 1 to 216021)	Primates: Catarrhini: Hominidae: Homo.
AUTHORS	Adams,M.D., Loftus,B.J., Zhou,L., Crosby,M., Fuhrmann,J., Mason,T.M., Brandon,R., Kim,U.J., Kerlavage,A.R. and Venter,J.C.	
TITLE	Homo sapiens Chromosome 16 BAC clone C119875K-A-952F10	
JOURNAL	Unpublished	
REFERENCE	2 (bases 1 to 216021)	Adams,M.D. and Loftus,B.J.
AUTHORS	Adams,M.D. and Loftus,B.J.	
TITLE	Direct Submission	
JOURNAL	Submitted (02-JUN-1998) The Institute for Genomic Research, 9712 Medical Center Dr, Rockville, MD 20850, USA, Email: bjofofust@tigr.org	
COMMENT	3 (bases 1 to 216021)	Submitted (24-JUL-1998) The Institute for Genomic Research, 9712 Medical Center Dr., Rockville, MD 20850, USA On Jul 24, 1998 this sequence version replaced 613241936. Addresses all correspondence to: Mark Adams The Institute for Genomic Research 9712 Medical Center Dr, Rockville, MD 20850, USA e-mail address: humgen@tigr.org. The orientation of the sequence is from Sp6 end to T7 end. Genes were identified by a combination of five methods including: XGRail (available by anonymous ftp from ahnr.epm.ornl.gov), GeneFinder (Phil Green, University of Washington), GenScan (Chris Burge, http://genomic.stanford.edu/~chris/GENSCANW.html), searches of the complete sequence against a peptide database, and the Human gene Index database at TIGR (http://www.tigr.org/tdb/hgi/hgi.html). Genes without peptide homology having spliced EST hits are termed 'Unknown gene product'. Genes encoding tRNAs are predicted by tRNAscan-SE (Sean Eddy, http://genome.wustl.edu/eddy/tRNAscan-SE/)
FEATURES	Location/Qualifiers	
source	1..216021	
	/organism="Homo sapiens"	
	/db_xref="taxon:9606"	
	/chromosome="16"	
	/map="16q21-22"	
	/clone="A-952F10"	
	2765..27872	
STS	/note="7766, STS1-cSRU-27g3-uA/cSRU-27g3-uZ, Chr. -, Homo sapiens"	
	/db_xref="dbSTS:G02280"	
	73826..73943	
STS	/note="7608, STS1-cSRU-24g1-uA/cSRU-24g1-uZ, Chr. -, Homo sapiens"	
	/db_xref="dbSTS:G02122"	
	175801..175945	
STS	/note="16084, CHC.GC110B02, Chr. -, Homo sapiens"	
	/db_xref="dbSTS:G09703"	
	175810..175945	
STS	/note="1616, CHC.GC115C04, Chr. -, Homo sapiens"	
	/db_xref="dbSTS:G09935"	
	199463..199572	
	/note="9824, WI-3555, Chr. 16, Homo sapiens"	
	/db_xref="dbSTS:G04338"	
BASE COUNT	60960 a 51778 c 49172 g 53987 t 124 others	
ORIGIN		
Query Match	13.9% Score 33; DB 31; Length 216021;	
Best local Similarity	12.2% Pred No. 4.91e-06;	
Matches	18; Conservative 72; Mismatches 57; Indels 0; Gaps 0;	
Db	1436 WYCSYTYCCYTCASRRRGKTKYMKSNRRARRRSAGKRRKKRYTYCYYYYYCYM 1495	
Oy	22 TCTCTCATCCAGGAGCGCGCATGCGGCGTCTGGCTGCGCCCTTGTCCTCT 81	
Db	1496 GRAMAAAMYRRRCAMYYRYRGARTRYYYARRRCASYYKMMAYMAWMTWCA 1555	
Oy	82 TGACCTCTCTGGCAGCTCAGCAGGAACAGGCGCGGGTATGACTTTCGACATGACGCTGA 141	
Db	1556 AAAMAATYTYMMAMMYKKWMTCT 1592	


```

/note="GRIll 2 excellent exon, frame 1"
repeat_region
36392..36663
/ftp_family="Alu"
36901..37222
/note="100% identity EST ou55c09.x1"
/misc_feature
/db_xref="dbEST:A1025011"
36901..37164
STS
/standard_name="STS-9983"
/db_xref="dbSTS:C26554"
complement(37595..37654)
/misc_feature
/note="GRIll 2 excellent exon, frame 0"
complement(join(38063..38218,38465..38578,38741..38959,39013..39205,39532..39630,39935..40048,40300..40410,40503..40661,41868..41972,42103..42225,42492..42569,44379..44507))
/standard_name="histidyl-tRNA synthetase"
/note="78%-100% protein identity GenPept:U18937"
misc_feature
complement(38069..38215)
/note="GRIll 2 excellent exon, frame 0"

```

Note: remainder of annotations omitted.

Query Match	12.28;	Score 29;	DB 31;	Length 74371;
-------------	--------	-----------	--------	---------------

Best local similarity 10.7%; Pled. NO. 1.43e-03;
Matches 14; Conservative 45; Mismatches 24; Indels 1; Gaps 1;

Db 15929 CMSRSKSKRGWGYRSWKKYRCAMMTCKSS-KCWCWSYRMRMKCYSCSYCYCSSGKKYYWC 15987

6 CCGGACTTCAGTGTCTCTCCATCCAGAGCGCAGTGGCCACTATGGGGTCTGGGCTG 65

Db 15988 RCSMYWTCYYSYKYYWSMSYCTC 16011

66 CCCCTTGTCCTCCTTGCACCTC 89

RESULT	7				
LOCUS	MV087256	1056 bp	DNA	MAM	02-JAN-1999
DEFINITION	Mustela vison	GT dinucleotide repeat,			
LOCATION		chromosome 1q.			

VERSION U87256.1 GI:4099442

SOURCE American mink.

SOURCE	American mink.
ORGANISM	Mustela vison

Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria; Carnivora; Fissipedia; Mustelidae; Mustela.

Carnivora; Fissipedia
1 /basos 1 to 1066

1 (bases 1 to 1030)
 AUTHORS Brusgaard, K., Shukri, N.M., Malchenko, S., Koroleva, I. and Lohi, O.

TITLE	DATE	REMARKS
Direct Submission	10/10/71	NOVOTREVA, L. AND LOHL, C.

Animal Science, Blichersalle K25, Tjele 8830, DK

FEATURES	Location/Qualifiers
source	1. 1056

source 1. .1056

```

/organism="Mustela vison"
/db="ncf-taxon-0667"

```

```
/db_xref="taxon:9667"
/chromosome="1"
```

```
/chromosome="1"  
/map="1q"
```

/map=1q
/note="primers: 1167F: agccctgcatactcttctt, 1167R:

gagatcttaccgctgttag"

```
primer_bind
98.0 .119
```

```
primer bind
complement(300 320)
/standard_name="1167F"
```

```
primer_bind complement(300. .320)
/standard name="1167R"
```

BASE COUNT	211 a	221 c	210 g	225
	/standard_name="116/R"			

[illegible]

Current Match

Query Match	11.8%;	Score 28;	DB
Best Local Similarity	12.8%;	Prod NO	5

Best Local Similarity	12.8%;	Pred. No. 5.6
Matches	12: Conservative	49: Mismatch

matches 12; conservative 49; Mismatch

Db 576 SCRHDVBMWSKWCWGKKSCKSTGDKDMSGCAYCGK

[illegible]

0Y 3 CCACCGGACTTCAGTGTCTCTCCATCCCGAGGAGC

Qy	63	CHGCCCTTGTCTCTCTCTTGACCCCTCTGCA	96
db	636	CDKKS6SGSKSHCKSKKRYKMDRYHCKRSCMA	669
LOCUS	8	HUAC004787 216021 bp	DNA
DEFINITION		Homo sapiens Chromosome 16 BAC clone C119878K-A-952F10, complete sequence.	24-JUL-1998
ACCESSION		AC004787	
NID		93337381	
VERSION		AC004787.1	
KEYWORDS		HTG.	
SOURCE		human.	
ORGANISM		Homo sapiens	
REFERENCE		Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.	
AUTHORS		1 (bases 1 to 216021)	
TITLE		Adams,M.D., Loftus,B.J., Zhou,L., Crosby,M., Fuhrmann,J., Mason,T.M., Brandon,R., Kim,U.J., Kerlavage,A.R. and Venter,J.C.	
JOURNAL		Homo sapiens Chromosome 16 BAC clone C119878K-A-952F10	
REFERENCE		Unpublished	
AUTHORS		2 (bases 1 to 216021)	
TITLE		Adams,M.D. and Loftus,B.J.	
JOURNAL		Direct Submission	
REFERENCE		Submitted (02-JUN-1998) The Institute for Genomic Research, 9712	
AUTHORS		Medical Center Dr, Rockville, MD 20850, USA, Email:	
TITLE		bjloftus@tigr.org	
JOURNAL		3 (bases 1 to 216021)	
REFERENCE		Adams,M.D. and Loftus,B.J.	
AUTHORS		Direct Submission	
TITLE		Submitted (24-JUL-1998) The Institute for Genomic Research, 9712	
JOURNAL		Medical Center Dr, Rockville, MD 20850, USA	
COMMENT		On Jul 24, 1998 this sequence version replaced gi:3241936.	
		Address all correspondence to: Mark Adams The Institute for Genomic Research 9712 Medical Center Dr, Rockville, MD 20850, USA e-mail address: humantset@tigr.org. The orientation of the sequence is from Sfp end to T7 end. Genes were identified by a combination of five methods including: Xcrair (available by anonymous ftp from archur.epm.ornl.gov), Genefinder (Phil Green, University of Washington), Genscan (Chris Burge, http://genomic.stanford.edu/~chris/GENSCANW.html) searches of the complete sequence against a peptide database, and the Human gene Index database at TIGR (http://www.tigr.org/cdb/hgi/ngi.html). Genes without peptide homology having significant EST hits are termed 'Unknown gene product'. Genes encoding tRNAs are predicted by tRNAscan-SE (Sean Eddy, http://genome.wustl.edu/eddy/tRNAscan-SE/).	
FEATURES		Location:Unalifers	
SOURCE		1. 216021	
		/organism="Homo sapiens"	
		/db_xref="taxon:9606"	
		/chromosome="16"	
		/map="16q21.22"	
		/clone="A-952F10"	
		27765. .27872	
		/note="7766, STS1-CSRL-2793-VA/CSRL-2793-UZ, Chr. -, Homo sapiens"	
		/db_xref="dbSTS:G02280"	
		73826. .73943	
		/note="7608, STS1-CSRL-2491-VA/CSRL-2491-UZ, Chr. -, Homo sapiens"	
		/db_xref="dbSTS:G02122"	
		175801. .175945	
		/note="16084, CHLC.GCT110B02, Chr. -, Homo sapiens"	
		/db_xref="dbSTS:G09703"	
		175810. .175945	
		/note="16316, CHLC.GCT15C04, Chr. -, Homo sapiens"	
		/db_xref="dbSTS:G09935"	
		199463. .199572	
		/note="9824, WT-3555, Chr. 16, Homo sapiens"	
		/db_xref="dbSTS:G04338"	
BASE COUNT	60960	a 51778 c 49172 g 53997 t 124	others

[illegible]


```

CDS
100% identity."
10104528.5045.5432.5497.6480.6575.8155.8249.
10156.10183.10562.10717.11845.11991.12086.12176.
13147.11250.14614.14679.18199.18248.18465.18512.
18635.18746.23665.23755.24574.24709.37283.37493)
/notes="Hypothetical human protein (partial)"
/codon_start=1
/evidence=not_experimental
/product="R29828_1"
/protein_id="AAD03161.1"
/db_xref="pid:q4106983"
/db_xref="GI:4106983"
/translation="WLSQQIPQEDVYKEAASLLSELYCOENSDAAKPLLRKAIQI
SCPPYHCHLLEPQLAHLHTENDYASGDLGLGVAEYARVSEYTRALFLSKGL
LIMPEKQVILITCGIIVENMGQRIQDLSEYFVAVITVTHASMGAGCYKVC
LKQDQCIQITSLHDELSPNADFLHREKEMKCYLVITVHSMQAGCYKVC
KTDALMQLKELKMLDPSFLSSFOYILHETICRVLVGHKATLDQGLCYKVC
MNAAPQATLALYSLERINPDHSPVSSCHLAALFVYRGFLSEFGGRNKAKEF
LRETLKSNMEDNRLTACSLVGLHIFVNLNHNSENNAVPMAPDLAKIPDVSVO
WSSALLRKLKACGNADHAEQAHQNFSQLDLEACSLPEHNLITVAVHMGVGL
IATLTPAEAMEQOSTTLYTSADIMKHIDQDEGESMAVPERCEIKSLRPTRAILL
PPLPD"
misc_feature
complement(5186..5264)
/notes="predicted exon, program: grail2exons_human_1.3,
frame: 0, quality: excellent, score: 86.000"
5432..5497
/misc_feature
/notes="BDS similarity to overlapping ESTs: AA963316
UT-R-E1-g1-c-06-0-UI-s1 UT-R-E1 Rattus norvegicus cDNA
clone UT-R-E1-g1-c-06-0-UI 3'; (238..303); 88%
identity.--AA893275 EST197078 Normalized rat kidney, Bentco
Soares Rattus sp. cDNA clone RK1BE38 3' end; (258..323);
88% identity."
complement(5602..5883)
/rpt_family="Aluou"
6480..6575
/misc_feature
/notes="BDS similarity to overlapping ESTs: AA963316
UT-R-E1-g1-c-06-0-UI-s1 UT-R-E1 Rattus norvegicus cDNA
clone UT-R-E1-g1-c-06-0-UI 3'; (304..399); 89%
identity.--AA893275 EST197078 Normalized rat kidney, Bentco
Soares Rattus sp. cDNA clone RK1BE38 3' end; (324..419);
89% identity.--(6480..6660) predicted exon, program:
grail2exons_human_1.3, frame: 2, quality: excellent,
score: 76.000"
8155..8249
/misc_feature
/notes="predicted exon, program: grail2exons_human_1.3,
frame: 0, quality: excellent, score: 94.000--BDS
similarity to overlapping ESTs: (8155..8237) AA963316
UT-R-E1-g1-c-06-0-UI-s1 UT-R-E1 Rattus norvegicus cDNA
clone UT-R-E1-g1-c-06-0-UI 3'; (400..482); 88%
identity.--(8155..8240) AA893275 EST197078 Normalized rat
kidney, Bentco Soares Rattus sp. cDNA clone RK1BE38 3' end;
(420..505); 85% identity."
8351..8477
/rpt_family="Aluub"
8480..8768
/rpt_family="Alusc"
8778..8837
/misc_feature
/notes="predicted exon, program: grail2exons_human_1.3,
frame: 2, quality: excellent, score: 83.000"
complement(8872..8996)
/rpt_family="Aluub"
9052..9196
/rpt_family="Alusc"
9197..9493
/rpt_family="Aluv"
9494..9658
/rpt_family="Alusc"
9658..9967
/rpt_family="Aluv"
10156..10183
/notes="predicted exon, program: grail2exons_human_1.3,
frame: 1, quality: excellent, score: 86.000"
10562..10721
misc_feature

```

```

/note="predicted exon, program: gra112exons_human_1.3,
frame: 1, quality: excellent, score: 100.000"
11845..11991
/note="predicted exon, program: gra112exons_human_1.3,
frame: 0, quality: excellent, score: 97.000"
12086..12176
/note="predicted exon, program: gra112exons_human_1.3,
frame: 1, quality: excellent, score: 96.000"
13147..13250
/note="predicted exon, program: gra112exons_human_1.3,
frame: 2, quality: excellent, score: 100.000"
13440..13741
/rpt_family="AluXs"
14614..14679
/note="predicted exon, program: gra112exons_human_1.3,
frame: 0, quality: excellent, score: 100.000"
16463..16747
/note="IDS similarity to AA212842 mw82d12.r1 Soares mouse
NHL Mus musculus CDNA clone 677207 5'; (200..468); 80%
identity."
17395..17687
/rpt_family="AluUb"
18199..18248
/note="predicted exon, program: gra112exons_human_1.3,
frame: 0, quality: excellent, score: 89.000"
18465..18542
/note="predicted exon, program: gra112exons_human_1.3,
frame: 0, quality: excellent, score: 100.000"
18635..18746
/note="predicted exon, program: gra112exons_human_1.3,
frame: 2, quality: excellent, score: 97.000"
complement(19286..19309)
/rpt_family="POLY.A"
19323..19623
/rpt_family="AluXs"
19632..19928
/rpt_family="AluXs"
19929..20226
/rpt_family="AluY"
20234..20341
/rpt_family="AluJo/FLAM"
complement(20344..20655)
repeat_region

Note: remainder of annotations omitted.

Query Match 10.5% Score 25; DB 31; Length 60966;
Best Local Similarity 85.7%; Pred.No. 3 008-01;
Matches 30; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Db 13976 TGTCACGATGGATGTGGCGCCCTTGCCCTC 14010
||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Oy 43 TGGCCACTATGGGCTGTGGCGCCCTGTCTCTC 77

RESULT 13
LOCUS A62989 60 bp DNA PAT 12-MAR-1998
DEFINITION Sequence 1 from Patent W09720068.
ACCESSION A62989
NID 93716861
VERSION A62989.1 GI:3716861
KEYWORDS
SOURCE unidentified.
ORGANISM unidentified
REFERENCE 1 (bases 1 to 60)
AUTHORS Oerum, H. and Seeger, C.
TITLE METHOD FOR GENERATING MULTIPLE DOUBLE STRANDED NUCLEIC ACIDS
JOURNAL Patent: WO 9720068-A 1 05-JUN-1997;
BOEHRINGER MANNHEIM GMBH (DE)
location/Qualifiers
FEATURES
1..60
/organism="unidentified"
/db_xref="taxon:32644"

```

BASE COUNT	0	a	30	c	0	g	0	t	30	others
ORIGIN										
Query Match	10.1%; Score 24; DB 25; Length 60;									
Best Local Similarity	6.2%; Pred. No. 1.07e+00;									
Matches	2; Conservative 26; Mismatches 4; Indels 0; Gaps 0;									
Db	29	CCRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR	60							
Cp	94	CCAGAGCGTCAGAGAGGACGACAGGCGCAG	63							
RESULT	14									
LOCUS	MV087256	1056	bp	DNA	MM	02-JAN-1999				
DEFINITION	Mustela vison	GT dinucleotide repeat, chromosome 1q.								
ACCESSION	U87256									
NID	94099442									
VERSION	U87256.1	GI:4099442								
KEYWORDS										
SOURCE	American mink.									
ORGANISM	Mustela vison									
REFERENCE	Eukaryote; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;									
AUTHORS	Carnivora; Fissipedia; Mustelidae; Mustela.									
TITLE	1 (bases 1 to 1056)									
JOURNAL	Brinsgaard, K., Shukri, N.M., Malchenko, S., Koroleva, I. and Lohi, O.									
FEATURES	Direct Submission									
source	Submitted (27-JAN-1997) Breeding and Genetics, Danish Institute of Animal Science, Blichersalle K25, Tjele 8830, DK									
location/Qualifiers	1..1056									
/organism="Mustela vison"										
/db_xref="taxon:9667"										
/chromosome="1"										
/map="1q"										
/note="primers: 1167F: agccctcgatctactctt, 1167R: ggagctcttcgcgcgttgag"										
98..119										
/standard_name="1167F"										
complement(300..320)"										
/standard_name="1167R"										
211 a	221 c	210 g	225 t	189	others					
BASE COUNT										
ORIGIN										
Query Match	10.1%; Score 24; DB 23; Length 1056;									
Best Local Similarity	10.8%; Pred. No. 1.07e+00;									
Matches	7; Conservative 40; Mismatches 17; Indels 1; Gaps 1;									
Db	611	KMRRCRCRYMMAMCYGSGTARCCCDKKSQSGDKSHCKSKRRYKMDRYHBC-KSMCA	669							
Cp	130	TCCAAAGCATACCGCGCCCTGTTCCATGTGAGTCGCAAGAGGAGGTCAMAAGAGGAGACA	71							
Db	670	MVGRK	674							
Cp	70	AGGCG	66							
RESULT	15									
LOCUS	AC005920	175793	bp	DNA	PRI	25-NOV-1998				
DEFINITION	Homo sapiens chromosome 17, clone hRPK.700_H_6, complete sequence.									
ACCESSION	AC005920									
NID	93927856									
VERSION	AC005920.1	GI:3927856								
KEYWORDS	HTG.									
SOURCE	human.									
ORGANISM	Homo sapiens									
REFERENCE	Eukaryote; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;									
AUTHORS	Primates; Catarrhini; Homiidae; Homo.									
TITLE	1 (bases 1 to 175793)									
JOURNAL	Birren, B., Linton, L., Nusbaum, C. and Lander, E.									
REFERENCE	Homo sapiens chromosome 17, clone hRPK.700_H_6									
AUTHORS	Unpublished									
	2 (bases 1 to 175793)									
	Birren, B., Linton, L., Nusbaum, C., Lander, E., Allen, N., Anderson, M.,									

[illegible]

```
repeat_region /rpt_family="L2" complement(8343, .8418)
repeat_region /rpt_family="MIR" 8478, .8847
repeat_region /rpt_family="L2" complement(8957, .9087)
repeat_region /rpt_family="MIR" complement(9088, .9389)
repeat_region /rpt_family="AluSx" complement(10229, .10415)
repeat_region /rpt_family="MIR" 10578, .10798
repeat_region /rpt_family="MIR" 11365, .11656
repeat_region /rpt_family="AluSg1" complement(12745, .12793)
repeat_region /rpt_family="MER33" complement(12794, .13103)
repeat_region /rpt_family="AluSx" complement(13104, .13377)
repeat_region /rpt_family="MER33" 13336, .13643
repeat_region /rpt_family="MIR" complement(13867, .13909)
repeat_region /rpt_family="A-rich" complement(13912, .14209)
repeat_region /rpt_family="AluSx" complement(14573, .14604)
repeat_region /rpt_family="(TAA)n" complement(14606, .14884)
repeat_region /rpt_family="AluSg" complement(15772, .15816)
repeat_region /rpt_family="(GGGGA)n" complement(15817, .16101)
repeat_region /rpt_family="AluSg" complement(16102, .16115)
repeat_region /rpt_family="(GGGGA)n" complement(16116, .16359)
repeat_region /rpt_family="AluJo" complement(16533, .16579)
repeat_region /rpt_family="MIR" complement(16855, .16946)
repeat_region /rpt_family="MIR" 17305, .17532
repeat_region /rpt_family="GC-rich" complement(19845, .19992)
repeat_region /rpt_family="MIR" complement(20570, .20601)
repeat_region /rpt_family="L2" complement(20617, .20643)
repeat_region /rpt_family="(GAA)n" complement(20648, .20927)
repeat_region /rpt_family="AluSx" complement(21024, .21122)
repeat_region /rpt_family="MIR" complement(21690, .21999)
repeat_region /rpt_family="AluY" complement(22181, .22464)
repeat_region /rpt_family="AluJo" complement(24268, .24408)
repeat_region /rpt_family="MIR" complement(24707, .25000)
repeat_region /rpt_family="AluJo" complement(25393, .25453)
repeat_region /rpt_family="L2" complement(25736, .25870)
repeat_region /rpt_family="MER5A" complement(25867, .26026)
repeat_region /rpt_family="MER5B" 26623, .26707
repeat_region /rpt_family="MIR" 26992, .27200
repeat_region /rpt_family="MIR"
```

```
repeat_region complement(27291, .27579)
repeat_region /rpt_family="AluSx" 27822, .28002
repeat_region /rpt_family="MIR" 27886, .28014
repeat_region /rpt_family="L2" 28023, .28090
repeat_region /rpt_family="MIR" 28051, .28103
repeat_region /rpt_family="L2" complement(28331, .28368)
repeat_region /rpt_family="(TGA)n" 28956, .29258
repeat_region /rpt_family="L2" complement(29275, .29774)
repeat_region /rpt_family="MIR1G" complement(29874, .30088)
repeat_region /rpt_family="AluSg/X" complement(30799, .31109)
repeat_region /rpt_family="AluSx" 32152, .32205
repeat_region /rpt_family="AluJ/FRAM" 32214, .32270
repeat_region /rpt_family="(GA)n" complement(32584, .33089)
repeat_region /rpt_family="L1M3e" 33605, .33898
repeat_region /rpt_family="AluSg" complement(33919, .34193)
repeat_region /rpt_family="MER7A" 34194, .34480
repeat_region /rpt_family="AluYb8" 34481, .34501
repeat_region /rpt_family="(TAA)n" complement(34502, .34565)
repeat_region /rpt_family="MER7A" complement(36171, .36324)
repeat_region /rpt_family="L2"
```


..: Note: remainder of annotations omitted.

Query Match 10.1%; Score 24; DB 31; Length 175793;
Best Local Similarity 72.3%; Pred. No. 1.07e+00;
Matches 47; Conservative 0; Mismatches 17; Indels 1; Gaps 1;

```
Db 18839 GGAGCCAGAGCCCAAGGCTCACTGGCCCGAGGAGGCTGG-GACACAGAGCTTG 18897
      || ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Cp 67 GGAGCCAGAGCCCAAGGCTCACTGGCCCGAGGAGGCTGG-GAGAGAGCACTGAAGTCCC 8

Db 18898 GGTGG 18902
      |||||
Cp 7 GGTGG 3
```

Search completed: Sun Oct 24 16:30:24 1999
Job time : 485 secs.



(TM)

Release 3.1a John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

Maspar_n n.a. - n.a. database search, using Smith-Waterman algorithm

Run on: Sun Oct 24 16:38:53 1999; Maspar time 73.89 Seconds

Tabular output not generated. 693.101 Million cell updates/sec

Title: >US-09-092-296-1
Description: (1-239) from US09092296.seq
Perfect Score: 238
N.A. Sequence: 1 GGCACCGGAGCTTCAGTGT.....CCCTTCAGGACGACGCTCA 239
Comp: CCGGTGGCCCTGAGTACAC.....GGGAGTCCCTGGTGGCAGT

Scoring table: TABLE default
Gap 6

Mismatch STD: Dbase 0; Query 0

Searched: 271905 seqs, 107135622 bases x 2

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database:

n-gene35
1:part1 2:part2 3:part3 4:part4 5:part5 6:part6 7:part7
8:part8 9:part9 10:part10 11:part11 12:part12 13:part13
14:part14 15:part15 16:part16 17:part17 18:part18
19:part19 20:part20 21:part21 22:part22 23:part23
24:part24 25:part25 26:part26 27:part27 28:part28
29:part29 30:part30 31:part31 32:part32 33:part33
34:part34 35:part35 36:part36 37:part37 38:part38
39:part39 40:part40 41:part41 42:part42 43:part43
44:part44 45:part45 46:part46 47:part47 48:part48
49:part49 50:part50 51:part51 52:part52 53:part53
54:part54 55:part55 56:part56 57:part57 58:part58
59:part59 60:part60

Statistics: Mean 7.797; Variance 4.949; scale 1.575

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description	Pred. No.
1	232	97.5	439	60	V84366 Human stomach carcinoma	1.08e-132
2	37	15.5	91	9	Q51746 Oligonucleotide probe	3.39e-08
3	37	15.5	204	1	N81164 Base substituted E.co	3.39e-08
4	37	15.5	204	1	N81164 Base substituted E.co	3.39e-08
5	36	15.1	91	9	Q51746 Oligonucleotide probe	1.21e-07
6	31	13.0	114	12	Q70470 Generic DNA sequence	6.14e-05
7	31	13.0	114	12	Q70467 Generic DNA sequence	6.14e-05
8	30	12.6	114	12	Q70468 Generic DNA sequence	2.07e-04
9	30	12.6	114	12	Q70470 Generic DNA sequence	2.07e-04

C	10	30	12.6	114	12	Q70468	Generic DNA sequence	2.07e-04
C	11	29	12.2	114	12	Q70467	Generic DNA sequence	6.89e-04
C	12	29	12.2	114	12	Q70465	Generic DNA sequence	6.89e-04
C	13	29	12.2	114	12	Q70469	Generic DNA sequence	6.89e-04
C	14	28	11.8	114	12	Q70465	Generic DNA sequence	2.27e-03
C	15	28	11.8	178	32	T76405	Human endothelin-1 an	2.27e-03
C	16	27	11.3	114	12	Q70466	Generic DNA sequence	7.35e-03
C	17	27	11.3	172	32	T76563	Human interleukin 8 a	7.35e-03
C	18	26	10.9	114	12	Q70472	Generic DNA sequence	2.35e-02
C	19	26	10.9	114	12	Q70469	Generic DNA sequence	2.35e-02
C	20	25	10.5	39	7	Q51787	Mixed oligonucleotide	7.40e-02
C	21	25	10.5	114	12	Q70472	Generic DNA sequence	7.40e-02
C	22	25	10.5	250	32	T76438	Substance P antisense	7.40e-02
C	23	24	10.1	114	12	Q70473	Generic DNA sequence	2.29e-01
C	24	24	10.1	114	12	Q70466	Generic DNA sequence	2.29e-01
C	25	24	10.1	114	12	Q70473	Generic DNA sequence	2.29e-01
C	26	23	9.7	114	12	Q70471	Generic DNA sequence	6.97e-01
C	27	23	9.7	114	12	Q70471	Generic DNA sequence	6.97e-01
C	28	23	9.7	565	6	Q35072	HCV envelope region n	6.97e-01
C	29	22	9.2	36	2	Q11195	Ballast Constituent c	2.08e+00
C	30	22	9.2	75	21	T13612	DC43 TSAR library gen	2.08e+00
C	31	22	9.2	81	21	T13611	DC43 TSAR library gen	2.08e+00
C	32	22	9.2	82	21	T13610	DC43 TSAR library gen	2.08e+00
C	33	22	9.2	89	32	T76219	Human IIS antisense o	2.08e+00
C	34	22	9.2	91	46	V44650	Mammalian DNA replica	2.08e+00
C	35	22	9.2	190	32	T76452	Chymase antisense oli	2.08e+00
C	36	22	9.2	264	32	T76445	Substance P receptor	2.08e+00
C	37	22	9.2	3088	16	T05628	ADP ribosylation fact	2.08e+00
C	38	21	8.8	168	32	T76270	Human MNCF antisense	6.06e+00
C	39	21	8.8	908	51	V63025	B. malayi ankyrin CDN	6.06e+00
C	40	21	8.8	908	52	V63315	Nucleotide nbnA908	6.06e+00
C	41	21	8.8	908	51	V63024	B. malayi ankyrin nm	6.06e+00
C	42	21	8.8	909	51	V63014	D. immitis ankyrin nd	6.06e+00
C	43	21	8.8	911	52	V63312	D. immitis ankyrin nd	6.06e+00
C	44	21	8.8	911	51	V63012	D. immitis ankyrin nd	6.06e+00
C	45	21	8.8	5503	51	V63020	D. immitis ankyrin nd	6.06e+00

ALIGNMENTS

RESULT 1
ID V84366 standard; cDNA to mRNA: 439 BP.
AC V84366; 30-MAR-1999 (first entry)
DT Human stomach carcinoma cDNA clone HP10408.
DE Transmembrane protein: HP10408; human; stomach cancer; ds.
KW Homo sapiens.
OS Homo sapiens.
FH Key
FT Key
FT CDS
FT Location/Qualifiers
FT /tag= "cDNA comprising the coding region (minus
FT /note= the stop codon) is claimed (Claim 3)"
FT
FT W0985508-A2.
FT 10-DEC-1998.
FT PD 03-JUN-1998; J02445.
FT PF 03-JUN-1997; JP-144948.
FT PA (PROT-) PROTEGENE INC.
FT PI (SAGA) SAGAMI CHEM RES CENTRE.
FT PI Kato S, Sekine S, Yamaguchi T;
FT PFI: 99-045730/04.
FT P-PSDB: W88498.
FT New human proteins containing transmembrane domains and their
FT encoding sequences - useful in the preparation of antibodies and
FT large-scale protein production, gene diagnosis, and gene therapy
FT Claim 4; Page 15; 178p; English.
FT This is the nucleotide sequence of cDNA clone HP10408, which
FT includes a coding region (also claimed) for a novel human
FT transmembrane protein (see W88498). The clone was isolated from a
FT stomach cancer cDNA library using a signal sequence detection
FT method, and by protein synthesis by in vitro translation. The
FT encoded protein has a putative signal sequence and a putative
FT internal transmembrane domain. The invention provides nucleotide
FT sequences (see W84359-76) coding for 18 transmembrane proteins

CC (see M884491-508), vectors containing such polynucleotides, and
CC (eukaryotic cells) containing the vectors. The proteins can be
CC used as antigens or as compositions in the preparation of
CC antibodies against the proteins. The polynucleotides can be used
CC as probes for gene diagnosis, and as gene sources for gene therapy
CC and large-scale production of proteins encoded by the cDNA. The
CC host cells are used for the detection of ligands corresponding to
CC the expressed proteins, and the screening of low mol wt. medicines
90 Sequence 439 BP, 89 A, 137 C, 109 G, 104 T;

Query Match	97.5%	Score 232;	DB 60;	Length 439;
Best Local Similarity	99.28;	Pred. No. 1.08e-132;		
Matches	238;	Conservative	0;	Mismatches 1; Indels 1; Gaps 1;

Db	25	gacacaggagctccagctctccatccacaggagccagctggccaatacggggtctg	84
Qy	1	ggcaccgggacattcagctgtctcccatcccaagagccagctggccacatgggggtctg	60
Db	85	gagctgccctgtctcctctctcttgacccctcttgcagctcacatgaaacaggccggta	144
Qy	61	ggctggccctgtctctctctcttgacccttgcctggcagctcacatgaaacaggccggta	120
Db	145	tgccttgcacatgaagctcgaaaggagctttctctgacaaattcctctataggtccagct	204
Qy	121	tgcatttgcaactgaacatcgaaaggagcttttctgcaaaattcctctataggtccagct	180
Db	205	tcttgaaattgcttgaaagaagctctgcctcctccatctcccttcagggagacaagcgta	264
Qy	181	tcttgaaattgcttgaaagaagctctgcctcctccatctcccttcagggagacaagcgta	239

RESULT 2
ID Q51746 standard; cDNA; 91 BP.
AC Q51746;
DT 31-MAY-1994 (first entry)
DE Oligonucleotide probe MK14-A
KM Oligonucleotide; DNA probe; mycobacteria; disease diagnosis;
KM ss.
OS Synthetic.
PN EP-571911-A.
PD 01-DEC-1993.
PE 24-MAY-1993; 108325.
PR 26-MAY-1992; US-889651.
PA (BECT) BECTON DICKINSON CO.
PI Shank DD. Spears PA.
DR WPI: 93-378844/48.
PT New Oligo:nucleotide probes specific for Mycobacteria - used for
PT detection and amplification of Mycobacteria nucleic acid in
PT samples
PS Claim 3: Page 14: 23pp. English.
CC Oligonucleotide probe MK14-A consists of nucleotides 5-95 of MK14
CC (Q51755). It hybridized to all spp. of mycobacteria tested, but
CC cross reacted to a few non-mycobacterial spp. The probe may
CC be useful as an initial screen for mycobacterial infection.
CC See also Q51735-45 and Q51747-59.
SQ Sequence 91 BP; 5 A; 17 C; 15 G; 4 T;

Query Match	15.58;	Score 37;	DB 9;	Length 91;
Best Local Similarity	5.78;	Pred. No. 3.39e-08;		
Matches	3;	Conservative	42;	Mismatches 8; Indels 0; Gaps 0

D8
Db 11 ssvhsyyvvhvshhsbhvhvhhvsvvvhvhvhhvhhyvsctc 63
::: : :: : : : : : : : : : : : : : : : |||
Cp 87 GGTCAGACGAGACAGGGCCAGACCATTAGTGCACACTGCGCTC 35

```

RESULT      3
ID          NB1164 standard; DNA; 204 BP.
AC          NB1164:
DN          08-NOV-1990 (first entry)
DE          Base substituted E.coli beta-galactosidase alpha-fragment..
KW          E.coli beta galactosidase alpha-fragment; base substitutions; ss
            Escherichia coli.

```

FN	Key	Location/Qualifiers
FT	misc_feature	19..69
FT		/*tag= a
FT		/function= multiple cloning site
FT		187..204
FT	primer_bind	/*tag= b
FN	EP-285123-A.	
PD	05-MAY-1988.	
PF	30-MAR-1988; 105163.	
PR	03-APR-1987; US-034819.	
PA	(SU50) SUOMEN SOKERI OY.	
PI	Lehtovaara P, Knowles J, Koivula A, Bamford J, Reiniakainen T;	
DR	WRI: 88-279927/40.	
PT	Introducing random point mutations into nucleic acids -	
PT	by prepn of single stranded template, annealing a primer, elongation	
PT	mishincorporation, completion of molecules and screening.	
PS	Disclosure; P; English.	
CC	Random point mutations were introduced into the alpha fragment of	
CC	E.coli beta-galactosidase. The wild type sequence was obtained as a	
CC	single stranded template and an oligonucleotide was hybridised to	
CC	it to generate a popn of DNA molecules which terminate at all	
CC	possible nucleotide positions within a specified region. The	
CC	variable 3' ends generated in this way are used as primers for	
CC	reverse transcriptase. Nucleotides are mishincorporated by the	
CC	transcriptase and the molecules are completed to forms that can be	
CC	amplified and then expressed in a suitable host-vector system.	
CC	The sequence covers all 176 diff base substitutions, most of which	
CC	occur singularly in any given mutant.	
SO	See also P80575.	
Sequence	204 BP;	21 A; 47 C; 17 G; 11 T; 108 Others;


Query Match	15.5%;	Score 37;	DB 1;	Length 204;
Best Local Similarity	8.7%;	Pred. No. 3.39e-08;		
Matches	10;	Conservative	59;	Mismatches 46;
			Indels	0;
			Gaps	0;

[illegible]

```

RESULT      4
ID          N81164 standard: DNA; 204 BP.
AC          N81164:
DE          08-NOV-1990 (first entry)
DI          Base substituted E.coli beta-galactosidase alpha-fragment.
KM          E.coli beta galactosidase alpha-fragment; base substitutions: ss.
OS          Escherichia coli.
FH          Key
FT          Location/Qualifiers
FT          misc_feature          19..69
FT          /*tag= a
FT          /function=multiple cloning site
FT          187..204
FT          primer_bind
FT          /*tag= b
PN          EP-285123-A.
PD          05-MAY-1988.
PF          30-MAR-1988; 105163.
PI          03-APR-1987; US-034619.
PI          (SUSO) SUOMEN SOKERT OY.
PI          LehtoVaara P, Knowles J, Kotivola A, Bamford J, Reinkainen T;
DR          WPI: 88-279927/40.
PT          Introducing random point mutations into nucleic acids -
PT          by prep of single stranded template, annealing a primer, elongation
PT          minicorporation, completion of molecules and screening.
PS          Disclosure; P. English.
CC          Random point mutations were introduced into the alpha fragment of
CC          E.coli beta-galactosidase. The wild type sequence was obtained as a
CC          single stranded template and an oligonucleotide was hybridised to
CC          it to generate a popn of DNA molecules which terminate at all
CC          possible nucleotide positions within a specified region. The

```

(TM)

Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

Mperch_n n.a. - n.a. database search, using Smith-Waterman algorithm

Run on: Sun Oct 24 16:40:29 1999; Maspar time 21.17 Seconds

Tabular output not generated. 976.635 Million cell updates/sec

Title: >US-09-092-296-1

Description: (1-239) from US0902296.seq

Perfect Score: 238

N.A. Sequence:

Comp: 1 GGCCACGGGACTTACGTCT.....CCCTCAGGACGACGCGTA 239
CCGGTGGCCCTGAGTACACA.....GGGAGTCCCTGTGCGCAT

Scoring table: TABLE default

Gap 6

Mmatch STD : Dbase 0; Query 0

Searched: 165359 seqs, 43243793 bases x 2

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database:

n-issued

1:5A.COMB 2:5B.COMB 3:5C.COMB 4:PCT9.COMB 5:backfiles1

Statistics: Mean 7.391; Variance 4.188; scale 1.765

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result	No.	Score	Query	Match	Length	DB	ID	Description	Pred. No.
C	1	47	19.7	7218	2	US-08-233-	Sequence 14, Applicati	8.84e-17	
C	2	36	15.1	215	1	US-08-238-	Sequence 5, Applicatio	1.01e-09	
C	3	31	13.0	965	3	US-08-388-	Sequence 22, Applicati	1.18e-06	
C	4	27	11.3	215	1	US-08-238-	Sequence 5, Applicatio	2.69e-04	
C	5	26	10.9	965	3	US-08-388-	Sequence 22, Applicati	1.01e-03	
C	6	22	9.2	75	4	PCT-US95-1	Sequence 99, Applicati	1.67e-01	
C	7	22	9.2	81	4	PCT-US95-1	Sequence 98, Applicati	1.67e-01	
C	8	22	9.2	82	4	PCT-US95-1	Sequence 97, Applicati	1.67e-01	
C	9	22	9.2	3088	3	US-08-418-	Sequence 1, Applicati	1.67e-01	
C	10	22	8.8	65	1	US-08-471-	Sequence 145, Applicat	5.69e-01	
C	11	21	8.8	66	1	US-08-471-	Sequence 144, Applicat	5.69e-01	
C	12	21	8.8	68	1	US-08-471-	Sequence 143, Applicat	5.69e-01	
C	13	21	8.8	69	1	US-08-471-	Sequence 142, Applicat	5.69e-01	
C	14	21	8.8	74	4	PCT-US95-1	Sequence 100, Applicat	5.69e-01	
C	15	21	8.8	74	4	PCT-US95-1	Sequence 99, Applicati	5.69e-01	
C	16	21	8.8	75	4	PCT-US95-1	Sequence 98, Applicati	5.69e-01	
C	17	21	8.8	81	4	PCT-US95-1	Sequence 97, Applicati	5.69e-01	
C	18	21	8.8	82	4	PCT-US95-1	Sequence 96, Applicati	5.69e-01	
C	19	21	8.8	906	3	US-09-031-	Sequence 41, Applicati	5.69e-01	
C	20	21	8.8	906	3	US-09-031-	Sequence 41, Applicati	5.69e-01	

21	21	8.8	906	3	US-08-847-	Sequence 41, Applicati	5.69e-01
22	21	8.8	906	3	US-08-847-	Sequence 40, Applicati	5.69e-01
23	21	8.8	906	3	US-09-031-	Sequence 40, Applicati	5.69e-01
24	21	8.8	908	3	US-09-031-	Sequence 39, Applicati	5.69e-01
25	21	8.8	908	3	US-08-847-	Sequence 39, Applicati	5.69e-01
26	21	8.8	908	3	US-08-847-	Sequence 37, Applicati	5.69e-01
27	21	8.8	908	3	US-09-031-	Sequence 37, Applicati	5.69e-01
28	21	8.8	909	3	US-08-847-	Sequence 26, Applicati	5.69e-01
29	21	8.8	909	3	US-09-031-	Sequence 26, Applicati	5.69e-01
30	21	8.8	909	3	US-09-031-	Sequence 25, Applicati	5.69e-01
31	21	8.8	909	3	US-08-847-	Sequence 25, Applicati	5.69e-01
32	21	8.8	911	3	US-09-031-	Sequence 24, Applicati	5.69e-01
33	21	8.8	911	3	US-08-847-	Sequence 24, Applicati	5.69e-01
34	21	8.8	911	3	US-08-847-	Sequence 22, Applicati	5.69e-01
35	21	8.8	911	3	US-09-031-	Sequence 22, Applicati	5.69e-01
36	21	8.8	5235	3	US-09-031-	Sequence 36, Applicati	5.69e-01
37	21	8.8	5235	3	US-08-847-	Sequence 36, Applicati	5.69e-01
38	21	8.8	5235	3	US-09-031-	Sequence 35, Applicati	5.69e-01
39	21	8.8	5235	3	US-08-847-	Sequence 35, Applicati	5.69e-01
40	21	8.8	5503	3	US-09-031-	Sequence 34, Applicati	5.69e-01
41	21	8.8	5503	3	US-08-847-	Sequence 34, Applicati	5.69e-01
42	21	8.8	5503	3	US-08-847-	Sequence 32, Applicati	5.69e-01
43	21	8.8	5503	3	US-09-031-	Sequence 32, Applicati	5.69e-01
44	20	8.4	66	4	PCT-US95-1	Sequence 93, Applicati	1.89e+00
45	20	8.4	1185	1	US-08-049-	Sequence 5, Applicatio	1.89e+00

ALIGNMENTS

RESULT 1
ID US-08-232-463-14 STANDARD; DNA; UNC; 7218 BP.
AC xxxxxx

Sequence 14, Application US/08232463
Patent No. 5670367
GENERAL INFORMATION:
APPLICANT: DORNER, F.
APPLICANT: SCHEIFLINGER, F.
APPLICANT: FALKNER, F. G.
TITLE OF INVENTION: RECOMBINANT FOWLPOX VIRUS
NUMBER OF SEQUENCES: 52
CORRESPONDENCE ADDRESS:
ADDRESSEE: Foley & Lardner
STREET: 1800 Diagonal Road, Suite 500
CITY: Alexandria
STATE: VA
COUNTRY: USA
ZIP: 22313-0299
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/232.463
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/07/935.313
FILING DATE:
APPLICATION NUMBER: EP 91 114 300.6
FILING DATE: 26-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: BENT, Stephen A.
REGISTRATION NUMBER: 29,768
REFERENCE/DOCKET NUMBER: 30472/114 IMMU
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703)836-9300
TELEFAX: (703)683-4109
TELEX: 899149
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:

CC LENGTH: 7218 base pairs
CC TYPE: nucleic acid
CC STRANDEDNESS: single
CC TOPOLOGY: linear
CC IMMEDIATE SOURCE:
CC CLONE: pT99bF-Fls
SQ SEQUENCE 7218 bp; 1944 A; 1491 C; 1486 G; 1929 T; 368 OTHER

Query Match	19.7%	Score 47;	DB 2;	Length 7218;
Best Local Similarity	2.3%	Pred. No. 8,84e-17;		
Matches	5;	Conservative	129;	Mismatches 88;
			Indels	0;
			Gaps	0

Db	1219	yy	1278
Oy	12	ctttcagtgcttccatccacgagcgcatgtggccactatggsgcttgcgccctt	71
Db	1279	yy	1338
Oy	72	gtctctccttgaccctcttgscagtacatgsaaagggcgggatgatcttcaca	131
Db	1339	yy	1398
Oy	132	ctgaagctgaaagagcttcttctgacaaaattcctcttgatgcacgctctcgaaatg	191
Db	1399	yyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyytaccac	1440
Oy	192	cttgaaaantgctctctctccatcatctcccttcaggsgacca	233

RESULT	2
ID	US-08-238-163-5 STANDARD; DNA; UNC; 215 BP.

DE Sequence 5, Application US/08238163
CC Sequence 5, Application US/08238163
CC Patent No. 5569830
CC GENERAL INFORMATION:
CC APPLICANT: BENNETT, Alan
CC APPLICANT: LABAVITCH, John W.
CC APPLICANT: POWELL, Ann
CC APPLICANT: STORTZ, Henrik
CC TITLE OF INVENTION: PLANT INHIBITORS OF FUNGAL
CC TITLE OF INVENTION: POLYGALACTURONASES AND THEIR USE TO CONTROL FUNGAL DISEASE
CC NUMBER OF SEQUENCES: 24
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Townsend and Townsend Kourlie and Crew
CC STREET: Stewart Street Tower, One Market Plaza
CC CITY: San Francisco
CC STATE: California
CC COUNTRY: US
CC ZIP: 94105-1493
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC COMPUTER: IBM PC compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: PatentIn Release #1.0, Version #1.25
CC -CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/238,163
CC FILING DATE: 03-MAY-1994
CC CLASSIFICATION: 800
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Bastian, Kevin L.
CC REGISTRATION NUMBER: 34,774
CC REFERENCE/DOCKET NUMBER: 2307E-540
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: (415) 543-9600
CC TELEFAX: (415) 543-5043
CC INFORMATION FOR SEQ ID NO: 5:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 215 base pairs
CC TYPE: nucleic acid
CC STRANDEDNESS: single
CC TOPOLOGY: unknown

```

CC      MOLECULE TYPE:  protein
CC      FEATURE:
CC      NAME/KEY:  misc_feature
CC      LOCATION:  1..215
CC      OTHER INFORMATION:  /standard_name="Deduced amino acid
CC      OTHER INFORMATION:  sequence of PGIP from bean."
CC      SEQUENCE 215 bp:  15 A; 8 C; 25 G; 26 T; 141 OTHER.
SQ

```

Query Match	15.1%;	Score 36;	DB 1;	Length 215;
Best Local Similarity	14.7%;	Pred. No. 1.01e-09;		
Matches	28;	Conservative	77;	Mismatches 83;
			Indels	2;
			Gaps	2;

[illegible]

RESULT	3
ID	US-08-388-672A-22 STANDARD; DNA; UNC; 965 BP
AC	xxxxxx

DE Sequence 22, Application US/08388672A
CC Sequence 22, Application US/08388672A
CC Patent No. 5795961
CC
CC GENERAL INFORMATION:
CC APPLICANT: Wallace, T. Paul
CC APPLICANT: Harris, William J.
CC APPLICANT: Carr, Frank J.
CC APPLICANT: Old, Lloyd J.
CC APPLICANT: Weitz, Sydney
CC APPLICANT: Kitamura, Kunito
CC TITLE OF INVENTION: Recombinant Human Anti-Lewis X
CC TITLE OF INVENTION: Antibodies
CC NUMBER OF SEQUENCES: 25
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Felfe and Lynch
CC STREET: 805 Third Avenue
CC CITY: New York
CC STATE: New York
CC COUNTRY: U.S.A.
CC ZIP: 10022
CC
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC COMPUTER: IBM PC compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: PatentIn Release #1.0, Version #1.30
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/388,672A
CC FILING DATE: 14-FEB-1995
CC
CC CLASSIFICATION:
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Hanson, No. 5795961man D.
CC REGISTRATION NUMBER: 30,946
CC REFERENCE/DOCKET NUMBER: IUD 5409
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: 212-688-9200
CC TELEFAX: 212-838-3884
CC INFORMATION FOR SEQ. ID NO: 22:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 965 base pairs
CC TYPE: nucleic acid

CC STRANDEDNESS: unknown
CC TOPOLOGY: unknown
CC MOLECULE TYPE: DNA (genomic)
SQ SEQUENCE 965 BP; 192 A; 170 C; 226 G; 200 T; 177 OTHER.
Query Match 13.0%; Score 31; DB 3; Length 965;
Best Local Similarity 19.3%; Pred. No. 1.18e-06;
Matches 23; Conservative 53; Mismatches 42; Indels 1; Gaps 1;
Db 845 SVTADTAVYVCVGRSGSDGDDYWGCTTYTSSHVVDMTSSSASVGDRTTCRST 904
QY 23 CCTCATCCAGAGCCAGCCAGTGGCTGTGGCTGCCCTCTCCTCCTCT 82
Db 905 THGNNGTYWYKGRKARYRVNSRSGSGSDTYTSSDATYTCGTHARTGTGKVG 963
QY 83 GACC-CTCCTTGACGCTCATCATGACAGGCGCGGTATGACTTGCACTGACACGCTG 140
RESULT 4
ID US-08-238-163-5 STANDARD; DNA; UNC; 215 BP.
AC xxxxxx
DE Sequence 5, Application US/08238163
CC Sequence 5, Application US/08238163
CC Patent No. 5569830
CC GENERAL INFORMATION:
CC APPLICANT: BENNETT, Alan
CC APPLICANT: LABAVITCH, John M.
CC APPLICANT: POWELL, Ann
CC APPLICANT: STOTZ, Henrik
CC TITLE OF INVENTION: PLANT INHIBITORS OF FUNGAL
CC TITLE OF INVENTION: POLYGALACTURONASES AND THEIR USE TO CONTROL FUNGAL DISEASE
CC NUMBER OF SEQUENCES: 24
CC CORRESPONDENCE ADDRESSES:
CC ADDRESSEE: Townsend and Townsend Kourie and Crew
CC STREET: Stewart Street Tower, One Market Plaza
CC CITY: San Francisco
CC STATE: California
CC COUNTRY: US
CC ZIP: 94105-1493
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC COMPUTER: IBM PC compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: Patentin Release #1.0, Version #1.25
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/238,163
CC FILING DATE: 03-MAY-1994
CC CLASSIFICATION: 800
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Bastian, Kevin L.
CC REGISTRATION NUMBER: 34,774
CC REFERENCE/DOCKET NUMBER: 2307E-540
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: (415) 543-9600
CC TELEFAX: (415) 543-5043
CC INFORMATION FOR SEQ ID NO: 5:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 215 base pairs
CC TYPE: nucleic acid
CC STRANDEDNESS: single
CC TOPOLOGY: unknown
CC MOLECULE TYPE: protein
CC FEATURE:
CC NAME/KEY: misc_feature
CC LOCATION: 1..215
CC OTHER INFORMATION: /standard_name="Deduced amino acid
CC OTHER INFORMATION: sequence of Pgip from bean."
SQ SEQUENCE 215 BP; 15 A; 8 C; 25 G; 26 T; 141 OTHER.
Query Match 11.3%; Score 27; DB 1; Length 215;
Best Local Similarity 20.0%; Pred. No. 2.69e-04;
Matches 22; Conservative 42; Mismatches 45; Indels 1; Gaps 1;

Db 18 CNDKAKDGTTSWTTDCCNRWGVCDITTYRVNNDGHNKYSANYNGNVGA 77
QY 89 CTTGGCAGCTCATCATGACAGCGCGGGGTATGACTTTCGACTGACTG- AAGGAGT 147
Db 78 THYTHNNVSGADSKTYVDSYNASGTSSNGTDCNRSAGDSTGSSKTM 127
QY 148 CTTTCTGACAAATTCCTCTATGATGACGCTCTCTGAAATGCTTGAA 197
RESULT 5
ID US-08-388-672A-22 STANDARD; DNA; UNC; 965 BP.
AC xxxxxx
DE Sequence 22, Application US/08388672A
CC Sequence 22, Application US/08388672A
CC Patent No. 5795961
CC GENERAL INFORMATION:
CC APPLICANT: Wallace, T. Paul
CC APPLICANT: Harris, William J.
CC APPLICANT: Carr, Frank J.
CC APPLICANT: Old, Lloyd J.
CC APPLICANT: Welt, Sydney
CC APPLICANT: Kitamura, Kunio
CC TITLE OF INVENTION: Recombinant Human Anti-Lewis B
CC NUMBER OF SEQUENCES: 25
CC CORRESPONDENCE ADDRESSES:
CC ADDRESSEE: Felfe and Lynch
CC STREET: 805 Third Avenue
CC CITY: New York
CC STATE: New York
CC COUNTRY: U.S.A.
CC ZIP: 10022
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC COMPUTER: IBM PC compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: Patentin Release #1.0, Version #1.30
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/388,672A
CC FILING DATE: 14-FEB-1995
CC CLASSIFICATION:
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Hanson, No. 5795961man D.
CC REGISTRATION NUMBER: 30,946
CC REFERENCE/DOCKET NUMBER: LUD 5409
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: 212-688-9200
CC TELEFAX: 212-838-3884
CC INFORMATION FOR SEQ ID NO: 22:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 965 base pairs
CC TYPE: nucleic acid
CC STRANDEDNESS: unknown
CC TOPOLOGY: unknown
CC MOLECULE TYPE: DNA (genomic)
SQ SEQUENCE 965 BP; 192 A; 170 C; 226 G; 200 T; 177 OTHER.
Query Match 10.9%; Score 26; DB 3; Length 965;
Best Local Similarity 17.8%; Pred. No. 1.01e-03;
Matches 16; Conservative 43; Mismatches 30; Indels 1; Gaps 1;
Db 781 GURHUVVSGGVSTSTCTASDTTSTYWGWRGHWGGGTYNGBRGVYTMADTSS 840
Cp 124 GTCAATACCGGGCCTGT-TCCATGTGAGCTCCCAAGAGGTCAAGAGCAAGGGG 66
Db 841 NRSSTVTADTAVYVCVGRSGSDGSDTYW 870
Cp 65 CAGCCAGACCCCAATGATGACGCTGCGCT 36
RESULT 6

[illegible][illegible]

CC SOFTWARE: Patentin Release #1.0, Version #1.25
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/471,052A
CC FILING DATE: 06-JUNE-1995
CC CLASSIFICATION: 530
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Mistrock, S. Leslie
CC REGISTRATION NUMBER: 18, 872
CC REFERENCE/DOCKET NUMBER: 1101-179
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: 212 790-9090
CC TELEFAX: 212 869-8864/9741
CC TELEX: 66141 PENNIE
CC INFORMATION FOR SEQ ID NO: 143:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 68 bases
CC TYPE: nucleic acid
CC STRANDEDNESS: single
CC TOPOLOGY: unknown
CC MOLECULE TYPE: DNA
SQ SEQUENCE 68 BP; 3 A; 3 C; 5 G; 3 T; 54 OTHER.

Db 4 CTGAGVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNNA 63
Cp 178 CTGCATCCATACAGAGAAATTGTTCAGAAAAGACTCTTCACTTGAGTTGGCAAGGCATA 119

Dd 64 CCTGG 68
Cc 11 11
Cp 118 CCCCG 114


RESULT 13
ID US-08-471-052A-142 STANDARD; DNA; UNC; 69 BP.
AC xxxxxx

Df Sequence 142, Application US/08471052A
De Sequence 142, Application US/08471052A
Cc Patent No. 5625033

Cc GENERAL INFORMATION:
Cc APPLICANT: Kay, B. K.
Cc APPLICANT: Fowlkes, D. M.
Cc TITLE OF INVENTION: Totally Synthetic Affinity Reagents
Cc NUMBER OF SEQUENCES: 166
Cc CORRESPONDENCE ADDRESSES:
Cc ADDRESSEE: Pennie & Edmonds
Cc STREET: 1155 Avenue of the Americas
Cc CITY: New York
Cc STATE: New York
Cc COUNTRY: U.S.A.
Cc ZIP: 10036-2711

Cc COMPUTER READABLE FORM:
Cc MEDIUM TYPE: Floppy disk
Cc COMPUTER: IBM PC compatible
Cc OPERATING SYSTEM: PC-DOS/MS-DOS
Cc SOFTWARE: Patentin Release #1.0, Version #1.25
Cc CURRENT APPLICATION DATA:
Cc APPLICATION NUMBER: US/08/471,052A
Cc FILING DATE: 06-JUNE-1995

Cc CLASSIFICATION: 530
Cc ATTORNEY/AGENT INFORMATION:
Cc NAME: Mistrock, S. Leslie
Cc REGISTRATION NUMBER: 18, 872
Cc REFERENCE/DOCKET NUMBER: 1101-179
Cc TELECOMMUNICATION INFORMATION:
Cc TELEPHONE: 212 790-9090
Cc TELEFAX: 212 869-8864/9741
Cc TELEX: 66141 PENNIE
Cc INFORMATION FOR SEQ ID NO: 142:
Cc SEQUENCE CHARACTERISTICS:



Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

Mperch_n n.a. - n.a. database search, using Smith-Waterman algorithm

Run on: Sun Oct 24 16:30:43 1999; MasPar time 462.56 Seconds

Tabular output not generated. 1210.689 Million cell updates/sec

Title: >US-09-092-296-1
Description: (1-239) from US09092296.seq
Perfect Score: 238
N.A. Sequence: 1 GGCCGACGGGACCTTCAGTGT.....CCCTTCAGGACGACGCTCA 239
Comp: CCGGTGGCCCTGTAAGTACACA.....GGGAGATCCCTGTGTCGACGT

Scoring table: TABLE default
Gap 6

Mmatch STD: Dbase 0; Query 0

Searched: 2883791 segs, 1171580779 bases x 2

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database:

embl-est58
1:em-est10 2:em-est11 3:em-est17 4:em-est18 5:em-est12
6:em-est9 7:em-gss1
Database: genbank-est111

8:gb-est1 9:gb-est10 10:gb-est11 11:gb-est12 12:gb-est13
13:gb-est14 14:gb-est15 15:gb-est16 16:gb-est17
17:gb-est18 18:gb-est19 19:gb-est2 20:gb-est20
21:gb-est21 22:gb-est22 23:gb-est23 24:gb-est24
25:gb-est25 26:gb-est26 27:gb-est27 28:gb-est28
29:gb-est29 30:gb-est3 31:gb-est4 32:gb-est5 33:gb-est6
34:gb-est7 35:gb-est8 36:gb-est9 37:gb-gss1 38:gb-gss2
39:gb-gss3 40:gb-gss4 41:gb-gss5 42:gb-gss6

Statistics: Mean 9.792; Variance 2.100; scale 4.663

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result	Query	Score	Match	Length	DB	ID	Description	Pred. No.
No.	8							
1	57	23	9	252	17	AA754459	97SN1787 Rice Immature	1.50e-56
2	54	22	7	328	23	AA116523	UI-R-C2P-ng-e-02-0-UI.	1.62e-51
3	51	21	4	252	17	AA754459	97SN1787 Rice Immature	1.52e-46
4	39	16	4	247	17	AA754458	97SN1784 Rice Immature	2.04e-27
5	33	13	0	2275	20	AF034173	AF034173 Human mRNA (T	1.24e-15
6	31	13	0	2275	20	AF034173	AF034173 Human mRNA (T	1.24e-15
7	27	11	3	2275	20	AF034173	AF034173 Human mRNA (T	1.24e-15
8	24	10	1	238	19	AF034173	AF034173 Human mRNA (T	1.24e-15
9	23	9	7	238	12	AA376266	HSC10C101 normalized i	2.31e-06
10	23	9	7	311	11	AA323964	EST16816 Cerebellum II	3.76e-05

C	11	23	9.7	364	34	W33870	mc56b03.r1 Soares mous	3.76e-05
C	12	23	9.7	412	18	AA769782	ah11b05.s1 Soares test	3.76e-05
C	13	23	9.7	426	8	T15255	cr5855 lambdaZAPSR Ric	3.76e-05
C	14	23	9.7	481	14	AA498488	vh44b06.r1 Barstead mo	3.76e-05
C	15	23	9.7	1287	20	AF038250	AF038250 Human mRNA (T	3.76e-05
C	16	22	9.2	308	8	DA0392	RIC22424 Rice shoot O	5.65e-04
C	17	22	9.2	339	19	F08745	HSC1DB011 normalized i	5.65e-04
C	18	22	9.2	404	17	AF730403	hw42c07.s1 NC1.CGAP_Ew	5.65e-04
C	19	22	9.2	433	34	W79098	zd75h10.r1 Soares.feta	5.65e-04
C	20	22	9.2	441	14	C28493	C28493 Rice callus CDN	5.65e-04
C	21	22	9.2	634	22	AI063013	GH02423 Spriame GH Dros	5.65e-04
C	22	22	9.2	1025	37	B12587	F22011-SP6.1 TGF Arabi	5.65e-04
C	23	21	8.8	288	11	AA335414	EST396832 EpiDidymus Ho	7.76e-03
C	24	21	8.8	299	8	M79528	WEST00065 Mixed stage,	7.76e-03
C	25	21	8.8	317	19	F10052	HSC39H122 normalized i	7.76e-03
C	26	21	8.8	343	8	T47417	Yb13f12.r1 Stratagene	7.76e-03
C	27	21	8.8	384	23	AA160316	qb66d04.x1 Soares.feta	7.76e-03
C	28	21	8.8	395	41	AQ375965	RPC111-161H11.TV RPC11	7.76e-03
C	29	21	8.8	401	42	AQ444216	GSSTC0313 Trypanosoma	7.76e-03
C	30	21	8.8	424	33	W13114	ma66e10.r1 Soares mous	7.76e-03
C	31	21	8.8	429	28	AI509530	vx09h04.r1 Soares mous	7.76e-03
C	32	21	8.8	440	18	AA822673	z550a10.r1 Soares 2bM	7.76e-03
C	33	21	8.8	449	26	AA046996	NCSP4887 Subtracted P	7.76e-03
C	34	21	8.8	479	26	AI398157	Yp14f01.r1 Soares recti	7.76e-03
C	35	21	8.8	499	37	B45020	HS-1060-B1-B01-MF.abi	7.76e-03
C	36	21	8.8	516	31	H41536	Yp11c01.s1 Soares adu1	7.76e-03
C	37	21	8.8	524	10	AA239967	mw24907.r1 Soares mous	7.76e-03
C	38	21	8.8	550	20	AA898701	NCMG677 Mycelial Neur	7.76e-03
C	39	21	8.8	567	30	R61539	Yh16f01.s1 Soares ifna	7.76e-03
C	40	21	8.8	601	32	N37023	Yy40d03.s1 Soares mela	7.76e-03
C	41	21	8.8	688	37	AG015068	Homo sapiens genomic D	7.76e-03
C	42	21	8.8	694	36	AA140679	CSRL-133C3.v CSRL flow	7.76e-03
C	43	21	8.8	749	37	B01542	T2711-SP6.1 TAMU Arabi	7.76e-03
C	44	21	8.8	762	37	B19344	Salmonella typhimurium	7.76e-03
C	45	21	8.8	796	37	AF035986		

ALIGNMENTS

RESULT	1	AA754459	252 bp	mRNA	EST	20-JAN-1998
LOCUS		97SN1787	Rice Immature Seed	lambda ZAP11 cDNA	Library	Oryza sativa
DEFINITION		CDNA clone 97SN1787, mRNA sequence.				
ACCESSION		AA754459				
VERSION		92801165				
KEYWORDS		AA754459.1	GI:2801165			
SOURCE		EST.				
ORGANISM		Oryza sativa.				
		Oryza sativa				
		Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;				
		euphyllophytes; Spermatophyta; Magnoliophyta; Liliopsida; Poales;				
		Poaceae; Oryza.				
		1 (bases 1 to 252)				
REFERENCE		Nahm,B.H., Kim,J.K., Cheong,J.J., Kim,S.I., Hahn,T.R., Moon,E.P.,				
AUTHORS		Kim,M.T., Kim,W.Y., Yang,M.S., Park,R.D., Sohn,U.I., Kang,K.Y.,				
		Lee,M.C. and Eun,M.Y.				
TITLE		Large-scale Sequencing Analysis of ESTs from Rice Immature Seed				
JOURNAL		Unpublished (1998)				
COMMENT		On Jan 14, 1998 this sequence version replaced gi:1797457.				

Contact: Eun M.Y.
Department of Cytogenetics
National Inst. of Agri. Sci. and Tech, RDA
Suwon, Kyungjido, Korea
Tel: 82 331 290 0301
Fax: 82 331 290 0307
Email: myeun@n20.asti.re.kr
Submitted by Beek Hie Nahm, Dept of Biological Science, Myongji
University, Yongin, Korea, 449-728 bina@bioserver.myongji.ac.kr
Seq primer: M13 Reverse Primer.
Location/Qualifiers
1..252
/organism="Oryza sativa"

JOURNAL C. R. Acad. Sci. III, Sci. Vie 318 (2), 263-272 (1995)
 MEDLINE 9527534
 COMMENT On Sep 21, 1992 this sequence version replaced gi:279286.

Contact: Genethon
 Genexpress-Genethon
 Genethon Centre de recherche sur le Genome Humain
 1, rue de l'Internationale, BP60 91002 Evry Cedex, FRANCE
 Tel: 33169472800
 Fax: 33160778698
 Email: genexpress@genethon.fr

Single read.
 Genexpress_library_id: C; Genexpress_sequence_id: y1c-1q10
 Insert Length: 639 Std Error: 0.00
 Seq primer: (-21)M13-universal
 High quality sequence stop: 150.

FEATURES

SOURCE

1..348
 Location/Qualifiers
 /organism="Homo sapiens"
 /note="Organ: Brain; Vector: lafmid BA; Site_1: HindIII;
 Site_2: NotI; sex=Female; dev_stage=3 months old;
 Isolate=muscular atrophy patient; tissue_type=total
 brain; total mRNA was oligo-(dT) primed and directionally
 cloned 5' -> 3' into the HindIII -> NotI sites of the
 lafmid BA vector. Clone library from B Soares, Psychiatry
 Dept. Columbia University, USA Normalization_method:
 Bento Soares, P.N.A.S. in press"
 /db_xref="taxon:9606"
 /clone_c-1q10
 /clone_lib="normalized infant brain cDNA"
 /sex="Female"
 /tissue_type="total brain"
 /dev_stage="3 months old"
 /dev_stage="3 months old"
 BASE COUNT 84 a 91 c 90 g 81 t 2 others
 ORIGIN

Query Match

Best Local Similarity 67.2%; Score 24; DB 19; Length 348;
 Matches 45; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

Db 5 TGTTCCTCCCTCCAGAGATCCCTTGTGATGATGTTGTCAGTGCACACACAC 64
 ||| ||||| ||||| ||| ||| ||||| || ||||| ||| ||| ||| ||| |||
 Qy 18 TGTCTCTCCATCCAGAGAGCGAGCGACGACTATGGGCTGTGCGCTGCTGCTC 77
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 65 CTCTAGA 71
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Qy 78 CTCTTGA 84

RESULT 9
 LOCUS AA376266 238 bp mRNA EST 21-APR-1997
 DEFINITION EST88915 HSC172 cells II Homo sapiens cDNA 5' end, mRNA sequence.
 ACCESSION AA376266
 NID 92028809
 VERSION AA376266.1 GI:2028809
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
 Eutheria; Primates; Catarrhini; Homiidae; Homo.
 1 (bases 1 to 238)

REFERENCE 1
 AUTHORS Adams,M.D., Kerlavage,A.R., Fleischmann,R.D., Fuldner,R.A.,
 Bult,C.J., Lee,N.H., Kirkness,E.F., Weinstock,K.G., Gocayne,J.D.,
 White,O., Sutton,G., Blake,J.A., Brandon,R.C., Man-Wai,C.,
 Clayton,R.A., Cline,T.R., Cotton,M.D., Earle-Hughes,J., Fine,L.D.,
 Fitzgerald,L.M., Fitzhugh,W.M., Fritchman,J.L., Geoghegan,N.S.,
 Glodex,A., Gnehm,C.L., Hanna,M.C., Hedblom,E., Hinkle,P.S.Jr.,
 Kelley,J.M., Kelley,J.C., Liu,L.-I., Marmaros,S.M., Merrick,J.M.,
 Moreno-Palauques,R.F., McDonald,L.A., Nguyen,D.T., Pelligrino,S.M.,
 Phillips,C.A., Ryder,S.E., Scott,J.L., Saudex,D.M., Shirley,R.,
 Small,K.V., Spriggs,T.A., Uterback,T.R., Weidman,J.F., Li,Y.,
 Bednarek,D.P., Cao,L., Cepeda,M.A., Coleman,T.A., Collins,E.J.,
 Dinke,D., Feng,D.-F., Ferrle,A., Fischer,C., Hastings,G.A.,
 He,W.W., Hu,J.S., Greene,J.M., Gruber,J., Hudson,P., Kim,A.K.,

TITLE
 JOURNAL Hu,W.W., Hu,J.S., Greene,J.M., Gruber,J., Hudson,P., Kim,A.K.,
 MEDLINE Kozak,D.L., Kunsch,C., Hungjun,J., Li,H., Weisner,P.S., Olsen,H.,
 COMMENT Raymond,L., Wei,Y.F., Wang,J., Xu,C., Yu,G.L., Ruben,S.M.,
 Dillon,P.J., Fannon,M.R., Rosen,C.A., Haseltine,W.A., Fields,C.,
 Fraser,C.M. and Venter,J.C.
 Initial assessment of human gene diversity and expression patterns
 based upon 83 million nucleotides of cDNA sequence
 Nature 377 (6547 Suppl), 3-174 (1995)
 96026280
 Other-ESTs: TNC191210
 Contact: Kerlavage, AR
 Bioinformatics
 The Institute for Genomic Research
 9712 Medical Center Drive, Rockville, MD 20850 USA
 Tel: 3018699056
 Fax: 3018699423
 Email: arkerlav@tigr.org

For clone availability, additional sequence and expression
 information related to this EST, please check the TIGR Human Gene
 Index (<http://www.tigr.org/tdb/hgi/hgi.html>)
 Seq primer: M13 Reverse.

FEATURES

SOURCE

1..238
 Location/Qualifiers
 /organism="Homo sapiens"
 /note="Organ: lung; Vector: pBluescript SK-; Site_1:
 EcoRI; Site_2: XhoI"
 /db_xref="ATCC (inhost):180944"
 /db_xref="taxon:9606"
 /clone_lib="HSC172 cells II"
 /cell_type="fibroblast"
 /cell_line="HSC172 (60PDL)"
 /dev_stage="fetal"
 BASE COUNT 48 a 70 c 50 g 66 t 4 others
 ORIGIN

Query Match

Best Local Similarity 9.7%; Score 23; DB 12; Length 238;
 Matches 45; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

Db 141 TGTTCCTCCCTCCAGAGATCCCTTGTGATGATGTTGTCAGTGCACACACAC 200
 ||| ||||| ||||| ||| ||| ||||| || ||||| ||| ||| ||| ||| |||
 Qy 18 TGTCTCTCCATCCAGAGAGCGAGCGACGACTATGGGCTGTGCGCTGCTGCTC 77
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 201 CTCTAGA 207
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Qy 78 CTCTTGA 84

RESULT 10
 LOCUS AA323964 311 bp mRNA EST 20-APR-1997
 DEFINITION EST26816 Cerebellum II Homo sapiens cDNA 5' end, mRNA sequence.
 ACCESSION AA323964
 NID 91976290
 VERSION AA323964.1 GI:1976290
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
 Eutheria; Primates; Catarrhini; Homiidae; Homo.
 1 (bases 1 to 311)

REFERENCE 1
 AUTHORS Adams,M.D., Kerlavage,A.R., Fleischmann,R.D., Fuldner,R.A.,
 Bult,C.J., Lee,N.H., Kirkness,E.F., Weinstock,K.G., Gocayne,J.D.,
 White,O., Sutton,G., Blake,J.A., Brandon,R.C., Man-Wai,C.,
 Clayton,R.A., Cline,T.R., Cotton,M.D., Earle-Hughes,J., Fine,L.D.,
 Fitzgerald,L.M., Fitzhugh,W.M., Fritchman,J.L., Geoghegan,N.S.,
 Glodex,A., Gnehm,C.L., Hanna,M.C., Hedblom,E., Hinkle,P.S.Jr.,
 Kelley,J.M., Kelley,J.C., Liu,L.-I., Marmaros,S.M., Merrick,J.M.,
 Moreno-Palauques,R.F., McDonald,L.A., Nguyen,D.T., Pelligrino,S.M.,
 Phillips,C.A., Ryder,S.E., Scott,J.L., Saudex,D.M., Shirley,R.,
 Small,K.V., Spriggs,T.A., Uterback,T.R., Weidman,J.F., Li,Y.,
 Bednarek,D.P., Cao,L., Cepeda,M.A., Coleman,T.A., Collins,E.J.,
 Dinke,D., Feng,D.-F., Ferrle,A., Fischer,C., Hastings,G.A.,
 He,W.W., Hu,J.S., Greene,J.M., Gruber,J., Hudson,P., Kim,A.K.,

Matches 33; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

Db 277 CTTCAAGTGTCAACACCTGCTGGAGCCAGCCAGTATATGG 319
 OY 12 CTTCAAGTGTCTCTCCATCCAGAGCCAGTGGCCTATATGG 54

RESULT 15 AF038250 1287 bp mRNA EST 30-MAR-1998

LOCUS AF038250 Human mRNA (Tripodis and Ragousis) Homo sapiens CDNA

DEFINITION clone ntcon9, mRNA sequence.

ACCESSION AF038250

NID 92815880

VERSION AF038250.1 GI:2815880

KEYWORDS EST.

SOURCE human.

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;

Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 1287)

Tripodis, N. and Ragousis, J.

Generation of a transcription map in the region immediately

centromeric to human MHC across the 6p21.2-6p21.3 chromosomal

boundary

Unpublished (1997)

COMMENT On Jan 19, 1998 this sequence version replaced gi:2045085.

Contact: Tripodis, Nikos
 Division of Medical and Molecular Genetics
 Guys Hospital
 7th floor, Guy's Tower, London SE1 9RT, UK
 Email: nikosenki.nl.

FEATURES
 source location/Qualifiers

1..1287
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /map="6p21.3"
 /clone="ntcon9"
 /clone_lib="Human mRNA (Tripodis and Ragousis)"

BASE COUNT 349 a 219 c 293 g 361 t 65 others

ORIGIN

Query Match 9.7%; Score 23; DB 20; Length 1287;

Best Local Similarity 25.8%; Pred. No. 3,76e-05;

Matches 24; Conservative 32; Mismatches 37; Indels 0; Gaps 0;

Db 381 VVATNAGSCCVACVTCBDCBTGGDYBSHBVCMCBANADGATBATCGKGVYGA 440

OY 53 GGGGTCTGGGGTGGCCCTTCTCTCTTGACCTCTTGACCTCTGACGCTCATGACAGG 112

Db 441 STCTHTNCCDCKTGSGAGTVNHHDSMAGA 473

OY 113 GCCGGGTATGACTTGTGACACTGAAGCTGAAGA 145

Search completed: Sun Oct 24 16:38:34 1999
 Job time : 471 secs.

=> d 1-4 ibib abs

L27 ANSWER 1 OF 4 CAPLUS COPYRIGHT 1999 ACS DUPLICATE 1
ACCESSION NUMBER: 1999:518247 CAPLUS
DOCUMENT NUMBER: 131:166197
TITLE: Methods for detecting lung
diseases
INVENTOR(S): Cohen, Maurice; Friedman, Paula
N.; Gordon, Julian; Hodges, Steven C.;
Klass, Michael R.; Kratochvil, Jon D.;
Roberts-Rapp, Lisa; Russell, John C.;
Stroupe, Steven D.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: U.S., 36 pp., Cont.-in-part of U.S. Ser. No.
744,211, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5939265	A	19990817	US 1997-964725	19971105
PRIORITY APPLN. INFO.:			US 1996-744211	19961105

AB A set of contiguous and partially overlapping RNA sequences and polypeptides encoded thereby, designated as LU103 and transcribed from lung tissue are described. A fully sequenced clone representing the longest continuous sequence of LU103 is also disclosed. These sequences are useful in detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or detg. the predisposition of an individual to diseases and conditions of the lung such as lung cancer.

L27 ANSWER 2 OF 4 CAPLUS COPYRIGHT 1999 ACS DUPLICATE 2
ACCESSION NUMBER: 1999:8152 CAPLUS
DOCUMENT NUMBER: 130:77055
TITLE: Protein LS170 and cDNA sequences useful for
detecting diseases of the human
lung
INVENTOR(S): Billing-Medel, Patricia A.;
Cohen, Maurice; Colpitts, Tracey
L.; Friedman, Paula N.; Gordon,
Julian; Granados, Edward N.; Hodges, Steven C.;
Searcher : Shears 308-4994

Klass, Michael R.; Kratochvil, Jon D.;
Roberts-Rapp, Lisa; Russell, John C.;
Stroupe, Stephen D.

PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9856951	A1	19981217	WO 1998-US11601	19980611
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

PRIORITY APPLN. INFO.: US 1997-49183 19970611

AB A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as LS170 and transcribed from human lung tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or detg. the predisposition of an individual to diseases and conditions of the lung, such as lung cancer. Also provided are antibodies which specifically bind to a LS170-encoded polypeptide or protein, and agonists or inhibitors which prevent action of tissue-specific LS170 polypeptides, which mols. are useful for the therapeutic treatment of lung diseases, tumors, or metastases.

L27 ANSWER 3 OF 4 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD

ACCESSION NUMBER: 1998-437479 [37] WPIDS

DOC. NO. NON-CPI: N1998-340776

DOC. NO. CPI: C1998-133112

TITLE: New nucleic acid for the lung
disease marker LU105 - polypeptides,
antibodies and genes, used for diagnosis,
prevention, treatment of lung
disease, specifically cancer.

DERWENT CLASS: B04 D16 S03

INVENTOR(S): BILLING-MEDEL, P A; COHEN, M;
COLPITTS, T L; FRIEDMAN, P N;
GORDON, J; GRANADOS, E N; HODGES, S C; KLASS,
M R; KRATOCHVIL, J D; ROBERTSRAPP, L;
RUSSELL, J C; STROUPE, S D

PATENT ASSIGNEE(S): (ABBO) ABBOTT LAB

COUNTRY COUNT: 19

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9833926	A1	19980806	(199837)*	EN	117
RW: AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE					
W: CA JP					

APPLICATION DETAILS:

Searcher : Shears 308-4994

PATENT NO	KIND	APPLICATION	DATE
WO 9833926	A1	WO 1998-US1766	19980130

PRIORITY APPLN. INFO: US 1997-791710 19970131

AN 1998-437479 [37] WPIDS

AB WO 9833926 A UPAB: 19980916

A method for detecting target LU105 nucleic acid (I) comprises treating a sample with at least one LU105-specific nucleic acid (II), or its complement. (II) is at least 50% identical with 190, 244, 225, 114, 562 or 519 bp sequences given in the specification, or their fragments and complements.

Also claimed are:

(1) (I) or its fragments able to hybridise selectively to the LU105 gene and having at least 50% identity with the 190, 244, 225, 114, 562 or 519 bp sequences given above;

(2) recombinant expression systems including (I) and control sequence;

(3) cells transformed with this expression system;

(4) LU105 polypeptides (III) at least 50% identical with the 104, 26, 19, 21, 18 or 19 amino acid (aa) sequences given in the specification or their fragments;

(5) antibodies (Ab) that bind to at least one LU105 epitope present in (III);

(6) cells transformed with the 190, 244, 225, 114, 562 or 519 bp sequences described above;

(7) LU105 specific nucleic acid (II); and

(8) genes, or their fragments, that encode a protein at least 50% identical with the 104 aa sequences as in (4).

USE - LU105 is a **lung disease** marker. Cells as in (3) are used to express recombinant (III) which are used to raise Ab. Ab are used to detect the LU105 antigen, and correspondingly this antigen is used to detect specific antibodies, in usual immunoassays. (I) and (III) are used for diagnosis, staging, monitoring, prognosis, prevention, treatment (e.g. using antisense molecules, ribozymes, Ab or other antagonists) and determination of susceptibility to, **lung disease**, specifically cancer. (III) are also used to screen for specific binding agents, potentially useful therapeutically. LU105 is a marker for **lung disease** (present at high concentration, in altered form or in an unusual body compartment).

ADVANTAGE - LU105 can be detected in blood, plasma or serum in an inexpensive, non-invasive test.

Dwg.0/6

L27 ANSWER 4 OF 4 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD

ACCESSION NUMBER: 1998-286957 [25] WPIDS

DOC. NO. NON-CPI: N1998-225472

DOC. NO. CPI: C1998-088988

TITLE: Lung tissue derived polynucleotide LU103 - useful to detect, diagnose, stage, monitor, prognose, prevent, treat or determine pre-disposition to **lung disease**, e.g. **lung cancer**.

Searcher : Shears 308-4994

• DERWENT CLASS: B04 D16 S03
 INVENTOR(S): COHEN, M; FRIEDMAN, P N;
 GORDON, J; HODGES, S C; KLASS, M R;
 KRATOCHVILL, J D; ROBERTS-RAPP, L; RUSSELL, J
 C; STROUPE, S D
 PATENT ASSIGNEE(S): (ABBO) ABBOTT LAB
 COUNTRY COUNT: 19
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9820143	A1	19980514	(199825)*	EN	86
RW: AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE					
W: CA JP					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9820143	A1	WO 1997-US20680	19971105

PRIORITY APPLN. INFO: US 1996-744211 19961105

AN 1998-286957 [25] WPIDS

AB WO 9820143 A UPAB: 19980715

The following are claimed: (1) a method for detecting the presence of a target LU103 polynucleotide in a test sample, comprising: (a) contacting the sample with at least 1 LU103-specific polynucleotide, and (b) detecting the target LU103 polynucleotide in the test sample, where the LU103 polynucleotide has at least 50% identity to the 269, 263, 225, 507 or 519 bp nucleic acid sequence given in the specification; (2) a method for detecting LU103 mRNA in a test sample, comprising: (a) performing reverse transcription with at least 1 primer in order to produce cDNA; (b) amplifying the cDNA using LU103 oligonucleotides as sense and antisense primers to obtain LU103 amplicon, and (c) detecting LU103 amplicon in the test sample, where the LU103 oligonucleotides utilised in steps (a) and (b) have at least 50% sequence identity to the 269, 263, 225, 507 or 519 bp sequence and (3) a method detecting a target LU103 polynucleotide in a test sample suspected of containing the target, comprising: (a) contacting the test sample with at least 1 LU103 oligonucleotide as a sense primer and at least 1 LU103 oligonucleotide as an anti-sense primer and amplifying to obtain a first stage reaction product; (b) contacting the first stage reaction product with at least 1 other LU103 oligonucleotide to obtain a second stage reaction product, provided that the other LU103 oligonucleotide is located 3' to the LU103 oligonucleotides utilised in step (a) and is complementary to the first stage reaction product, and (c) detecting the second stage reaction product as an indication of the presence of the target LU103 polynucleotide, where the LU103 oligonucleotides utilised in steps (a) and (b) have at least 50% sequence identity to the 269, 263, 225, 507 or 519 bp sequence; (4) a purified polynucleotide derived from an LU103 gene, where the polynucleotide is capable of selectively hybridising to the nucleic acid of the LU103 gene and has at least 50% identity to the 269, 263, 225, 507 or 519 bp

Searcher : Shears 308-4994

- . . . • sequence; (5) a recombinant expression system comprising a nucleic acid sequence that includes an ORF derived from LU103 operably linked to a control sequence compatible with a desired host, where the nucleic acid sequence has at least 50% identity to the 269, 263, 225, 507 or 519 bp sequence; (6) cell transfected with the recombinant expression system; (7) cell transfected with a nucleic acid sequence encoding at least 1 LU103 epitope, where the nucleic acid sequence has the 269, 263, 225, 507 or 519 bp sequence; (8) composition comprising a LU103 polynucleotide, where the polynucleotide has at least 50% identity to the 269, 263, 225, 507 or 519 bp sequence; (9) gene which encodes a LU103 protein which comprises an amino acid sequence with at least 50% identity with the 93 residue amino acid sequence given in the specification, and (10) gene comprising DNA having at least 50% identity with the 507 or 519 bp sequence.

USE - The methods and products of the invention may be used to detect, diagnose, stage, monitor, prognose, prevent, treat or determine the predisposition diseases and conditions of the lung, e.g. lung cancer.

Dwg.0/4

Burke
09/092296

09/092296

(FILE 'CAPLUS' ENTERED AT 12:09:17 ON 25 OCT 1999)

L1 10217 SEA ABB=ON PLU=ON LUNG(3A)(DISEAS? OR DISORDER)
L2 583 SEA ABB=ON PLU=ON L1(S)(IDENTIF? OR DETECT? OR DET##
OR DETERM? OR DIAGNOS?)
L3 14 SEA ABB=ON PLU=ON L2 AND (REAGENT OR EPITOPE OR LS147
OR LS 147)

L3 ANSWER 1 OF 14 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1999:556186 CAPLUS

TITLE: Pigeon fanciers' lung:
identification of disease

-associated carbohydrate epitopes on
pigeon intestinal mucin

AUTHOR(S): Baldwin, C. I.; Todd, A.; Bourke, S. J.; Allen,
A.; Calvert, J. E.

CORPORATE SOURCE: Department of Immunology, The Medical School,
University of Newcastle upon Tyne, Newcastle
upon Tyne, NE2 4HH, UK

SOURCE: Clin. Exp. Immunol. (1999), 117(2), 230-236
CODEN: CEXIAL; ISSN: 0009-9104

PUBLISHER: Blackwell Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Pigeon intestinal mucin, a complex high mol. wt. glycoprotein, is a key antigen in the development of pigeon fanciers' lung (PFL). We have studied the specificity of antibodies to mucin in patients with PFL and asymptomatic antibody-pos. individuals. Extensive papain digestion, which removes the non-glycosylated regions of the mucin leaving the heavily glycosylated "bottle brush" regions, resulted in a 600-fold decrease in IgG3 antibody titers with little effect on IgG1 and IgG2 titers. This suggests that IgG1 and IgG2 are directed against the region rich in O-linked sugar chains while the majority of the IgG3 is directed against epitopes which are proteinase-sensitive. Lectin mapping of the carbohydrates present on pigeon intestinal mucin demonstrated high levels of exposed N-acetyl neuraminic acid, N-acetyl galactosamine and N-acetyl glucosamine, with lower levels of fucose and some galactose. Sera from pigeon fanciers inhibited binding of lectins specific for N-acetyl neuraminic acid, N-acetyl galactosamine, internal N-acetyl glucosamine and fucose. Sera from people with PFL, compared with sera from asymptomatic antibody-pos. fanciers, had significantly higher titers of antibody that inhibited binding of four lectins specific for N-acetyl galactosamine and one fucose-specific lectin, suggesting that these sugars may play a dominant role in disease-assocd. epitopes. The results suggest that different IgG subclasses recognize different epitopes on mucin and that the epitopes recognized by the major subclasses are present on the O-linked oligosaccharides. Further, the carbohydrate-specific anti-mucin antibodies produced by PFL

Searcher : Shears 308-4994

09/092296

patients may differ in their specificity from those found in asymptomatic individuals.

L3 ANSWER 2 OF 14 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1999:8152 CAPLUS

DOCUMENT NUMBER: 130:77055

TITLE: Protein LS170 and cDNA sequences useful for
detecting diseases of the
human lung

INVENTOR(S): Billing-Medel, Patricia A.; Cohen, Maurice;
Colpitts, Tracey L.; Friedman, Paula N.; Gordon,
Julian; Granados, Edward N.; Hodges, Steven C.;
Klass, Michael R.; Kratochvil, Jon D.;
Roberts-Rapp, Lisa; Russell, John C.; Stroupe,
Stephen D.

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 120 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9856951	A1	19981217	WO 1998-US11601	19980611
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

PRIORITY APPLN. INFO.: US 1997-49183 19970611

AB A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as LS170 and transcribed from human lung tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or detg. the predisposition of an individual to diseases and conditions of the lung, such as lung cancer. Also provided are antibodies which specifically bind to a LS170-encoded polypeptide or protein, and agonists or inhibitors which prevent action of tissue-specific LS170 polypeptides, which mols. are useful for the therapeutic treatment of lung diseases, tumors, or metastases.

L3 ANSWER 3 OF 14 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1998:674032 CAPLUS

DOCUMENT NUMBER: 130:64487

TITLE: Immunohistochemical detection of multidrug
resistance protein in human lung cancer and
normal lung

AUTHOR(S): Wright, Scott R.; Boag, Alexander H.;
Searcher : Shears 308-4994

09/092296

CORPORATE SOURCE: Valdimarsson, Gunnar; Hipfner, David R.;
Campling, Barbara G.; Cole, Susan P. C.; Deeley,
Roger G.
Departments of Pathology and Cancer Research
Laboratories, Queen's University, Kingston, ON,
K7L 3N6, Can.

SOURCE: Clin. Cancer Res. (1998), 4(9), 2279-2289
CODEN: CCREF4; ISSN: 1078-0432

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Monoclonal antibody QCRL-1 is highly specific for a defined linear
epitope in a relatively poorly conserved region of the human
multidrug resistance protein (MRP). The authors have used QCRL-1 to
examine MRP expression in archival and fresh snap-frozen samples of
untreated small cell (SC) and non-small cell (NSC) lung cancers
(LCs), as well as normal lung. The authors found that the majority
(87%) of all histol. subtypes of NSCLC had detectable levels of MRP
in most of the tumor mass. In a substantial proportion of
adenocarcinomas (55%) and squamous cell carcinomas (28%),
immunoreactivity approached that obtained with the highly multidrug
resistant cell line H69AR from which the MRP was originally cloned.
Both the level and frequency of MRP expression in untreated SCLC was
significantly lower than in NSCLC. The MRP was detectable in only
56% of SCLC tumors and, in most cases, was expressed in small focal
clusters of cells. Immunofluorescence studies of tumor tissue and
normal lung confirmed the plasma membrane location of the MRP.
However, in normal bronchial epithelium and seromucous glands,
unlike in tumor cells, the MRP was detected only on basolateral
membranes. In addn., strong MRP immunoreactivity was detected in
reactive type II pneumocytes present in hyperplastic alveoli, but
not in normal type I and type II pneumocytes. No potentially
confounding correlation independent of its possible role in drug
resistance was obsd. between MRP expression in untreated NSCLC and
any clinicopathol. parameter examd., including overall survival.

L3 ANSWER 4 OF 14 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1997:692333 CAPLUS

DOCUMENT NUMBER: 127:316564

TITLE: Diagnosis of chronic respiratory failure and
pulmonary emphysema, and diagnostic
reagents

INVENTOR(S): Okuda, Yukichi; Morita, Riichiro; Hanatani,
Mitsuya; Matsuo, Katsuhiko

PATENT ASSIGNEE(S): Toa Gosei Chemical Industry Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

Searcher : Shears 308-4994

09/092296

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	JP 09274037	A2	19971021	JP 1996-104629	19960402
AB	Detn. of human serum vascular endothelial growth factor/vascular permeability factor (VPF) is useful for accurate diagnosis of the title diseases. The detn. is carried out by using anti-VPF antibodies or VPF receptors. The serum level of VPF in patients with the diseases is much higher than healthy humans.				

L3 ANSWER 5 OF 14 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1997:44677 CAPLUS

DOCUMENT NUMBER: 126:55930

TITLE: Detection of neoplastic cells based on alternatively spliced transcripts of the p15INK4B and p16INK4A cyclin/CDK inhibitors
INVENTOR(S): Sidransky, David; Baylin, Stephen B.
PATENT ASSIGNEE(S): Johns Hopkins University School of Medicine, USA
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	WO 9635704	A1	19961114	WO 1996-US6666	19960510
	W: AU, CA, CN, JP, KR RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5767258	A	19980616	US 1995-439962	19950512
	US 5856094	A	19990105	US 1995-497535	19950630
	AU 9657399	A1	19961129	AU 1996-57399	19960510
PRIORITY APPLN. INFO.:				US 1995-439962	19950512
				US 1995-497535	19950630
				WO 1996-US6666	19960510
AB	Novel cell cycle regulatory polynucleotide transcripts and their encoded polypeptides are provided which were identified as the products of alternatively spliced mRNA for cyclin/CDK inhibitors, p16INK4A and p15INK4B, and a 5' nucleotide sequence referred to as 5'ALT. The p16 and p15 genes colocalize to human chromosome 9p21, which has been identified as a region having homozygous deletions in many tumors. 5'ALT also resides on chromosome 9p21, just 5' of exon 2 of p15, and about 30 kb upstream from p16. Polynucleotide transcripts are provided in which a 5'ALT polynucleotide is operatively linked to (1) exon 2 and exon 3 of p15 or (2) exon 2 of				

Searcher : Shears 308-4994

2

p15. These transcripts are assocd. with normal growth control and regulation of cellular proliferation and provide a means for the development of more accurate diagnostic, prognostic, and therapeutic regimes for disorders assocd. with control of cell cycle progression and cell differentiation and the loss of such control. Methylation of p16 DNA and a resultant decrease in p16 gene expression is assocd. with transcriptional block and is assocd. with a variety of neoplasms. Thus, a method for detecting a neoplasm in a subject by detecting methylation of 5'CpG islands in p16 DNA, or detecting p16 mRNA or polypeptide levels in a sample is also provided. Preferably, the method utilizes a methylation-sensitive restriction endonuclease in order to detect p16 methylation. The 5'ALT, or 5'ALT-p16 or 5'ALT-p15 polypeptides can also be used to produce antibodies which are immunoreactive or bind to **epitopes** of the resp. polypeptides.

L3 ANSWER 6 OF 14 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1996:68700 CAPLUS

DOCUMENT NUMBER: 124:169878

TITLE: Difference in sero-diagnostic values among
KL-6-associated mucins classified as Cluster 9

AUTHOR(S): Kohno, Nobuoki; Inoue, Yoshikazu; Hamada,
Hironobu; Fujioka, Seiji; Fujino, Shun;
Yokoyama, Akihito; Hiwada, Kunio; Ueda,
Norifumi; Akiyama, Mitoshi

CORPORATE SOURCE: School Medicine, Ehime University, Ehime,
791-02, Japan

SOURCE: Int. J. Cancer, Suppl. (1994), 8(Third
International IASLC Workshop on Lung Tumor and
Differentiation Antigens, 1993), 81-3
CODEN: IJSUEZ; ISSN: 0898-6924

DOCUMENT TYPE: Journal

LANGUAGE: English

AB KL-6 classified as Cluster 9 (MUC-1) is a circulating high-mol.-wt. mucin-like mol. Serum level of KL-6 was measured by a sandwich assay using KL-6 antibody as not only a catcher but also as a tracer. The authors established 2 addnl. monoclonal antibodies (MAbs), LISA 101 and EH-123, reacting with KL-6 **epitopes** different from the **epitope** recognized by KL-6 antibody. The KL-6-assocd. mucins detected by the sandwich assay using LISA 101 or EH-123 antibody as a catcher and KL-6 antibody as a tracer were designated as LISA 1-6 and CAM 123-6 resp. The diagnostic values as the serum markers of KL-6, LISA 1-6 and CAM 123-6 were evaluated measuring their levels in the same serum from healthy individuals and from patients with pulmonary, pancreatic and breast adenocarcinomas. KL-6 was increased abnormally at high rates of more than 50% in pancreatic cancer and in benign lung diseases, LISA 1-6 only in pancreatic cancer, and CAM 123-6 only in pulmonary adenocarcinoma. In benign lung diseases, however, LISA 1-6 and CAM

Searcher : Shears 308-4994

24

09/092296

123-6 were increased abnormally at the rates of only 5.3% and 0% resp. These observations clearly indicate that LISA 1-6 and CAM 123-6 constitute a part of KL-6, but that they are superior to KL-6 as tumor markers for pancreatic cancer and for pulmonary adenocarcinoma resp., because of their much lower false-pos. rates.

L3 ANSWER 7 OF 14 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1994:104481 CAPLUS
DOCUMENT NUMBER: 120:104481
TITLE: Monoclonal antibodies against farmer's lung antigens having specific binding to IgG antibodies
AUTHOR(S): Kumar, Anoop; Elms, Nancy; Kurup, Viswanath P.
CORPORATE SOURCE: Dep. Med., Med. Coll. Wisconsin, V., Milwaukee, WI, USA
SOURCE: Int. Arch. Allergy Immunol. (1993), 102(1), 67-71
CODEN: IAAIEG; ISSN: 1018-2438
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Hypersensitivity pneumonitis resulting from environmental exposure to *Saccharopolyspora rectivirgula* (*Microspolyspora faeni*) among farmers has been well recognized. The diagnosis of the disease depends on demonstration of circulating antibodies against *S. rectivirgula*. However, dependable pure antigens are not available for serodiagnosis. The authors employed hybridoma technol. to obtain monoclonal antibodies against *S. rectivirgula* antigens. These monoclonal antibodies were employed to purify antigens through affinity chromatog. When tested in ELISA, high levels of antibodies were demonstrated against these antigens in farmer's lung patient sera compared to exposed but asymptomatic individuals from the same household. In Western blots, patient sera reacted with components of crude antigens with mol. masses of 28, 35, 60, 65 and 68 kD and 4 components above 100 kD, while the monoclonal antibodies reacted only with the 60-kD protein. These purified antigens can be used as reliable **reagents** in the specific **diagnosis** of farmer's lung diseases.

L3 ANSWER 8 OF 14 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1993:467319 CAPLUS
DOCUMENT NUMBER: 119:67319
TITLE: Test **reagent** for hemoptysic sputum for diagnosis of lung cancer
INVENTOR(S): Qin, Dexing
PATENT ASSIGNEE(S): Chinese Academy of Medical Sciences, Tumour Hospital, Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 4 pp.
CODEN: CNXXEV
Searcher : Shears 308-4994

09/092296

DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
	CN 1069341	A	19930224	CN 1991-105479	19910814
AB	The title reagent contg. alc., H ₂ O ₂ , glacial AcOH, and guaiac gum is used for detecting hidden blood in sputum for alerting a possible lung cancer disease . Using the test reagent , the incidence of lung cancer was 40 times higher in pos.-responding people than in neg.-responding people.				

L3 ANSWER 9 OF 14 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1993:444470 CAPLUS
DOCUMENT NUMBER: 119:44470
TITLE: Automated determination of crosslinked fibrin derivatives in plasma
AUTHOR(S): Elms, M. J.; Bundesen, P. G.; Rowbury, D.; Goodall, S.; Wakeham, N.; Rowell, J. A.; Hillyard, C. J.; Rylatt, D. B.
CORPORATE SOURCE: Pathol. Dep., R. Brisbane Hosp., Brisbane, Australia
SOURCE: Blood Coagulation Fibrinolysis (1993), 4(1), 159-64
CODEN: BLFIE7; ISSN: 0957-5235
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Automated assays for the measurement of crosslinked fibrin derivs. in plasma (XL-FbDP) were developed by using latex beads coated with anti-D-dimer monoclonal antibody (DD-3B6/22) for both the Cobas Fara Chem. Centrifugal and the Cobas Mira analyzers (Roche, Basle, Switzerland). The analyzers were programmed to mix plasma and latex **reagent** simultaneously and analyze absorbance changes over a 10-15 min period. Results were interpolated by the analyzer from a std. curve derived from a polymer of D-dimer. Both assays had high precision (<5% CV) for values between 100 and 1000 ng/mL and provided clear discrimination between normal samples and samples from patients suffering from the thrombotic diseases deep vein thrombosis/pulmonary embolism and disseminated intravascular coagulation. The results obtained for XL-FbDP detn. with both methods compared well with established methods: a high correlation was obtained with a semiquant. manual latex method for both the Fara ($r = 0.92$) and Mira ($r = 0.83$) and correlations (r) of 0.81 (Fara) and 0.84 (Mira) were obtained with an EIA. Correlation between the 2 automated procedures was high ($r = 0.96$). The automated method will enable labs. to provide a rapid and accurate quantitation of

Searcher : Shears 308-4994

09/092296

XL-FbDP.

L3 ANSWER 10 OF 14 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1992:608482 CAPLUS

DOCUMENT NUMBER: 117:208482

TITLE: Detection of early platelet activation and
prediagnosis of thrombotic events by immunoassay
for platelet surface thrombospondin (TSP)

INVENTOR(S): Aiken, Martha L.; Painter, Richard G.

PATENT ASSIGNEE(S): University of Texas System, USA

SOURCE: PCT Int. Appl., 105 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9215886	A1	19920917	WO 1992-US1757	19920309
W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
US 5256538	A	19931026	US 1991-668272	19910308
AU 9216554	A1	19921006	AU 1992-16554	19920309
PRIORITY APPLN. INFO.:			US 1991-668272	19910308
			WO 1992-US1757	19920309

AB Persons at risk for a thrombotic event are identified by early immunol. detn. of elevated platelet surface TSP using a (labeled) monoclonal antibody to TSP. Thus, IgG-coated magnetic beads were exposed to an anti-TSP monoclonal antibody and then mixed with paraformaldehyde-fixed human platelets. After magnetic sepn. of the beads, the no. of platelets remaining in suspension was inversely related to TSP surface expression on the platelets. Diagnostic kits contg. **reagents** for the assay are described.

L3 ANSWER 11 OF 14 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1992:233421 CAPLUS

DOCUMENT NUMBER: 116:233421

TITLE: Human surfactant protein-A contains blood group
A antigenic determinants

AUTHOR(S): Stahlman, Mildred T.; Gray, Mary E.; Ross, Gary
F.; Hull, William M.; Wikenheiser, Kathryn;
Dingle, Sharon; Zelenski-Low, Kay R.; Whitsett,
Jeffrey A.

CORPORATE SOURCE: Sch. Med., Vanderbilt Univ., Nashville, TN,
37232-2370, USA

SOURCE: Pediatr. Res. (1992), 31(4, Pt. 1), 364-71

Searcher : Shears 308-4994



09/092296

CODEN: PEREBL; ISSN: 0031-3998

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A major blood group antigenic **epitope** was identified on human pulmonary surfactant protein A (SP-A). Monoclonal (Mab) and polyclonal antibodies generated against purified human SP-A aggregated blood group A human erythrocytes and immunostained epithelial cells in a variety of human tissues, consistent with the tissue distribution of major blood group antigens. SP-A Mab (Mab-8) agglutinated red cells and immunostained tissues from A or AB blood groups, but did not react with cells or tissues from O or B individuals. Mab-8 immunostaining of tissue from blood group A individuals was ablated by incubation with blood group A red cells. Mab and polyclonal antibodies directed against A blood group antigens reacted strongly with purified SP-A obtained from a blood group A individual with alveolar proteinosis. Mab and polyclonal antibodies specific for B blood group antigen failed to react with SP-A from this patient or from patients who were in blood group B. Reactivity of anti-blood group Mab was lost after treatment of SP-A with endoglycosidase-F, demonstrating its reactivity with an **epitope** dependent on the asparagine-linked oligosaccharide at asparagine 187. Reactivity of Mab-8 with SP-A persisted after endoglycosidase-F treatment, but was lost after digestion with collagenase as assessed by Western blot after SDS-PAGE. Reactivity of Mab to SP-A was sensitive to β -elimination, supporting the presence of another blood group antigenic site distinct from the **epitope** dependent on the asparagine-linked carbohydrate. The finding that the SP-A mol. contains a major blood group **epitope** has implication for the clin. use of surfactant replacement preps. and diagnostic **reagents** based on this protein.

L3 ANSWER 12 OF 14 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1989:210563 CAPLUS

DOCUMENT NUMBER: 110:210563

TITLE: Monoclonal antibodies to angiotensin-converting enzyme: a powerful tool for lung and vessel studies

AUTHOR(S): Danilov, S.; Sakharov, I.; Martynov, A.; Faerman, A.; Muzykantov, V.; Klibanov, A.; Trakht, I.

CORPORATE SOURCE: Inst. Exp. Cardiol., Cardiol. Res. Cent., Moscow, 121552, USSR

SOURCE: J. Mol. Cell. Cardiol. (1989), 21(Suppl. 1), 165-70

CODEN: JMCDAY; ISSN: 0022-2828

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series (12 clones) of hybridomas were obtained, which produce
Searcher : Shears 308-4994

6

09/092296

monoclonal antibodies (Mab) to 5 different **epitopes** of the angiotensin-converting enzyme (ACE) mol. These antibodies may be used to (1) map antigenic structure of ACE, including the study of immunol. heterogeneity of ACE from different organs and tissues; (2) study the immunohistochem. distribution of ACE in human tissues, including the diagnosis of sarcoidosis; (3) develop an ACE immunoassay, and (4) prep. an immunosorbent for large-scale ACE isolation and for ACE-apheresis. One of the antibodies, 9B9, when injected into the circulation of rat and monkey, accumulated with high specificity in the lungs as compared with either normal mouse IgG or other organs and blood. The highly specific and nontoxic accumulation of Mab 9B9 suggests that it also may be used for .gamma. scintigraphy visualization of the pulmonary vascular bed, detection of lung injury, and as a vector for targeted drug delivery to the lung.

L3 ANSWER 13 OF 14 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1988:585013 CAPLUS

DOCUMENT NUMBER: 109:185013

TITLE: Diisocyanate antigens that detect specific antibodies in exposed workers and guinea pigs

AUTHOR(S): Jin, Ruzhi; Karol, Meryl H.

CORPORATE SOURCE: Jilin Prov. Inst. Ind. Health Occup. Dis.,
Jilin, Peop. Rep. China

SOURCE: Chem. Res. Toxicol. (1988), 1(5), 288-93
CODEN: CRTOEC

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Evaluation of the immunol. contribution to the pathogenesis of isocyanate **lung disease** necessitates prepn. of isocyanate-protein conjugates to **detect** anti-isocyanate antibodies. Sera were obtained from 2 guinea pigs immunized with MDI and from 3 workers with occupational exposure to MDI. By use of Western blot anal., guinea pig IgG antibodies were best detected by the monomeric component of MDI-guinea pig serum albumin. ELISA addnl. indicated that conjugates which contained a high d. of hapten detected greater amts. of antibody than did conjugates contg. low amts. of hapten. The same procedures were then used to assess the amt. of MDI-specific IgG and IgE antibody in sera from symptomatic workers. Effective MDI-HSA antigens were those that were monomeric and had high haptenic content. Highly substituted conjugates of monoisocyanates (Ph isocyanate and p-tolyl isocyanate) with serum albumins were also effective in detecting antibodies to MDI. These results indicate the importance of the compn. of isocyanate conjugate antigens in detecting antibodies to diisocyanates and suggest that stds. be developed for prepn. and characterization of these diagnostic serol. **reagents**.

L3 ANSWER 14 OF 14 CAPLUS COPYRIGHT 1999 ACS

Searcher : Shears 308-4994

22

09/092296

ACCESSION NUMBER: 1974:57087 CAPLUS
DOCUMENT NUMBER: 80:57087
TITLE: Modified procedure for evaluation of the
lecithin/sphingomyelin ratio in amniotic fluid
AUTHOR(S): Coch, Emily; Meyer, John S.; Goldman, Gordon;
Kessler, Gerald
CORPORATE SOURCE: Dep. Pathol. Lab. Med., Jew. Hosp., St. Louis,
Mo., USA
SOURCE: Clin. Chem. (1973), 19(9), 967-72
CODEN: CLCHAU
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Several modifications were made to the procedure of L. Gluck, et al.
(1971) for evaluation of amniotic fluid lecithin/sphingomyelin (L/S)
ratios. The acetone-pptn. step was eliminated, resulting in a
faster extn. procedure and higher concns. of phospholipids. For
faster thin-layer chromatog., silica gel-impregnated sheets of
glass-fiber and a modified solvent system are used. For spot
detection, a noncorrosive Bi subnitrate reagent specific
for lecithin and sphingomyelin and an I vapor method to confirm the
L/S ratio were used. The Bi spray also detected significant
specimen contamination by phospholipids from plasma or erythrocytes.
The L/S ratio was evaluated by visually comparing the relative size
and color intensity of the lecithin and sphingomyelin TLC spots. An
L/S ratio of 5 or more is consistent with mature pulmonary function
and an L/S ratio of less than 2 suggests fetal pulmonary immaturity.

(FILE 'MEDLINE, BIOSIS, EMBASE, LIFESCI, WPIDS, CONFSCI, SCISEARCH,
JICST-EPLUS, PROMT, CANCERLIT' ENTERED AT 12:12:56 ON 25 OCT 1999)

L4 210 S L3
L5 113 DUP REM L4 (97 DUPLICATES REMOVED)
L6 14 S L5 AND (HYBRIDIZ? OR HYBRIDIS?)

L6 ANSWER 1 OF 14 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD

ACCESSION NUMBER: 1999-418749 [35] WPIDS
CROSS REFERENCE: 1998-414099 [35]; 1998-414100 [35]; 1998-414105
[35]; 1998-414114 [35]; 1998-427559 [35];
1998-506364 [42]; 1998-520811 [44]; 1998-609887
[42]; 1999-059865 [05]; 1999-080881 [07];
1999-120770 [10]; 1999-132229 [11]; 1999-132234
[11]; 1999-204988 [17]; 1999-430031 [36]

DOC. NO. CPI: C1999-123038
TITLE: New isolated human genes encoding secreted
polypeptides.

DERWENT CLASS: B04 D16
INVENTOR(S): CARTER, K C; DUAN, R D; FENG, P; FERRIE, A M;
FLORENCE, C; FLORENCE, K; GREENE, J M; JANAT, F;
KYAW, H; MOORE, P A; NI, J; ROSEN, C A; RUBEN, S M;
SHI, Y; SOPPET, D R; WEI, Y; YU, G
Searcher : Shears 308-4994

09/092296

PATENT ASSIGNEE(S): (HUMA-N) HUMAN GENOME SCI INC
COUNTRY COUNT: 82
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG

WO 9931117	A1	19990624	(199935)*	EN	536
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC					
MW NL OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI					
GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT					
LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL					
TJ TM TR TT UA UG US UZ VN YU ZW					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE

WO 9931117	A1	WO 1998-US27059	19981217

PRIORITY APPLN. INFO: US 1997-68369 19971219; US 1997-68006
19971218; US 1997-68007 19971218; US
1997-68008 19971218; US 1997-68053
19971218; US 1997-68054 19971218; US
1997-68057 19971218; US 1997-68064
19971218; US 1997-70923 19971218; US
1997-68169 19971219; US 1997-68365
19971219; US 1997-68367 19971219; US
1997-68368 19971219

AN 1999-418749 [35] WPIDS
CR 1998-414099 [35]; 1998-414100 [35]; 1998-414105 [35]; 1998-414114
[35]; 1998-427559 [35]; 1998-506364 [42]; 1998-520811 [44];
1998-609887 [42]; 1999-059865 [05]; 1999-080881 [07]; 1999-120770
[10]; 1999-132229 [11]; 1999-132234 [11]; 1999-204988 [17];
1999-430031 [36]

AB WO 9931117 A UPAB: 19990908
NOVELTY - Isolated human nucleic acids (I) encoding secreted
proteins, are new.

DETAILED DESCRIPTION - (I) comprises a polynucleotide (PN)
having a nucleotide sequence (NS) at least 95% identical to:

(a) a PN fragment of one of a total of 110 defined human cDNA
sequences given in the specification or a PN fragment of the cDNA
sequence included in ATCC Deposit No. Z which is
hybridizable to one of the 110 defined cDNA sequences;

(b) a PN which is an (allelic) variant of one of the 110
defined cDNA sequences;

(c) a PN encoding a biologically active polypeptide or a
polypeptide fragment, domain or **epitope** of one of the 110

Searcher : Shears 308-4994

defined amino acid sequences given in the specification or a polypeptide fragment, domain or **epitope**, respectively, encoded by a cDNA sequence included in ATCC Deposit No. Z which is **hybridizable** to one of the defined cDNA sequences;

(d) a PN which encodes a species homolog of one of the 110 defined polypeptides; or

(e) a PN capable of **hybridizing** under stringent conditions to any one of the PNs specified in (a)-(d), where the PN does not **hybridize** under stringent conditions to a sequence of only A residues or of only T residues.

ATCC Deposit No. Z refers to the representative clones, each containing a subset of the defined cDNA sequences, which have been deposited with the ATCC. The deposit numbers are ATCC 209463, 209511, 209551.

INDEPENDENT CLAIMS are also included for the following:

- (1) a recombinant vector comprising (I);
- (2) a method of making a recombinant host cell comprising (I);
- (3) a recombinant host cell produced by a method as in (2);
- (4) an isolated polypeptide comprising an amino acid sequence at least 95% identical to a polypeptide fragment (preferably having biological activity), domain, **epitope**, secreted form, full-length protein, (allelic) variant or species homologue of one of the 110 defined amino acid sequences or the encoded sequence included in ATCC Deposit No. Z;
- (5) an isolated antibody that binds specifically to an isolated polypeptide as in (4);
- (6) a recombinant host cell that expresses an isolated polypeptide as above;
- (7) a method of making an isolated polypeptide by culturing the host cell of (6);
- (8) the polypeptide produced by the method of (7);
- (9) a gene corresponding to a cDNA sequence of the 110 defined amino acid sequences;
- (10) a method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
 - (a) determining the presence or absence of a mutation in (I); and
 - (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of the mutation;
- (11) a method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
 - (a) determining the presence or amount of expression of the polypeptide of (4) in a biological sample; and
 - (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide;
- (12) a method for identifying a binding partner to the polypeptide of (4) comprising:

09/092296

- (a) contacting the polypeptide of (4) with a binding partner;
- (b) determining whether the binding partner effects an activity of the polypeptide; and
- (13) a method of identifying an activity in a biological assay, where the method comprises:
 - (a) expressing one of the 110 defined cDNAs in a cell;
 - (b) isolating the supernatant;
 - (c) detecting an activity in a biological assay; and
 - (d) identifying the protein in the supernatant having the activity; and
- (14) the product produced by the method of (13).

ACTIVITY - Cytostatic; Nootropic; Neuroprotective; Osteopathic; Antiseborreic; Dermatological; Antipsoritic; Antidiabetic; Antiasthmatic.

MECHANISM OF ACTION - None given.

USE - The PNs and their corresponding secreted polypeptides are useful for preventing, treating or ameliorating medical conditions (claimed), e.g. by protein or gene therapy. Also pathological conditions can be diagnosed by determining the amount of the new polypeptides in a sample or by determining the presence of mutations in the new PNs (claimed). Specific uses are described for each of the 110 PNs, based on which tissues they are most highly expressed in, and include developing products for the diagnosis or treatment of cancer, tumors, neurodegenerative disorders, developmental abnormalities and fetal deficiencies, reproductive disorders, blood disorders, leukemias, diseases of the immune system, autoimmune diseases, hepatic and renal disease, lymphomas, inflammation, allergies, Alzheimer's and cognitive disorders, schizophrenia, disorders involving osteoclasts such as osteoporosis, arthritis, sepsis, acne, asthma, psoriasis, stroke, trauma, diseases of testes, lung or prostate, digestive/endocrine disorders, diabetes and AIDS. The polypeptides are also useful for identifying their binding partners (claimed).

Dwg.0/0

L6 ANSWER 2 OF 14 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1999-303069 [25] WPIDS
CROSS REFERENCE: 1999-312869 [25]
DOC. NO. NON-CPI: N1999-227015
DOC. NO. CPI: C1999-089015
TITLE: New isolated human genes and the secreted polypeptides they encode.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): BREWER, L A; CARTER, K C; DUAN, D R; EBNER, R; ENDRESS, G A; FENG, P; FLORENCE, C; FLORENCE, K A; GREENE, J M; JANAT, F; KAYW, H; LAFLEUR, D W; MOORE, P A; NI, J; OLSEN, H S; ROSEN, C A; RUBEN, S M; SHI, Y; SOPPET, D R; WEI, Y; YOUNG, P
PATENT ASSIGNEE(S): (HUMA-N) HUMAN GENOME SCI INC.
Searcher : Shears 308-4994

09/092296

COUNTRY COUNT: 83
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG

WO 9922243	A1	19990506	(199925)*	EN	546
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC					
MW NL OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI					
GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS					
LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK					
SL TJ TM TR TT UA UG US UZ VN YU ZW					
AU 9912734	A	19990517	(199939)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE

WO 9922243	A1	WO 1998-US22376	19981023
AU 9912734	A	AU 1999-12734	19981023

FILING DETAILS:

PATENT NO	KIND	PATENT NO

AU 9912734	A Based on	WO 9922243

PRIORITY APPLN. INFO: US 1997-63387 19971024; US 1997-62784
19971024; US 1997-63088 19971024; US
1997-63089 19971024; US 1997-63090
19971024; US 1997-63091 19971024; US
1997-63092 19971024; US 1997-63097
19971024; US 1997-63098 19971024; US
1997-63099 19971024; US 1997-63100
19971024; US 1997-63101 19971024; US
1997-63109 19971024; US 1997-63110
19971024; US 1997-63111 19971024; US
1997-63148 19971024; US 1997-63386 19971024

AN 1999-303069 [25] WPIDS

CR 1999-312869 [25]

AB WO 9922243 A UPAB: 19990707

NOVELTY - One hundred and forty eight isolated human genes and secreted proteins they encode are new.

DETAILED DESCRIPTION - An isolated nucleic acid molecule (NAM) (I) comprising a polynucleotide (PN) having a nucleotide sequence (NS) at least 95% identical to:

(a) a PN fragment of one of a total of 148 defined human cDNA sequences given in the specification or a PN fragment of the cDNA sequence included in ATCC Deposit No. Z which is

Searcher : Shears 308-4994



hybridisable to one of the 148 defined cDNA sequence;

(b) a PN which is an (allelic) variant of one of the 148 defined cDNA sequences;

(c) a PN encoding a biologically active polypeptide or a polypeptide fragment, domain or **epitope** of one of the 148 defined amino acid sequences given in the specification or a polypeptide fragment encoded by a cDNA sequence included in ATCC Deposit No. Z which is **hybridisable** to one of the defined cDNA sequences;

(d) a PN which encodes a species homologue of one of the 148 defined polypeptides; or

(e) a PN capable of **hybridising** under stringent conditions to any one of the PNs specified in (a)-(d), where the PN does not **hybridise** under stringent conditions to a sequence of only A residues or of only T residues.

INDEPENDENT CLAIMS are also included for:

(1) a recombinant vector comprising (I);

(2) a method of making a recombinant host cell comprising (I);

(3) a recombinant host cell produced by a method as in (2);

(4) an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from a polypeptide fragment (preferably having biological activity), domain, **epitope**, secreted form, full-length protein, (allelic) variant or species homologue of one of the 148 defined amino acid sequences or the encoded sequence included in ATCC Deposit No. Z;

(5) an isolated antibody that binds specifically to an isolated polypeptide as in (4); and

(6) a recombinant host cell that expresses a gene corresponding to a cDNA sequence of the 148 defined amino acid sequences.

Note: From the disclosure 'ATCC Deposit No. Z' refers to the representative clones, each containing a subset of the defined cDNA sequences, which have been deposited with the ATCC. The deposit numbers are: ATCC 209299, 209346, 209300, 209324. an isolated polypeptide as above;

ACTIVITY - None given.

MECHANISM OF ACTION - None given.

USE - The PNs and their corresponding secreted polypeptides are useful for preventing, treating or ameliorating medical conditions (claimed), e.g. by protein or gene therapy. Also pathological conditions can be **diagnosed** by **determining** the amount of the new polypeptides in a sample or by **determining** the presence of mutations in the new PNs (claimed). Specific uses are described for each of the 148 PNs, based on which tissues they are most highly expressed in, and include developing products for the **diagnosis** or treatment of cancer, tumours, neurodegenerative disorders, developmental abnormalities and fetal deficiencies, blood disorders, leukemias, diseases of the immune system, autoimmune diseases, hepatic and renal disease, lymphomas, inflammation, allergies, ischemic shock, Alzheimer's and cognitive

09/092296

disorders, schizophrenia, prostate diseases, obesity, disorders involving osteoclasts such as osteoporosis, arthritis or malignancies, diseases of testes, lung or thymus, digestive/endocrine disorders, infections and AIDS. The polypeptides are also useful for identifying their binding partners (claimed).

L6 ANSWER 3 OF 14 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1999-167452 [14] WPIDS
DOC. NO. CPI: C1999-048990
TITLE: New isolated human genes encoding secreted polypeptides - useful for diagnosis and treatment of pathological diseases.
DERWENT CLASS: B04 D16
INVENTOR(S): BREWER, L A; EBNER, R; FERRIE, A M; GREENE, J M; JANAT, F; NI, J; OLSEN, H S; ROSEN, C A; RUBEN, S M; SOPPET, D R; YOUNG, P E; YU, G
PATENT ASSIGNEE(S): (HUMA-N) HUMAN GENOME SCI INC
COUNTRY COUNT: 82
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9907891	A1	19990218	(199914)*	EN	329
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC					
MW NL OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI					
GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT					
LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL					
TJ TM TR TT UA UG US UZ VN YU ZW					
AU 9887684	A	19990301	(199928)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9907891	A1	WO 1998-US16235	19980804
AU 9887684	A	AU 1998-87684	19980804

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9887684	A Based on	WO 9907891

PRIORITY APPLN. INFO: US 1997-56732 19970819; US 1997-54798
19970805; US 1997-54803 19970805; US
1997-54804 19970805; US 1997-54806
19970805; US 1997-54807 19970805; US
Searcher : Shears 308-4994

09/092296

1997-54808 19970805; US 1997-54809
19970805; US 1997-55309 19970805; US
1997-55310 19970805; US 1997-55311
19970805; US 1997-55312 19970805; US
1997-55386 19970805; US 1997-55970
19970818; US 1997-55986 19970818; US
1997-56364 19970819; US 1997-56365
19970819; US 1997-56366 19970819; US
1997-56367 19970819; US 1997-56370
19970819; US 1997-56371 19970819; US
1997-56557 19970819; US 1997-56563
19970819; US 1997-56731 19970819

AN 1999-167452 [14] WPIDS

AB WO 9907891 A UPAB: 19990412

NOVELTY - A total of 90 new isolated human genes encode secreted polypeptides which can be used in the diagnosis and treatment of pathological diseases such as cancers, neurological disorders, immune diseases, inflammation or blood disorders.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following: (1) An isolated nucleic acid molecule (NAM) (I) is claimed comprising a polynucleotide (PN) having a nucleotide sequence (NS) at least 95% identical to: (a) a PN fragment of one of a total of 90 defined human cDNA sequences given in the specification or a PN fragment of the cDNA sequence included in ATCC Deposit No. Z which is **hybridisable** to one of the 90 defined cDNA sequence; (b) a PN which is an (allelic) variant of one of the 90 defined cDNA sequences; (c) a PN encoding a biologically active polypeptide or a polypeptide fragment, domain or **epitope** of one of the 90 defined amino acid sequences given in the specification or a polypeptide fragment encoded by a cDNA sequence included in ATCC Deposit No. Z which is **hybridisable** to one of the defined cDNA sequences; (d) a PN which encodes a species homologue of one of the 90 defined polypeptides; or (e) a PN capable of **hybridising** under stringent conditions to any one of the PNs specified in (a)-(d), where the PN does not **hybridise** under stringent conditions to a sequence of only A residues or of only T residues; (2) a recombinant vector comprising (I); (3) a method of making a recombinant host cell comprising (I); (4) a recombinant host cell produced by a method as in (3); (5) an isolated polypeptide comprising an amino acid sequence homologous to a sequence selected from a polypeptide fragment (preferably having biological activity), domain, **epitope**, secreted form, full-length protein, (allelic) variant or species homologue of one of the 90 defined amino acid sequences or the encoded sequence included in ATCC Deposit No. Z; (6) an isolated antibody that binds specifically to an isolated polypeptide as in (5); (7) a recombinant host cell that expresses an isolated polypeptide as above; and (8) a gene corresponding to a cDNA sequence of the 90 defined amino acid

Searcher : Shears 308-4994

09/092296

sequences. Note: From the disclosure 'ATCC Deposit No. Z' refers to the representative clones, each containing a subset of the defined cDNA sequences, which have been deposited with the ATCC. The deposit numbers are: ATCC 209146, 209177, 209179 and 209180.

USE - The PNs and their corresponding secreted polypeptides are useful for preventing, treating or ameliorating medical conditions (claimed), e.g. by protein or gene therapy. Also pathological conditions can be **diagnosed by determining** the amount of the new polypeptides in a sample or by **determining** the presence of mutations in the new PNs (claimed). Specific uses are described for each of the 90 PNs, based on which tissues they are most highly expressed in, and include developing products for the **diagnosis** or treatment of cancer, tumours, neurodegenerative disorders, developmental abnormalities and foetal deficiencies, blood disorders, CNS disorders, diseases of the immune system, autoimmune diseases, hepatic and renal disease, diabetes, inflammation, allergies, ischemic shock, Alzheimer's and cognitive disorders, schizophrenia, cardiovascular disorders, prostate diseases, asthma, disorders involving osteoclasts such as osteoporosis, arthritis or malignancies, **diseases** of testes, lung or thymus, digestive/endocrine disorders, infections and AIDS. The polypeptides are also useful for **identifying** their binding partners (claimed).

Dwg.0/0

L6 ANSWER 4 OF 14 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1999-153691 [13] WPIDS
DOC. NO. CPI: C1999-045418
TITLE: New isolated human genes and the secreted polypeptides they encode - useful for diagnosis and treatment of e.g. cancers, neurological disorders, immune diseases, inflammation or blood disorders.
DERWENT CLASS: B04 D16
INVENTOR(S): CARTER, K C; ENDRESS, G A; FAN, P; FENG, P; KYAW, H; LAFLEUR, D W; LI, Y; MOORE, P A; ROSEN, C A; RUBEN, S M; SHI, Y; WEI, Y; ZENG, Z
PATENT ASSIGNEE(S): (HUMA-N) HUMAN GENOME SCI INC
COUNTRY COUNT: 82
PATENT INFORMATION:


PATENT NO	KIND	DATE	WEEK	LA	PG
-----------	------	------	------	----	----

WO 9906423	A1	19990211	(199913)*	EN	311
------------	----	----------	-----------	----	-----

RW:	AT	BE	CH	CY	DE	DK	EA	ES	FI	FR	GB	GH	GM	GR	IE	IT	KE	LS	LU	MC
	MW	NL	OA	PT	SD	SE	SZ	UG	ZW											

W:	AL	AM	AT	AU	AZ	BA	BB	BG	BR	BY	CA	CH	CN	CU	CZ	DE	DK	EE	ES	FI
	GB	GE	GH	GM	HR	HU	ID	IL	IS	JP	KE	KG	KP	KR	KZ	LC	LK	LR	LS	LT
	LU	LV	MD	MG	MK	MN	MW	MX	NO	NZ	PL	PT	RO	RU	SD	SE	SG	SI	SK	SL
	TJ	TM	TR	TT	UA	UG	US	UZ	VN	YU	ZW									

Searcher : Shears 308-4994



09/092296

AU 9887634 A 19990222 (199927)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9906423	A1	WO 1998-US15949	19980729
AU 9887634	A	AU 1998-87634	19980729

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9887634	A Based on	WO 9906423

PRIORITY APPLN. INFO: US 1997-56730 19970819; US 1997-54209
19970730; US 1997-54211 19970730; US
1997-54212 19970730; US 1997-54213
19970730; US 1997-54214 19970730; US
1997-54215 19970730; US 1997-54217
19970730; US 1997-54218 19970730; US
1997-54234 19970730; US 1997-54236
19970730; US 1997-55968 19970818; US
1997-55969 19970818; US 1997-55972
19970818; US 1997-56534 19970819; US
1997-56543 19970819; US 1997-56554
19970819; US 1997-56561 19970819; US
1997-56727 19970819; US 1997-56729 19970819

AN 1999-153691 [13] WPIDS

AB WO 9906423 A UPAB: 19990331

An isolated nucleic acid molecule (NAM) (I) is claimed comprising a polynucleotide (PN) having a nucleotide sequence (NS) at least 95% identical to: (a) a PN fragment of one of a total of 83 defined human cDNA sequences given in the specification or a PN fragment of the cDNA sequence included in ATCC Deposit No. Z which is **hybridisable** to one of the 83 defined cDNA sequence; (b) a PN which is an (allelic) variant of one of the 83 defined cDNA sequences; (c) a PN encoding a biologically active polypeptide or a polypeptide fragment, domain or **epitope** of one of the 83 defined amino acid sequences given in the specification or a polypeptide fragment encoded by a cDNA sequence included in ATCC Deposit No. Z which is **hybridisable** to one of the defined cDNA sequences; (d) a PN which encodes a species homologue of one of the 83 defined polypeptides; or (e) a PN capable of **hybridising** under stringent conditions to any one of the PNs specified in (a)-(d), where the PN does not **hybridise** under stringent conditions to a sequence of only A residues or of only T residues. Also claimed are: (1) a recombinant vector comprising (I); (2) a method of making a recombinant host cell

Searcher : Shears 308-4994

comprising (1); (2) a recombinant host cell produced by a method as in (2); (4) an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from a polypeptide fragment (preferably having biological activity), domain, **epitope**, secreted form, full-length protein, (allelic) variant or species homologue of one of the 83 defined amino acid sequences or the encoded sequence included in ATCC Deposit No. Z; (5) an isolated antibody that binds specifically to an isolated polypeptide as in (4); (6) a recombinant host cell that expresses an isolated polypeptide as above; and (7) a gene corresponding to a cDNA sequence of the 83 defined amino acid sequences. Note: From the disclosure ATCC Deposit No. Z refers to the representative clones, each containing a subset of the defined cDNA sequences, which have been deposited with the ATCC. The deposit numbers are: ATCC 209145, 209148, 209147.

USE- The PNs and their corresponding secreted polypeptides are useful for preventing, treating or ameliorating medical conditions (claimed), e.g. by protein or gene therapy. Also pathological conditions can be **diagnosed** by **determining** the amount of the new polypeptides in a sample or by **determining** the presence of mutations in the new PNs (claimed). Specific uses are described for each of the 83 PNs, based on which tissues they are most highly expressed in, and include developing products for the **diagnosis** or treatment of cancer, tumours, neurodegenerative disorders, developmental abnormalities and foetal deficiencies, blood disorders, leukemias, diseases of the immune system, autoimmune diseases, hepatic and renal disease, lymphomas, inflammation, allergies, ischemic shock, Alzheimer's and cognitive disorders, schizophrenia, restenosis, prostate diseases, obesity, disorders involving osteoclasts such as osteoporosis, arthritis or malignancies, **diseases** of lung or skin, digestive/endocrine disorders, infections and AIDS. The polypeptides are also useful for **identifying** their binding partners (claimed).

Dwg.0/0

L6 ANSWER 5 OF 14 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD
 ACCESSION NUMBER: 1999-120770 [10] WPIDS
 CROSS REFERENCE: 1998-414099 [35]; 1998-414100 [35]; 1998-414105 [35]; 1998-414114 [35]; 1998-427559 [35]; 1998-506364 [42]; 1998-520811 [44]; 1998-609887 [42]; 1999-059865 [05]; 1999-080881 [07]; 1999-132229 [11]; 1999-132234 [11]; 1999-204988 [17]; 1999-418749 [32]; 1999-430031 [36]
 DOC. NO. CPI: C1999-035369
 TITLE: New isolated human genes and the secreted polypeptides they encode - useful for diagnosis and treatment of e.g. cancers, neurological disorders, immune diseases, inflammation or blood disorders.
 Searcher : Shears 308-4994



09/092296

DERWENT CLASS: B04 D16
INVENTOR(S): BREWER, L A; EBNER, R; FISCHER, C L; KYAW, H;
LAFLEUR, D W; LI, Y; MOORE, P A; OLSEN, H S; ROSEN,
C A; RUBEN, S M; SHI, Y; SOPPET, D R; ZENG, Z
PATENT ASSIGNEE(S): (HUMA-N) HUMAN GENOME SCI INC
COUNTRY COUNT: 83
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9902546	A1	19990121	(199910)*	EN	462
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC					
MW NL OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI					
GB GE GH GM GW HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS					
LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK					
SL TJ TM TR TT UA UG US UZ VN YU ZW					
AU 9884743	A	19990208	(199924)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9902546	A1	WO 1998-US13684	19980707
AU 9884743	A	AU 1998-84743	19980707

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9884743	A Based on	WO 9902546

PRIORITY APPLN. INFO: US 1997-58785 19970912; US 1997-51916
19970708; US 1997-51918 19970708; US
1997-51919 19970708; US 1997-51920
19970708; US 1997-51925 19970708; US
1997-51926 19970708; US 1997-51928
19970708; US 1997-51929 19970708; US
1997-51930 19970708; US 1997-51931
19970708; US 1997-51932 19970708; US
1997-52732 19970708; US 1997-52733
19970708; US 1997-52793 19970708; US
1997-52795 19970708; US 1997-52803
19970708; US 1997-55684 19970818; US
1997-55722 19970818; US 1997-55723
19970818; US 1997-55947 19970818; US
1997-55948 19970818; US 1997-55949
19970818; US 1997-55950 19970818; US
1997-55953 19970818; US 1997-55954
Searcher : Shears 308-4994

09/092296

19970818; US 1997-55964 19970818; US
1997-55984 19970818; US 1997-56360
19970818; US 1997-58660 19970912; US
1997-58661 19970912; US 1997-58664 19970912

AN 1999-120770 [10] WPIDS

CR 1998-414099 [35]; 1998-414100 [35]; 1998-414105 [35]; 1998-414114
[35]; 1998-427559 [35]; 1998-506364 [42]; 1998-520811 [44];
1998-609887 [42]; 1999-059865 [05]; 1999-080881 [07]; 1999-132229
[11]; 1999-132234 [11]; 1999-204988 [17]; 1999-418749 [32];
1999-430031 [36]

AB WO 9902546 A UPAB: 19990908

An isolated nucleic acid molecule (NAM) (I) is claimed comprising a polynucleotide (PN) having a nucleotide sequence (NS) at least 95% identical to: (a) a PN fragment of one of a total of 123 defined human cDNA sequences given in the specification or a PN fragment of the cDNA sequence included in ATCC Deposit No. Z which is **hybridisable** to one of the 123 defined cDNA sequence; (b) a PN which is an (allelic) variant of one of the 123 defined cDNA sequences; (c) a PN encoding a biologically active polypeptide or a polypeptide fragment, domain or **epitope** of one of the 123 defined amino acid sequences given in the specification or a polypeptide fragment encoded by a cDNA sequence included in ATCC Deposit No. Z which is **hybridisable** to one of the defined cDNA sequences; (d) a PN which encodes a species homologue of one of the 123 defined polypeptides; or (e) a PN capable of **hybridising** under stringent conditions to any one of the PNs specified in (a)-(d), where the PN does not **hybridise** under stringent conditions to a sequence of only A residues or of only T residues. Also claimed are: (1) a recombinant vector comprising (I); (2) a method of making a recombinant host cell comprising (I); (3) a recombinant host cell produced by a method as in (2); (4) an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from a polypeptide fragment (preferably having biological activity), domain, **epitope**, secreted form, full-length protein, (allelic) variant or species homologue of one of the 123 defined amino acid sequences or the encoded sequence included in ATCC Deposit No. Z; (5) an isolated antibody that binds specifically to an isolated polypeptide as in (4); (6) a recombinant host cell that expresses an isolated polypeptide as above; and (7) a gene corresponding to a cDNA sequence of the 123 defined amino acid sequences. Note: From the disclosure 'ATCC Deposit No. Z' refers to the representative clones, each containing a subset of the defined cDNA sequences, which have been deposited with the ATCC. The deposit numbers are: ATCC 209119, 209124, 209125, 209126.

USE - The PNs and their corresponding secreted polypeptides are useful for preventing, treating or ameliorating medical conditions (claimed), e.g. by protein or gene therapy. Also pathological conditions can be **diagnosed by determining the**

Searcher : Shears 308-4994

09/092296

amount of the new polypeptides in a sample or by **determining** the presence of mutations in the new PNs (claimed). Specific uses are described for each of the 123 PNs, based on which tissues they are most highly expressed in, and include developing products for the **diagnosis** or treatment of cancer, tumours, neurodegenerative disorders, developmental abnormalities and foetal deficiencies, blood disorders, leukemias, diseases of the immune system, autoimmune diseases, hepatic and renal disease, lymphomas, inflammation, allergies, ischemic shock, Alzheimer's and cognitive disorders, schizophrenia, restenosis, prostate diseases, obesity, disorders involving osteoclasts such as osteoporosis, arthritis or malignancies, **diseases** of testes, lung or thyroid, digestive/endocrine disorders, infections and AIDS. The polypeptides are also useful for **identifying** their binding partners (claimed).

Dwg.0/0

L6 ANSWER 6 OF 14 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1999-070066 [06] WPIDS
DOC. NO. CPI: C1999-020600
TITLE: New isolated human genes and the secreted polypeptides they encode - useful for diagnosis and treatment of e.g. cancers, neurological disorders, immune diseases, inflammation or blood disorders.
DERWENT CLASS: B04 D16
INVENTOR(S): BREWER, L A; DUAN, R; EBNER, R; FERRIE, A M; FLORENCE, K A; GREENE, J M; HU, J; LAFLEUR, D W; MOORE, P A; NI, J; OLSEN, H S; ROSEN, C A; RUBEN, S M; SHI, Y; YOUNG, P
PATENT ASSIGNEE(S): (HUMA-N) HUMAN GENOME SCI INC
COUNTRY COUNT: 81
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9842738	A1	19981001	(199906)*	EN	385
RW: AT BE CH DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW					
AU 9865646	A	19981020	(199909)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9842738	A1	WO 1998-US5311	19980319
		Searcher :	Shears 308-4994

09/092296

AU 9865646 A

AU 1998-65646 19980319

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9865646	A Based on	WO 9842738

PRIORITY APPLN. INFO: US 1997-50937 19970530; US 1997-41276
19970321; US 1997-41277 19970321; US
1997-41281 19970321; US 1997-42344
19970321; US 1997-48069 19970530; US
1997-48094 19970530; US 1997-48095
19970530; US 1997-48096 19970530; US
1997-48099 19970530; US 1997-48131
19970530; US 1997-48135 19970530; US
1997-48154 19970530; US 1997-48160
19970530; US 1997-48186 19970530; US
1997-48187 19970530; US 1997-48188
19970530; US 1997-48351 19970530; US
1997-48352 19970530; US 1997-48355 19970530

AN 1999-070066 [06] WPIDS

AB WO 9842738 A UPAB: 19990210

An isolated nucleic acid molecule (NAM) (I) comprises a polynucleotide (PN) having a nucleotide sequence (NS) at least 95% identical to: (a) a PN fragment of one of a total of 87 defined human cDNA sequences given in the specification or a PN fragment of the cDNA sequence included in ATCC Deposit No. Z which is **hybridisable** to one of the 87 defined cDNA sequences; (b) a PN which is an (allelic) variant of one of the 87 defined cDNA sequences; (c) a PN encoding a biologically active polypeptide or a polypeptide fragment, domain or **epitope** of one of the 87 defined amino acid sequences given in the specification or a polypeptide fragment encoded by a cDNA sequence included in ATCC Deposit No. Z which is **hybridisable** to one of the defined cDNA sequence; (d) a PN which encodes a species homologue of one of the 87 defined polypeptides; or (e) a PN capable of **hybridising** under stringent conditions to any one of the PNs specified in (a)-(d), where the PN does not **hybridise** under stringent conditions to a sequence of only A residues or of only T residues. Also claimed are: (1) a recombinant vector comprising (I); (2) a method of making a recombinant host cell comprising (I); (3) a recombinant host cell produced by a method as in (2); (4) an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from a polypeptide fragment (preferably having biological activity), domain, **epitope**, secreted form, full-length protein, (allelic) variant or species homologue of one of the 87 defined amino acid sequences or the encoded sequence included in ATCC

Searcher : Shears 308-4994



09/092296

Deposit No. Z; (5) an isolated antibody that binds specifically to an isolated polypeptide as in (4); (6) a recombinant host cell that expresses an isolated polypeptide as in (4); and (7) a gene corresponding to a cDNA sequence of the 87 defined amino acid sequences. Note: From the disclosure 'ATCC Deposit No. Z' refers to the representative clones, each containing a subset of the defined cDNA sequences, which have been deposited with the ATCC. The deposit numbers are: ATCC 97923, 97924, 97957, 97958, 209071, 209641, 209072 and 209073.

USE - The PNs and their corresponding secreted polypeptides are useful for preventing, treating or ameliorating medical conditions (claimed), e.g. by protein or gene therapy. Also pathological conditions can be **diagnosed by determining** the amount of the new polypeptides in a sample or by **determining** the presence of mutations in the new PNs (claimed). Specific uses are described for each of the 87 PNs, based on which tissues they are most highly expressed in, and include developing products for the **diagnosis** or treatment of cancer, tumours, neurodegenerative disorders, developmental abnormalities and foetal deficiencies, blood disorders, leukaemias, diseases of the immune system (including allergies or asthma), lymphocytic diseases, brain associated diseases, hepatic and renal disease, lymphomas, inflammation, ischemic shock, Alzheimer's and cognitive disorders, schizophrenia, restenosis, prostate diseases, obesity, disorders involving osteoclasts such as osteoporosis, arthritis or malignancies, **diseases** of testis, **lung** or thymus, digestive/endocrine disorders, including metabolic regulation, malabsorption, gastritis and neoplasms, and AIDS. The polypeptides are also useful for **identifying** their binding partners (claimed).

Dwg.0/0

L6 ANSWER 7 OF 14 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1999-060335 [05] WPIDS
DOC. NO. NON-CPI: N1999-044750
DOC. NO. CPI: C1999-018022
TITLE: New LS170 nucleic acid from lung tissue - useful
for **detecting**, monitoring, preventing and
treating **lung disease**,
particularly cancer.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): BILLING-MEDEL, P A; COHEN, M; COLPITTS, T L;
FRIEDMAN, P N; GORDON, J; GRANADOS, E N; HODGES, S
C; KLASS, M R; KRATOCHVIL, J D; ROBERTS-RAPP, L;
RUSSELL, J C; STROUPE, S D
PATENT ASSIGNEE(S): (ABBO) ABBOTT LAB
COUNTRY COUNT: 20
PATENT INFORMATION:

Searcher : Shears 308-4994

44

09/092296

PATENT NO	KIND	DATE	WEEK	LA	PG

WO 9856951	A1	19981217	(199905)*	EN	119
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE					
W: CA JP					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE

WO 9856951	A1	WO 1998-US11601	19980611

PRIORITY APPLN. INFO: US 1997-49183 19970611

AN 1999-060335 [05] WPIDS

AB WO 9856951 A UPAB: 19990210

Detection of a target LS170 polynucleotide (I) comprises treating a test sample with at least one LS170-specific nucleic acid (II) that has at least 50% identity with any of 9 sequences ((1)-(9), reproduced, of 251, 243, 258, 202, 458, 273, 200,1009 and 1027 bp, respectively), their fragments or complements. Also new are (a) LS170 sequences, or their fragments, that **hybridise** selectively to the LS170 gene and have at least 50% identity with (i) (1)-(9), other than (5) or their complements, or (ii) fragments of (1)-(7); (b) recombinant expression system containing (II) plus a control sequence; (c) cells transformed with this expression system; (d) LS170 polypeptides (III) at least 50% identical with 9 sequences ((23)-(31), of 256, 18, 26, 29, 12, 15, 11 or 19 amino acids (aa), reproduced), or their fragments, containing at least one LS170 **epitope**; (e) antibodies (Ab) specific for at least one LS170 **epitope** present on (III); (f) cells transformed with any of (1)-(9), their fragments or complements, encoding at least one **epitope** of LS170; (g) (I) having at least 50% identity with (i) any of (1)-(9), their fragments or complements or (ii) fragments of (1)-(7); (h) genes, or their fragments, encoding LS170 proteins at least 50% identical with (23); (j) genes, or their fragments, at least 50% identical with (8) or (9).

USE - LS170 represents a set of contiguous, partially overlapping sequences transcribed from lung tissue. They are used for **diagnosis**, staging, monitoring, in vivo imaging, prevention and treatment of **lung disease**, specifically cancer, and to indicate predisposition to such disease. Particularly **detection** of (I), LS170 antigens (using Ab in immunoassays) or anti-LS170 antibodies (using LS170 as antigen) is indicative of disease. Cells of (c) are used to express recombinant (III), used to raise Ab and for drug screening. LS170-related nucleic acid can be used to isolate related sequences; as standards and **reagents** in assays; as targets for drug screening, and as components or targets for therapy, e.g. as antisense, ribozyme or

Searcher : Shears 308-4994

09/092296

triplex-forming agents. Ab can be used to deliver therapeutic agents to LS170-expressing cells; directly as therapeutic agents (by neutralising LS170 polypeptides); in competitive binding drug screens, and to generate anti-idiotypic antibodies for use in rational drug design.

Dwg.0/4

L6 ANSWER 8 OF 14 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1999-059865 [05] WPIDS
CROSS REFERENCE: 1998-414099 [35]; 1998-414100 [35]; 1998-414105 [35]; 1998-414114 [35]; 1998-427559 [35]; 1998-506364 [42]; 1998-520811 [44]; 1998-609887 [42]; 1999-080881 [07]; 1999-120770 [10]; 1999-132229 [11]; 1999-132234 [11]; 1999-204988 [17]; 1999-418749 [32]; 1999-430031 [36]
DOC. NO. NON-CPI: N1999-044486
DOC. NO. CPI: C1999-017701
TITLE: New isolated human genes and the secreted polypeptides they encode - useful for diagnosis and treatment of e.g. cancers, neurological disorders, immune diseases, inflammation or blood disorders.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): BREWER, L A; CARTER, K C; DILLON, P J; EBNER, R; ENDRESS, G A; FAN, P; FENG, P; FERRIE, A M; FISCHER, C L; FLORENCE, C; FLORENCE, K; GREENE, J M; HU, J; KYAW, H; LAFLEUR, D W; LI, Y; MOORE, P A; NI, J; OLSEN, H S; ROSEN, C A; RUBEN, S M; SHI, Y; SOPPET, D R; WEI, Y; YOUNG, P; YU, G; ZENG, Z
PATENT ASSIGNEE(S): (HUMA-N) HUMAN GENOME SCI INC
COUNTRY COUNT: 82
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9854963	A2	19981210	(199905)*	EN	770
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW					
AU 9878120	A	19981221	(199919)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9854963	A2	WO 1998-US11422	19980604
AU 9878120	A	AU 1998-78120	19980604
Searcher		:	Shears 308-4994

10

09/092296

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9878120	A Based on	WO 9854963

PRIORITY APPLN. INFO: US 1997-70923 19971218; US 1997-48875
19970606; US 1997-48876 19970606; US
1997-48877 19970606; US 1997-48878
19970606; US 1997-48880 19970606; US
1997-48881 19970606; US 1997-48882
19970606; US 1997-48883 19970606; US
1997-48884 19970606; US 1997-48885
19970606; US 1997-48892 19970606; US
1997-48893 19970606; US 1997-48894
19970606; US 1997-48895 19970606; US
1997-48896 19970606; US 1997-48897
19970606; US 1997-48898 19970606; US
1997-48899 19970606; US 1997-48900
19970606; US 1997-48901 19970606; US
1997-48915 19970606; US 1997-48916
19970606; US 1997-48917 19970606; US
1997-48949 19970606; US 1997-48962
19970606; US 1997-48963 19970606; US
1997-48964 19970606; US 1997-48970
19970606; US 1997-48971 19970606; US
1997-48972 19970606; US 1997-48974
19970606; US 1997-49019 19970606; US
1997-49020 19970606; US 1997-49373
19970606; US 1997-49374 19970606; US
1997-49375 19970606; US 1997-57584
19970905; US 1997-57627 19970905; US
1997-57628 19970905; US 1997-57629
19970905; US 1997-57634 19970905; US
1997-57635 19970905; US 1997-57642
19970905; US 1997-57643 19970905; US
1997-57644 19970905; US 1997-57645
19970905; US 1997-57646 19970905; US
1997-57647 19970905; US 1997-57648
19970905; US 1997-57649 19970905; US
1997-57650 19970905; US 1997-57651
19970905; US 1997-57654 19970905; US
1997-57661 19970905; US 1997-57662
19970905; US 1997-57666 19970905; US
1997-57667 19970905; US 1997-57668
19970905; US 1997-57760 19970905; US
1997-57761 19970905; US 1997-57762
19970905; US 1997-57763 19970905; US
Searcher : Shears 308-4994

09/092296

1997-57764 19970905; US 1997-57765
19970905; US 1997-57769 19970905; US
1997-57770 19970905; US 1997-57771
19970905; US 1997-57774 19970905; US
1997-57775 19970905; US 1997-57776
19970905; US 1997-57777 19970905; US
1997-57778 19970905

AN 1999-059865 [05] WPIDS

CR 1998-414099 [35]; 1998-414100 [35]; 1998-414105 [35]; 1998-414114
[35]; 1998-427559 [35]; 1998-506364 [42]; 1998-520811 [44];
1998-609887 [42]; 1999-080881 [07]; 1999-120770 [10]; 1999-132229
[11]; 1999-132234 [11]; 1999-204988 [17]; 1999-418749 [32];
1999-430031 [36]

AB WO 9854963 A UPAB: 19990908

An isolated nucleic acid molecule (NAM) (I) comprising a polynucleotide (PN) having a nucleotide sequence (NS) at least 95% identical to: (a) a PN fragment of one of a total of 207 defined human cDNA sequences given in the specification or a PN fragment of the cDNA sequence included in ATCC Deposit No. Z which is **hybridisable** to one of the 207 defined cDNA sequence; (b) a PN which is an (allelic) variant of one of the 207 defined cDNA sequences; (c) a PN encoding a biologically active polypeptide or a polypeptide fragment, domain or **epitope** of one of the 207 defined amino acid sequences given in the specification or a polypeptide fragment encoded by a cDNA sequence included in ATCC Deposit No. Z which is **hybridisable** to one of the defined cDNA sequences; (d) a PN which encodes a species homologue of one of the 207 defined polypeptides; or (e) a PN capable of **hybridising** under stringent conditions to any one of the PNs specified in (a)-(d), where the PN does not **hybridise** under stringent conditions to a sequence of only A residues or of only T residues. Also claimed are: (1) a recombinant vector comprising (I); (2) a method of making a recombinant host cell comprising (I); (3) a recombinant host cell produced by a method as in (2); (4) an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from a polypeptide fragment (preferably having biological activity), domain, **epitope**, secreted form, full-length protein, (allelic) variant or species homologue of one of the 207 defined amino acid sequences or the encoded sequence included in ATCC Deposit No. Z; (5) an isolated antibody that binds specifically to an isolated polypeptide as in (4); (6) a recombinant host cell that expresses an isolated polypeptide as above; and (7) a gene corresponding to a cDNA sequence of the 207 defined amino acid sequences.

Note: From the disclosure 'ATCC Deposit No. Z' refers to the representative clones, each containing a subset of the defined cDNA sequences, which have been deposited with the ATCC. The deposit numbers are: ATCC 97979, 97974, 97975, 97976, 97977, 209007, 209008,

Searcher : Shears 308-4994



09/092296

209009, 209010, 209011, 209080, 209081, 209082, 209083, 209084,
209085, 209511,.

USE The PNs and their corresponding secreted polypeptides are useful for preventing, treating or ameliorating medical conditions (claimed), e.g. by protein or gene therapy. Also pathological conditions can be **diagnosed** by **determining** the amount of the new polypeptides in a sample or by **determining** the presence of mutations in the new PNs (claimed). Specific uses are described for each of the 207 PNs, based on which tissues they are most highly expressed in, and include developing products for the **diagnosis** or treatment of cancer, tumours, neurodegenerative disorders, developmental abnormalities and foetal deficiencies, blood disorders, leukemias, diseases of the immune system, autoimmune diseases, hepatic and renal disease, lymphomas, inflammation, allergies, ischemic shock, Alzheimer's and cognitive disorders, schizophrenia, restenosis, prostate diseases, obesity, disorders involving osteoclasts such as osteoporosis, arthritis or malignancies, **diseases** of testes, **lung** or thymus, digestive/endocrine disorders, infections and AIDS. The polypeptides are also useful for **identifying** their binding partners (claimed).

Dwg.0/0

L6 ANSWER 9 OF 14 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1998-609887 WPIDS
CROSS REFERENCE: 1998-414099 [35]; 1998-414100 [35]; 1998-414105
[35]; 1998-414114 [35]; 1998-427559 [35];
1998-506364 [42]; 1998-520811 [44]; 1999-059865
[05]; 1999-080881 [07]; 1999-120770 [10];
1999-132229 [11]; 1999-132234 [11]; 1999-204988
[17]; 1999-418749 [32]; 1999-430031 [36]
DOC. NO. NON-CPI: N1998-474475
DOC. NO. CPI: C1998-182720
TITLE: New isolated human genes and the secreted
polypeptides they encode - useful for diagnosis and
treatment of e.g. cancers, neurological disorders,
immune diseases, inflammation or blood disorders.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): BEDNARIK, D P; BREWER, L A; CARTER, K C; DUAN, R;
EBNER, R; ENDRESS, G A; FENG, P; FERRIE, A M;
FISCHER, C L; FLORENCE, K A; GREENE, J M; HU, J;
NI, J; OLSEN, H S; ROSEN, C A; RUBEN, S M; SOPPET,
D R; YOUNG, P E; YU, G; KYAW, H; LAFLEUR, D W; LI,
Y; MOORE, P A; SHI, Y; ZENG, Z
PATENT ASSIGNEE(S): (HUMA-N) HUMAN GENOME SCI INC
COUNTRY COUNT: 81
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
	Searcher	:	Shears	308-4994	

09/092296

WO 9839446 A2 19980911 (199851)* EN 447
RW: AT BE CH DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW
NL OA PT SD SE SZ UG ZW
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI
GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT
LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL
TJ TM TR TT UA UG US UZ VN YU ZW
AU 9865452 A 19980922 (199908)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9839446	A2	WO 1998-US4482	19980306
AU 9865452	A	AU 1998-65452	19980306

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9865452	A Based on	WO 9839446

PRIORITY APPLN. INFO: US 1997-57761 19970905; US 1997-38621
19970307; US 1997-40161 19970307; US
1997-40162 19970307; US 1997-40163
19970307; US 1997-40333 19970307; US
1997-40334 19970307; US 1997-40336
19970307; US 1997-40626 19970307; US
1997-43311 19970411; US 1997-43312
19970411; US 1997-43313 19970411; US
1997-43314 19970411; US 1997-43315
19970411; US 1997-43568 19970411; US
1997-43569 19970411; US 1997-43576
19970411; US 1997-43578 19970411; US
1997-43580 19970411; US 1997-43669
19970411; US 1997-43670 19970411; US
1997-43671 19970411; US 1997-43672
19970411; US 1997-43674 19970411; US
1997-47492 19970523; US 1997-47500
19970523; US 1997-47501 19970523; US
1997-47502 19970523; US 1997-47503
19970523; US 1997-47581 19970523; US
1997-47582 19970523; US 1997-47583
19970523; US 1997-47584 19970523; US
1997-47585 19970523; US 1997-47586
19970523; US 1997-47587 19970523; US
1997-47588 19970523; US 1997-47589
19970523; US 1997-47590 19970523; US
Searcher : Shears 308-4994

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

09/092296

1997-47592 19970523; US 1997-47593
19970523; US 1997-47594 19970523; US
1997-47595 19970523; US 1997-47596
19970523; US 1997-47597 19970523; US
1997-47598 19970523; US 1997-47599
19970523; US 1997-47600 19970523; US
1997-47601 19970523; US 1997-47612
19970523; US 1997-47613 19970523; US
1997-47614 19970523; US 1997-47615
19970523; US 1997-47617 19970523; US
1997-47618 19970523; US 1997-47632
19970523; US 1997-47633 19970523; US
1997-48964 19970606; US 1997-48974
19970606; US 1997-56630 19970822; US
1997-56631 19970822; US 1997-56632
19970822; US 1997-56636 19970822; US
1997-56637 19970822; US 1997-56662
19970822; US 1997-56664 19970822; US
1997-56845 19970822; US 1997-56862
19970822; US 1997-56864 19970822; US
1997-56872 19970822; US 1997-56874
19970822; US 1997-56875 19970822; US
1997-56876 19970822; US 1997-56877
19970822; US 1997-56878 19970822; US
1997-56879 19970822; US 1997-56880
19970822; US 1997-56881 19970822; US
1997-56882 19970822; US 1997-56884
19970822; US 1997-56886 19970822; US
1997-56887 19970822; US 1997-56888
19970822; US 1997-56889 19970822; US
1997-56892 19970822; US 1997-56893
19970822; US 1997-56894 19970822; US
1997-56903 19970822; US 1997-56908
19970822; US 1997-56909 19970822; US
1997-56910 19970822; US 1997-56911
19970822; US 1997-57650 19970905

AN 1998-609887 WPIDS

CR 1998-414099 [35]; 1998-414100 [35]; 1998-414105 [35]; 1998-414114
[35]; 1998-427559 [35]; 1998-506364 [42]; 1998-520811 [44];
1999-059865 [05]; 1999-080881 [07]; 1999-120770 [10]; 1999-132229
[11]; 1999-132234 [11]; 1999-204988 [17]; 1999-418749 [32];
1999-430031 [36]

AB WO 9839446 A UPAB: 19990908

An isolated nucleic acid molecule (NAM) (I) comprising a
polynucleotide (PN) having a nucleotide sequence (NS) at least 95%
identical to:

(a) a PN fragment of one of a total of 70 defined human cDNA
sequences given in the specification or a PN fragment of the cDNA
sequence included in ATCC Deposit No. Z, which is

Searcher : Shears 308-4994

hybridisable to one of the 70 defined cDNA sequence;

(b) a PN which is an (allelic) variant of one of the 70 defined cDNA sequences;

(c) a PN encoding a biologically active polypeptide or a polypeptide fragment, domain or **epitope** of one of the 70 defined amino acid sequences given in the specification or a polypeptide fragment encoded by a cDNA sequence included in ATCC Deposit No. Z which is **hybridisable** to one of the defined cDNA sequence;

(d) a PN which encodes a species homologue of one of the 70 defined polypeptides., or

(e) a PN capable of **hybridising** under stringent conditions to any one of the PNs specified in (a)-(d), where the PN does not **hybridise** under stringent conditions to a sequence of only A residues or of only T residues.

Also claimed are:

(1) a recombinant vector comprising (I),

(2) a method of making a recombinant host cell comprising (1);

(3) a recombinant host cell produced by a method as in (2):

(4) an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from a polypeptide fragment (preferably having biological activity), domain, **epitope**, secreted form, full-length protein, (allelic) variant or species homologue of one of the 70 defined amino acid sequences or the encoded sequence included in ATCC Deposit No. Z;

(5) an isolated antibody that binds specifically to an isolated polypeptide as in (4);


(6) a recombinant host cell that expresses an isolated polypeptide as in (4), and

(7) a gene corresponding to a cDNA sequence of the 70 defined amino acid sequences.

Note., From the disclosure 'ATCC Deposit No. Z' refers to the representative clones, each containing a subset of the defined cDNA sequences, which have been deposited with the ATCC. The deposit numbers are- ATCC 97900, 97901, 97903, 97898, 209010, 97897, 97899, 97897, 97976, 97904, 97926, 209043-209050, 209085, 209084, 209236.

USE - The PNs and their corresponding secreted polypeptides are useful for preventing, treating or ameliorating medical conditions (claimed), e.g. by protein or gene therapy. Also pathological conditions can be **diagnosed** by **determining** the amount of the new polypeptides in a sample or by **determining** the presence of mutations in the new PNs (claimed). Specific uses are described for each of the 70 PNs, based on which tissues they are most highly expressed in, and include developing products for the **diagnosis** or treatment of cancer, tumours, neurodegenerative disorders, developmental abnormalities and foetal deficiencies, blood disorders, leukaemias, diseases of the immune system (including allergies or asthma), lymphocytic diseases, brain associated diseases, hepatic and renal disease, lymphomas,

Searcher : Shears 308-4994



09/092296

inflammation, ischemic shock, Alzheimer's and cognitive disorders, schizophrenia, restenosis, prostate diseases, obesity, disorders involving osteoclasts such as osteoporosis, arthritis or malignancies, ~~diseases~~ of testis, lung or thymus, digestive/endocrine disorders, including metabolic regulation, malabsorption, gastritis and neoplasms, and AIDS. The polypeptides are also useful for identifying their binding partners (claimed).

Dwg.0/10

L6 ANSWER 10 OF 14 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1998-594496 [50] WPIDS
DOC. NO. NON-CPI: N1998-462620
DOC. NO. CPI: C1998-178291
TITLE: New isolated human genes and secreted polypeptide(s) they encode - useful for the diagnosis and treatment of e.g. cancers, CNS disorders, immune system disorders, inflammatory disease and bacterial infections.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): FENG, P; NI, J; ROSEN, C A; RUBEN, S M; YU, G
PATENT ASSIGNEE(S): (HUMA-N) HUMAN GENOME SCI INC
COUNTRY COUNT: 82
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG

WO 9845712	A2	19981015	(199850)*	EN	141
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC					
MW NL OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI					
GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT					
LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL					
TJ TM TR TT UA UG US UZ VN YU ZW					
AU 9869529	A	19981030	(199911)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE

WO 9845712	A2	WO 1998-US6801	19980407
AU 9869529	A	AU 1998-69529	19980407

FILING DETAILS:

PATENT NO	KIND	PATENT NO

AU 9869529	A Based on	WO 9845712

Searcher : Shears 308-4994

09/092296

PRIORITY APPLN. INFO: US 1997-48184 19970530; US 1997-42726
19970408; US 1997-42727 19970408; US
1997-42728 19970408; US 1997-42754
19970408; US 1997-42825 19970408; US
1997-48068 19970530; US 1997-48070 19970530

AN 1998-594496 [50] WPIDS

AB WO 9845712 A UPAB: 19990210

An isolated nucleic acid molecule (NAM) (I) is claimed comprising a polynucleotide (PN) having a nucleotide sequence (NS) at least 95% identical to: (a) a PN fragment of a total of 20 defined human cDNA sequences given in the specification or a PN fragment of the cDNA sequence included in ATCC Deposit No. Z which is **hybridisable** to one of the 20 defined cDNA sequences; (b) a PN which is an (allelic) variant of one of the 20 defined cDNA sequence; (c) a PN encoding a biologically active polypeptide or a polypeptide fragment, domain or **epitope** of one of the 20 defined amino acid sequences given in the specification or a polypeptide fragment encoded by a cDNA sequence included in ATCC Deposit No. Z which is **hybridisable** to one of the defined cDNA sequences; (d) a PN which encodes a species homologue of one of the 20 defined polypeptides; or (e) a PN capable of **hybridising** under stringent conditions to any one of the PNs specified in (a)-(d), where the PN does not **hybridise** under stringent conditions to a sequence of only A residues or of only T residues. Also claimed are: (1) a recombinant vector comprising (I); (2) a method of making a recombinant host cell comprising (I); (3) a recombinant host cell produced by a method as in (2); (4) an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from a polypeptide fragment (preferably having biological activity), domain, **epitope**, secreted form, full-length protein, (allelic) variant or species homologue of one of the 20 defined amino acid sequences or the encoded sequence included in ATCC Deposit No. Z; (5) an isolated antibody that binds specifically to an isolated polypeptide as in (4); (6) a recombinant host cell that expresses an isolated polypeptide as in (4); (7) a gene corresponding to a cDNA sequence of one of the 20 nucleotide sequences given in the specification. Note: From the disclosure "'ATCC deposit No. Z'" refers to ATCC No's 97955 and 209074.

USE - The PNs and their corresponding secreted polypeptides are useful for preventing, treating or ameliorating medical conditions (claimed), e.g. by protein or gene therapy. Also pathological conditions can be **diagnosed** by **determining** the amount of the new polypeptides in a sample or by **determining** the presence of mutations in the new PNs (claimed). Specific uses are described for each of the 20 PNs, based on which tissues they are most highly expressed in, and include developing products for the **diagnosis** or treatment of central nervous system (CNS) and immune system diseases, reproductive disorders, cancers,

Searcher : Shears 308-4994

09/092296

congenital malformations, degenerative diseases, trauma, inflammatory disease, neoplasia, metabolic disorders, diseases in testes, placenta, liver, brain and activated T cells, spleen diseases, lung diseases, heart diseases, rhabdomyosarcoma and disorders of the endocrine system or other endocrinopathies, e.g. endocrine polyglandular syndrome, endocrinoma, and endocrine ophthalmopathy, osteoclastoma and other bone remodelling disorders, bacterial infections and sepsis. The polypeptides are also useful for identifying their binding partners (claimed).
Dwg.0/0

L6 ANSWER 11 OF 14 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1998-506364 [43] WPIDS
CROSS REFERENCE: 1998-414099 [35]; 1998-414100 [35]; 1998-414105 [35]; 1998-414114 [35]; 1998-427559 [35]; 1998-520811 [44]; 1998-609887 [42]; 1999-059865 [05]; 1999-080881 [07]; 1999-120770 [10]; 1999-132229 [11]; 1999-132234 [11]; 1999-204988 [17]; 1999-418749 [32]; 1999-430031 [36]
DOC. NO. NON-CPI: N1998-394741
DOC. NO. CPI: C1998-152795
TITLE: New isolated human genes and the secreted polypeptide(s) they encode - useful for diagnosis and treatment of e.g. cancers, neurological disorders, immune diseases, inflammation or blood disorders.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): BEDNARIK, D P; BREWER, L A; CARTER, K C; DUAN, R; EBNER, R; ENDRESS, G A; FENG, P; FERRIE, A M; FISCHER, C L; FLORENCE, K A; GREENE, J M; HU, J; NI, J; OLSEN, H S; ROSEN, C A; RUBEN, S M; SOPPET, D R; YOUNG, P E; YU, G; KYAW, H; LAFLEUR, D W; LI, Y; MOORE, P A; SHI, Y; ZENG, Z
PATENT ASSIGNEE(S): (HUMA-N) HUMAN GENOME SCI INC
COUNTRY COUNT: 81
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG

WO 9839448	A2	19980911	(199843)*	EN	721
RW: AT BE CH DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW					
NL OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI					
GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT					
LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL					
TJ TM TR TT UA UG US UZ VN YU ZW					
AU 9865453	A	19980922	(199908)		
AU 9891304	A	19990322	(199931)		

Searcher : Shears 308-4994

09/092296

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9839448	A2	WO 1998-US4493	19980306
AU 9865453	A	AU 1998-65453	19980306
AU 9891304	A	AU 1998-91304	19980903

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9865453	A Based on	WO 9839448
AU 9891304	A Based on	WO 9911293

PRIORITY APPLN. INFO: US 1997-61060 19971002; US 1997-38621
19970307; US 1997-40161 19970307; US
1997-40162 19970307; US 1997-40163
19970307; US 1997-40333 19970307

AN 1998-506364 [43] WPIDS
CR 1998-414099 [35]; 1998-414100 [35]; 1998-414105 [35]; 1998-414114
[35]; 1998-427559 [35]; 1998-520811 [44]; 1998-609887 [42];
1999-059865 [05]; 1999-080881 [07]; 1999-120770 [10]; 1999-132229
[11]; 1999-132234 [11]; 1999-204988 [17]; 1999-418749 [32];
1999-430031 [36]

AB WO 9839448 A UPAB: 19990908
An isolated nucleic acid molecule (I) comprises a polynucleotide
(PN) having a nucleotide sequence at least 95% identical to: (a) a
PN fragment of one of a total of 186 defined human cDNA sequences
given in the specification or a PN fragment of the cDNA sequence
included in ATCC Deposit No: Z, which is **hybridisable** to
one of the 186 defined cDNA sequences; (b) a PN which is an
(allelic) variant of one of the 186 defined cDNA sequences; (c) a PN
encoding a biologically active polypeptide or a polypeptide
fragment, domain or **epitope** of one of the 186 defined
amino acid sequences given in the specification or a polypeptide
fragment encoded by a cDNA sequence included in ATCC Deposit No. Z,
which is **hybridisable** to one of the defined cDNA
sequences; (d) a PN which encodes a species homologue of one of the
186 defined polypeptides; or (e) a PN capable of **hybridising**
under stringent conditions to any one of the PNs specified in
(a)-(d), where the PN does not **hybridise** under stringent
conditions to a sequence of only A residues or of only T residues.

Also claimed is an isolated polypeptide comprising an amino
acid sequence at least 95% identical to a sequence selected from:
(a) a polypeptide fragment (preferably having biological activity),
domain, **epitope**, secreted form, full-length protein,
(allelic) variant or species homologue of one of the 186 defined

Searcher : Shears 308-4994

100

100

100

100

09/092296

amino acid sequences or the encoded sequence included in ATCC
Deposit No: Z.

Note: From the disclosure ''ATCC Deposit No: Z'' refers to the representative clones, each containing a subset of the defined cDNA sequences, which have been deposited with the American Type Culture Collection. The deposit numbers are: ATCC 97897-97904 and ATCC 209076, 209215, 209139, 209011, 209119, 209235, 209627 and 209043-209050.

USE - The polynucleotides and their corresponding secreted polypeptides are useful for preventing, treating or ameliorating medical conditions (claimed), e.g. by protein or gene therapy. Also, pathological conditions can be **diagnosed** by **determining** the amount of the new polypeptides in a sample or by **determining** the presence of mutations in the new polynucleotides (claimed). Specific uses are described for each of the 186 polynucleotides, based on which tissues they are most highly expressed in, and include developing products for the **diagnosis** or treatment of: cancer; tumours; neurodegenerative disorders; developmental abnormalities and foetal deficiencies; blood disorders; leukaemias; diseases of the immune system (including allergies or asthma); lymphocytic diseases; brain associated diseases; hepatic and renal disease; lymphomas; inflammation; ischaemic shock; Alzheimer's and cognitive disorders; schizophrenia; restenosis; prostate diseases; obesity; disorders involving osteoclasts such as osteoporosis, arthritis or malignancies; **diseases** of testis, lung or thymus; thyroiditis and thyroid tumours; digestive/endocrine disorders, including metabolic regulation, malabsorption, gastritis and neoplasms; and AIDS. The polypeptides are also useful for **identifying** their binding partners (claimed).

Dwg.0/0

L6 ANSWER 12 OF 14 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1998-437479 [37] WPIDS
DOC. NO. NON-CPI: N1998-340776
DOC. NO. CPI: C1998-133112
TITLE: New nucleic acid for the lung
disease marker LU105 - polypeptides,
antibodies and genes, used for **diagnosis**,
prevention, treatment of lung
disease, specifically cancer.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): BILLING-MEDEL, P A; COHEN, M; COLPITTS, T L;
FRIEDMAN, P N; GORDON, J; GRANADOS, E N; HODGES, S
C; KLASS, M R; KRATOCHVIL, J D; ROBERTSRAPP, L;
RUSSELL, J C; STROUPE, S D
PATENT ASSIGNEE(S): (ABBO) ABBOTT LAB
COUNTRY COUNT: 19
PATENT INFORMATION:

Searcher : Shears 308-4994

09/092296

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9833926	A1	19980806	(199837)*	EN	117
RW: AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE					
W: CA JP					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9833926	A1	WO 1998-US1766	19980130

PRIORITY APPLN. INFO: US 1997-791710 19970131

AN 1998-437479 [37] WPIDS

AB WO 9833926 A UPAB: 19980916

A method for detecting target LU105 nucleic acid (I) comprises treating a sample with at least one LU105-specific nucleic acid (II), or its complement. (II) is at least 50% identical with 190, 244, 225, 114, 562 or 519 bp sequences given in the specification, or their fragments and complements.

Also claimed are:

(1) (I) or its fragments able to **hybridise** selectively to the LU105 gene and having at least 50% identity with the 190, 244, 225, 114, 562 or 519 bp sequences given above;

(2) recombinant expression systems including (I) and control sequence;

(3) cells transformed with this expression system;

(4) LU105 polypeptides (III) at least 50% identical with the 104, 26, 19, 21, 18 or 19 amino acid (aa) sequences given in the specification or their fragments;

(5) antibodies (Ab) that bind to at least one LU105 **epitope** present in (III);

(6) cells transformed with the 190, 244, 225, 114, 562 or 519 bp sequences described above;

(7) LU105 specific nucleic acid (II); and

(8) genes, or their fragments, that encode a protein at least 50% identical with the 104 aa sequences as in (4).

USE - LU105 is a **lung disease** marker. Cells as in (3) are used to express recombinant (III) which are used to raise Ab. Ab are used to **detect** the LU105 antigen, and correspondingly this antigen is used to **detect** specific antibodies, in usual immunoassays. (I) and (III) are used for **diagnosis**, staging, monitoring, prognosis, prevention, treatment (e.g. using antisense molecules, ribozymes, Ab or other antagonists) and **determination** of susceptibility to, **lung disease**, specifically cancer. (III) are also used to screen for specific binding agents, potentially useful

Searcher : Shears 308-4994

.

.

.

.

.

.

.

.

09/092296

therapeutically. LU105 is a marker for lung disease (present at high concentration, in altered form or in an unusual body compartment).

ADVANTAGE - LU105 can be detected in blood, plasma or serum in an inexpensive, non-invasive test.

Dwg.0/6

L6 ANSWER 13 OF 14 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1998-333327 [29] WPIDS
DOC. NO. NON-CPI: N1998-260122
DOC. NO. CPI: C1998-103375
TITLE: Human chemokine beta-13 polypeptide - useful in diagnosis and treatment of immune-system related disorders e.g. cancer of the immune system, leukaemias, autoimmune diseases etc..
DERWENT CLASS: B04 D16 S03
INVENTOR(S): LI, H; SEIBEL, G
PATENT ASSIGNEE(S): (HUMA-N) HUMAN GENOME SCI INC
COUNTRY COUNT: 79
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9824908	A1	19980611	(199829)*	EN	86
RW: AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL					
OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI					
GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV					
MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM					
TR TT UA UG US UZ VN YU ZW					
AU 9853834	A	19980629	(199845)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9824908	A1	WO 1997-US23144	19971205
AU 9853834	A	AU 1998-53834	19971205

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9853834	A Based on	WO 9824908

PRIORITY APPLN. INFO: US 1996-32432 19961205
AN 1998-333327 [29] WPIDS
AB WO 9824908 A UPAB: 19980722
Isolated human chemokine beta -13 (CK beta -13) polypeptide
Searcher : Shears 308-4994



09/092296

comprises amino acid sequence: (a) 95 % identical or more to 93 amino acid sequence (I) given in the specification, (b) mature CK beta -13 polypeptide sequence comprising amino acids 25-93 or 29-93 of sequence (I); (c) encoded by cDNA clone contained in ATCC 97113; or (d) a sequence complementary to the sequences as in (a)-(b).

Also claimed are: (1) polypeptide comprising **epitope**-bearing portion of CK beta -13 protein comprising amino acids Thr22-Gly28, Asn30-Leu47, Thr56-Val65 or Phe70-Trp83 of sequence (I); (2) nucleic acid molecules as follows: (i) encoding CK beta -13 polypeptide sequences as above; (ii) complementary to (i); (iii) **hybridising** to (i) but not to polynucleotide with sequence consisting of only A or only T residues; (iv) encoding **epitope**-bearing portion of (i), optionally as in (1); (v) having 282 bp sequence (II) and optionally encoding CK beta -13 polypeptide sequences as above; (vi) at least 95 % identical to sequence encoding polypeptide with amino acids n-93, 1-m and n-m (n and m are integers between 1-35 and 77-93 respectively) of (i); and (vii) encoding polypeptide which is a portion of CK beta -13 sequence encoded by cDNA clone in ATCC 97113 excluding 1-35 amino acids from amino terminus and/or 1-17 amino acids from carboxy terminus; (3) recombinant vectors produced by inserting (i) into vector; (4) host cells produced by introducing the vector as in (4); and (5) antibody binding specifically to CK beta -13 polypeptide.

USE - The polypeptides and nucleic acids are useful in **diagnosis** and treatment of immune system-related disorders in mammals (preferably humans). Such disorders include tumours, cancers, **interstitial lung disease** and disregulation of immune cell function including leukaemias, lymphomas, autoimmune diseases etc. For example, certain tissues in mammals with cancer of the immune system express enhanced/decreased levels of CK beta -13 and mRNA encoding CK beta -13, and **diagnosis** can be achieved by assaying CK beta -13 gene expression and comparing to standard levels. The polypeptides can be administered therapeutically in pharmaceutical compositions e.g. to treat immune system-related disorders as above, treat sepsis, inhibit bone marrow stem cell colony formation during cancer therapy, regulate haematopoiesis, stimulate wound healing etc. Compositions comprising the polynucleotides may also be administered, especially to express CK beta -13 polypeptide in hosts to treat dysfunctions associated with aberrant endogenous CK beta -13 activity. The polynucleotides are also useful for mapping of chromosomes/chromosome sites. The polypeptides are useful to screen for agonists and antagonists of CK beta -13 activity. The antibodies are useful **diagnostically** or therapeutically e.g. as antagonists to treat subjects requiring CK beta -13 reduction.

Dwg.0/4

09/092296

DOC. NO. NON-CPI: N1998-225472
DOC. NO. CPI: C1998-088988
TITLE: Lung tissue derived polynucleotide LU103 - useful
to detect, diagnose, stage,
monitor, prognose, prevent, treat or
determine pre-disposition to lung
disease, e.g. lung cancer.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): COHEN, M; FRIEDMAN, P N; GORDON, J; HODGES, S C;
KLASS, M R; KRATOCHVILL, J D; ROBERTS-RAPP, L;
RUSSELL, J C; STROUPE, S D
PATENT ASSIGNEE(S): (ABBO) ABBOTT LAB
COUNTRY COUNT: 19
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9820143	A1	19980514	(199825)*	EN	86
RW: AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE					
W: CA JP					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9820143	A1	WO 1997-US20680	19971105

PRIORITY APPLN. INFO: US 1996-744211 19961105

AN 1998-286957 [25] WPIDS

AB WO 9820143 A UPAB: 19980715

The following are claimed: (1) a method for detecting the presence of a target LU103 polynucleotide in a test sample, comprising: (a) contacting the sample with at least 1 LU103-specific polynucleotide, and (b) detecting the target LU103 polynucleotide in the test sample, where the LU103 polynucleotide has at least 50% identity to the 269, 263, 225, 507 or 519 bp nucleic acid sequence given in the specification; (2) a method for detecting LU103 mRNA in a test sample, comprising: (a) performing reverse transcription with at least 1 primer in order to produce cDNA; (b) amplifying the cDNA using LU103 oligonucleotides as sense and antisense primers to obtain LU103 amplicon, and (c) detecting LU103 amplicon in the test sample, where the LU103 oligonucleotides utilised in steps (a) and (b) have at least 50% sequence identity to the 269, 263, 225, 507 or 519 bp sequence and (3) a method detecting a target LU103 polynucleotide in a test sample suspended of containing the target, comprising: (a) contacting the test sample with at least 1 LU103 oligonucleotide as a sense primer and at least 1 LU103 oligonucleotide as an anti-sense primer and amplifying to obtain a

Searcher : Shears 308-4994

09/092296

first stage reaction product; (b) contacting the first stage reaction product with at least 1 other LU103 oligonucleotide to obtain a second stage reaction product, provided that the other LU103 oligonucleotide is located 3' to the LU103 oligonucleotides utilised in step (a) and is complementary to the first stage reaction product, and (c) detecting the second stage reaction product as an indication of the presence of the target LU103 polynucleotide, where the LU103 oligonucleotides utilised in steps (a) and (b) have at least 50% sequence identity to the 269, 263, 225, 507 or 519 bp sequence; (4) a purified polynucleotide derived from an LU103 gene, where the polynucleotide is capable of selectively **hybridising** to the nucleic acid of the LU103 gene and has at least 50% identity to the 269, 263, 225, 507 or 519 bp sequence; (5) a recombinant expression system comprising a nucleic acid sequence that includes an ORF derived from LU103 operably linked to a control sequence compatible with a desired host, where the nucleic acid sequence has at least 50% identity to the 269, 263, 225, 507 or 519 bp sequence; (6) cell transfected with the recombinant expression system; (7) cell transfected with a nucleic acid sequence encoding at least 1 LU103 **epitope**, where the nucleic acid sequence has the 269, 263, 225, 507 or 519 bp sequence; (8) composition comprising a LU103 polynucleotide, where the polynucleotide has at least 50% identity to the 269, 263, 225, 507 or 519 bp sequence; (9) gene which encodes a LU103 protein which comprises an amino acid sequence with at least 50% identity with the 93 residue amino acid sequence given in the specification, and (10) gene comprising DNA having at least 50% identity with the 507 or 519 bp sequence.

USE - The methods and products of the invention may be used to detect, diagnose, stage, monitor, prognose, prevent, treat or determine the predisposition diseases and conditions of the lung, e.g. lung cancer.

Dwg.0/4

(FILE 'USPATFULL' ENTERED AT 12:18:19 ON 25 OCT 1999)

L9 7 S L2(S) (REAGENT OR EPITOPE OR LS147 OR LS 147)

L9 ANSWER 1 OF 7 USPATFULL

ACCESSION NUMBER: 1999:96216 USPATFULL

TITLE: **Reagents and methods useful for
detecting diseases of the
lung**

INVENTOR(S): Cohen, Maurice, Highland Park, IL, United States
Friedman, Paula N., Deerfield, IL, United States
Gordon, Julian, Lake Bluff, IL, United States
Hodges, Steven C., Buffalo Grove, IL, United States
Klass, Michael R., Libertyville, IL, United States

Searcher : Shears 308-4994

44

1

09/092296

Kratochvil, Jon D., Kenosha, WI, United States
Roberts-Rapp, Lisa, Gurnee, IL, United States
Russell, John C., Kenosha, WI, United States
Stroupe, Steven D., Libertyville, IL, United States
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5939265	19990817
APPLICATION INFO.:	US 1997-964725	19971105 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-744211, filed on 5 Nov 1996, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Degren, Nancy	
ASSISTANT EXAMINER:	Wang, Andrew	
LEGAL REPRESENTATIVE:	Becker, Cheryl L.; Goller, Mimi C.	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 6 Drawing Page(s)	
LINE COUNT:	3052	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A set of contiguous and partially overlapping RNA sequences and polypeptides encoded thereby, designated as LU103 and transcribed from lung tissue is described. A fully sequenced clone representing the longest continuous sequence of LU103 is also disclosed. These sequences are useful for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the lung such as lung cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

INCL INCLM: 435/006.000
INCLS: 435/172.300; 435/320.100; 435/325.000; 536/023.100;
536/023.500
NCL NCLM: 435/006.000
NCLS: 435/320.100; 435/325.000; 536/023.100; 536/023.500

L9 ANSWER 2 OF 7 USPATFULL

ACCESSION NUMBER: 1999:43653 USPATFULL
TITLE: Amidinohydrazones as protease inhibitors
INVENTOR(S): Soll, Richard M., Lawrenceville, NJ, United States
Lu, Tianbao, Exton, PA, United States
Fedde, Cynthia L., Warrington, PA, United States
Tomczuk, Bruce E., Collegeville, PA, United States
Illig, Carl, Phoenixville, PA, United States
Searcher : Shears 308-4994

44

09/092296

PATENT ASSIGNEE(S): 3-Dimensional Pharmaceuticals, Inc., Exton, PA,
United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5891909	19990406
APPLICATION INFO.:	US 1997-828160	19970327 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-14317	19960329 (60)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Richter, Johann	
ASSISTANT EXAMINER:	Oswecki, Jane C.	
LEGAL REPRESENTATIVE:	Sterne, Kessler, Goldstein & Fox P.L.L.C.	
NUMBER OF CLAIMS:	76	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5001	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Amidino and benzamidino compounds, including compounds of the formula: ##STR1## wherein R.sup.1 -R.sup.4, R.sup.6 -R.sup.9, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula I.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

INCL INCLM: 514/517.000
INCLS: 514/309.000; 514/312.000; 514/345.000; 514/361.000;
514/401.000; 514/406.000; 514/518.000; 514/530.000;
514/567.000; 514/632.000; 546/141.000; 546/172.000;
546/290.000; 548/127.000; 548/353.100; 548/367.100;
549/230.000; 558/056.000; 560/303.000; 562/431.000;
562/432.000; 564/228.000

NCL NCLM: 514/517.000
NCLS: 514/309.000; 514/312.000; 514/345.000; 514/361.000;
514/401.000; 514/406.000; 514/518.000; 514/530.000;
514/567.000; 514/632.000; 546/141.000; 546/172.000;
546/290.000; 548/127.000; 548/353.100; 548/367.100;
549/230.000; 558/056.000; 560/303.000; 562/431.000;
562/432.000; 564/228.000

L9 ANSWER 3 OF 7 USPATFULL

ACCESSION NUMBER: 1998:157475 USPATFULL
TITLE: Hybridomas producing monoclonal antibodies to new
mucin epitopes
INVENTOR(S): Linsley, Peter S., Seattle, WA, United States
Horn, Diane, Seattle, WA, United States
Searcher : Shears 308-4994

44

09/092296

PATENT ASSIGNEE(S): Brown, Joseph P., Seattle, WA, United States
Sanofi, Paris, France (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5849876	19981215
APPLICATION INFO.:	US 1994-179875	19940111 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1992-913740, filed on 14 Jul 1992, now abandoned which is a continuation of Ser. No. US 1987-104511, filed on 8 Oct 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-932781, filed on 19 Nov 1986, now abandoned	

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Scheiner, Laurie
LEGAL REPRESENTATIVE: Merchant, Gould, Smith, Edell, Welter & Schmidt
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1849

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel hybridoma cell lines producing monoclonal antibodies reactive with purified mucin antigens from normal and tumor sources are generated using mucins, including purified mucins from tumor sources. Epitopes on mucin antigens from normal and tumor

APPLICATION INFO.: US 1996-698401 19960815 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-536939,
filed on 29 Sep 1995, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Ivy, C. Warren
ASSISTANT EXAMINER: Covington, Raymond
LEGAL REPRESENTATIVE: Sterne, Kessler Goldstein & Fox P.L.L.C.
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
LINE COUNT: 4363

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula: ##STR1## wherein R.sup.1 --R.sup.4, R.sup.7 --R.sup.8, R.sup.a, R.sup.b, R.sup.c, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit a number of proteolytic enzymes are described. Also described are methods for preparing the compounds of Formula I.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

INCL INCLM: 514/255.000
INCLS: 514/317.000; 514/330.000; 514/331.000; 514/603.000;
514/604.000; 514/634.000; 514/822.000; 544/398.000;
544/399.000; 544/400.000; 544/402.000; 546/021.000;
546/229.000; 546/230.000; 546/231.000; 564/237.000
Searcher : Shears 308-4994



09/092296

NCL NCLM: 514/255.000
NCLS: 514/317.000; 514/330.000; 514/331.000; 514/603.000;
514/604.000; 514/634.000; 514/822.000; 544/398.000;
544/399.000; 544/400.000; 544/402.000; 546/021.000;
546/229.000; 546/230.000; 546/231.000; 564/237.000

L9 ANSWER 5 OF 7 USPATFULL

ACCESSION NUMBER: 1998:69171 USPATFULL
TITLE: Cell cycle regulatory gene
INVENTOR(S): Sidransky, David, Baltimore, MD, United States
PATENT ASSIGNEE(S): The Johns Hopkins University School of Medicine,
Baltimore, MD, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5767258	19980616
APPLICATION INFO.:	US 1995-439962	19950512 (8)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Elliot, George C.	
ASSISTANT EXAMINER:	McGarry, Sean	
LEGAL REPRESENTATIVE:	Fish & Richardson, P.C.	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	1506	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel cell cycle regulatory gene called 5'ALT is disclosed.
Methods for determining mutations or polymorphisms in 5'ALT or
5'ALT regulated genes in tissues are also provided. Novel
5'ALT-p16 and 5'ALT-p15 transcripts and truncated expression
products are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

INCL INCLM: 536/023.100
INCLS: 536/023.500; 435/006.000; 435/172.100; 435/320.100;
435/325.000; 435/243.000
NCL NCLM: 536/023.100
NCLS: 435/006.000; 435/243.000; 435/320.100; 435/325.000;
536/023.500

L9 ANSWER 6 OF 7 USPATFULL

ACCESSION NUMBER: 85:8964 USPATFULL
TITLE: .alpha.-Aminoboronic acid peptides
INVENTOR(S): Shenvi, Ashokkumar B., Wilmington, DE, United
States
Kettner, Charles A., Wilmington, DE, United
States
PATENT ASSIGNEE(S): E. I. Du Pont de Nemours and Company, Wilmington,
DE, United States (U.S. corporation)
Searcher : Shears 308-4994

09/092296

	NUMBER	DATE
PATENT INFORMATION:	US 4499082	19850212
APPLICATION INFO.:	US 1983-558362	19831205 (6)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Phillips, Delbert R.	
LEGAL REPRESENTATIVE:	Hallquist, Scott G.	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	1528	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Peptides comprising C-terminal .alpha.-aminoboronic acid residues are potent, reversible inhibitors of proteolytic enzymes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

INCL INCLM: 514/002.000
INCLS: 260/112.500R; 514/018.000; 514/019.000
NCL NCLM: 514/002.000
NCLS: 260/001.000; 514/018.000; 514/019.000; 514/506.000;
530/331.000; 562/007.000; 930/010.000; 930/023.000;
930/250.000

L9 ANSWER 7 OF 7 USPATFULL

ACCESSION NUMBER: 85:3359 USPATFULL
TITLE: Determination of oxidized .alpha.-1-proteinase inhibitor in serum or plasma
INVENTOR(S): Travis, James, Athens, GA, United States
PATENT ASSIGNEE(S): University of Georgia Research Foundation, Inc., Athens, GA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4493891	19850115
APPLICATION INFO.:	US 1982-402442	19820727 (6)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Kepplinger, Esther M.	
LEGAL REPRESENTATIVE:	Oblon, Fisher, Spivak, McClelland & Maier	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	603	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A new method of determining oxidized .alpha.-1-proteinase inhibitor in serum or plasma for use in studying the development of chronic obstructive lung disease is disclosed. Levels of oxidized .alpha.-1-proteinase inhibitor indicate the potential for emphysema development with higher levels showing a decrease in

Searcher : Shears 308-4994



09/092296

lung protection against elastolytic enzymes such as elastase. This method can be used for patients with a potential for chronic obstructive lung disease rather than having to use bronchial lavage methods for such patients. No other method is known to exist for determining oxidized .alpha.-1-proteinase inhibitor in serum or plasma.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

INCL INCLM: 435/023.000

INCLS: 435/184.000

NCL NCLM: 435/023.000

NCLS: 435/184.000

(FILE 'CAPLUS, MEDLINE, BIOSIS, EMBASE, LIFESCI, WPIDS, CONFSCI, SCISEARCH, JICST-EPLUS, PROMT, CANCERLIT, USPATFULL' ENTERED AT 12:20:18 ON 25 OCT 1999)

L10 134 SEA ABB=ON PLU=ON (BILLING MEDEL P? OR BILLING P? OR
MEDEL P? OR MEDEL BILLING P?)/AU
L11 26222 SEA ABB=ON PLU=ON COHEN M?/AU
L12 123 SEA ABB=ON PLU=ON COLPITTS T?/AU
L13 2767 SEA ABB=ON PLU=ON FRIEDMAN P?/AU
L14 262 SEA ABB=ON PLU=ON KLASS M?/AU
L15 12902 SEA ABB=ON PLU=ON RUSSELL J?/AU
L16 310 SEA ABB=ON PLU=ON STROUPE S?/AU
L17 48 SEA ABB=ON PLU=ON L10 AND L11 AND L12 AND L13 AND L14
AND L15 AND L16
L18 51 SEA ABB=ON PLU=ON L10 AND (L11 OR L12 OR L13 OR L14 OR
L15 OR L16)
L19 62 SEA ABB=ON PLU=ON L11 AND (L12 OR L13 OR L14 OR L15)
L20 51 SEA ABB=ON PLU=ON L12 AND (L13 OR L14 OR L15)
L21 62 SEA ABB=ON PLU=ON L13 AND (L14 OR L15)
L22 59 SEA ABB=ON PLU=ON L14 AND L15

L26 7 SEA ABB=ON PLU=ON (L17 OR L18 OR L19 OR L20 OR L21 OR
L22) AND L1
L27 4 DUP REM L26 (3 DUPLICATES REMOVED)

44

RESULT 10
 LOCUS AA323964 311 bp mRNA EST 20-APR-1997
 DEFINITION EST26816 Cerebellum II Homo sapiens cDNA 5' end, mRNA sequence.
 ACCESSION AA323964
 NID g1976290
 VERSION AA323964.1 GI:1976290
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
 Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 311)
 AUTHORS Adams,M.D., Kerlavage,A.R., Fleischmann,R.D., Fuldner,R.A.,
 Bult,C.J., Lee,N.H., Kirkness,E.F., Weinstock,K.G., Gocayne,J.D.,
 White,O., Sutton,G., Blake,J.A., Brandon,R.C., Man-Wai,C.,
 Clayton,R.A., Cline,T.R., Cotton,M.D., Earle-Hughes,J., Fine,L.D.,
 Fitzgerald,L.M., Fitzhugh,W.M., Fritchman,J.L., Geoghagen,N.S.,
 Glodek,A., Gnehm,C.L., Hanna,M.C., Hedblom,E., Hinkle,P.S.Jr.,
 Kelley,J.M., Kelley,J.C., Liu,L.-I., Marmaros,S.M., Merrick,J.M.,
 Moreno-Palanques,R.F., McDonald,L.A., Nguyen,D.T., Pelligrino,S.M.,
 Phillips,C.A., Ryder,S.E., Scott,J.L., Saudek,D.M., Shirley,R.,
 Small,K.V., Spriggs,T.A., Utterback,T.R., Weidman,J.F., Li,Y.,
 Bednarik,D.P., Cao,L., Cepeda,M.A., Coleman,T.A., Collins,E.J.,
 Dimke,D., Feng,D.-F., Ferrie,A., Fischer,C., Hastings,G.A.,
 He,W.W., Hu,J.S., Greene,J.M., Gruber,J., Hudson,P., Kim,A.K.,
 Kozak,D.L., Kunsch,C., Hungjun,J., Li,H., Meissner,P.S., Olsen,H.,
 Raymond,L., Wei,Y.F., Wing,J., Xu,C., Yu,G.L., Ruben,S.M.,
 Dillion,P.J., Fannon,M.R., Rosen,C.A., Haseltine,W.A., Fields,C.,
 Fraser,C.M. and Venter,J.C.
 TITLE Initial assessment of human gene diversity and expression patterns
 based upon 83 million nucleotides of cDNA sequence
 JOURNAL Nature 377 (6547 Suppl), 3-174 (1995)
 MEDLINE 96026280
 COMMENT On Apr 14, 1993 this sequence version replaced gi:693635.
 *
 Contact: Kerlavage, AR
 Bioinformatics
 The Institute for Genomic Research
 9712 Medical Center Drive, Rockville, MD 20850 USA
 Tel: 3018699056
 Fax: 3018699423
 Email: arkerlav@tigr.org
 For clone availability, additional sequence and expression
 information related to this EST, please check the TIGR Human Gene
 Index (<http://www.tigr.org/tdb/hgi/hgi.html>)
 Seq primer: M13 Reverse.
 FEATURES Location/Qualifiers
 source 1..311
 /organism="Homo sapiens"
 /note="Organ: brain; Vector: pBluescript SK-; Site_1:
 EcoRI; Site_2: XhoI"
 /db_xref="ATCC (inhost):124516"
 /db_xref="taxon:9606"
 /clone_lib="Cerebellum II"
 /tissue_type="cerebellum"
 /dev_stage="adult"
 BASE COUNT 59 a 110 c 74 g 64 t 4 others
 ORIGIN
 Query Match 9.7%; Score 23; DB 11; Length 311;
 Best Local Similarity 89.7%; Pred. No. 3.76e-05;
 Matches 26; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Db 8 TGGCCACTGGGGGGCCTGGGCTGCCCTT 36
 ||||| |||| |||||
 Qy 43 TGGCCACTATGGGGTCTGGGCTGCCCTT 71



RESULT 9
 ID US-08-418-444A-1 STANDARD; DNA; UNC; 3088 BP.
 AC xxxxxx
 DT
 DE Sequence 1, Application US/08418444A
 CC Sequence 1, Application US/08418444A
 CC Patent No. 5773688
 CC
 CC GENERAL INFORMATION:
 CC APPLICANT: KURODA, HISAO
 CC APPLICANT: HIROTA, NAOHITO
 CC APPLICANT: ITO, KAZUOSHI
 CC TITLE OF INVENTION: GENE EXPRESSION VECTOR USING THE GENE
 CC TITLE OF INVENTION: EXPRESSION REGULATING REGION OF THE ADP RIBOSYLATION
 CC TITLE OF INVENTION: FACTOR
 CC NUMBER OF SEQUENCES: 9
 CC CORRESPONDENCE ADDRESS:
 CC ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MATER & NEUSTADT
 CC STREET: 1755 S. JEFFERSON DAVIS HIGHWAY, SUITE 400
 CC CITY: ARLINGTON
 CC STATE: VIRGINIA
 CC COUNTRY: USA
 CC ZIP: 22202
 CC
 CC COMPUTER READABLE FORM:
 CC MEDIUM TYPE: Floppy disk
 CC COMPUTER: IBM PC compatible
 CC OPERATING SYSTEM: PC-DOS/MS-DOS
 CC SOFTWARE: Patentin Release #1.0, Version #1.30
 CC CURRENT APPLICATION DATA:
 CC APPLICATION NUMBER: US/08/418,444A
 CC FILING DATE: 07-APR-1995
 CC CLASSIFICATION: 800
 CC PRIOR APPLICATION DATA:
 CC APPLICATION NUMBER: JP HEI 6-71048
 CC FILING DATE: 08-APR-1994
 CC ATTORNEY/AGENT INFORMATION:
 CC NAME: Oblon, No. 5773688man F.
 CC REGISTRATION NUMBER: 24,618
 CC REFERENCE/DOCKET NUMBER: 2589-024-0
 CC TELECOMMUNICATION INFORMATION:
 CC TELEPHONE: (703) 413-3000
 CC TELEFAX: (703) 413-2220
 CC TELEX: 248855 OPAT UR
 CC INFORMATION FOR SEQ ID NO: 1:
 CC SEQUENCE CHARACTERISTICS:
 CC LENGTH: 3088 base pairs
 CC TYPE: nucleic acid
 CC STRANDEDNESS: double
 CC TOPOLOGY: linear
 CC MOLECULE TYPE: DNA (genomic)
 CC

SEQ SEQUENCE 3088 BP; 716 A; 761 C; 672 G; 939 T; 0 OTHER.
 Query Match 9.6%; Score 22; DB 3; Length 3088;
 Best Local Similarity 72.0%; Pred. No. 1.54e-01;
 Matches 36; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
 Db 15 CCGAAGATGGCCAGAGGAGGCGGCGGCTGCCCCAGGCGCCCTGCTGCG 64
 Cp 90 CCAAGAGGCTCAAGAGAGACAAAGGCGCACCCAGACCCATATGTGCG 41



888 Oct 25 11:53:59 1999

US-09-092-296-3.rni

Page 5

TELEX: 24885 OPAT UR
INFORMATION FOR SEQ. ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 3088 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE 3088 BP: 716 A; 761 C; 672 G; 939 T; 0 OTHER.

Query Match 12.24; Score 22; DB 3; Length 3088;
Best Local Similarity 72.04; Pred. No. 7,70e-02;
Matches 36; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
15 CCGAAGATGGGCGCAGAGGGGGCGGCGCTGCCAGGCGCCCTGCTGCGC 64
63 CCAAGAGGGGTCAAGAGGAGGACAAAGGGGCGAGCCCGACCCATAGTGGC 14

RESULT 8
ID US-08-418-444A-1 STANDARD; DNA; UNC; 3088 BP.
AC xxxxxx
DT Sequence 1, Application US/08418444A
CC Sequence 1, Application US/08418444A
CC Patent No. 5773688
CC GENERAL INFORMATION:
CC APPLICANT: KURODA, HISAO
CC APPLICANT: HIROTA, NAOKI
CC APPLICANT: ITO, KAZUTOSHI
CC TITLE OF INVENTION: GENE EXPRESSION VECTOR USING THE GENE
CC TITLE OF INVENTION: EXPRESSION REGULATING REGION OF THE ADP RIBOSYLATION
CC TITLE OF INVENTION: FACTOR
CC NUMBER OF SEQUENCES: 9
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: OBION, SPIVAK, MCCLELLAND, MAIER & NEUSTADT
CC STREET: 1755 S. JEFFERSON DAVIS HIGHWAY, SUITE 400
CC CITY: ARLINGTON
CC STATE: VIRGINIA
CC COUNTRY: USA
CC ZIP: 22202
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC COMPUTER: IBM PC compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: Patentin Release #1.0, Version #1.30
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/418,444A
CC FILING DATE: 07-APR-1995
CC CLASSIFICATION: 800
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: JP HEI 6-71048
CC FILING DATE: 08-APR-1994
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Obion, No. 5773688man F.
CC REGISTRATION NUMBER: 24,618
CC REFERENCE/DOCKET NUMBER: 2589-024-0
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: (703) 413-3000
CC TELEFAX: (703) 413-2220



1 2 3